CUMULATIVE SUPPLEMENT 9
September 2025



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2025

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

Cumulative Supplement 9
September 2025

CONTENTS

PAGE

Contents

1.0 INTRODUCTION v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT vi
1.2 CUMULATIVE SUPPLEMENT CONTENT vi
1.3 APPLICANT NAME CHANGES vii
1.4 LEVOTHYROXINE SODIUM ix
1.5 AVAILABILITY OF THE EDITION x
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST xi
1.7 CUMULATIVE SUPPLEMENT LEGEND xii

DRUG PRODUCT LISTS

Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Products Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

CUMULATIVE SUPPLEMENT 9
September 2025

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALLIED PHARMA INC (ALLIED)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	TP ANDA HOLDINGS LLC (TP ANDA HOLDINGS)
AVIV PHARMA INC (AVIV PHARMA)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
BEXIMCO PHARMACEUTICALS USA INC (BEXIMCO PHARMS USA)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
BEXIMCO PHARMACEUTICALS USA INC (BEXIMCO USA)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
CARNEGIE PHARMACEUTICALS LLC (CARNEGIE)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
DR REDDYS LABORATORIES INC (DR REDDYS LABS INC)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)

DR REDDYS LABORATORIES LTD
(DR REDDYS)

DR REDDYS LABORATORIES LTD
(DR REDDYS LABS LTD)

DR REDDYS LABORATORIES SA
(DR REDDYS LABS SA)

ENDO OPERATIONS LTD
(ENDO OPERATIONS)

ESJAY PHARMA LLC
(ESJAY PHARMA)

GRAVITI PHARMACEUTICALS INC
(GRAVITI PHARMS)

GRAVITI PHARMACEUTICALS PRIVATE LTD (GRAVITI PHARMS)

ICU MEDICAL INC
(ICU MEDICAL INC)

INDOCO REMEDIES LTD
(INDOCO)

INDOCO REMEDIES LTD
(INDOCO REMEDIES)

MYLAN INSTITUTIONAL LLC
(MYLAN INSTITUTIONAL)

MYLAN LABORATORIES LTD
(MYLAN LABS LTD)

MYLAN PHARMACEUTICALS INC
(MYLAN)

MYLAN PHARMACEUTICALS INC
(MYLAN PHARMS INC)

MYLAN TECHNOLOGIES INC
(MYLAN TECHNOLOGIES)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

RUBICON RESEARCH PRIVATE LTD
(RUBICON)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

PH HEALTH LTD
(PH HEALTH)

NOVITIUM PHARMA LLC
(NOVITUM PHARMA)

RISING PHARMA HOLDINGS INC
(RISING)

RISING PHARMA HOLDINGS INC
(RISING)

OTSUKA ICU MEDICAL LLC
(OTSUKA ICU MEDCL)

REGCON HOLDINGS LLC
(REGCON HOLDINGS)

REGCON HOLDINGS LLC
(REGCON HOLDINGS)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

PHARMOBEDIENT CONSULTING LLC
(PHARMOBEDIENT)

RUBICON RESEARCH LTD
(RUBICON RESEARCH)

ANDA REPOSITORY LLC
(ANDA REPOSITORY)

ONESOURCE SPECIALTY PTE LTE
(ONESOURCE SPECIALTY)

STRIDES SOFTGELS PTE LTD (STRIDES SOFTGELS)	ONESOURCE SPECIALTY PTE LTD (ONESOURCE SPECIALTY)
TRUPHARMA LLC (TRUPHARMA)	TP ANDA HOLDINGS LLC (TP ANDA HOLDINGS)
WOCKHARDT LTD (WOCKHARDT)	WOCKHARDT BIO AG (WOCKHARDT BIO AG)
XTTRIUM LABORATORIES INC (XTTRIUM)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
XTTRIUM LABORATORIES INC (XTTRIUM LABS INC)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

[2] Please consult the Active Section of the Orange Book for information on other strengths.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2024	MAR 2025	JUN 2025	SEP 2025	DEC 2025
DRUG PRODUCTS	23856	23679	23798	24012	
LISTED SINGLE SOURCE	2772 (11.8%)	2740 (11.6%)	2744 (11.5%)	2776 (11.6%)	
MULTISOURCE	20814 (88.2%)	20939 (88.4%)	21054 (88.5%)	21236 (88.4%)	

THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)	20952 (88%)	21137 (88%)
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)	102 (0.4%)	99 (0.4%)
EXCEPTIONS[4]	47 (0.2%)	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	43	13	7	20
NUMBER OF APPLICANTS	1197	1209	1226	1200

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).
[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

	AB		HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
		@	MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024	Jun DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

>D>	AB		FLORIDA	500MG	A215086	001	Mar 23, 2023	Sep CAHN
>A>	AB		REGCON HOLDINGS	500MG	A215086	001	Mar 23, 2023	Sep CAHN
		@	TEVA PHARMS USA	250MG	A208432	001	Oct 31, 2018	Mar DISC
		@		500MG	A210726	001	Jan 26, 2023	Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

>A>	AB		BIONPHARMA	333MG	A219904	001	Sep 18, 2025	Sep NEWA
	AB		GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Mar CMFD

ACECLIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VIZZ

		+!	LENZ THERAP	EQ 1.44% BASE	N218585	001	Jul 31, 2025	Jul NEWA

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

	AP1		ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar CTEC
	AP	+!	B BRAUN MEDICAL	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar CFTG
	AP2	+!		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar CFTG
		!	BAXTER HLTHCARE CORP	650MG/65ML (10MG/ML)	A214331	002	May 21, 2025	May NEWA
	AP1			1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar CTEC
	AP1		EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar CTEC
	AP		GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar NFTG
	AP2			1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar NFTG
	AP1		HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar CTEC
	AP1		INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar CTEC
	AP1		MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar CTEC
	AP1	!	SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar CTEC
	AP1		WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar CTEC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

>D>	AA	!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015	Sep CAHN
>A>	AA	!	PHARMOBEDIENT	325MG;25MG	A203484	001	Dec 04, 2015	Sep CAHN

BUTALBITAL AND ACETAMINOPHEN

>A>	AA		ANDA REPOSITORY	300MG;50MG	A207386	001	Nov 15, 2016	Sep CAHN
>D>	AA		LARKEN LABS INC	325MG;50MG	A203484	002	Dec 04, 2015	Sep CAHN
>D>	AA		MIKART	300MG;50MG	A207386	001	Nov 15, 2016	Sep CAHN
>A>	AA		PHARMOBEDIENT	325MG;50MG	A203484	002	Dec 04, 2015	Sep CAHN

BUTAPAP

>A>	AA	!	ANDA REPOSITORY	325MG;50MG	A089987	001	Oct 26, 1992	Sep CAHN
>D>	AA	!	MIKART	325MG;50MG	A089987	001	Oct 26, 1992	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	AA		ANDA REPOSITORY	325MG;50MG;40MG	A089175	001	Jan 21, 1987	Sep CAHN
>D>	AA		MIKART	325MG;50MG;40MG	A089175	001	Jan 21, 1987	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

		@	AVIV PHARMA	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

>D>		@	LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016	Sep CAHN
>A>		@	PHARMOBEDIENT	325MG;30MG;16MG	A204209	001	Sep 30, 2016	Sep CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@	CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Feb DISC
		!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A087508	001		Feb CTEC
		@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML	A087006	001		Feb CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@	ANI PHARMS	300MG;15MG	A088629	002	Mar 06, 1985	May CAHN
		@		300MG;30MG	A088629	003	Mar 06, 1985	May CAHN
		@ +		300MG;60MG	A088629	001	Mar 06, 1985	May CAHN
>A>	AA		HIBROW HLTHCARE	300MG;15MG	A211610	001	Jun 27, 2019	Sep CAHN
>A>	AA			300MG;30MG	A211610	002	Jun 27, 2019	Sep CAHN
>A>	AA			300MG;60MG	A211610	003	Jun 27, 2019	Sep CAHN
>D>	AA		WES PHARMA INC	300MG;15MG	A211610	001	Jun 27, 2019	Sep CAHN
>D>	AA			300MG;30MG	A211610	002	Jun 27, 2019	Sep CAHN
>D>	AA			300MG;60MG	A211610	003	Jun 27, 2019	Sep CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Feb DISC
	AA	!	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb CHRS

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Feb DISC
		@		300MG;7.5MG	A040658	002	Mar 24, 2006	Feb DISC
		@		300MG;10MG	A040658	003	Jun 23, 2004	Feb DISC
		@		325MG;7.5MG	A040432	001	Jan 22, 2003	Feb DISC
>A>	AA		HIBROW HLTHCARE	300MG;5MG	A207509	001	Oct 29, 2018	Sep CAHN
>A>	AA			300MG;7.5MG	A207509	002	Oct 29, 2018	Sep CAHN
>A>	AA			300MG;10MG	A207509	003	Oct 29, 2018	Sep CAHN
		@	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Jan DISC
		@		300MG;7.5MG	A207808	002	Mar 30, 2018	Jan DISC
		@		300MG;10MG	A207808	003	Mar 30, 2018	Jan DISC
	AA	!	SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017	Feb CHRS
	AA	!		300MG;7.5MG	A206718	002	Mar 31, 2017	Feb CHRS
	AA	!		300MG;10MG	A206718	003	Mar 31, 2017	Feb CHRS
>D>	AA		WES PHARMA INC	300MG;5MG	A207509	001	Oct 29, 2018	Sep CAHN
>D>	AA			300MG;7.5MG	A207509	002	Oct 29, 2018	Sep CAHN
>D>	AA			300MG;10MG	A207509	003	Oct 29, 2018	Sep CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	!	ABHAI LLC	325MG/5ML;5MG/5ML	A211499	001	Dec 31, 2018	Sep CTEC
>A>		!		325MG/5ML;5MG/5ML	A211499	001	Dec 31, 2018	Sep CTEC
>D>	AA		SANKALP LIFECARE	325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021	Sep DISC
>A>		@		325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021	Sep DISC
	AA			325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021	Apr CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

		@	CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019	Feb DISC
		@		325MG;7.5MG	A207834	002	Aug 15, 2019	Feb DISC
		@		325MG;10MG	A207834	003	Aug 15, 2019	Feb DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

		@	MPP PHARMA	325MG;37.5MG	A078778	001	Apr 07, 2014	Jun CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	MPP PHARMA	500MG	A204691	001	Mar 29, 2016	May	CAHN

TABLET;ORAL

ACETAZOLAMIDE

AB	AUROBINDO PHARMA LTD	125MG	A212089	001	May 30, 2025	May	NEWA
AB		250MG	A212089	002	May 30, 2025	May	NEWA

DIAMOX

@ +	TEVA BRANDED PHARM	125MG	N008943	001		Feb	CAHN
@ +		250MG	N008943	002		Feb	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	GLAND	EQ 500MG BASE/VIAL	A219775	001	Jun 17, 2025	Jun	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

@	TARO	2%	A088638	001	Sep 06, 1984	Aug	DISC

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN	CONBA USA	10%	A214177	001	Mar 14, 2025	Mar	NEWA
AN		20%	A214177	002	Mar 14, 2025	Mar	NEWA
AN	SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan	NEWA
AN		20%	A219194	002	Feb 12, 2025	Jan	NEWA

ACETYLCYSTEINE LYSINE

FOR SOLUTION;ORAL

LEGUBETI

@ +	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jul	DISC
+!		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	CMFD
@ +		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jul	DISC
+!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	CMFD

ACITRETIN

CAPSULE;ORAL

ACITRETIN

@	MYLAN	17.5MG	A203707	001	Sep 10, 2015	Apr	CAHN
@		22.5MG	A203707	002	Sep 10, 2015	Apr	CAHN

ACOLTREMON

SOLUTION/DROPS;OPHTHALMIC

TRYPTYR

+!	ALCON LABS INC	0.003%	N217370	001	May 28, 2025	May	NEWA

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>D> AB	ADAPTIS	200MG	A075090	001	Jan 26, 1999	Sep	CAHN
>A> AB	REGCON HOLDINGS	200MG	A075090	001	Jan 26, 1999	Sep	CAHN

CREAM;TOPICAL

ACYCLOVIR

@	CIPLA	5%	A212981	001	May 02, 2025	May	DISC
AB		5%	A212981	001	May 02, 2025	Apr	NEWA
BX	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar	CTEC

OINTMENT;TOPICAL

ACYCLOVIR

@	APOTEX	5%	A210774	001	Sep 06, 2019	Jan	DISC
@	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb	CAHN
@	CIPLA	5%	A211794	001	Jan 18, 2019	May	DISC
BX		5%	A211794	001	Jan 18, 2019	Mar	CTEC

TABLET;BUCCAL

SITAVIG

@ +	LIGAND PHARMS	50MG	N203791	001	Apr 12, 2013	Jul	DISC
+!		50MG	N203791	001	Apr 12, 2013	Jun	CAHN

TABLET;ORAL
ACYCLOVIR

AB	AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998	Aug CMFD
AB		800MG	A075211	002	Sep 28, 1998	Aug CMFD

ACYCLOVIR SODIUM
INJECTABLE;INJECTION
ACYCLOVIR SODIUM

AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	May CMFD
@		EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Feb DISC

ALBUTEROL SULFATE
AEROSOL, METERED;INHALATION
ALBUTEROL SULFATE

AB2	PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CMFD

POWDER, METERED;INHALATION
PROAIR DIGIHALER

@ +	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb CAHN

PROAIR RESPICLICK

+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb CAHN

SOLUTION;INHALATION
ALBUTEROL SULFATE

AN	RITEDOSE CORP	EQ 0.5% BASE	A218386	001	Mar 12, 2025	Feb NEWA

SYRUP;ORAL
ALBUTEROL SULFATE

@	COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan DISC

TABLET;ORAL
ALBUTEROL SULFATE

AB	ACERTIS PHARMS	EQ 2MG BASE	A211397	001	Oct 26, 2018	May CAHN
AB		EQ 4MG BASE	A211397	002	Oct 26, 2018	May CAHN

ALCLOMETASONE DIPROPIONATE
CREAM;TOPICAL
ALCLOMETASONE DIPROPIONATE

@	GLENMARK PHARMS LTD	0.05%	A079061	001	Jun 23, 2009	Jul DISC

OINTMENT;TOPICAL
ALCLOMETASONE DIPROPIONATE

@	GLENMARK PHARMS LTD	0.05%	A079227	001	Jul 30, 2009	Jul DISC

ALCOHOL
SOLUTION;INTRA-ARTERIAL
ABLYSINOL

AP +!	BPI LABS	99% (5ML)	N207987	002	Jun 21, 2018	Jun CFTG

DEHYDRATED ALCOHOL

AP	ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jun NFTG
AP	BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jun NFTG
AP	INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jun NEWA
AP	XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jun NFTG

ALENDRONATE SODIUM
TABLET;ORAL
ALENDRONATE SODIUM

@	APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar DISC
@		EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar DISC
@		EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar DISC
@		EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar DISC

ALFENTANIL HYDROCHLORIDE
INJECTABLE;INJECTION
ALFENTA

+!	RISING	EQ 0.5MG BASE/ML	N019353	001	Dec 29, 1986	Aug CTEC

ALFENTANIL

@	HOSPIRA	EQ 0.5MG BASE/ML	A075221	001	Oct 28, 1999	Aug DISC

ALLOPURINOL
TABLET;ORAL
ALLOPURINOL

AB	AUROBINDO PHARMA LTD	100MG	A215091	001	Apr 14, 2025	Apr NEWA
AB		300MG	A215091	002	Apr 14, 2025	Apr NEWA
AB	INDOCO	200MG	A204467	003	May 22, 2025	May NEWA
@	NORTHSTAR HLTHCARE	100MG	A078253	001	Sep 11, 2007	Aug DISC

TABLET;ORAL
ALLOPURINOL

	@		300MG	A078253	002	Sep 11, 2007	Aug DISC
AB		ZYDUS PHARMS	200MG	A210117	003	Jun 13, 2025	Jun NEWA

ALOSETRON HYDROCHLORIDE
TABLET;ORAL
ALOSETRON HYDROCHLORIDE

AB		HIBROW HLTHCARE	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Aug CMFD
AB			EQ 1MG BASE	A211621	002	Sep 16, 2019	Aug CMFD

ALPRAZOLAM
TABLET;ORAL
ALPRAZOLAM

	@	APOTEX INC	0.25MG	A077741	001	Jan 19, 2007	Mar DISC
	@		0.5MG	A077741	002	Jan 19, 2007	Mar DISC
	@		1MG	A077741	003	Jan 19, 2007	Mar DISC
	@		2MG	A077741	004	Jan 19, 2007	Mar DISC
	@	SUN PHARM	0.25MG	A090082	001	Jun 17, 2010	Jul DISC
	@		0.5MG	A090082	002	Jun 17, 2010	Jul DISC
	@		1MG	A090082	003	Jun 17, 2010	Jul DISC
	@		2MG	A090082	004	Jun 17, 2010	Jul DISC

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

	@	APOTEX INC	0.5MG	A078449	001	Nov 12, 2008	Mar DISC
	@		1MG	A078449	004	Dec 23, 2015	Mar DISC
	@		2MG	A078449	002	Nov 12, 2008	Mar DISC
	@		3MG	A078449	003	Nov 12, 2008	Mar DISC

ALPROSTADIL
SUPPOSITORY;URETHRAL
MUSE

	@ +	VIATRIS	0.125MG	N020700	001	Nov 19, 1996	Feb CAHN
	@ +		0.25MG	N020700	002	Nov 19, 1996	Feb CAHN
	@ +		0.5MG	N020700	003	Nov 19, 1996	Feb CAHN
	@ +		1MG	N020700	004	Nov 19, 1996	Feb CAHN

AMANTADINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
AMANTADINE HYDROCHLORIDE

	@	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	May DISC

GOCOVRI

	+	SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	May CTEC

SYRUP;ORAL
AMANTADINE HYDROCHLORIDE

>A>	@	ADAPTIS	50MG/5ML	A075819	001	Sep 11, 2002	Sep CAHN
>A>	@	AEONIUM PHARMA PVT	50MG/5ML	A075819	001	Sep 11, 2002	Sep CAHN
>D>	@	BAJAJ	50MG/5ML	A075819	001	Sep 11, 2002	Sep CAHN
	@		50MG/5ML	A075819	001	Sep 11, 2002	Mar CAHN
AA		SHREE HARI INTL	50MG/5ML	A214178	001	Aug 20, 2021	Aug CAHN

AMCINONIDE
LOTION;TOPICAL
AMCINONIDE

	!	SOLUBIOMIX	0.1%	A076329	001	Nov 06, 2002	Feb CAHN

OINTMENT;TOPICAL
AMCINONIDE

	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Aug CTEC
	@	TARO PHARM INDS	0.1%	A076367	001	Mar 19, 2003	Aug DISC

AMINOCAPROIC ACID
INJECTABLE;INJECTION
AMINOCAPROIC ACID

AP		GEN ILAC	250MG/ML	A215374	001	Aug 28, 2025	Aug NEWA

SOLUTION;ORAL
AMINOCAPROIC ACID

AA		AJENAT PHARMS	0.25GM/ML	A213825	001	Apr 08, 2021	Jan CAHN
>D> AA		APOZEAL PHARMS	0.25GM/ML	A213216	001	May 19, 2025	Sep CAHN
AA			0.25GM/ML	A213216	001	May 19, 2025	May NEWA
>D> AA		FLORIDA	0.25GM/ML	A215510	001	Mar 23, 2022	Sep CAHN
>A> AA		REGCON HOLDINGS	0.25GM/ML	A215510	001	Mar 23, 2022	Sep CAHN
>A> AA		SCIEGEN PHARMS INC	0.25GM/ML	A213216	001	May 19, 2025	Sep CAHN

SOLUTION;ORAL
AMINOCAPROIC ACID

		@	TARO	0.25GM/ML	A214458	001	Mar 24, 2023	Aug DISC
	AA	!	TP ANDA HOLDINGS	0.25GM/ML	A212494	001	Aug 11, 2020	Aug CAHN

TABLET;ORAL
AMINOCAPROIC ACID

>D>	AB		APPCO	500MG	A213944	001	Sep 14, 2022	Sep CAHN
>D>	AB			1GM	A213944	002	Sep 14, 2022	Sep CAHN
>A>	AB		SOMERSET THERAPS LLC	500MG	A213944	001	Sep 14, 2022	Sep CAHN
>A>	AB			1GM	A213944	002	Sep 14, 2022	Sep CAHN

AMINOPHYLLINE
INJECTABLE;INJECTION
AMINOPHYLLINE

		+!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Jun CRLD

AMINOSALICYLIC ACID
GRANULE, DELAYED RELEASE;ORAL
PASER

>A>		!	ADAPTIS	4GM/PACKET	A074346	001	Jun 30, 1994	Sep CAHN
>D>		!	EUROCEPT PHARMS	4GM/PACKET	A074346	001	Jun 30, 1994	Sep CAHN

AMIODARONE HYDROCHLORIDE
TABLET;ORAL
AMIODARONE HYDROCHLORIDE

		@	TARO	300MG	A076362	002	Dec 02, 2003	Aug DISC
		@		400MG	A076362	001	Nov 29, 2002	Aug DISC

AMITRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

		@	BRECKENRIDGE	10MG	A216243	001	Jun 06, 2022	Aug DISC
		@		25MG	A216243	002	Jun 06, 2022	Aug DISC
		@		50MG	A216243	003	Jun 06, 2022	Aug DISC
		@		75MG	A216243	004	Jun 06, 2022	Aug DISC
		@		100MG	A216243	005	Jun 06, 2022	Aug DISC
		@		150MG	A216243	006	Jun 06, 2022	Aug DISC
	BX		RUBICON	10MG	A215376	001	May 01, 2023	Mar CTEC
	BX			25MG	A215376	002	May 01, 2023	Mar CTEC
	BX			50MG	A215376	003	May 01, 2023	Mar CTEC
	BX			75MG	A215376	004	May 01, 2023	Mar CTEC
	BX			100MG	A215376	005	May 01, 2023	Mar CTEC
	BX			150MG	A215376	006	May 01, 2023	Mar CTEC
	AB		UNIQUE PHARM	10MG	A218389	001	Jun 23, 2025	Jun NEWA
	AB			25MG	A218389	002	Jun 23, 2025	Jun NEWA
	AB			50MG	A218389	003	Jun 23, 2025	Jun NEWA
	AB			75MG	A218389	004	Jun 23, 2025	Jun NEWA
	AB			100MG	A218389	005	Jun 23, 2025	Jun NEWA
	AB			150MG	A218389	006	Jun 23, 2025	Jun NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE
TABLET;ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>D>		@	ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep CAHN
		@	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Apr DISC
		@		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Apr DISC
			MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Apr CTEC
		!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Apr CTEC
>A>		@	TP ANDA HOLDINGS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
TABLET;ORAL
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

		@	CHARTWELL RX	50MG;4MG	A071863	001	Dec 21, 1987	Jun CAHN

AMLODIPINE BESYLATE
FOR SOLUTION;ORAL
SDAMLO

		@ +	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Aug DISC
		+!		EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jul NEWA
		@ +		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Aug DISC
		+!		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jul NEWA

FOR SOLUTION;ORAL
SDAMLO

		@ +		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Aug DISC
		+!		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jul NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

	AB		ALEMBIC	EQ 2.5MG BASE;EQ 10MG BASE	A217279	001	May 22, 2025	May NEWA
	AB			EQ 2.5MG BASE;EQ 20MG BASE	A217279	002	May 22, 2025	May NEWA
	AB			EQ 2.5MG BASE;EQ 40MG BASE	A217279	003	May 22, 2025	May NEWA
	AB			EQ 5MG BASE;EQ 10MG BASE	A217279	004	May 22, 2025	May NEWA
	AB			EQ 5MG BASE;EQ 20MG BASE	A217279	005	May 22, 2025	May NEWA
	AB			EQ 5MG BASE;EQ 40MG BASE	A217279	006	May 22, 2025	May NEWA
	AB			EQ 5MG BASE;EQ 80MG BASE	A217279	007	May 22, 2025	May NEWA
	AB			EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025	May NEWA
	AB			EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025	May NEWA
	AB			EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025	May NEWA
	AB			EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025	May NEWA
>D>	AB		APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Sep CAHN
	AB			EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Sep CAHN
	AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Sep CAHN
	AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Sep CAHN
	AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Sep CAHN
	AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Sep CAHN
	AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Sep CAHN
	AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Sep CAHN
	AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Sep CAHN
	AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Sep CAHN
	AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CAHN
>D>	AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Sep CAHN
	AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CAHN
>A>	AB		NEOCUBES PHARMA	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Sep CAHN
>A>	AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Sep CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

		@	CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr CAHN
		@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr CAHN
		@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr CAHN
		@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr CAHN
		@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr CAHN
		@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr CAHN
		@	RISING	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Aug CAHN
		@		EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Aug CAHN
		@		EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Aug CAHN
		@		EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Aug CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>A>	AB		HETERO LABS LTD V	EQ 5MG BASE;12.5MG;20MG	A209242	001	Oct 06, 2025	Sep NEWA
>A>	AB			EQ 5MG BASE;12.5MG;40MG	A209242	002	Oct 06, 2025	Sep NEWA
>A>	AB			EQ 5MG BASE;25MG;40MG	A209242	003	Oct 06, 2025	Sep NEWA

TABLET;ORAL
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>A>	AB			EQ 10MG BASE;12.5MG;40MG	A209242	004	Oct 06, 2025	Sep	NEWA
>A>	AB			EQ 10MG BASE;25MG;40MG	A209242	005	Oct 06, 2025	Sep	NEWA
	AB		MACLEODS PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A207088	001	Jul 18, 2025	Jul	NEWA
	AB			EQ 5MG BASE;12.5MG;40MG	A207088	002	Jul 18, 2025	Jul	NEWA
	AB			EQ 5MG BASE;25MG;40MG	A207088	003	Jul 18, 2025	Jul	NEWA
	AB			EQ 10MG BASE;12.5MG;40MG	A207088	004	Jul 18, 2025	Jul	NEWA
	AB			EQ 10MG BASE;25MG;40MG	A207088	005	Jul 18, 2025	Jul	NEWA
	AB		PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025	May	NEWA
	AB			EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025	May	NEWA
	AB			EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025	May	NEWA
	AB			EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025	May	NEWA
	AB			EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025	May	NEWA
		@	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Jun	DISC
		@		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Jun	DISC
		@		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL
WIDAPLIK

>A>		@ +	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Sep	CAHN
>A>		@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Sep	CAHN
>A>		@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Sep	CAHN
>D>		@ +	GEORGE MEDICINES	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Sep	CAHN
		+		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	NEWA
		@ +		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	DISC
>D>		@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Sep	CAHN
		+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	NEWA
		@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	DISC
>D>		@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Sep	CAHN
		+!		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	NEWA
		@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMIL

	AB		HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb	NEWA
	AB			EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb	NEWA
	AB			EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb	NEWA
	AB			EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

	AP		SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar	CAHN

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
ADZENYS XR-ODT

	AB	+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jul	CTEC
	AB	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jul	CTEC
	AB	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jul	CTEC
	AB	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jul	CTEC
	AB	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jul	CTEC
	AB	+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jul	CTEC

AMPHETAMINE

	AB		ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jul	CMFD
	AB			EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jul	CMFD
	AB			EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jul	CMFD
	AB			EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jul	CMFD
	AB			EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jul	CMFD
	AB			EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jul	CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	AB		CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan	CMFD
	AB			2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan	CMFD
	AB			3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan	CMFD
	AB			5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan	CMFD
	AB			7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan	CMFD

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	AB		ORYZA	1.25MG;1.25MG;1.25MG;1.25MG	A	210293	001	Apr 03, 2020	Sep CAHN
>D>	AB			1.875MG;1.875MG;1.875MG;1.875MG	A	210293	002	Apr 03, 2020	Sep CAHN
>D>	AB			2.5MG;2.5MG;2.5MG;2.5MG	A	210293	003	Apr 03, 2020	Sep CAHN
>D>	AB			3.75MG;3.75MG;3.75MG;3.75MG	A	210293	004	Apr 03, 2020	Sep CAHN
>D>	AB			5MG;5MG;5MG;5MG	A	210293	005	Apr 03, 2020	Sep CAHN
>D>	AB			7.5MG;7.5MG;7.5MG;7.5MG	A	210293	006	Apr 03, 2020	Sep CAHN
>A>	AB		PHARMOBEDIENT	1.25MG;1.25MG;1.25MG;1.25MG	A	210293	001	Apr 03, 2020	Sep CAHN
>A>	AB			1.875MG;1.875MG;1.875MG;1.875MG	A	210293	002	Apr 03, 2020	Sep CAHN
>A>	AB			2.5MG;2.5MG;2.5MG;2.5MG	A	210293	003	Apr 03, 2020	Sep CAHN
>A>	AB			3.75MG;3.75MG;3.75MG;3.75MG	A	210293	004	Apr 03, 2020	Sep CAHN
>A>	AB			5MG;5MG;5MG;5MG	A	210293	005	Apr 03, 2020	Sep CAHN
>A>	AB			7.5MG;7.5MG;7.5MG;7.5MG	A	210293	006	Apr 03, 2020	Sep CAHN

AMPHETAMINE SULFATE

TABLET;ORAL
AMPHETAMINE SULFATE

		@	RHODES PHARMS	5MG	A	213852	001	Sep 07, 2021	Jan DISC
		@		10MG	A	213852	002	Sep 07, 2021	Jan DISC

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION
ABELCET

		@ +	LEADIANT BIOSCI INC	5MG/ML	N	050724	001	Nov 20, 1995	Aug DISC

INJECTABLE, LIPOSOMAL;INJECTION
AMPHOTERICIN B

	AB		AVET LIFESCIENCES	50MG/VIAL	A	215354	001	Jun 02, 2025	May NEWA
	AB		MYLAN LABS LTD	50MG/VIAL	A	212967	001	Jun 30, 2025	Jun NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION
AMPICILLIN AND SULBACTAM

		@	HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A	065074	001	Mar 19, 2002	Mar DISC
		@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A	065074	002	Mar 19, 2002	Mar DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL
ANAGRELIDE HYDROCHLORIDE

		@	BARR LABS	EQ 0.5MG BASE	A	076530	001	Apr 18, 2005	Mar CAHN
		@		EQ 1MG BASE	A	076530	002	Apr 18, 2005	Mar CAHN
	AB		CIPLA	EQ 0.5MG BASE	A	076468	001	Apr 18, 2005	Aug CAHN
	AB	!		EQ 1MG BASE	A	076468	002	Apr 18, 2005	Aug CAHN
>D>		@	NOVITIUM PHARMA	EQ 0.5MG BASE	A	076811	001	Apr 18, 2005	Sep CMFD
>A>	AB			EQ 0.5MG BASE	A	076811	001	Apr 18, 2005	Sep CMFD
>D>		@		EQ 1MG BASE	A	076811	002	Apr 18, 2005	Sep CMFD
>A>	AB			EQ 1MG BASE	A	076811	002	Apr 18, 2005	Sep CMFD

ANASTROZOLE

TABLET;ORAL
ANASTROZOLE

>D>		@	NORVIUM BIOSCIENCE	1MG	A	091051	001	Jun 28, 2010	Sep CAHN
>A>		@	PHARMOBEDIENT	1MG	A	091051	001	Jun 28, 2010	Sep CAHN

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS
ANGIOTENSIN ll ACETATE

	AP		GLAND	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	A	216966	001	Jun 03, 2025	May NFTG

GIAPREZA

	AP	+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N	209360	001	Dec 21, 2017	May CFTG

APALUTAMIDE

TABLET;ORAL
APALUTAMIDE

	AB		ZYDUS	60MG	A	217113	001	Mar 17, 2025	Mar NFTG

ERLEADA

	AB	+	JANSSEN BIOTECH	60MG	N	210951	001	Feb 14, 2018	Mar CFTG

APIXABAN

FOR SUSPENSION;ORAL

ELIQUIS SPRINKLE

	+!	BRISTOL	0.15MG	N220073	001	Apr 17, 2025	Apr	NEWA

TABLET;ORAL

APIXABAN

	@	HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023	Apr	DISC
	@		5MG	A210066	002	Nov 21, 2023	Apr	DISC
	@	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Jul	DISC
AB			2.5MG	A209810	001	Feb 14, 2025	Feb	NEWA
	@		5MG	A209810	002	Feb 14, 2025	Jul	DISC
AB			5MG	A209810	002	Feb 14, 2025	Feb	NEWA
	@	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Jun	DISC
AB			2.5MG	A210067	001	Feb 27, 2025	Feb	NEWA
	@		5MG	A210067	002	Feb 27, 2025	Jun	DISC
AB			5MG	A210067	002	Feb 27, 2025	Feb	NEWA
	@	TORRENT	2.5MG	A210156	001	Dec 17, 2024	Jun	DISC
	@		5MG	A210156	002	Dec 17, 2024	Jun	DISC

TABLET, FOR SUSPENSION;ORAL

ELIQUIS

	+!	BRISTOL MYERS SQUIBB	0.5MG	N202155	003	Apr 17, 2025	Apr	NEWA

APOMORPHINE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ONAPGO

	+!	MDD US	98MG/20ML (4.9MG/ML)	N214056	001	Feb 03, 2025	Feb	NEWA

APREMILAST

TABLET;ORAL

APREMILAST

	@	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023	Jun	DISC
	@		20MG	A211674	002	Oct 16, 2023	Jun	DISC
	@		30MG	A211674	003	Oct 16, 2023	Jun	DISC
	@	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024	Jun	DISC
	@		20MG	A211788	002	Nov 25, 2024	Jun	DISC
	@		30MG	A211788	003	Nov 25, 2024	Jun	DISC
	@	TORRENT	10MG	A211834	001	Jun 20, 2025	Jul	DISC
AB			10MG	A211834	001	Jun 20, 2025	Jun	NEWA
	@		20MG	A211834	002	Jun 20, 2025	Jul	DISC
AB			20MG	A211834	002	Jun 20, 2025	Jun	NEWA
	@		30MG	A211834	003	Jun 20, 2025	Jul	DISC
AB			30MG	A211834	003	Jun 20, 2025	Jun	NEWA

TABLET, EXTENDED RELEASE;ORAL

OTEZLA XR

	+!	AMGEN INC	75MG	N210745	001	Aug 29, 2025	Aug	NEWA

APREPITANT

CAPSULE;ORAL

EMEND

	@ +	MSD	40MG	N021549	003	Jun 30, 2006	Aug	CAHN
AB	+		80MG	N021549	001	Mar 26, 2003	Aug	CAHN
AB	+!		125MG	N021549	002	Mar 26, 2003	Aug	CAHN

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		AUCTA	EQ 0.015MG BASE/2ML	A218380	001	Feb 03, 2025	Jan	NEWA
>D> AN		BE PHARMS	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Sep	CAHN
>D> AN		CF PHARMTECH	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	Sep	CAHN
AN		MICRO LABS	EQ 0.015MG BASE/2ML	A218555	001	Mar 07, 2025	Feb	NEWA
>A> AN		NEOCUBES PHARMA	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	Sep	CAHN
AN		SABA ILAC SANAYI	EQ 0.015MG BASE/2ML	A218429	001	Apr 25, 2025	Apr	NEWA
>A> AN		SLATE RUN PHARMA	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Sep	CAHN

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

	@	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Jul	DISC

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP	+!	PLANO PHARMS	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Mar	CAHN

ARIPIPRAZOLE

FILM;ORAL

MEZOFY

	@ +	CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025	Aug DISC
	+		5MG	N211448	001	Apr 15, 2025	Apr NEWA
	@ +		10MG	N211448	002	Apr 15, 2025	Aug DISC
	+!		10MG	N211448	002	Apr 15, 2025	Apr NEWA
	@ +		15MG	N211448	003	Apr 15, 2025	Aug DISC
	+		15MG	N211448	003	Apr 15, 2025	Apr NEWA

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Jan CTEC
+!		400MG/VIAL	N202971	002	Feb 28, 2013	Jan CTEC
+!		400MG	N202971	004	Sep 29, 2014	Jul CHRS

ARIPIPRAZOLE

@	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan DISC
@		400MG/VIAL	A216608	002	Dec 03, 2024	Jan DISC

SOLUTION;ORAL

ARIPIPRAZOLE

AA	VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan CAHN

TABLET;ORAL

ARIPIPRAZOLE

@	RISING	2MG	A206240	001	Sep 19, 2018	Aug CAHN
@		5MG	A206240	002	Sep 19, 2018	Aug CAHN
@		10MG	A206240	003	Sep 19, 2018	Aug CAHN
@		15MG	A206240	004	Sep 19, 2018	Aug CAHN
@		20MG	A206240	005	Sep 19, 2018	Aug CAHN
@		30MG	A206240	006	Sep 19, 2018	Aug CAHN

ARMODAFINIL

TABLET;ORAL

NUVIGIL

AB	+	NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan CAHN
	@ +		100MG	N021875	002	Mar 26, 2009	Jan CAHN
AB	+		150MG	N021875	003	Jun 15, 2007	Jan CAHN
AB	+		200MG	N021875	005	Mar 26, 2009	Jan CAHN
AB	+!		250MG	N021875	004	Jun 15, 2007	Jan CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

>A> AP	MSN	1MG/ML	A217413	001	Apr 20, 2023	Sep CAHN
>A> AP		2MG/ML	A217413	002	Apr 20, 2023	Sep CAHN
AP	NOVAST LABS	1MG/ML	A209315	001	Nov 15, 2018	Aug CAHN
@		2MG/ML	A209315	002	Jan 14, 2021	Aug CAHN
>D> AP	ORBICULAR	1MG/ML	A217413	001	Apr 20, 2023	Sep CAHN
>D> AP		2MG/ML	A217413	002	Apr 20, 2023	Sep CAHN

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYKLX

+!	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Aug NEWA

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCOR

AP	+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Aug CFTG

ASCORBIC ACID

AP	FRESENIUS KABI USA	25,000MG/50ML (500MG/ML)	A217131	001	Aug 07, 2025	Aug NFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

@	TARO	4.7GM;100GM;1.015GM;5.9GM;2.69 1GM;7.5GM	A207498	001	Jun 28, 2024	Aug DISC

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	AA		MPP PHARMA	325MG;50MG;40MG	A078149	001	Jun 13, 2007	May CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

>A>		@	CHARTWELL	325MG;200MG	A040116	001	Apr 25, 1996	Sep CAHN
>D>		@	GENUS	325MG;200MG	A040116	001	Apr 25, 1996	Sep CAHN

ATENOLOL

TABLET;ORAL

ATENOLOL

	AB		AIPING PHARM INC	25MG	A072304	002	Jul 31, 1992	Jul CAHN
	AB			50MG	A072304	003	Jul 18, 1988	Jul CAHN
	AB			100MG	A072304	001	Jul 15, 1988	Jul CAHN
>D>	AB		HLTHCARE	25MG	A073026	002	May 01, 1992	Sep CAHN
>D>	AB			50MG	A073026	003	Sep 17, 1991	Sep CAHN
>D>	AB			100MG	A073026	001	Sep 17, 1991	Sep CAHN
		@	NOVITIUM PHARMA	100MG	A073543	001	Dec 19, 1991	Aug CAHN
>A>	AB		PHARMOBEDIENT	25MG	A073026	002	May 01, 1992	Sep CAHN
>A>	AB			50MG	A073026	003	Sep 17, 1991	Sep CAHN
>A>	AB			100MG	A073026	001	Sep 17, 1991	Sep CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

	AB		AIPING PHARM INC	50MG;25MG	A072302	002	May 31, 1990	Jul CAHN
	AB			100MG;25MG	A072302	001	May 31, 1990	Jul CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

	AB	!	HETERO LABS LTD V	EQ 60MG BASE	A202682	005	Mar 11, 2021	Aug CHRS

STRATTERA

		@ +	LILLY	EQ 10MG BASE	N021411	002	Nov 26, 2002	Aug DISC
		@ +		EQ 18MG BASE	N021411	003	Nov 26, 2002	Aug DISC
		@ +		EQ 25MG BASE	N021411	004	Nov 26, 2002	Aug DISC
		@ +		EQ 40MG BASE	N021411	005	Nov 26, 2002	Aug DISC
		@ +		EQ 60MG BASE	N021411	006	Nov 26, 2002	Aug DISC
		@ +		EQ 80MG BASE	N021411	007	Feb 14, 2005	Aug DISC
		@ +		EQ 100MG BASE	N021411	008	Feb 14, 2005	Aug DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

	AB		APOTEX	EQ 10MG BASE	A214969	001	Sep 02, 2021	Jun CAHN
	AB			EQ 20MG BASE	A214969	002	Sep 02, 2021	Jun CAHN
	AB			EQ 40MG BASE	A214969	003	Sep 02, 2021	Jun CAHN
	AB			EQ 80MG BASE	A214969	004	Sep 02, 2021	Jun CAHN
		@	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Mar DISC
		@		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr DISC
		@		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr DISC
		@		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr DISC

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LYPQOZET

			NORVIUM BIOSCIENCE	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Aug CAHN
				EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Aug CAHN
				EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Aug CAHN
		!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Aug CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

		@	APOTEX	750MG/5ML	A209750	001	Oct 11, 2017	Mar DISC
	AB		PAI HOLDINGS	750MG/5ML	A214272	001	Oct 25, 2021	Jun CAHN

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

		@	EUGIA PHARMA	10MG/ML	A206011	001	Apr 08, 2015	Jul DISC

ATRACURIUM BESYLATE PRESERVATIVE FREE

		@	EUGIA PHARMA	10MG/ML	A206010	001	Apr 08, 2015	Jul DISC

ATRASENTAN HYDROCHLORIDE

TABLET;ORAL

VANRAFIA

		+!	NOVARTIS	EQ 0.75MG BASE	N219208	001	Apr 02, 2025	Apr NEWA

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

>D>	AP	+!	ACCORD HLTHCARE	1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	Sep CHRS
>A>	AP	+		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	Sep CHRS
>D>	AP		AM REGENT	1MG/ML (1MG/ML)	A216120	002	May 26, 2022	Sep CHRS
>A>	AP	!		1MG/ML (1MG/ML)	A216120	002	May 26, 2022	Sep CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

		+!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Jul CRLD

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>		@	ANI PHARMS	0.025MG;2.5MG	A086727	001		Sep CMFD
>A>	AA			0.025MG;2.5MG	A086727	001		Sep CMFD

AVANAFIL

TABLET;ORAL

STENDRA

	AB	+	VIVUS LLC	50MG	N202276	001	Apr 27, 2012	Jul CAHN
	AB	+		100MG	N202276	002	Apr 27, 2012	Jul CAHN
	AB	+!		200MG	N202276	003	Apr 27, 2012	Jul CAHN

AVATROMBOPAG MALEATE

GRANULE;ORAL

DOPTELET SPRINKLE

		+!	AKARX INC	EQ 10MG BASE	N219696	001	Jul 24, 2025	Jul NEWA

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS

EMBLAVEO

		+!	ABBVIE	EQ 0.5GM BASE/VIAL;1.5GM/VIAL	N217906	001	Feb 07, 2025	Feb NEWA

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

CAPSULE, TABLET;ORAL

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

		+!	VERASTEM INC	EQ 0.8MG BASE;EQ 200MG BASE	N219616	001	May 08, 2025	May NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

	AP		RELIANCE LIFE	100MG/VIAL	A217453	001	May 20, 2025	May NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OPTIVAR

>D>		@ +	NORVIUM BIOSCIENCE	0.05%	N021127	001	May 22, 2000	Sep CAHN
>A>		@ +	RISING	0.05%	N021127	001	May 22, 2000	Sep CAHN

SPRAY, METERED;NASAL

ASTELIN

>D>		@ +	NORVIUM BIOSCIENCE	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Sep CAHN
>A>		@ +	RISING	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Sep CAHN

ASTEPRO

		@ +	NORVIUM BIOSCIENCE	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Jan CAHN
		@		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jan CAHN
		@ +	VIATRIS	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Apr CAHN
		@		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Apr CAHN

		SPRAY, METERED;NASAL						
		AZELASTINE HYDROCHLORIDE						
		@ BIONPHARMA	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Jan	DISC
		@ PADAGIS US	0.137MG/SPRAY	A202609	001	Mar 17, 2017	Aug	DISC
	AB		0.137MG/SPRAY	A202609	001	Mar 17, 2017	Jun	CAHN
		AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE						
		SPRAY, METERED;NASAL						
		AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE						
	AB	TEVA PHARMS USA INC	0.137MG/SPRAY;0.05MG/SPRAY	A208436	001	Apr 08, 2025	Mar	NEWA
		AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE						
		TABLET;ORAL						
		AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE						
	AB	ALKEM LABS LTD	EQ 40MG MEDOXOMIL;12.5MG	A217490	001	Jan 21, 2025	Jan	NFTG
	AB		EQ 40MG MEDOXOMIL;25MG	A217490	002	Jan 21, 2025	Jan	NFTG
		EDARBYCLOR						
	AB	+ AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan	CFTG
	AB	+!	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan	CFTG
		AZITHROMYCIN						
		FOR SUSPENSION;ORAL						
		AZITHROMYCIN						
>D>	AB	AMNEAL	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018	Sep	DISC
>A>		@	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018	Sep	DISC
>D>	AB		EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018	Sep	DISC
>A>		@	EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018	Sep	DISC
	AB	CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Feb	CMFD
	AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Feb	CMFD
	AB	ZHEJIANG POLY PHARM	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Mar	CAHN
	AB		EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Mar	CAHN
		ZITHROMAX						
		@ + PFIZER	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994	Apr	DISC
		INJECTABLE;INJECTION						
		AZITHROMYCIN						
		@ HOSPIRA	EQ 500MG BASE/VIAL	A065511	001	Jun 26, 2009	Apr	DISC
		BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
		OINTMENT;OPHTHALMIC						
		LUMI-SPORYN						
	AT	+ CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Feb	CPOT
		BACLOFEN						
		GRANULES;ORAL						
		LYVISPAH						
		@ + AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Jun	DISC
		@ +	10MG/PACKET	N215422	002	Nov 22, 2021	Jun	DISC
		@ +	20MG/PACKET	N215422	003	Nov 22, 2021	Jun	DISC
		SOLUTION;ORAL						
		BACLOFEN						
		RUBICON RESEARCH	5MG/5ML	A214445	001	Dec 06, 2024	May	CAHN
	AA		10MG/5ML	A214445	002	Jun 03, 2025	May	NFTG
		OZOBAX DS						
	AA	+! METACEL PHARMS LLC	10MG/5ML	N208193	002	Oct 12, 2023	May	CFTG
		TABLET;ORAL						
		BACLOFEN						
	AB	APPCO	5MG	A090334	003	Jan 31, 2025	Jan	NEWA
	AB	! RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jul	CAHN
	AB		10MG	A209102	002	Nov 28, 2017	Jul	CAHN
	AB		15MG	A209102	004	Feb 05, 2024	Jul	CAHN
	AB		20MG	A209102	003	Nov 28, 2017	Jul	CAHN
	AB	YILING	10MG	A074584	001	Aug 19, 1996	Jun	CAHN
	AB		20MG	A074584	002	Aug 19, 1996	Jun	CAHN
		BALOXAVIR MARBOXIL						
		FOR SUSPENSION;ORAL						
		XOFLUZA						
		+ GENENTECH INC	30MG/PACKET	N214410	002	May 30, 2025	Jun	NEWA
		+!	40MG/PACKET	N214410	003	May 30, 2025	Jun	NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Mar NEWA

TABLET;ORAL

BALSALAZIDE DISODIUM

	@	AARXION ANDA HLDING	1.1GM	A206336	001	Sep 08, 2015	Aug CAHN

BARICITINIB

TABLET;ORAL

OLUMIANT

AB	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug CTEC
AB	+		2MG	N207924	001	May 31, 2018	Aug CTEC
AB	+!		4MG	N207924	003	May 10, 2022	Aug CFTG
AB		MSN	1MG	A217585	001	Aug 08, 2025	Aug NEWA
AB			2MG	A217585	002	Aug 08, 2025	Aug NEWA
AB			4MG	A217585	003	Aug 08, 2025	Aug NFTG

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-CAT DRY

@	+	BRACCO	40%	N208036	003	Jan 03, 2017	Aug CPOT

E-Z-HD

	+!	BRACCO	98%	N208036	001	Jan 11, 2016	Aug CPOT

E-Z-PAQUE

	+!	BRACCO	96%	N208036	002	Apr 07, 2017	Aug CPOT

VARIBAR THIN LIQUID

	+!	BRACCO	81%	N208036	004	Apr 30, 2019	Aug CPOT

SUSPENSION;ORAL

ENTERO VU 24%

	+!	BRACCO	24%	N208143	008	May 29, 2020	Aug CPOT

LIQUID E-Z-PAQUE

	+!	BRACCO	60%	N208143	003	Mar 01, 2017	Aug CPOT

READI-CAT 2

	+!	BRACCO	2%	N208143	001	Jan 15, 2016	Aug CPOT

READI-CAT 2 SMOOTHIE

	+!	BRACCO	2%	N208143	002	Jan 15, 2016	Aug CPOT

TAGITOL V

	+!	BRACCO	40%	N208143	005	Aug 04, 2017	Aug CPOT

VARIBAR HONEY

	+!	BRACCO	40%	N208143	007	Mar 26, 2018	Aug CPOT

VARIBAR NECTAR

	+!	BRACCO	40%	N208143	004	Jul 07, 2017	Aug CPOT

VARIBAR THIN HONEY

	+!	BRACCO	40%	N208143	006	Jan 23, 2018	Aug CPOT

TABLET;ORAL

E-Z-DISK

	+!	BRACCO	700MG	N219840	001	Aug 01, 2025	Aug NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR 40

@	+	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Mar CAHN

QVAR 80

@	+	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Mar CAHN

AEROSOL, METERED;NASAL

QNASL

	+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb CAHN
	+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

@		APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May DISC
@			100MG/VIAL	A204230	002	Jun 05, 2023	May DISC

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

@	+	DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Jul DISC
	+!		100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Jul NEWA

BENZOYL PEROXIDE

CREAM;TOPICAL

EPSOLAY

	+!	MAYNE PHARMA	5%	N214510	001	Apr 22, 2022	May	CAHN

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL

TWYNEO

	+!	MAYNE PHARMA	3%;0.1%	N214902	001	Jul 26, 2021	May	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA		QUAGEN	0.5MG	A212694	001	Feb 11, 2025	Jan	NEWA
AA			1MG	A212694	002	Feb 11, 2025	Jan	NEWA
AA			2MG	A212694	003	Feb 11, 2025	Jan	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	@	CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb	CAHN
	@	GLENMARK PHARMS INC	EQ 0.05% BASE	A078930	001	Sep 23, 2008	Jul	DISC
AB	!	TARO	EQ 0.05% BASE	A076543	001	Dec 09, 2003	Jul	CHRS

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

	@	TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Jul	DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	@	TARO	EQ 0.05% BASE	A076753	001	Oct 12, 2004	Aug	DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

	@	PADAGIS ISRAEL	0.064%;0.005%	A212367	001	Sep 11, 2020	Jan	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

	@	GLENMARK SPECLT	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Aug	DISC

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB		KANCHAN HLTHCARE	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		CHARTWELL RX	EQ 0.5% BASE	A078694	001	Nov 16, 2009	Aug	CAHN
>A>	@	PHARMOBEDIENT	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Sep	CAHN
>D>	@	RENOVA PHARMS	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Sep	CAHN
	@		EQ 0.5% BASE	A075386	001	Jun 30, 2000	Jun	CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA		HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Jul	CMFD
AA			10MG	A091256	002	May 04, 2010	Jul	CMFD
AA			25MG	A091256	003	May 04, 2010	Jul	CMFD
AA			50MG	A091256	004	May 04, 2010	Jul	CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

	@	CIPLA	75MG	A210352	001	Dec 10, 2024	Jan	DISC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

	@	APOTEX	50MG	A200274	001	May 21, 2015	Mar	DISC

BIMATOPROST

GEL;OPHTHALMIC

ZOLYMBUS

>A>	+!	THEA PHARMA	0.01%	N217307	001	Sep 09, 2025	Sep	NEWA

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

>A> AB		AMNEAL	0.01%	A217289	001	Sep 22, 2025	Sep	NEWA
AB		MANKIND PHARMA	0.01%	A218196	001	Mar 17, 2025	Mar	NFTG

LUMIGAN

AB	+!	ABBVIE	0.01%	N022184	001	Aug 31, 2010	Mar	CFTG

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

		RUBICON	2.5MG	A075643	003	Mar 07, 2025	Mar	NEWA
AB		TP ANDA HOLDINGS	5MG	A075474	001	Oct 25, 2002	Aug	CAHN
AB			10MG	A075474	002	Oct 25, 2002	Aug	CAHN
AB		UNIQUE PHARM	5MG	A219044	001	Apr 16, 2025	Apr	NEWA
AB			10MG	A219044	002	Apr 16, 2025	Apr	NEWA

ZEBETA

	@ +	TEVA BRANDED PHARM	5MG	N019982	002	Jul 31, 1992	Apr	CAHN
	@ +		10MG	N019982	001	Jul 31, 1992	Apr	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ZIAC

AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Apr	CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Apr	CAHN
AB	+!		10MG;6.25MG	N020186	002	Mar 26, 1993	Apr	CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	@	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	May	DISC
AP		MEDICAMEN BIOTECH	3.5MG/VIAL	A218688	001	Jun 02, 2025	May	NEWA
AP		VILIN BIO MED	3.5MG/VIAL	A218688	001	Jun 02, 2025	Aug	CAHN

BOSENTAN

TABLET, FOR SUSPENSION;ORAL

BOSENTAN

AB		NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan	NFTG

TRACLEER

AB	+!	ACTELION	32MG	N209279	001	Sep 05, 2017	Jan	CFTG

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

AB	+!	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012	May	CFTG
AB	+		EQ 500MG BASE	N203341	002	Sep 04, 2012	May	CFTG

BOSUTINIB MONOHYDRATE

AB		ALEMBIC	EQ 100MG BASE	A209543	001	May 23, 2025	May	NFTG
AB			EQ 500MG BASE	A209543	002	May 23, 2025	May	NFTG

BRENSOCATIB

TABLET;ORAL

BRINSUPRI

	+	INSMED INC	10MG	N217673	001	Aug 12, 2025	Aug	NEWA
	+!		25MG	N217673	002	Aug 12, 2025	Aug	NEWA

BREXANOLONE

SOLUTION;INTRAVENOUS

ZULRESSO

	@ +	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan	DISC

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

	AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan NEWA
	AB			0.5MG	A213683	002	Jan 13, 2025	Jan NEWA
	AB			1MG	A213683	003	Jan 13, 2025	Jan NEWA
	AB			2MG	A213683	004	Jan 13, 2025	Jan NEWA
	AB			3MG	A213683	005	Jan 13, 2025	Jan NEWA
	AB			4MG	A213683	006	Jan 13, 2025	Jan NEWA
>D>		@	ANDA REPOSITORY	0.25MG	A213758	001	Oct 25, 2023	Sep CAHN
>D>		@		0.5MG	A213758	002	Oct 25, 2023	Sep CAHN
>D>		@		1MG	A213758	003	Oct 25, 2023	Sep CAHN
>D>		@		2MG	A213758	004	Oct 25, 2023	Sep CAHN
>D>		@		3MG	A213758	005	Oct 25, 2023	Sep CAHN
>D>		@		4MG	A213758	006	Oct 25, 2023	Sep CAHN
		@	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar DISC
	AB			0.25MG	A213731	001	Feb 24, 2025	Feb NEWA
		@		0.5MG	A213731	002	Feb 24, 2025	Mar DISC
	AB			0.5MG	A213731	002	Feb 24, 2025	Feb NEWA
		@		1MG	A213731	003	Feb 24, 2025	Mar DISC
	AB			1MG	A213731	003	Feb 24, 2025	Feb NEWA
		@		2MG	A213731	004	Feb 24, 2025	Mar DISC
	AB			2MG	A213731	004	Feb 24, 2025	Feb NEWA
		@		3MG	A213731	005	Feb 24, 2025	Mar DISC
	AB			3MG	A213731	005	Feb 24, 2025	Feb NEWA
>A>		@	CHARTWELL RX	0.25MG	A213758	001	Oct 25, 2023	Sep CAHN
>A>		@		0.5MG	A213758	002	Oct 25, 2023	Sep CAHN
>A>		@		1MG	A213758	003	Oct 25, 2023	Sep CAHN
>A>		@		2MG	A213758	004	Oct 25, 2023	Sep CAHN
>A>		@		3MG	A213758	005	Oct 25, 2023	Sep CAHN
>A>		@		4MG	A213758	006	Oct 25, 2023	Sep CAHN

REXULTI

	AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan CTEC
	AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan CTEC
	AB	+		1MG	N205422	003	Jul 10, 2015	Jan CTEC
	AB	+!		2MG	N205422	004	Jul 10, 2015	Jan CTEC
	AB	+		3MG	N205422	005	Jul 10, 2015	Jan CTEC
	AB	+		4MG	N205422	006	Jul 10, 2015	Jan CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

	AB		UPSHER SMITH LABS	0.1%	A217599	001	Jul 30, 2025	Jul NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

		@	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan DISC
	AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb NEWA
>D>	AB		FLORIDA	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep CAHN
>A>	AB		REGCON HOLDINGS	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

		@	PADAGIS US	1%	A211914	001	Jul 28, 2023	Jul DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

	AA	+	XTTRIUM LABS INC	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Feb CAHN

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	AA		BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May CMFD
>A>	AA		HIBROW HLTHCARE	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Sep CAHN
		@	TARO	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Aug DISC
>D>	AA		WES PHARMA INC	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Sep CAHN

BUDESONIDE

SUSPENSION;INHALATION

BUDESONIDE

AN		EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	Aug CMFD
	@	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb DISC
	@		0.5MG/2ML	A201966	002	Sep 27, 2013	Feb DISC
	@		1MG/2ML	A201966	001	Sep 27, 2013	Feb DISC

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb NEWA

>A> SPRAY;NASAL

>A> ENBUMYST

>A>	+!	CORSTASIS THERAP	0.5MG/SPRAY	N219500	001	Sep 12, 2025	Sep NEWA

TABLET;ORAL

BUMETANIDE

AB		JUBILANT GENERICS	0.5MG	A212470	001	Aug 05, 2025	Jul NEWA
AB			1MG	A212470	002	Aug 05, 2025	Jul NEWA
AB			2MG	A212470	003	Aug 05, 2025	Jul NEWA
AB		MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar NEWA
AB			1MG	A219291	002	Apr 03, 2025	Mar NEWA
AB			2MG	A219291	003	Apr 03, 2025	Mar NEWA

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

BUPIVACAINE LIPOSOME

	@	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Aug DISC
	@		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Aug DISC

EXPAREL

	+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Aug CTEC
	+!		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Aug CTEC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

>D> AB		ALVOGEN	5MCG/HR	A207490	001	May 17, 2022	Sep CAHN
>D>	@		7.5MCG/HR	A207490	005	Mar 21, 2023	Sep CAHN
>D> AB			10MCG/HR	A207490	002	May 17, 2022	Sep CAHN
>D> AB			15MCG/HR	A207490	003	May 17, 2022	Sep CAHN
>D> AB			20MCG/HR	A207490	004	May 17, 2022	Sep CAHN
>A> AB		STRIDES PHARMA INTL	5MCG/HR	A207490	001	May 17, 2022	Sep CAHN
>A>	@		7.5MCG/HR	A207490	005	Mar 21, 2023	Sep CAHN
>A> AB			10MCG/HR	A207490	002	May 17, 2022	Sep CAHN
>A> AB			15MCG/HR	A207490	003	May 17, 2022	Sep CAHN
>A> AB			20MCG/HR	A207490	004	May 17, 2022	Sep CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

	@	PHARMOBEDIENT	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun CAHN
	@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DIFGEN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>A> AB3		ANNORA PHARMA	150MG	A217898	001	Oct 01, 2025	Sep NEWA
>A> AB3			300MG	A217898	002	Oct 01, 2025	Sep NEWA
AB1		AUROBINDO PHARMA USA	100MG	A090325	001	Apr 08, 2010	Aug CMFD
AB1			150MG	A090325	002	Apr 08, 2010	Aug CMFD
AB1			200MG	A090325	003	Apr 08, 2010	Aug CMFD
AB1		IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

	AB1			150MG		A207874	002	May 02, 2025 Apr NEWA
	AB1			200MG		A207874	003	May 02, 2025 Apr NEWA
		@	SUN PHARM	150MG		A200216	001	Nov 30, 2020 Feb DISC
		@		300MG		A203650	001	Dec 31, 2020 Feb DISC
		@	TWI PHARMS	150MG		A210081	001	Nov 03, 2017 Aug DISC
		@		300MG		A210081	002	Nov 03, 2017 Aug DISC

FORFIVO XL

		@ +	TWI PHARMS	450MG		N022497	001	Nov 10, 2011 Jun DISC

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL
BUSPIRONE HYDROCHLORIDE

			EPIC PHARMA LLC	7.5MG		A218628	001	Mar 13, 2025 Feb NEWA
				10MG		A218628	002	Mar 13, 2025 Feb NEWA
				15MG		A218628	003	Mar 13, 2025 Feb NEWA
			PANGEA	7.5MG		A218628	001	Mar 13, 2025 Jul CAHN
				10MG		A218628	002	Mar 13, 2025 Jul CAHN
				15MG		A218628	003	Mar 13, 2025 Jul CAHN

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

	AB		ACCORD HLTHCARE	15MG		A202557	004	Dec 30, 2014 Apr CHRS
	AB		AIPING PHARM INC	7.5MG		A202087	005	Jul 03, 2025 Jun NEWA
	BX		EPIC PHARMA LLC	5MG		A208972	001	Apr 16, 2019 Mar CTEC
	BX			7.5MG		A208972	002	Apr 16, 2019 Mar CTEC
	BX			10MG		A208972	003	Apr 16, 2019 Mar CTEC
	BX			15MG		A208972	004	Apr 16, 2019 Mar CTEC
	BX			30MG		A208972	005	Apr 16, 2019 Mar CTEC
	BX		INVENTIA HLTHCARE	5MG		A209696	001	May 03, 2018 Mar CTEC
	BX			7.5MG		A209696	002	May 03, 2018 Mar CTEC
	BX			10MG		A209696	003	May 03, 2018 Mar CTEC
	BX			15MG		A209696	004	May 03, 2018 Mar CTEC
	BX			30MG		A209696	005	May 03, 2018 Mar CTEC
>A>	AB		RISING	7.5MG		A075413	004	Oct 06, 2025 Sep NEWA
>A>	AB			30MG		A075413	005	Oct 06, 2025 Sep NEWA
	AB	!	UNICHEM	15MG		A210907	003	Nov 14, 2019 Apr CHRS

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

		@	APOTEX	6MG/ML		A210448	001	May 07, 2019 Jan DISC

BUTABARBITAL SODIUM

TABLET;ORAL
BUTISOL SODIUM

>D>		@	NORVIUM BIOSCIENCE	15MG		N000793	002	Sep CAHN
>D>		@ +		30MG		N000793	004	Sep CAHN
>D>		@		50MG		N000793	003	Sep CAHN
>D>		@		100MG		N000793	005	Sep CAHN
>A>		@	PHARMOBEDIENT	15MG		N000793	002	Sep CAHN
>A>		@ +		30MG		N000793	004	Sep CAHN
>A>		@		50MG		N000793	003	Sep CAHN
>A>		@		100MG		N000793	005	Sep CAHN

BUTORPHANOL TARTRATE

SPRAY, METERED;NASAL
BUTORPHANOL TARTRATE

	AB	!	HIKMA	1MG/SPRAY		A075824	001	Mar 12, 2002 May CHRS
		@	RISING	1MG/SPRAY		A075759	001	Aug 08, 2001 May DISC

STADOL

		@ +	BRISTOL MYERS SQUIBB	1MG/SPRAY		N019890	001	Dec 12, 1991 May CRLD

CABERGOLINE

TABLET;ORAL
CABERGOLINE

>A>	AB		AMNEAL	0.5MG		A218618	001	Jun 26, 2024 Sep CAHN
>D>	AB		SKG PHARMA	0.5MG		A218618	001	Jun 26, 2024 Sep CAHN

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

		@	EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A	205013	001	Sep 22, 2015	Jul DISC

SOLUTION;ORAL

CAFFEINE CITRATE

		@	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A	090357	001	Sep 30, 2009	Feb DISC

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

>A>		!	ANDA REPOSITORY	100MG;1MG	A	040590	001	Sep 16, 2005	Sep CAHN
>D>		!	MIKART	100MG;1MG	A	040590	001	Sep 16, 2005	Sep CAHN

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

>A>	AP		AMNEAL	200 IU/ML	A	216294	001	Sep 26, 2025	Sep NEWA
	AP		SAGENT	200 IU/ML	A	219196	001	Jul 09, 2025	Jun NEWA

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

	AB		ONESOURCE SPECIALTY	0.25MCG	A	091356	001	Dec 12, 2014	Jun CAHN
	AB	!		0.5MCG	A	091356	002	Dec 12, 2014	Jun CAHN

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

	AB		MPP PHARMA	667MG	A	203179	001	Oct 26, 2015	May CAHN

PHOSLO

>D>		@	FRESENIUS MEDCL	333.5MG	N	021160	001	Apr 02, 2001	Sep CAHN
>D>		@		667MG	N	021160	002	Apr 02, 2001	Sep CAHN
>A>		@	FRESENIUS MEDCL CARE	333.5MG	N	021160	001	Apr 02, 2001	Sep CAHN
>A>		@		667MG	N	021160	002	Apr 02, 2001	Sep CAHN

PHOSLO GELCAPS

>D>		@ +	FRESENIUS MEDCL	667MG	N	021160	003	Apr 02, 2001	Sep CAHN
>A>		@ +	FRESENIUS MEDCL CARE	667MG	N	021160	003	Apr 02, 2001	Sep CAHN

SOLUTION;ORAL

PHOSLYRA

>D>		@ +	FRESENIUS MEDCL	667MG/5ML	N	022581	001	Apr 18, 2011	Sep CAHN
>A>		@ +	FRESENIUS MEDCL CARE	667MG/5ML	N	022581	001	Apr 18, 2011	Sep CAHN

TABLET;ORAL

PHOSLO

>D>		@ +	FRESENIUS MEDCL	667MG	N	019976	001	Dec 10, 1990	Sep CAHN
>A>		@ +	FRESENIUS MEDCL CARE	667MG	N	019976	001	Dec 10, 1990	Sep CAHN

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

>A>	AP		SQUARE PHARMS PLC	100MG/ML	A	217463	001	Sep 29, 2025	Sep NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

		@ +	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	010	Oct 10, 2008	Feb CAHN

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

		@	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	012	Oct 10, 2008	Feb CAHN

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

		+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	011	Oct 10, 2008	Feb CAHN

INJECTABLE;INJECTION

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Feb	CAHN

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb	CAHN

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb	CAHN

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb	CAHN

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb	CAHN

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb	CAHN

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb	CAHN

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb	CAHN

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb	CAHN

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb	CAHN

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb	CAHN

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb	CAHN

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Feb	CTEC

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Feb	CTEC

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Feb	CTEC

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2	N017512	001		Feb	CAHN

SOLUTION;INTRAPERITONEAL

		DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
			MG/100ML;567MG/100ML;392MG/100 ML						
		DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	003			Feb CAHN
		DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2 MG/100ML;567MG/100ML;392MG/100 ML	N	017512	002			Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020183	001	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020183	002	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
	@ +	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020183	003	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N	020183	004	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	012	Jan 10, 1989		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	013	Jul 11, 1990		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER							
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	014	Jul 11, 1990		Feb CTEC
AT	+		18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	014	Jul 11, 1990		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N	017512	015	Jul 11, 1990		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	007	Jul 09, 1984		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	008	Jul 09, 1984		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	010	Nov 18, 1985		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2 MG/100ML;567MG/100ML;392MG/100 ML	N	017512	009	Jul 09, 1984		Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	004			Feb CAHN
AT	+		25.7MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020163	001	Dec 04, 1992		Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	005			Feb CAHN
AT	+		25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020163	002	Dec 04, 1992		Feb CAHN

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	@ +	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N	017512	011	Nov 18, 1985	Feb	CAHN

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N	017512	006		Feb	CAHN
AT	+		25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N	020163	003	Dec 04, 1992	Feb	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314 GM/1000ML;2.21GM/1000ML;6.95GM /1000ML;0.187GM/1000ML (5000ML)	N	207026	002	Jan 13, 2015	Feb	CAHN

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0. 314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0 .187GM/1000ML (5000ML)	N	207026	001	Jan 13, 2015	Feb	CAHN

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE IN SODIUM CHLORIDE

	!	AMNEAL	1GM/50ML (20MG/ML)	A	217174	001	Sep 05, 2023	Aug	CTEC
AP	!		1GM/50ML (20MG/ML)	A	217174	001	Sep 05, 2023	Aug	CHRS
	!		2GM/100ML (20MG/ML)	A	217174	002	Sep 05, 2023	Aug	CTEC
AP	!		2GM/100ML (20MG/ML)	A	217174	002	Sep 05, 2023	Aug	CHRS
	@ +	FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N	208418	004	Jun 17, 2021	Aug	DISC
	@ +		2GM/100ML (20MG/ML)	N	208418	005	Jun 17, 2021	Aug	DISC

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB		ZYDUS LIFESCIENCES	4MG	A	091390	001	Aug 23, 2017	Jan	CMFD
AB			8MG	A	091390	002	Aug 23, 2017	Jan	CMFD
AB			16MG	A	091390	003	Aug 23, 2017	Jan	CMFD
AB			32MG	A	091390	004	Aug 23, 2017	Jan	CMFD

CANGRELOR

POWDER;INTRAVENOUS

CANGRELOR

AP		GLAND	50MG/VIAL	A	213551	001	Aug 11, 2025	Aug	NFTG

KENGREAL

AP	+!	CHIESI	50MG/VIAL	N	204958	001	Jun 22, 2015	Aug	CFTG

CAPECITABINE

TABLET;ORAL

CAPECITABINE

BX		TEYRO LABS	150MG	A	217237	001	Oct 23, 2023	Mar	CTEC
BX			500MG	A	217237	002	Oct 23, 2023	Mar	CTEC

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPREOMYCIN SULFATE

>D>	@	NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A	202634	001	Nov 27, 2017	Sep	CAHN
>A>	@	PHARMOBEDIENT	EQ 1GM BASE/VIAL	A	202634	001	Nov 27, 2017	Sep	CAHN

CAPTOPRIL

TABLET;ORAL

CAPOTEN

>A>	@ +	AARXION ANDA HLDING	12.5MG	N	018343	005	Jan 17, 1985	Sep	CAHN
>A>	@ +		25MG	N	018343	002		Sep	CAHN
>A>	@ +		37.5MG	N	018343	006	Sep 17, 1986	Sep	CAHN
>A>	@ +		50MG	N	018343	001		Sep	CAHN
>A>	@ +		75MG	N	018343	007	Jun 13, 1995	Sep	CAHN
>A>	@ +		100MG	N	018343	003		Sep	CAHN
>A>	@ +		150MG	N	018343	004	Jun 13, 1995	Sep	CAHN

TABLET;ORAL
CAPOTEN

>D>	@ +	STRIDES PHARMA	12.5MG	N018343	005	Jan 17, 1985	Sep	CAHN
>D>	@ +		25MG	N018343	002		Sep	CAHN
>D>	@ +		37.5MG	N018343	006	Sep 17, 1986	Sep	CAHN
>D>	@ +		50MG	N018343	001		Sep	CAHN
>D>	@ +		75MG	N018343	007	Jun 13, 1995	Sep	CAHN
>D>	@ +		100MG	N018343	003		Sep	CAHN
>D>	@ +		150MG	N018343	004	Jun 13, 1995	Sep	CAHN

CAPTOPRIL

AB		AIPING PHARM INC	12.5MG	A214442	001	Jan 27, 2023	Jul	CAHN
AB			25MG	A214442	002	Jan 27, 2023	Jul	CAHN
AB			50MG	A214442	003	Jan 27, 2023	Jul	CAHN
AB			100MG	A214442	004	Jan 27, 2023	Jul	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB		ANI PHARMS	100MG	A076697	001	May 20, 2011	May	CAHN
AB			200MG	A076697	002	May 20, 2011	May	CAHN
AB			300MG	A076697	003	May 20, 2011	May	CAHN
	@	TARO	100MG	A201106	001	Jun 21, 2013	Aug	DISC
	@		200MG	A201106	002	Jun 21, 2013	Aug	DISC
	@		300MG	A201106	003	Jun 21, 2013	Aug	DISC

TABLET;ORAL
CARBAMAZEPINE

AB		ALEMBIC	200MG	A216623	001	Apr 16, 2025	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB		ALEMBIC	100MG	A219939	001	Jul 25, 2025	Jul	NEWA
AB			200MG	A219939	002	Jul 25, 2025	Jul	NEWA
AB			400MG	A219939	003	Jul 25, 2025	Jul	NEWA
AB		ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025	Jan	NEWA
AB			200MG	A217277	002	Jan 14, 2025	Jan	NEWA
AB			400MG	A217277	003	Jan 14, 2025	Jan	NEWA
	@	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Apr	DISC
	@		200MG	A215664	002	Oct 22, 2024	Apr	DISC
	@		400MG	A215664	003	Oct 22, 2024	Apr	DISC
AB		SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Jun	CAHN
AB			200MG	A216235	002	Mar 02, 2023	Jun	CAHN
AB			400MG	A216235	003	Mar 02, 2023	Jun	CAHN
AB		TORRENT	100MG	A212524	001	Jan 13, 2025	Jan	NEWA
AB			200MG	A212524	002	Jan 13, 2025	Jan	NEWA
AB			400MG	A212524	003	Jan 13, 2025	Jan	NEWA
AB		YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan	NEWA
AB			200MG	A219072	002	Jan 16, 2025	Jan	NEWA
AB			400MG	A219072	003	Jan 16, 2025	Jan	NEWA

CARBIDOPA

TABLET;ORAL
CARBIDOPA

	@	ALVOGEN	25MG	A204291	001	Jan 08, 2016	Aug	DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL
CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A214495	001	Apr 15, 2025	Apr	NEWA
AB			18.75MG;200MG;75MG	A214495	002	Apr 15, 2025	Apr	NEWA
AB			25MG;200MG;100MG	A214495	003	Apr 15, 2025	Apr	NEWA
AB			31.25MG;200MG;125MG	A214495	004	Apr 15, 2025	Apr	NEWA
AB			37.5MG;200MG;150MG	A214495	005	Apr 15, 2025	Apr	NEWA
AB			50MG;200MG;200MG	A214495	006	Apr 15, 2025	Apr	NEWA
	@	SUN PHARM	25MG;200MG;100MG	A079085	001	May 10, 2012	Jul	DISC
	@		37.5MG;200MG;150MG	A079085	002	May 10, 2012	Jul	DISC

CARBIDOPA; LEVODOPA

TABLET;ORAL
CARBIDOPA AND LEVODOPA

	@	APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008	Mar	DISC
	@		25MG;100MG	A077120	002	Jun 02, 2008	Mar	DISC
	@		25MG;250MG	A077120	003	Jun 02, 2008	Mar	DISC
AB		ASCENT PHARMS INC	10MG;100MG	A218939	001	Jan 14, 2025	Jan	NEWA
AB			25MG;100MG	A218939	002	Jan 14, 2025	Jan	NEWA

TABLET;ORAL
CARBIDOPA AND LEVODOPA

AB			25MG;250MG	A218939	003	Jan 14, 2025	Jan NEWA
	@	NORVIUM BIOSCIENCE	10MG;100MG	A090324	001	Sep 28, 2009	Jul DISC
	@		25MG;250MG	A090324	003	Sep 28, 2009	Jun DISC

TABLET, EXTENDED RELEASE;ORAL
CARBIDOPA AND LEVODOPA

	@	APOTEX	25MG;100MG	A076212	001	Jun 16, 2004	Mar DISC
	@		50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC

CARBINOXAMINE MALEATE

TABLET;ORAL
CARBINOXAMINE MALEATE

	@	SENORES PHARMS	4MG	A090435	001	Apr 15, 2010	Jan CAHN

CARBOPLATIN

SOLUTION;INTRAVENOUS
KYXATA

>D>	+!	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N219921	001	Aug 08, 2025	Sep DISC
>A>	@ +		20MG/2ML (10MG/ML)	N219921	001	Aug 08, 2025	Sep DISC
	+!		20MG/2ML (10MG/ML)	N219921	001	Aug 08, 2025	Aug NEWA
	+!		80MG/8ML (10MG/ML)	N219921	002	Aug 08, 2025	Aug NEWA
	+!		500MG/50ML (10MG/ML)	N219921	003	Aug 08, 2025	Aug NEWA

CARFILZOMIB

POWDER;INTRAVENOUS
KYPROLIS

	+!	ONYX PHARMS AMGEN	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CHRS
	+!		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CHRS

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AA		FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Jan CAHN
AB		HERITAGE	250MG	A205126	001	Jul 08, 2015	Jun CAHN
AA			350MG	A205126	002	Jul 08, 2015	Jun CAHN
AB		INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun CAHN
AA			350MG	A205126	002	Jul 08, 2015	Jun CAHN
AB		MPP PHARMA	250MG	A207237	001	May 11, 2017	May CAHN
AA			350MG	A207237	002	Sep 21, 2020	May CAHN
AA		POINTVIEW HLDINGS	350MG	A211789	001	Oct 20, 2021	Apr CAHN

CARMUSTINE

INJECTABLE;INJECTION
CARMUSTINE

>D> AP		HENGRUI PHARMA	100MG/VIAL	A211202	001	Mar 12, 2021	Sep DISC
>A>	@		100MG/VIAL	A211202	001	Mar 12, 2021	Sep DISC
	@	NOVAST LABS	100MG/VIAL	A211011	001	Jun 21, 2022	Aug CAHN

CARVEDILOL

TABLET;ORAL
CARVEDILOL

AB		GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb CAHN
AB			6.25MG	A076649	002	Sep 05, 2007	Feb CAHN
AB			12.5MG	A076649	003	Sep 05, 2007	Feb CAHN
AB			25MG	A076649	004	Sep 05, 2007	Feb CAHN
	@	NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb CAHN
	@		6.25MG	A077316	002	Sep 05, 2007	Mar DISC
AB			6.25MG	A077316	002	Sep 05, 2007	Feb CAHN
	@		12.5MG	A077316	003	Sep 05, 2007	Apr DISC
AB			12.5MG	A077316	003	Sep 05, 2007	Feb CAHN
	@		25MG	A077316	004	Sep 05, 2007	Apr DISC
AB			25MG	A077316	004	Sep 05, 2007	Feb CAHN
	@	TARO	3.125MG	A077780	001	Sep 05, 2007	Aug DISC
	@		6.25MG	A077780	002	Sep 05, 2007	Aug DISC
	@		12.5MG	A077780	003	Sep 05, 2007	Aug DISC
	@		25MG	A077780	004	Sep 05, 2007	Aug DISC

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

COREG CR

AB	+	WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Jun	CMFD
AB	+		20MG	N022012	002	Oct 20, 2006	Jun	CMFD
AB	+		40MG	N022012	003	Oct 20, 2006	Jun	CMFD
AB	+		80MG	N022012	004	Oct 20, 2006	Jun	CMFD

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

AP		HANGZHOU ZHONGMEI	50MG/VIAL	A216506	001	Jul 18, 2025	Jul	NEWA
AP			70MG/VIAL	A216506	002	Jul 18, 2025	Jul	NEWA

CEDAZURIDINE; DECITABINE

TABLET;ORAL

INQOVI

	+!	TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

		QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan	CAHN
			EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan	CAHN
AP	!		EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

	!	QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	CAHN
AP	!		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	CAHN
AP	!		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	CAHN

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

AB		AJENAT PHARMS	100MG/5ML	A206938	001	Feb 06, 2017	Jul	CAHN
AB			200MG/5ML	A206938	002	Feb 06, 2017	Jul	CAHN
AB			500MG/5ML	A206939	001	Feb 06, 2017	Jul	CAHN

TABLET;ORAL

CEFIXIME

	@	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jul	DISC

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

VANTIN

	@ +	PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar	CAHN
	@ +		EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar	CAHN

TABLET;ORAL

VANTIN

	@ +	PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar	CAHN
	@ +		EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar	CAHN

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

	@	APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar	DISC
	@		250MG/5ML	A065351	002	Feb 29, 2012	Mar	DISC

TABLET;ORAL

CEFPROZIL

	@	APOTEX INC	250MG	A065327	001	Mar 26, 2008	Mar	DISC
	@		500MG	A065327	002	Mar 26, 2008	Mar	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

	@	BURKE THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jul	CAHN

	FOR SUSPENSION;ORAL						
	CEDAX						
@ +	BURKE THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jul	CAHN
@ +		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jul	CAHN
	CEFTOBIPROLE MEDOCARIL SODIUM						
	POWDER;INTRAVENOUS						
	ZEVTERA						
+!	ISTX	667MG/VIAL	N218275	001	Apr 03, 2024	Apr	CMFD
@ +		667MG/VIAL	N218275	001	Apr 03, 2024	Mar	CAHN
	CEFTRIAXONE SODIUM						
	INJECTABLE;INJECTION						
	CEFTRIAXONE						
AP	QILU ANTIBIOTICS	EQ 10GM BASE/VIAL	A209218	001	Oct 17, 2018	Jan	CAHN
	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS						
	CEFTRIAXONE						
AP	QILU ANTIBIOTICS	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jan	CAHN
	CEFUROXIME AXETIL						
	TABLET;ORAL						
	CEFUROXIME AXETIL						
@	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar	DISC
@		EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar	DISC
	CELECOXIB						
	CAPSULE;ORAL						
	CELECOXIB						
@	PANGEA	200MG	A212925	001	Dec 09, 2020	Feb	CAHN
@		400MG	A212925	002	Dec 09, 2020	Feb	CAHN
@	STRIDES PHARMA	100MG	A213127	001	Apr 29, 2025	Jul	DISC
AB		100MG	A213127	001	Apr 29, 2025	Apr	NEWA
@		200MG	A213127	002	Apr 29, 2025	Jul	DISC
AB		200MG	A213127	002	Apr 29, 2025	Apr	NEWA
@		400MG	A213127	003	Apr 29, 2025	Jul	DISC
AB		400MG	A213127	003	Apr 29, 2025	Apr	NEWA
AB	ZYDUS PHARMS	50MG	A205938	001	Jul 14, 2025	Jul	NEWA
AB		100MG	A205938	002	Jul 14, 2025	Jul	NEWA
AB		200MG	A205938	003	Jul 14, 2025	Jul	NEWA
AB		400MG	A205938	004	Jul 14, 2025	Jul	NEWA
	SUSPENSION;ORAL						
	VYSCOXA						
+!	CARWIN PHARM ASSOC	10MG/ML	N211759	001	Jul 29, 2025	Aug	CAHN
+!	CODADOSE INC	10MG/ML	N211759	001	Jul 29, 2025	Jul	NEWA
	CEPHALEXIN						
	CAPSULE;ORAL						
	CEPHALEXIN						
AB	AJENAT PHARMS	EQ 250MG BASE	A062713	001	Jul 15, 1988	Jul	CAHN
AB		EQ 500MG BASE	A062713	002	Jul 15, 1988	Jul	CAHN
	TABLET;ORAL						
	CEPHALEXIN						
	TEVA	EQ 250MG BASE	A063024	002	Jan 12, 1989	Aug	CMS1
	CETIRIZINE HYDROCHLORIDE						
	SOLUTION;ORAL						
	CETIRIZINE HYDROCHLORIDE						
AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	May	CMFD
	ZYRTEC						
@ +	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CRLD
	CETRORELIX ACETATE						
	POWDER;SUBCUTANEOUS						
	CETRORELIX ACETATE						
AP	XIROMED	EQ 0.25MG BASE/VIAL	A218061	001	Jun 03, 2025	May	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

	AB		RUBICON	30MG	A216682	001	Apr 06, 2023	Jun CTEC
	BX			30MG	A216682	001	Apr 06, 2023	Mar CTEC

CHENODIOL

TABLET;ORAL

CTEXLI

		+!	MIRUM	250MG	N219488	001	Feb 21, 2025	Feb NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

	AP		SUN PHARM	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Jun CMFD

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CHLOROTHIAZIDE-RESERPINE

>D>		@	NORVIUM BIOSCIENCE	500MG;0.125MG	A087745	001	May 06, 1982	Sep CAHN
>A>		@	PHARMOBEDIENT	500MG;0.125MG	A087745	001	May 06, 1982	Sep CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>		@	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Sep CAHN
		@		4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Apr CAHN
>A>		@	SCIEGEN PHARMS INC	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Sep CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

SONAZINE

>D>		@	ALLIED	30MG/ML	A080983	004		Sep CAHN
		@		30MG/ML	A080983	004		Jul CAHN
>D>		@		100MG/ML	A080983	005		Sep CAHN
		@		100MG/ML	A080983	005		Jul CAHN
>A>		@	SAPTALIS PHARMS	30MG/ML	A080983	004		Sep CAHN
>A>		@		100MG/ML	A080983	005		Sep CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	AB		AUROBINDO PHARMA LTD	10MG	A216788	001	Apr 25, 2025	Apr NEWA
	AB			25MG	A216788	002	Apr 25, 2025	Apr NEWA
	AB			50MG	A216788	003	Apr 25, 2025	Apr NEWA
	AB			100MG	A216788	004	Apr 25, 2025	Apr NEWA
	AB			200MG	A216788	005	Apr 25, 2025	Apr NEWA
>A>	AB		CHARTWELL RX	10MG	A212630	001	Nov 29, 2021	Sep CAHN
>A>	AB			25MG	A212630	002	Nov 29, 2021	Sep CAHN
>A>	AB			50MG	A212630	003	Nov 29, 2021	Sep CAHN
>A>	AB			100MG	A212630	004	Nov 29, 2021	Sep CAHN
>A>	AB			200MG	A212630	005	Nov 29, 2021	Sep CAHN
		@	SUN PHARM	10MG	A214256	001	Oct 26, 2020	Jul DISC
		@		25MG	A214256	002	Oct 26, 2020	Jul DISC
		@		50MG	A214256	003	Oct 26, 2020	Jul DISC
		@		100MG	A214256	004	Oct 26, 2020	Jul DISC
		@		200MG	A214256	005	Oct 26, 2020	Jul DISC
>D>	AB		ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Sep CAHN
	AB			10MG	A212630	001	Nov 29, 2021	Feb CAHN
>D>	AB			25MG	A212630	002	Nov 29, 2021	Sep CAHN
	AB			25MG	A212630	002	Nov 29, 2021	Feb CAHN
>D>	AB			50MG	A212630	003	Nov 29, 2021	Sep CAHN
	AB			50MG	A212630	003	Nov 29, 2021	Feb CAHN
>D>	AB			100MG	A212630	004	Nov 29, 2021	Sep CAHN
	AB			100MG	A212630	004	Nov 29, 2021	Feb CAHN
>D>	AB			200MG	A212630	005	Nov 29, 2021	Sep CAHN
	AB			200MG	A212630	005	Nov 29, 2021	Feb CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

>D>		@	NORVIUM BIOSCIENCE	100MG		A088549	002	Jun 01, 1984	Sep CAHN
>D>		@		250MG		A088549	001	Jun 01, 1984	Sep CAHN
>A>		@	PHARMOBEDIENT	100MG		A088549	002	Jun 01, 1984	Sep CAHN
>A>		@		250MG		A088549	001	Jun 01, 1984	Sep CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

		@	AIPING PHARM INC	25MG		A087380	001		Jan CAHN
		@		25MG		A087381	002		Aug CMS1
		@		50MG		A087381	001		Jan CAHN

HEMICLOR

		+!	PRM PHARMA	12.5MG		N218647	001	Mar 17, 2025	Mar NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

	AA		AJENAT PHARMS	250MG		A215540	001	Jan 24, 2023	Jan CAHN
>A>	AA	!	ANDA REPOSITORY	250MG		A207483	001	Jun 24, 2016	Sep CAHN
>A>	AB	!		375MG		A040861	001	Jun 01, 2010	Sep CAHN
>A>	AB	!		750MG		A040861	002	Jun 01, 2010	Sep CAHN
	AB		APPCO	375MG		A212047	001	Jan 27, 2023	Mar CAHN
	AB			750MG		A212047	002	Jan 27, 2023	Mar CAHN
		@	CHARTWELL RX	250MG		A087981	001	Sep 20, 1983	Apr CAHN
>D>	AA	!	MIKART	250MG		A207483	001	Jun 24, 2016	Sep CAHN
>D>	AB	!		375MG		A040861	001	Jun 01, 2010	Sep CAHN
>D>	AB	!		750MG		A040861	002	Jun 01, 2010	Sep CAHN

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

		@	AIPING PHARM INC	EQ 4GM RESIN/PACKET		A214877	001	Jan 21, 2022	Jul CAHN
		@		EQ 4GM RESIN/SCOOPFUL		A214877	002	Jan 21, 2022	Jul CAHN

CHOLESTYRAMINE LIGHT

		@	MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL		A209109	001	Oct 31, 2024	Jun DISC
		@		EQ 4GM RESIN/PACKET		A209109	002	Oct 31, 2024	Jun DISC
	AB		PHARMOBEDIENT CNSLTG	EQ 4GM RESIN/PACKET		A209599	001	Nov 12, 2020	Apr CAHN
	AB			EQ 4GM RESIN/SCOOPFUL		A209599	002	Nov 12, 2020	Apr CAHN

PREVALITE

	AB		AIPING PHARM INC	EQ 4GM RESIN/PACKET		A073263	001	Feb 22, 1996	Jul CAHN
	AB			EQ 4GM RESIN/SCOOPFUL		A073263	002	Oct 30, 1997	Jul CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

	AB	!	AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID		A212598	002	Jul 25, 2019	Apr CHRS

TRILIPIX

		@ +	ABBVIE	EQ 45MG FENOFIBRIC ACID		N022224	001	Dec 15, 2008	Jul DISC
		@ +		EQ 135MG FENOFIBRIC ACID		N022224	002	Dec 15, 2008	Apr DISC

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

	AT	!	PADAGIS US	1%		A078594	001	Feb 16, 2010	Mar CHRS

LOPROX

		@ +	BAUSCH	1%		N021159	001	Feb 28, 2003	Mar DISC

SOLUTION;TOPICAL

CICLOPIROX

		@	TARO PHARM INDS	8%		A078144	001	Sep 18, 2007	Aug DISC

SUSPENSION;TOPICAL

CICLOPIROX

		@	TARO	0.77%		A077092	001	Aug 10, 2005	Aug DISC

CIDOFOVIR

SOLUTION;INTRAVENOUS

CIDOFOVIR

AP			AVET LIFESCIENCES	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	May CDFR
AP				EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A202501	001	Jul 26, 2012	May CPOT
AP		!	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CDFR
AP		!		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A201276	001	Jun 27, 2012	May CPOT

VISTIDE

	@	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May CDFR
	@	+		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	N020638	001	Jun 26, 1996	May CPOT

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

	@		SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009	Apr CAHN
	@			100MG	A077708	002	Sep 28, 2009	Apr CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	@		HIKMA	200MG	A074890	001	Dec 18, 1998	Jun CAHN
	@			300MG	A074890	002	Dec 18, 1998	Jun CAHN
	@			400MG	A074890	003	Dec 18, 1998	Jun CAHN
	@			800MG	A074890	004	Dec 18, 1998	Jun CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB			PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan CAHN
AB				EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan CAHN
AB				EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan CAHN
	@		RISING	EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug CAHN
	@			EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug CAHN
	@			EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>A>	@		PHARMOBEDIENT	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Sep CAHN
>D>	@		RENOVA PHARMS	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Sep CAHN

SOLUTION/DROPS;OTIC

CETRAXAL

AB		+!	LAB SALVAT	EQ 0.2% BASE	N021918	001	May 01, 2009	Aug CAHN

CIPROFLOXACIN HYDROCHLORIDE

AB			NEW HEIGHTSRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Jul CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN AND DEXAMETHASONE

AB			AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Apr CTNA

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

	@		EUGIA PHARMA	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Jul DISC
AP			GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar CAHN
AP				EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar CAHN
AP				EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar CAHN
	@		HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb DISC
AP			HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb CMS1

CISATRACURIUM BESYLATE PRESERVATIVE FREE

	@		EUGIA PHARMA	EQ 2MG BASE/ML	A209665	001	Oct 27, 2020	Jul DISC
	@		HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb DISC
	@			EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

	@	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar DISC
	@		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar DISC
	@		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar DISC
	@	GLENMARK PHARMS LTD	EQ 10MG BASE	A077654	001	Feb 27, 2009	Aug DISC
	@		EQ 20MG BASE	A077654	002	Feb 27, 2009	Aug DISC
	@		EQ 40MG BASE	A077654	003	Feb 27, 2009	Aug DISC

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

	@	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr CAHN
	@		500MG	A206714	002	Apr 25, 2019	Apr CAHN
AB		NOVITIUM PHARMA	250MG	A202710	001	Jun 10, 2013	Aug CAHN
AB			500MG	A202710	002	Jun 10, 2013	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		MPP PHARMA	500MG	A203243	001	Feb 29, 2016	May CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

	@	ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb DISC
	@		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb DISC
	@	FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007	Jun DISC
	@		EQ 150MG BASE/ML	A065347	001	May 09, 2007	Jun DISC

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		CARNEGIE	EQ 1% BASE	A219612	001	Jun 13, 2025	Jun NEWA

CLOBAZAM

FILM;ORAL

SYMPAZAN

	+	ASSERTIO SPECLTY	5MG	N210833	001	Nov 01, 2018	Aug CAHN
	+		10MG	N210833	002	Nov 01, 2018	Aug CAHN
	+!		20MG	N210833	003	Nov 01, 2018	Aug CAHN

SUSPENSION;ORAL

CLOBAZAM

	@	VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan CAHN

TABLET;ORAL

CLOBAZAM

>D>	@	ANDA REPOSITORY	10MG	A211959	001	Dec 09, 2020	Sep CAHN
>D>	@		20MG	A211959	002	Dec 09, 2020	Sep CAHN
>A>	@	CHARTWELL RX	10MG	A211959	001	Dec 09, 2020	Sep CAHN
>A>	@		20MG	A211959	002	Dec 09, 2020	Sep CAHN
	@	ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb CAHN
	@		10MG	A209308	001	Oct 22, 2018	Jul DISC
AB			10MG	A209308	001	Oct 22, 2018	Feb CAHN
	@		20MG	A209308	002	Oct 22, 2018	Feb CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

>D>	@	NOVAST LABS	0.05%	A206805	001	Jul 31, 2017	Sep CAHN
>A>	@		0.05%	A206805	001	Jul 31, 2017	Sep CAHN
	@	TARO	0.05%	A208563	001	Mar 14, 2024	Aug DISC

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	@	GLENMARK SPECLT	0.05%	A209095	001	May 10, 2018	Jul DISC

LOTION;TOPICAL

CLOBETASOL PROPIONATE

	@	BEACH PRODS	0.05%	A208667	001	Nov 29, 2016	May CAHN

IMPEKLO

	@ +	NORVIUM BIOSCIENCE	0.05%	N213691	001	May 19, 2020	Jan CAHN

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

	@	GLENMARK SPECLT	0.05%	A208933	001	Mar 20, 2017	Jul DISC

		SOLUTION;TOPICAL							
		CLOBETASOL PROPIONATE							
		@	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Jul	DISC
		@	TARO	0.05%	A075363	001	Dec 29, 2000	Aug	DISC
		SPRAY;TOPICAL							
		CLOBETASOL PROPIONATE							
		@	GLENMARK SPECLT	0.05%	A209004	001	Mar 26, 2018	Jul	DISC
		@	MACLEODS PHARMS LTD	0.05%	A214345	001	Dec 02, 2024	Jun	DISC
		SUSPENSION/DROPS;OPHTHALMIC							
		BYQLOVI							
>D>		+!	FORMOSA	0.05%	N218158	001	Mar 04, 2024	Sep	CAHN
		+!		0.05%	N218158	001	Mar 04, 2024	May	CTNA
		+!		0.05%	N218158	001	Mar 04, 2024	Feb	CAHN
>A>		+!	HARROW EYE	0.05%	N218158	001	Mar 04, 2024	Sep	CAHN
	CLOFARABINE								
		SOLUTION;INTRAVENOUS							
		CLOFARABINE							
	AP	!	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jul	CHRS
		CLOLAR							
		@ +	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Jul	DISC
	CLOMIPHENE CITRATE								
		TABLET;ORAL							
		CLOMIPHENE CITRATE							
>A>	AB		ACCORD HLTHCARE	50MG	A219406	001	Oct 03, 2025	Sep	NEWA
		MILOPHENE							
	AB		GRANATA BIO CORP	50MG	A072196	001	Dec 20, 1988	Aug	CMFD
		@		50MG	A072196	001	Dec 20, 1988	Aug	CAHN
	CLOMIPRAMINE HYDROCHLORIDE								
		CAPSULE;ORAL							
		CLOMIPRAMINE HYDROCHLORIDE							
>A>	AB		IXORA LIFESCIENCE	25MG	A211364	001	Feb 07, 2020	Sep	CAHN
>A>	AB			50MG	A211364	002	Feb 07, 2020	Sep	CAHN
>A>	AB			75MG	A211364	003	Feb 07, 2020	Sep	CAHN
>D>	AB		LEADING	25MG	A211364	001	Feb 07, 2020	Sep	CAHN
	AB			25MG	A211364	001	Feb 07, 2020	Jun	CAHN
>D>	AB			50MG	A211364	002	Feb 07, 2020	Sep	CAHN
	AB			50MG	A211364	002	Feb 07, 2020	Jun	CAHN
>D>	AB			75MG	A211364	003	Feb 07, 2020	Sep	CAHN
	AB			75MG	A211364	003	Feb 07, 2020	Jun	CAHN
	CLONAZEPAM								
		TABLET, ORALLY DISINTEGRATING;ORAL							
		CLONAZEPAM							
		@	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Jan	DISC
		@		0.25MG	A078654	002	Aug 27, 2014	Jan	DISC
		@		0.5MG	A078654	003	Aug 27, 2014	Jan	DISC
		@		1MG	A078654	004	Aug 27, 2014	Jan	DISC
		@		2MG	A078654	005	Aug 27, 2014	Jan	DISC
	CLONIDINE								
		SYSTEM;TRANSDERMAL							
		CLONIDINE							
>D>	AB		DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN
>D>	AB			0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN
>D>	AB			0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN
>A>	AB		INGENUS PHARMS LLC	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN
>A>	AB			0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN
>A>	AB			0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN
	CLONIDINE HYDROCHLORIDE								
		TABLET, EXTENDED RELEASE;ORAL							
		CLONIDINE HYDROCHLORIDE							
		@	RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018	Apr	CAHN
	AB1		SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	Mar	CMFD

CLOTRIMAZOLE

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT		TP ANDA HOLDINGS	1%	A212281	001	Jul 25, 2019	Aug	CAHN

>A> SOLUTION/DROPS;OTIC

>A> CLOTIC

>A>	+!	LAB SALVAT	1%	N217628	001	Sep 26, 2025	Sep	NEWA

CLOZAPINE

TABLET;ORAL

CLOZAPINE

@		SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Apr	DISC
@			50MG	A075713	003	Aug 19, 2005	Apr	DISC
@			100MG	A075713	002	Nov 15, 2002	Apr	DISC
@			200MG	A075713	004	Nov 07, 2017	Apr	DISC

COBICISTAT

TABLET;ORAL

TYBOST

+		GILEAD SCIENCES INC	90MG	N203094	002	Jun 20, 2025	Jul	NEWA

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+		JANSSEN PRODS	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar	NEWA
+!			150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Mar	CPOT
+!			150MG;800MG	N205395	001	Jan 29, 2015	Mar	CAIN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>A> AA	!	CHARTWELL	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Sep	CAHN
>D> AA	!	GENUS	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Sep	CAHN

PROMETH VC W/ CODEINE

@		CHARTWELL RX	10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984	Apr	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		CHARTWELL RX	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Apr	CAHN
AA	!	COSETTE	10MG/5ML;6.25MG/5ML	A200386	001	Jun 29, 2012	May	CAHN
AA		XTTRIUM LABS INC	10MG/5ML;6.25MG/5ML	A088875	001	Dec 17, 1984	Feb	CAHN

PROMETHAZINE WITH CODEINE

@		PHARM ASSOC	10MG/5ML;6.25MG/5ML	A040650	001	Jan 31, 2006	Jan	DISC

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@		HIKMA	30MG/5ML	N202245	001	Jun 30, 2011	Jun	CAHN

TABLET;ORAL

CODEINE SULFATE

AB	+	HIKMA	15MG	N022402	001	Jul 16, 2009	Jun	CAHN
AB	+		30MG	N022402	002	Jul 16, 2009	Jun	CAHN
AB	+!		60MG	N022402	003	Jul 16, 2009	Jun	CAHN

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@		MACLEODS PHARMS LTD	625MG	A204893	001	Apr 18, 2025	Jul	DISC
AB			625MG	A204893	001	Apr 18, 2025	Apr	NEWA

COLESTIPOL HYDROCHLORIDE

TABLET;ORAL

COLESTIPOL HYDROCHLORIDE

>A> AB		CARNEGIE	1GM	A220012	001	Sep 15, 2025	Sep	NEWA

COLISTIMETHATE SODIUM

		INJECTABLE;INJECTION						
		COLISTIMETHATE SODIUM						
>D>		@ ADRASTEA PHARMA	EQ 150MG BASE/VIAL	A	064216	001	Feb 26, 1999	Sep CAHN
		@	EQ 150MG BASE/VIAL	A	064216	001	Feb 26, 1999	Jul DISC
		@ NEXUS	EQ 150MG BASE/VIAL	A	065177	001	Mar 19, 2004	Apr DISC
>A>		@ PHARMOBEDIENT	EQ 150MG BASE/VIAL	A	064216	001	Feb 26, 1999	Sep CAHN

COPPER

		SYSTEM;INTRAUTERINE						
		MIUDELLA						
		+! SEBELA WOMENS HLTH	N/A	N	218201	001	Feb 24, 2025	Feb NEWA

COPPER CU-64 DOTATATE

		SOLUTION;INTRAVENOUS						
		DETECTNET						
		+! CURIUM	4mL (1mCi/ML)	N	213227	001	Sep 03, 2020	Jan CAHN

CROMOLYN SODIUM

		CONCENTRATE;ORAL						
		GASTROCROM						
	AA	+! VIATRIS SPECIALTY	100MG/5ML	N	020479	001	Feb 29, 1996	Feb CAHN
		SOLUTION;INHALATION						
		CROMOLYN SODIUM						
	AN	FERA PHARMS LLC	10MG/ML	A	075437	001	Apr 21, 2000	Apr CAHN
		@ HIKMA	10MG/ML	A	075333	001	Apr 30, 2002	Jun CAHN

CUPRIC SULFATE

		INJECTABLE;INJECTION						
		CUPRIC SULFATE						
		! AM REGENT	EQ 0.4MG COPPER/ML	A	216324	001	Dec 16, 2022	Jan CTEC
		@ APOTEX CORP	EQ 0.4MG COPPER/ML	A	218745	001	Aug 19, 2024	Jan DISC

CYANOCOBALAMIN

		INJECTABLE;INJECTION						
		CYANOCOBALAMIN						
	AP	MEITHEAL	1MG/ML	A	214316	001	Nov 15, 2024	Apr CAHN
		DODEX						
		@ ACCORD HLTHCARE	1MG/ML	A	083022	001		Jan DISC
		SPRAY, METERED;NASAL						
		CALOMIST						
		@ PH HEALTH	25MCG/SPRAY	N	022102	001	Jul 27, 2007	Jul CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

		TABLET;SUBLINGUAL						
		TONMYA						
		+! TONIX	2.8MG	N	219428	001	Aug 15, 2025	Aug NEWA

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

		SOLUTION/DROPS;OPHTHALMIC						
		CYCLOMYDRIL						
		+! ALCON LABS INC	0.2%;1%	A	084300	001		May CRLD

CYCLOPHOSPHAMIDE

		CAPSULE;ORAL						
		CYCLOPHOSPHAMIDE						
	AB	EIRGEN	25MG	A	218282	001	Dec 03, 2024	Aug CAHN
	AB		50MG	A	218282	002	Dec 03, 2024	Aug CAHN
>D>	AB	KANCHAN HLTHCARE	25MG	A	209872	001	May 07, 2018	Sep CAHN
>D>	AB		50MG	A	209872	002	May 07, 2018	Sep CAHN
>A>	AB	SENORES PHARMS	25MG	A	209872	001	May 07, 2018	Sep CAHN
>A>	AB		50MG	A	209872	002	May 07, 2018	Sep CAHN
	AB	TRI-SOURCE PHARMA	25MG	A	218282	001	Dec 03, 2024	Apr CAHN
	AB		50MG	A	218282	002	Dec 03, 2024	Apr CAHN
		SOLUTION;INTRAVENOUS						
>D>		CYCLOPHOSPHAMIDE						
>D>		+! AVYXA HOLDINGS	500MG/ML (500MG/ML)	N	210852	001	Jun 07, 2023	Sep CTNA
>D>		+!	1GM/2ML (500MG/ML)	N	210852	002	Jun 07, 2023	Sep CTNA
>D>		+!	2GM/4ML (500MG/ML)	N	210852	003	Jun 07, 2023	Sep CTNA

		SOLUTION;INTRAVENOUS							
>A>		FRINDOVYX							
>A>		+!	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Sep	CTNA
>A>		+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Sep	CTNA
>A>		+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Sep	CTNA
		CYCLOSPORINE							
		CAPSULE;ORAL							
		CYCLOSPORINE							
>A>	AB1		QILU	25MG	A219049	001	Sep 15, 2025	Sep	NEWA
>A>	AB1			100MG	A219049	002	Sep 15, 2025	Sep	NEWA
		EMULSION;OPHTHALMIC							
		CYCLOSPORINE							
		@	APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr	DISC
	BX			0.05%	A207606	001	Jan 12, 2023	Mar	CTEC
		SOLUTION;ORAL							
		CYCLOSPORINE							
		@	ABBVIE	100MG/ML	A065025	001	Mar 03, 2000	Feb	DISC
		CYPROHEPTADINE HYDROCHLORIDE							
		SYRUP;ORAL							
		CYPROHEPTADINE HYDROCHLORIDE							
>D>	AA		ELYSIUM	2MG/5ML	A209108	001	Oct 16, 2018	Sep	CAHN
>A>	AA		INVATECH	2MG/5ML	A209108	001	Oct 16, 2018	Sep	CAHN
		CYTARABINE; DAUNORUBICIN							
		POWDER;INTRAVENOUS							
		VYXEOS							
		+!	JAZZ PHARMS THERAP	100MG;44MG	N209401	001	Aug 03, 2017	Jul	CAHN
		DABIGATRAN ETEXILATE MESYLATE							
		CAPSULE;ORAL							
		DABIGATRAN ETEXILATE MESYLATE							
	AB		AUROBINDO PHARMA	EQ 75MG BASE	A208039	001	May 14, 2025	May	NEWA
	AB			EQ 110MG BASE	A208039	002	May 14, 2025	May	NEWA
	AB			EQ 150MG BASE	A208039	003	May 14, 2025	May	NEWA
		@	BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024	Jun	DISC
		@		EQ 110MG BASE	A207922	003	Dec 19, 2024	Jun	DISC
		@		EQ 150MG BASE	A207922	002	Dec 19, 2024	Jun	DISC
	AB		DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan	NEWA
	AB			EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan	NEWA
	AB			EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan	NEWA
	AB		MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan	NEWA
	AB			EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan	NEWA
		DACARBAZINE							
		INJECTABLE;INJECTION							
		DACARBAZINE							
		@	HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001	Mar	DISC
		DALFAMPRIDINE							
		TABLET, EXTENDED RELEASE;ORAL							
		AMPYRA							
	AB	+!	MERZ	10MG	N022250	001	Jan 22, 2010	Feb	CAHN
		DALFAMPRIDINE							
		@	SUN PHARM	10MG	A208292	001	May 21, 2019	Aug	DISC
		DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE							
		TABLET;ORAL							
		QTERN							
		@ +	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	Jun	DISC
		@ +		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017	Jun	DISC
		DAPSONE							
		GEL;TOPICAL							
		DAPSONE							
	AB		AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar	NEWA
		TABLET;ORAL							
		DAPSONE							
	AB		SOLIS PHARMS	25MG	A203887	001	May 06, 2016	Apr	CAHN
	AB			100MG	A203887	002	May 06, 2016	Apr	CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

	@		FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan DISC
	@		HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021	Jun DISC
	@	+	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024	May DISC
		+!		500MG/VIAL	N217630	002	Nov 21, 2024	Jun CHRS
		+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun CMFD
	@	+		500MG/VIAL	N217630	002	Nov 21, 2024	May DISC

DARUNAVIR

TABLET;ORAL

DARUNAVIR

AB			ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan NEWA
AB				800MG	A216168	002	Jan 21, 2025	Jan NEWA
AB			HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023	Jul CTEC
AB			MYLAN	75MG	A202136	001	Jul 22, 2025	Jul NFTG
AB				150MG	A202136	002	Jul 22, 2025	Jul NFTG
				300MG	A202136	003	Jul 22, 2025	Jul NFTG
AB				400MG	A202136	004	Jul 22, 2025	Jul NEWA
AB				600MG	A202136	005	Jul 22, 2025	Jul NEWA
	@		TEVA PHARMS USA	600MG	A202118	001	Nov 21, 2017	Jul DISC

PREZISTA

AB		+	JANSSEN PRODS	75MG	N021976	004	Dec 18, 2008	Jul CFTG
AB		+		150MG	N021976	005	Dec 18, 2008	Jul CFTG

DASATINIB

TABLET;ORAL

DASATINIB

AB			BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb NEWA
AB				50MG	A217217	002	Mar 03, 2025	Feb NEWA
AB				70MG	A217217	003	Mar 03, 2025	Feb NEWA
AB				80MG	A217217	004	Mar 03, 2025	Feb NEWA
AB				100MG	A217217	005	Mar 03, 2025	Feb NEWA
AB				140MG	A217217	006	Mar 03, 2025	Feb NEWA
AB			DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb NEWA
AB				50MG	A213383	002	Mar 03, 2025	Feb NEWA
AB				70MG	A213383	003	Mar 03, 2025	Feb NEWA
AB				80MG	A213383	004	Mar 03, 2025	Feb NEWA
AB				100MG	A213383	005	Mar 03, 2025	Feb NEWA
AB				140MG	A213383	006	Mar 03, 2025	Feb NEWA
AB			EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr NEWA
AB				50MG	A216547	002	Apr 22, 2025	Apr NEWA
AB				70MG	A216547	003	Apr 22, 2025	Apr NEWA
AB				80MG	A216547	004	Apr 22, 2025	Apr NEWA
AB				100MG	A216547	005	Apr 22, 2025	Apr NEWA
AB				140MG	A216547	006	Apr 22, 2025	Apr NEWA
AB			LUPIN	20MG	A214350	001	Aug 25, 2025	Aug NEWA
AB				50MG	A214350	002	Aug 25, 2025	Aug NEWA
AB				70MG	A214350	003	Aug 25, 2025	Aug NEWA
AB				80MG	A214350	004	Aug 25, 2025	Aug NEWA
AB				100MG	A214350	005	Aug 25, 2025	Aug NEWA
AB				140MG	A214350	006	Aug 25, 2025	Aug NEWA
AB			TEVA PHARMS USA	20MG	A211094	001	Aug 27, 2025	Aug NEWA
AB				50MG	A211094	002	Aug 27, 2025	Aug NEWA
AB				70MG	A211094	003	Aug 27, 2025	Aug NEWA
AB				80MG	A211094	004	Aug 27, 2025	Aug NEWA
AB				100MG	A211094	005	Aug 27, 2025	Aug NEWA
AB				140MG	A211094	006	Aug 27, 2025	Aug NEWA
AB			ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb NEWA
AB				50MG	A218719	002	Mar 03, 2025	Feb NEWA
AB				70MG	A218719	003	Mar 03, 2025	Feb NEWA
AB				80MG	A218719	004	Mar 03, 2025	Feb NEWA
AB				100MG	A218719	005	Mar 03, 2025	Feb NEWA
AB				140MG	A218719	006	Mar 03, 2025	Feb NEWA

PHYRAGO

		+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
		+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
		+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
		+		80MG	N216099	004	Dec 05, 2023	Jan CAHN
		+!		100MG	N216099	005	Dec 05, 2023	Jan CAHN
		+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

	AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr CHRS
	AP	!	DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr CHRS

POWDER;INTRAVENOUS

DECITABINE

		@ +	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014	Aug DISC

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

>D>	AB		AUCTA	90MG	A214559	001	Mar 09, 2021	Sep CAHN
>D>	AB			180MG	A214559	002	Mar 09, 2021	Sep CAHN
>D>	AB			360MG	A214559	003	Mar 09, 2021	Sep CAHN
	AB		AUROBINDO PHARMA	90MG	A215137	001	Sep 08, 2025	Aug NEWA
	AB			180MG	A215137	002	Sep 08, 2025	Aug NEWA
	AB			360MG	A215137	003	Sep 08, 2025	Aug NEWA
>A>	AB		EPIC PHARMA LLC	90MG	A214559	001	Mar 09, 2021	Sep CAHN
>A>	AB			180MG	A214559	002	Mar 09, 2021	Sep CAHN
>A>	AB			360MG	A214559	003	Mar 09, 2021	Sep CAHN

TABLET;ORAL

DEFERASIROX

	AB		JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr NEWA
	AB			180MG	A211660	002	Apr 11, 2025	Apr NEWA
	AB			360MG	A211660	003	Apr 11, 2025	Apr NEWA
		@	SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr DISC
		@		180MG	A211641	003	Jun 15, 2020	Apr DISC
		@		360MG	A211641	002	Jan 02, 2020	Apr DISC

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

>D>		@	NORVIUM BIOSCIENCE	125MG	A206585	001	May 17, 2024	Sep CAHN
>D>		@		250MG	A206585	002	May 17, 2024	Sep CAHN
>D>		@		500MG	A206585	003	May 17, 2024	Sep CAHN
>A>		@	PHARMOBEDIENT	125MG	A206585	001	May 17, 2024	Sep CAHN
>A>		@		250MG	A206585	002	May 17, 2024	Sep CAHN
>A>		@		500MG	A206585	003	May 17, 2024	Sep CAHN
		@	TORRENT	125MG	A209426	001	Nov 05, 2024	Jun DISC
		@		250MG	A209426	002	Nov 05, 2024	Jun DISC
		@		500MG	A209426	003	Nov 05, 2024	Jun DISC

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DESFERAL

	AP	+!	MITEM PHARMA	500MG/VIAL	N016267	001		Aug CAHN
		@ +		2GM/VIAL	N016267	002	May 25, 2000	Aug CAHN

DEFLAZACORT

SUSPENSION;ORAL

DEFLAZACORT

	AB		UPSHER SMITH LABS	22.75MG/ML	A216992	001	Aug 11, 2025	Aug NEWA
>A>	AB		ZYDUS LIFESCIENCES	22.75MG/ML	A220042	001	Oct 03, 2025	Sep NEWA

PYQUVI

	AB		AUCTA	22.75MG/ML	A219417	001	Jun 30, 2025	Jun NEWA

TABLET;ORAL

DEFLAZACORT

	AB		SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar NEWA
	AB			18MG	A217741	002	Mar 18, 2025	Mar NEWA
	AB			30MG	A217741	003	Mar 18, 2025	Mar NEWA
	AB			36MG	A217741	004	Mar 18, 2025	Mar NEWA

JAYTHARI

	AB		ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar NEWA
	AB			18MG	A219254	002	Apr 08, 2025	Mar NEWA
	AB			30MG	A219254	003	Apr 08, 2025	Mar NEWA
	AB			36MG	A219254	004	Apr 08, 2025	Mar NEWA

DELGOCITINIB

CREAM;TOPICAL

ANZUPGO

		+!	LEO PHARMA AS	2%	N219155	001	Jul 23, 2025	Jul NEWA

DESLORATADINE

SOLUTION;ORAL

DESLORATADINE

>D>		@	TARO	0.5MG/ML	A202936	001	May 26, 2016	Sep CMFD
>A>		!		0.5MG/ML	A202936	001	May 26, 2016	Sep CMFD

TABLET;ORAL

DESLORATADINE

	AB		AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DDAVP

	AP	+!	NORDIC PHARMA	0.004MG/ML	N018938	001	Mar 30, 1984	Aug CAHN
		@		0.015MG/ML	N018938	002	Apr 25, 1995	Aug CAHN

TABLET;ORAL

DESMOPRESSIN ACETATE

		@	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May DISC
		@		0.2MG	A201831	002	May 28, 2015	May DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

AVERI

			AVION PHARMS	0.15MG;0.03MG	A218933	001	May 02, 2025	Apr NEWA

TABLET;ORAL-28

AVERI

	AB		AVION PHARMS	0.15MG;0.03MG	A218933	002	May 02, 2025	Apr NEWA

DESONIDE

CREAM;TOPICAL

DESONIDE

	AB	!	CADILA	0.05%	A210198	001	Nov 20, 2019	Jul CHRS
		@	GLENMARK SPECLT	0.05%	A209729	001	Jul 24, 2017	Jul DISC
		@ +	PADAGIS US	0.05%	N017010	001		Jul DISC

GEL;TOPICAL

DESONIDE

>D>		!	CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Sep CAHN
>A>		!	SENORES PHARMS	0.05%	A202470	001	May 11, 2020	Sep CAHN

LOTION;TOPICAL

DESONIDE

>D>	AB		ALEMBIC	0.05%	A213632	001	Aug 24, 2020	Sep CHRS
>A>	AB	!		0.05%	A213632	001	Aug 24, 2020	Sep CHRS
		@	GLENMARK SPECLT	0.05%	A209494	001	Sep 26, 2017	Jul DISC

DESOWEN

>D>	AB	!	GALDERMA LABS LP	0.05%	A072354	001	Jan 24, 1992	Sep DISC
>A>		@		0.05%	A072354	001	Jan 24, 1992	Sep DISC

OINTMENT;TOPICAL

DESONIDE

		@	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Jul DISC

DESOWEN

		@	GALDERMA LABS LP	0.05%	A071425	001	Jun 15, 1988	May DISC

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

		@	GLENMARK PHARMS LTD	0.25%	A202838	001	Sep 20, 2013	Jul DISC
	AB	!	ZYDUS LIFESCIENCES	0.25%	A205206	001	Sep 19, 2017	Jul CHRS

SPRAY;TOPICAL

TOPICORT

	AT	+!	SUN PHARMA CANADA	0.25%	N204141	001	Apr 11, 2013	Aug CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		HIKMA	EQ 25MG BASE	A204083	002	Feb 16, 2016	Aug CMS1
AB			EQ 50MG BASE	A204083	003	Feb 16, 2016	Aug CMS1
AB		MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
AB			EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
AB		MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINE

TABLET;ORAL

AUSTEDO

	+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
	+		6MG	N208082	001	Apr 03, 2017	Jan CTEC
	+		9MG	N208082	002	Apr 03, 2017	Feb CAHN
	+		9MG	N208082	002	Apr 03, 2017	Jan CTEC
	+!		12MG	N208082	003	Apr 03, 2017	Feb CAHN
	+!		12MG	N208082	003	Apr 03, 2017	Jan CTEC

DEUTETRABENAZINE

	@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
	@		9MG	A215971	002	Dec 26, 2024	Jan DISC
	@		12MG	A215971	003	Dec 26, 2024	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

	+	TEVA	24MG	N216354	003	Feb 17, 2023	Jul CHRS
	+!		48MG	N216354	007	May 29, 2024	Jul CHRS

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

AB	+	HIKMA	0.5MG	A084612	002		Apr CMS1
AB	+		0.75MG	A084612	003		Apr CMS1
AB	+!		1MG	A084612	004	Sep 15, 1983	Apr CMS1
AB	+		1.5MG	A084612	005		Apr CMS1
AB	+!		2MG	A084612	006		Apr CMS1
AB	+!		6MG	A084612	007	Sep 15, 1983	Apr CMS1
>D> AB		LARKEN LABS INC	1.5MG	A201270	001	Jul 17, 2017	Sep CAHN
>A> AB		PHARMOBEDIENT	1.5MG	A201270	001	Jul 17, 2017	Sep CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@	EUGIA PHARMA	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015	Jul DISC

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLMON

	!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
	!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Feb CAHN
	!	PHARMOBEDIENT	2MG/5ML	A202520	001	Jul 16, 2018	Aug CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		HIKMA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	A206407	003	May 30, 2025	May NFTG
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	May CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	May CAHN

PRECEDEX

AP	+!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	May CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb CAHN
AB			10MG	A078992	002	Nov 23, 2021	Feb CAHN
AB			15MG	A078992	003	Nov 18, 2013	Feb CAHN
AB			30MG	A078992	004	Nov 18, 2013	Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB			20MG		A078992	005	Nov 23, 2021	Feb CAHN
AB			40MG		A078992	006	Nov 23, 2021	Feb CAHN
	@	SUN PHARM INDS INC	5MG		A206734	001	Nov 05, 2021	Jul DISC
	@		10MG		A206734	002	Nov 05, 2021	Jul DISC
	@		15MG		A206734	003	Nov 05, 2021	Jul DISC
	@		20MG		A206734	004	Nov 05, 2021	Jul DISC
	@		25MG		A206734	005	Nov 05, 2021	Jul DISC
	@		30MG		A206734	006	Nov 05, 2021	Jul DISC
	@		35MG		A206734	007	Nov 05, 2021	Jul DISC
	@		40MG		A206734	008	Nov 05, 2021	Jul DISC

TABLET;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

	@	RHODES PHARMS	2.5MG		A208756	001	Nov 20, 2017	Jan DISC
	@		5MG		A208756	002	Nov 20, 2017	Jan DISC
	@		10MG		A208756	003	Nov 20, 2017	Jan DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXRAZOXANE HYDROCHLORIDE

AP		MSN	EQ 250MG BASE/VIAL		A216748	001	Mar 26, 2025	Mar NEWA
AP			EQ 500MG BASE/VIAL		A216748	002	Mar 26, 2025	Mar NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE DM

AA	!	PAI HOLDINGS	15MG/5ML;6.25MG/5ML		A040649	001	Feb 14, 2006	Apr CAHN

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		COSETTE	15MG/5ML;6.25MG/5ML		A091687	001	Jun 28, 2012	May CAHN

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		XTTRIUM LABS INC	15MG/5ML;6.25MG/5ML		A088864	001	Jan 04, 1985	Feb CAHN

DIAZEPAM

INJECTABLE;INJECTION
DIAZEPAM

AP		GALENICUM HLTH	50MG/10ML (5MG/ML)		A216422	001	May 19, 2025	May NEWA

DIAZOXIDE CHOLINE

TABLET, EXTENDED RELEASE;ORAL
VYKAT XR

	+	SOLENO THERAP	25MG		N216665	001	Mar 26, 2025	Mar NEWA
	+		75MG		N216665	002	Mar 26, 2025	Mar NEWA
	+!		150MG		N216665	003	Mar 26, 2025	Mar NEWA

DICLOFENAC POTASSIUM

CAPSULE;ORAL
DICLOFENAC POTASSIUM

AB		ONESOURCE SPECIALTY	25MG		A210078	001	Dec 03, 2019	Jun CAHN

ZIPSOR

AB	+!	ASIO HOLDINGS	25MG		N022202	001	Jun 16, 2009	Aug CAHN

FOR SOLUTION;ORAL
CAMBIA

AB	+!	ASIO HOLDINGS	50MG		N022165	001	Jun 17, 2009	Aug CAHN

DICLOFENAC POTASSIUM

AB		TORRENT	50MG		A215891	001	Jan 22, 2025	Jan NEWA
AB		UMEDICA	50MG		A217010	001	Aug 29, 2025	Aug NEWA

TABLET;ORAL
DICLOFENAC POTASSIUM

AB		RK PHARMA	50MG		A075463	001	Jul 26, 1999	Mar CHRS
AB	!	RUBICON	50MG		A075229	001	Nov 20, 1998	Mar CHRS
AB		UMEDICA	25MG		A215750	002	Jun 30, 2025	Jun NEWA

DICLOFENAC SODIUM

GEL;TOPICAL
DICLOFENAC SODIUM

BX		ALEMBIC	3%		A212351	001	Jul 27, 2022	Mar CTEC

SOLUTION;TOPICAL
DICLOFENAC SODIUM

AB		ENCUBE	2%		A217646	001	Apr 09, 2025	Mar NEWA

TABLET, DELAYED RELEASE;ORAL
DICLOFENAC SODIUM

AB	AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002	Apr	CMFD
AB		75MG	A075281	003	Feb 12, 2002	Apr	CMFD

TABLET, EXTENDED RELEASE;ORAL
DICLOFENAC SODIUM

AB	NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr	CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL
DICYCLOMINE HYDROCHLORIDE

AB	RISING	10MG	A219242	001	Jun 23, 2025	Jun	NEWA

INJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE

@	NEXUS	10MG/ML	A206468	001	Feb 01, 2019	Apr	DISC

TABLET;ORAL
DICYCLOMINE HYDROCHLORIDE

AB	PRINSTON INC	20MG	A218310	001	Jun 06, 2025	May	NEWA
AB	RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar	CAHN
!		40MG	A216736	002	Mar 25, 2025	Mar	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL
TENUATE

@ +	MPP PHARMA	25MG	N011722	002		Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
TENUATE DOSPAN

@ +	ANI PHARMS	75MG	N012546	001		Apr	CAHN

DIFELIKEFALIN ACETATE

SOLUTION;INTRAVENOUS
KORSUVA

+!	VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr	CAHN

DIFLUPREDNATE

EMULSION;OPHTHALMIC
DIFLUPREDNATE

AB	MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar	NEWA
AB	UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan	NEWA

DIGOXIN

ELIXIR;ORAL
DIGOXIN

AA +!	HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Jun	CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

@	BAXTER HLTHCARE CORP	1MG/ML	A216747	001	Jan 07, 2025	Jun	DISC
@	CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Jan	DISC
>A> AP	MILLA PHARMS	1MG/ML	A212046	001	Jan 07, 2020	Sep	CAHN
>D> AP	PROVEPHARM SAS	1MG/ML	A212046	001	Jan 07, 2020	Sep	CAHN

POWDER;NASAL
ATZUMI

+!	SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025	Apr	NEWA

SOLUTION;SUBCUTANEOUS
BREKIYA (AUTOINJECTOR)

+!	AMNEAL	1MG/ML	N215400	001	May 14, 2025	May	NEWA

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

>D> AB	AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Sep	CAHN
AB		0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb	NEWA
>A> AB	SOMERSET THERAPS LLC	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Sep	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1	AMTA	60MG	A219073	001	Mar 24, 2025	Mar	NEWA
AB1		90MG	A219073	002	Mar 24, 2025	Mar	NEWA
AB1		120MG	A219073	003	Mar 24, 2025	Mar	NEWA

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1		NOVAST LABS	60MG		A218032	001	Jul 02, 2025	Jun NEWA
AB1			90MG		A218032	002	Jul 02, 2025	Jun NEWA
AB1			120MG		A218032	003	Jul 02, 2025	Jun NEWA
	@	SUN PHARM	120MG		A203023	001	Jun 08, 2017	Apr DISC
	@		180MG		A203023	002	Jun 08, 2017	Mar DISC
	@		240MG		A203023	003	Jun 08, 2017	Mar DISC
	@		300MG		A203023	004	Jun 08, 2017	Feb DISC
AB1		UTOPIC PHARMS	60MG		A219073	001	Mar 24, 2025	Apr CAHN
AB1			90MG		A219073	002	Mar 24, 2025	Apr CAHN
AB1			120MG		A219073	003	Mar 24, 2025	Apr CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

	@	EUGIA PHARMA	5MG/ML		A216552	001	Mar 29, 2023	Aug DISC

SOLUTION;INTRAVENOUS
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

	+!	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)		N218038	001	Feb 21, 2025	Feb NEWA
	+!		250MG/250ML (1MG/ML)		N218038	002	Feb 21, 2025	Feb NEWA

TABLET;ORAL
DILTIAZEM HYDROCHLORIDE

AB		ZYDUS LIFESCIENCES	30MG		A219253	001	Aug 08, 2025	Aug NEWA
AB			60MG		A219253	002	Aug 08, 2025	Aug NEWA
AB			90MG		A219253	003	Aug 08, 2025	Aug NEWA
AB			120MG		A219253	004	Aug 08, 2025	Aug NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

	@	CIPLA	120MG		A210305	001	Sep 24, 2020	Feb DISC
	@		240MG		A210305	002	Sep 24, 2020	Feb DISC
	@	TORRENT	120MG		A210390	001	Jan 06, 2025	Jun DISC
	@		240MG		A210390	002	Jan 06, 2025	Jun DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP		AVET LIFESCIENCES	50MG/ML		A205336	001	Jun 24, 2025	Jun NEWA
AP		MICRO LABS	50MG/ML		A219845	001	Aug 22, 2025	Aug NEWA
AP	!	NORVIUM BIOSCIENCE	50MG/ML		A040498	001	Jul 12, 2005	Feb CAHN

DIPYRIDAMOLE

TABLET;ORAL
DIPYRIDAMOLE

AB		BARR LABS	75MG		A087717	001	Oct 03, 1990	Mar CAHN

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL
DIVALPROEX SODIUM

AB		MANKIND PHARMA	EQ 125MG VALPROIC ACID		A217358	001	Aug 12, 2025	Aug NEWA

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

	@	APOTEX	EQ 125MG VALPROIC ACID		A077615	003	Jul 29, 2008	Mar DISC
	@		EQ 250MG VALPROIC ACID		A077615	002	Jul 29, 2008	Mar DISC
	@		EQ 500MG VALPROIC ACID		A077615	001	Jul 29, 2008	Mar DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

AB		SCIEGEN PHARMS INC	EQ 250MG VALPROIC ACID		A078705	002	Feb 10, 2009	Jul CAHN
AB			EQ 500MG VALPROIC ACID		A078705	001	Aug 04, 2009	Jul CAHN
	@	YICHANG HUMANWELL	EQ 250MG VALPROIC ACID		A214462	001	Mar 15, 2021	Jul CAHN
	@		EQ 500MG VALPROIC ACID		A214462	002	Mar 15, 2021	Jul CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP	!	AMNEAL	20MG/ML (20MG/ML)		A209640	001	Jan 19, 2018	Apr CHRS
AP	!		80MG/4ML (20MG/ML)		A209640	002	Jan 19, 2018	Apr CHRS
AP	!		160MG/8ML (20MG/ML)		A209640	003	Jan 19, 2018	Apr CHRS
	@	EUGIA PHARMA	20MG/2ML (10MG/ML)		A214575	001	Jun 25, 2021	Aug DISC
	@		80MG/8ML (10MG/ML)		A214575	002	Jun 25, 2021	Aug DISC
	@		160MG/16ML (10MG/ML)		A214575	003	Jun 25, 2021	Aug DISC
AP		GUANGDONG SUNHO	20MG/ML (20MG/ML)		A213768	001	May 13, 2025	May NEWA

		INJECTABLE;INJECTION						
		DOCETAXEL						
	AP		80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	May	NEWA
>D>		@ NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Sep	CAHN
>A>		@	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Sep	CAHN
>D>	AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Sep	CAHN
>A>	AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Sep	CAHN
>D>	AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Sep	CAHN
>A>	AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Sep	CAHN
		TAXOTERE						
		@ + SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr	DISC
		@ +	80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr	DISC
	AP	+	160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Apr	CHRS
		SOLUTION;INTRAVENOUS						
		BEIZRAY						
>D>		@ + ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Sep	CMFD
>A>		+!	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Sep	CMFD
		@ +	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Apr	DISC
		DONEPEZIL HYDROCHLORIDE						
		TABLET;ORAL						
		DONEPEZIL HYDROCHLORIDE						
		@ INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr	DISC
		@	10MG	A201634	002	Jun 13, 2012	Apr	DISC
		DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE;ORAL						
		MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE						
	AB	AMNEAL	10MG;7MG	A208328	003	Feb 27, 2025	Feb	NFTG
	AB		10MG;21MG	A208328	004	Feb 27, 2025	Feb	NEWA
	AB	MACLEODS PHARMS LTD	10MG;14MG	A208672	001	Jul 15, 2025	Jul	NEWA
	AB		10MG;28MG	A208672	002	Jul 15, 2025	Jul	NEWA
	AB	XIAMEN LP PHARM CO	10MG;14MG	A216901	001	Jul 15, 2025	Jul	NEWA
	AB		10MG;28MG	A216901	002	Jul 15, 2025	Jul	NEWA
		NAMZARIC						
	AB	+ ABBVIE	10MG;7MG	N206439	003	Jul 18, 2016	Feb	CFTG
		DONIDALORSEN SODIUM						
		SOLUTION;SUBCUTANEOUS						
		DAWNZERA (AUTOINJECTOR)						
		+! IONIS PHARMS INC	EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)	N219407	001	Aug 21, 2025	Aug	NEWA
		DORDAVIPRONE HYDROCHLORIDE						
		CAPSULE;ORAL						
		MODEYSO						
		+! CHIMERIX	EQ 125MG BASE	N219876	001	Aug 06, 2025	Aug	NEWA
		DORZOLAMIDE HYDROCHLORIDE						
		SOLUTION/DROPS;OPHTHALMIC						
		DORZOLAMIDE HYDROCHLORIDE						
	AT	SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan	NEWA
		DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE						
		SOLUTION/DROPS;OPHTHALMIC						
		DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
	AT2	IDENTIRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb	NEWA
	AT2	NEW HEIGHTSRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Jul	CAHN
		DOXAZOSIN MESYLATE						
		TABLET;ORAL						
		DOXAZOSIN MESYLATE						
	AB	APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar	CAHN
	AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar	CAHN
	AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar	CAHN
	AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

		@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan DISC
>A>	AB		IXORA LIFESCIENCE	EQ 10MG BASE	A211619	001	Mar 09, 2021	Sep CAHN
>A>	AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Sep CAHN
>A>	AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Sep CAHN
>A>	AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Sep CAHN
>A>	AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Sep CAHN
>D>	AB		LEADING	EQ 10MG BASE	A211619	001	Mar 09, 2021	Sep CAHN
>D>	AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Sep CAHN
>D>	AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Sep CAHN
>D>	AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Sep CAHN
>D>	AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Sep CAHN
	AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
	AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
	AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
	AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
	AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
		@	TARO	EQ 10MG BASE	A213063	001	Jul 01, 2020	Aug DISC
		@		EQ 25MG BASE	A213063	002	Jul 01, 2020	Aug DISC
		@		EQ 50MG BASE	A213063	003	Jul 01, 2020	Aug DISC
		@		EQ 75MG BASE	A213063	004	Jul 01, 2020	Aug DISC
		@		EQ 100MG BASE	A213063	005	Jul 01, 2020	Aug DISC
	BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CTEC
	BX			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CTEC
	BX			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CTEC
	BX			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CTEC
	BX			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CTEC
	BX			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

	AB		AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Aug CMFD
	AB			EQ 6MG BASE	A218564	002	Jul 01, 2024	Aug CMFD
	AB		AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Jun CMFD
	AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jun CMFD
	BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar CTEC
	BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar CTEC
	AB		TARO	EQ 3MG BASE	A219058	001	Aug 06, 2025	Jul NEWA
	AB			EQ 6MG BASE	A219058	002	Aug 06, 2025	Jul NEWA

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

	AB	!	AVET	2.5MCG	A205360	003	Sep 15, 2020	Aug CHRS

HECTOROL

		@ +	SANOFI	0.5MCG	N020862	002	Apr 23, 2004	Aug DISC
		@ +		1MCG	N020862	003	Jul 13, 2009	Aug DISC
		@ +		2.5MCG	N020862	001	Jun 09, 1999	Aug DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

	AB		ALEMBIC	20MG/10ML (2MG/ML)	A219199	001	Jun 27, 2025	Jun NEWA
	AB			50MG/25ML (2MG/ML)	A219199	002	Jun 27, 2025	Jun NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

>A>	AB		CHANGZHOU PHARM	40MG	A219978	001	Oct 01, 2025	Sep NEWA
	AB		MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar NEWA
	AB		PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

		@	BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr CAHN
		@		EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr CAHN
	AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb CHRS
	AB		STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
	AB			EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD

CAPSULE;ORAL
VIBRAMYCIN
@ + PFIZER EQ 100MG BASE N050007 002 Feb DISC
INJECTABLE;INJECTION
DOXYCYCLINE HYCLATE
@ AMNEAL EQ 100MG BASE/VIAL A217487 001 Dec 04, 2024 Jan DISC
AP ASPIRO EQ 100MG BASE/VIAL A218888 001 Aug 05, 2025 Jul NEWA
AP DR REDDYS EQ 100MG BASE/VIAL A218753 001 Jul 01, 2025 Jun NEWA
AP PRECISION DOSE INC EQ 100MG BASE/VIAL A217078 001 Feb 21, 2025 Feb NEWA
TABLET;ORAL
DOXYCYCLINE HYCLATE
@ AVIV PHARMA EQ 100MG BASE A209560 001 Apr 15, 2024 May CAHN
>D> AB LARKEN LABS EQ 20MG BASE A065287 001 Feb 28, 2006 Sep CAHN
@ MYLAN EQ 100MG BASE A062432 001 Feb 15, 1983 Jun DISC
>D> @ ORYZA EQ 100MG BASE A213475 001 Mar 10, 2021 Sep CAHN
>A> AB PHARMOBEDIENT EQ 20MG BASE A065287 001 Feb 28, 2006 Sep CAHN
>A> @ EQ 100MG BASE A213475 001 Mar 10, 2021 Sep CAHN

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET;ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL
>D> AB HLTHCARE 3MG;0.02MG A203291 001 Jul 18, 2017 Sep CAHN
>A> AB PHARMOBEDIENT 3MG;0.02MG A203291 001 Jul 18, 2017 Sep CAHN

DROXIDOPA
CAPSULE;ORAL
DROXIDOPA
AB JUBILANT CADISTA 100MG A214391 001 Feb 18, 2021 Apr CAHN
AB 200MG A214391 002 Feb 18, 2021 Apr CAHN
AB 300MG A214391 003 Feb 18, 2021 Apr CAHN

DULOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS;ORAL
CYMBALTA
@ + LILLY EQ 20MG BASE N021427 001 Aug 03, 2004 Aug DISC
@ + EQ 30MG BASE N021427 002 Aug 03, 2004 Aug DISC
@ + EQ 60MG BASE N021427 004 Aug 03, 2004 Aug DISC
DULOXETINE HYDROCHLORIDE
>D> @ ADAPTIS EQ 20MG BASE A090723 001 Dec 11, 2013 Sep CAHN
@ EQ 20MG BASE A090723 001 Dec 11, 2013 Aug CAHN
>D> @ EQ 30MG BASE A090723 002 Dec 11, 2013 Sep CAHN
@ EQ 30MG BASE A090723 002 Dec 11, 2013 Aug CAHN
>D> @ EQ 60MG BASE A090723 003 Dec 11, 2013 Sep CAHN
@ EQ 60MG BASE A090723 003 Dec 11, 2013 Aug CAHN
AB ! AJANTA PHARMA LTD EQ 60MG BASE A208706 003 Jan 06, 2017 Aug CHRS
>A> @ GRAVITI PHARMS EQ 20MG BASE A090723 001 Dec 11, 2013 Sep CAHN
>A> @ EQ 30MG BASE A090723 002 Dec 11, 2013 Sep CAHN
>A> @ EQ 60MG BASE A090723 003 Dec 11, 2013 Sep CAHN
@ TORRENT EQ 20MG BASE A090774 001 Dec 11, 2013 Jul DISC
@ EQ 30MG BASE A090774 002 Dec 11, 2013 Jul DISC
@ EQ 60MG BASE A090774 003 Dec 11, 2013 Jul DISC

DUTASTERIDE
CAPSULE;ORAL
DUTASTERIDE
>D> AB ADAPTIS 0.5MG A204376 001 Apr 07, 2017 Sep CAHN
@ AVIV PHARMA 0.5MG A204705 001 Nov 20, 2015 May CAHN
>A> AB GRAVITI PHARMS 0.5MG A204376 001 Apr 07, 2017 Sep CAHN
@ PH HEALTH 0.5MG A202421 001 Nov 20, 2015 Jul CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE
CAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
>D> AB ZYDUS PHARMS 0.5MG;0.4MG A207769 001 May 24, 2018 Sep CHRS
>A> AB ! 0.5MG;0.4MG A207769 001 May 24, 2018 Sep CHRS
JALYN
>D> AB +! WAYLIS THERAP 0.5MG;0.4MG N022460 001 Jun 14, 2010 Sep CHRS
>A> AB + 0.5MG;0.4MG N022460 001 Jun 14, 2010 Sep CHRS

EDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

	@	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	DISC
>A> AP		PHARMOBEDIENT	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Sep	CAHN
>A> AP			60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Sep	CAHN
>D> AP		XGEN PHARMS	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Sep	CAHN
>D> AP			60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Sep	CAHN

SUSPENSION;ORAL

RADICAVA ORS

	+!	KK BCJ-94	105MG/5ML	N215446	001	May 12, 2022	Jul	CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB		NORVIUM BIOSCIENCE	600MG	A204869	001	Mar 12, 2018	May	CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@	CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr	CAHN

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

	@ +	ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb	CAHN

>A> ELAMIPRETIDE HYDROCHLORIDE

>A> SOLUTION;SUBCUTANEOUS

>A> FORZINITY

>A>	+!	STEALTH BIOTHERAPS	EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML)	N215244	001	Sep 19, 2025	Sep	NEWA

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB		ANNORA PHARMA	EQ 20MG BASE	A219143	001	Jul 07, 2025	Jun	NEWA
AB			EQ 40MG BASE	A219143	002	Jul 07, 2025	Jun	NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

	@	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan	DISC

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB		HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan	NFTG
AB			EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan	NFTG
AB			EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan	NFTG
AB			EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan	NFTG

PROMACTA

AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan	CFTG
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan	CFTG
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan	CFTG
AB	+!		EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan	CFTG

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

	@	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Aug	DISC
AB			75MG	A213522	001	Mar 14, 2025	Mar	NFTG
	@		100MG	A213522	002	Mar 14, 2025	Aug	DISC
AB			100MG	A213522	002	Mar 14, 2025	Mar	NFTG

VIBERZI

	+	ABBVIE	75MG	N206940	001	May 27, 2015	Aug	CTEC
AB	+		75MG	N206940	001	May 27, 2015	Mar	CFTG
	+!		100MG	N206940	002	May 27, 2015	Aug	CTEC
AB	+!		100MG	N206940	002	May 27, 2015	Mar	CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

COMPLERA

AB	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May	CFTG

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		MYLAN	200MG;EQ 25MG BASE;300MG	A208452	001	May 20, 2025	May	NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb	NEWA
AB			133MG;200MG	A201806	003	Mar 03, 2025	Feb	NEWA
AB			167MG;250MG	A201806	004	Mar 03, 2025	Feb	NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB		SENORES PHARMS	2.5MG	A075483	001	Aug 22, 2000	Jun	CAHN
AB			5MG	A075483	002	Aug 22, 2000	Jun	CAHN
AB			10MG	A075483	003	Aug 22, 2000	Jun	CAHN
AB			20MG	A075483	004	Aug 22, 2000	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@		MPP PHARMA	5MG;12.5MG	A076486	001	Oct 27, 2004	Jun	CAHN
@			10MG;25MG	A076486	002	Oct 27, 2004	Jun	CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

@		HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Aug	DISC

ENFUVIRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

@	+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003	Mar	DISC

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

>A>	AB		EMERGE BIOSCIENCE	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Sep	CAHN
>D>	AB		NANJING KING-FRIEND	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Sep	CAHN

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>A>	AP		EMERGE BIOSCIENCE	30MG/0.3ML (100MG/ML)	A206834	001	Nov 29, 2019	Sep	CAHN
>A>	AP			40MG/0.4ML (100MG/ML)	A206834	002	Nov 29, 2019	Sep	CAHN
>A>	AP			60MG/0.6ML (100MG/ML)	A206834	003	Nov 29, 2019	Sep	CAHN
>A>	AP			80MG/0.8ML (100MG/ML)	A206834	004	Nov 29, 2019	Sep	CAHN
>A>	AP			100MG/ML (100MG/ML)	A206834	005	Nov 29, 2019	Sep	CAHN
>A>	AP			120MG/0.8ML (150MG/ML)	A206834	006	Nov 29, 2019	Sep	CAHN
>A>	AP			150MG/ML (150MG/ML)	A206834	007	Nov 29, 2019	Sep	CAHN
>D>	AP		NANJING KING-FRIEND	30MG/0.3ML (100MG/ML)	A206834	001	Nov 29, 2019	Sep	CAHN
>D>	AP			40MG/0.4ML (100MG/ML)	A206834	002	Nov 29, 2019	Sep	CAHN
>D>	AP			60MG/0.6ML (100MG/ML)	A206834	003	Nov 29, 2019	Sep	CAHN
>D>	AP			80MG/0.8ML (100MG/ML)	A206834	004	Nov 29, 2019	Sep	CAHN
>D>	AP			100MG/ML (100MG/ML)	A206834	005	Nov 29, 2019	Sep	CAHN
>D>	AP			120MG/0.8ML (150MG/ML)	A206834	006	Nov 29, 2019	Sep	CAHN
>D>	AP			150MG/ML (150MG/ML)	A206834	007	Nov 29, 2019	Sep	CAHN

ENTECAVIR

TABLET;ORAL

ENTECAVIR

@		BRECKENRIDGE	0.5MG	A208721	001	Mar 15, 2018	May	DISC
@			1MG	A208721	002	Mar 15, 2018	May	DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

	@	ZYDUS PHARMS	40MG		A209667	001	Sep 26, 2024	Feb DISC

XTANDI

	+!	ASTELLAS	40MG		N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

	@ +	DR REDDYS LABS SA	47MG/10ML (4.7MG/ML)		N213536	004	Dec 07, 2023	May DISC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP3	+!	EXELA PHARMA	25MG/5ML (5MG/ML)		N208289	002	Aug 02, 2021	Mar CTEC

EMERPHED

AP1	+!	NEXUS	50MG/10ML (5MG/ML)		N213407	001	Apr 17, 2020	Mar CTEC
AP	+!		50MG/10ML (5MG/ML)		N213407	001	Apr 17, 2020	Jan CFTG

EPHEDRINE SULFATE

AP2	+!	ENDO OPERATIONS	25MG/5ML (5MG/ML)		N213994	002	Apr 22, 2022	Mar CTEC
AP	+!		25MG/5ML (5MG/ML)		N213994	002	Apr 22, 2022	Feb CFTG
AP2	+!		50MG/10ML (5MG/ML)		N213994	001	Oct 16, 2020	Mar CTEC
AP	+!		50MG/10ML (5MG/ML)		N213994	001	Oct 16, 2020	Feb CFTG
AP2		FRESENIUS KABI USA	25MG/5ML (5MG/ML)		A218271	001	Mar 11, 2025	Mar CTEC
AP			25MG/5ML (5MG/ML)		A218271	001	Mar 11, 2025	Feb NFTG
AP2			50MG/10ML (5MG/ML)		A218271	002	Mar 11, 2025	Mar CTEC
AP			50MG/10ML (5MG/ML)		A218271	002	Mar 11, 2025	Feb NFTG
AP1		GLAND	50MG/10ML (5MG/ML)		A218211	001	Jan 16, 2025	Mar CTEC
AP			50MG/10ML (5MG/ML)		A218211	001	Jan 16, 2025	Jan NFTG
AP3		HIKMA	25MG/5ML (5MG/ML)		A217721	001	Oct 11, 2024	Mar CTEC
AP2	+!	PH HEALTH	25MG/5ML (5MG/ML)		N213994	002	Apr 22, 2022	Aug CAHN
AP2	+!		50MG/10ML (5MG/ML)		N213994	001	Oct 16, 2020	Aug CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>A>	@	PHARMOBEDIENT	0.05%		A090870	001	Mar 14, 2011	Sep CAHN
>D>	@	RENOVA PHARMS	0.05%		A090870	001	Mar 14, 2011	Sep CAHN
	@		0.05%		A090870	001	Mar 14, 2011	Feb CAHN

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR

EPI E Z PEN JR

	@	VIATRIS	0.15MG/DELIVERY		N019430	004	Aug 03, 1995	May CAHN

EPIPEN E Z PEN

	@	VIATRIS	0.3MG/DELIVERY		N019430	003	Aug 03, 1995	May CAHN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPIPEN

AB	+!	VIATRIS	0.3MG/DELIVERY		N019430	001	Dec 22, 1987	May CAHN

EPIPEN JR.

AB	+!	VIATRIS	0.15MG/DELIVERY		N019430	002	Dec 22, 1987	May CAHN

TWINJECT

	@	IMPAX	EQ 0.15MG/DELIVERY		N020800	002	May 28, 2004	May CTNA
	@		EQ 0.3MG/DELIVERY		N020800	001	May 30, 2003	May CTNA

SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

EPINEPHRINE

AP		GLAND PHARMA LTD	10MG/10ML (1MG/ML)		A219239	001	Feb 06, 2025	Jan NFTG

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

AP	+!	BPI LABS	10MG/10ML (1MG/ML)		N205029	002	Feb 04, 2022	Jan CFTG
>D>	+!		30MG/30ML (1MG/ML)		N205029	004	Feb 14, 2024	Sep CFTG
>A> AP	+!		30MG/30ML (1MG/ML)		N205029	004	Feb 14, 2024	Sep CFTG
	+!	FRESENIUS KABI USA	30MG/30ML (1MG/ML)		N215425	001	Mar 13, 2025	Mar NEWA
AP		GLAND	10MG/10ML (1MG/ML)		A219239	001	Feb 06, 2025	Mar CDFR
>A> AP			30MG/30ML (1MG/ML)		A219239	002	Oct 02, 2025	Sep NFTG

SOLUTION;INTRAVENOUS

ADRENALIN

	+!	PH HEALTH	2MG/250ML (8MCG/ML)		N215875	001	Apr 21, 2023	Jul CAHN
	+!		4MG/250ML (16MCG/ML)		N215875	002	Apr 21, 2023	Jul CAHN
	+!		5MG/250ML (20MCG/ML)		N215875	003	Apr 21, 2023	Jul CAHN

		SOLUTION;INTRAVENOUS						
		ADRENALIN						
		+!	8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Jul	CAHN
		+!	10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Jul	CAHN
		SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS						
		EPINEPHRINE						
	AP	GLAND	1MG/ML (1MG/ML)	A218144	001	Jun 03, 2025	May	NEWA
		SPRAY;NASAL						
		NEFFY						
		+! ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Apr	CHRS
		+	1MG/SPRAY	N214697	002	Mar 05, 2025	Mar	NEWA
		EPINEPHRINE BITARTRATE						
		SOLUTION;INTRAVENOUS						
		EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
		+! BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb	NEWA
		EPIRUBICIN HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		EPIRUBICIN HYDROCHLORIDE						
		@ PHARMOBEDIENT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Aug	CAHN
		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Aug	CAHN
		EPLERENONE						
		TABLET;ORAL						
		EPLERENONE						
>A>		@ AARXION ANDA HLDING	25MG	A203896	001	Feb 02, 2017	Sep	CAHN
>A>		@	50MG	A203896	002	Feb 02, 2017	Sep	CAHN
>D>		@ THINKRX	25MG	A203896	001	Feb 02, 2017	Sep	CAHN
		@	25MG	A203896	001	Feb 02, 2017	Mar	CAHN
>D>		@	50MG	A203896	002	Feb 02, 2017	Sep	CAHN
		@	50MG	A203896	002	Feb 02, 2017	Mar	CAHN
		EPTIFIBATIDE						
		INJECTABLE;INJECTION						
		EPTIFIBATIDE						
	AP	MEITHEAL	2MG/ML	A213599	001	May 09, 2024	Apr	CAHN
	AP		75MG/100ML	A213599	002	May 09, 2024	Apr	CAHN
		ERGOCALCIFEROL						
		CAPSULE;ORAL						
		ERGOCALCIFEROL						
	AA	! ONESOURCE SPECIALTY	50,000 IU	A090455	001	Aug 03, 2010	Jun	CAHN
		ERIBULIN MESYLATE						
		SOLUTION;INTRAVENOUS						
		ERIBULIN MESYLATE						
	AP	CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb	NEWA
	AP	DR REDDYS	1MG/2ML (0.5MG/ML)	A217473	001	Jul 03, 2025	Jun	NEWA
>A>	AP	GLENMARK PHARMS INC	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Sep	CAHN
	AP	JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr	CAHN
	AP	SANDOZ	1MG/2ML (0.5MG/ML)	A214310	001	Jun 09, 2025	May	NEWA
>D>	AP	XILING LAB	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Sep	CAHN
	AP		1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Jul	NEWA
		ERLOTINIB HYDROCHLORIDE						
		TABLET;ORAL						
		ERLOTINIB HYDROCHLORIDE						
		@ APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan	DISC
		@	EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan	DISC
		@	EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan	DISC
		@ NATCO PHARMA LTD	EQ 100MG BASE	A208488	002	Nov 05, 2019	Aug	DISC
		@ SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan	DISC
		@	EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb	DISC
		@	EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan	DISC

ERTUGLIFLOZIN

TABLET;ORAL

ERTUGLIFLOZIN

	@		HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr DISC
	@			15MG	A217071	002	Sep 17, 2024	Apr DISC
	@		HIKMA	5MG	A216842	001	Jan 21, 2025	Feb DISC
AB				5MG	A216842	001	Jan 21, 2025	Jan NEWA
	@			15MG	A216842	002	Jan 21, 2025	Feb DISC
AB				15MG	A216842	002	Jan 21, 2025	Jan NEWA

STEGLATRO

	+		MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr CTEC
	+!			15MG	N209803	002	Dec 19, 2017	Apr CTEC

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

>A>	AB		ABON PHARMS LLC	250MG	A219691	001	Sep 23, 2025	Sep NEWA
>A>	AB			500MG	A219691	002	Sep 23, 2025	Sep NEWA
>D>	AB		CARNEGIE	250MG	A061621	001		Sep CAHN
>D>	AB			500MG	A061621	002		Sep CAHN
>A>	AB		PHARMOBEDIENT	250MG	A061621	001		Sep CAHN
>A>	AB			500MG	A061621	002		Sep CAHN

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

	@		AZURITY	EQ 250MG BASE	A060359	001		Apr DISC

ESCITALOPRAM OXALATE

CAPSULE;ORAL

ESCITALOPRAM

	+!		ALMATICA	EQ 15MG BASE	N219130	001	Aug 29, 2025	Aug NEWA

ESCITALOPRAM OXALATE

	@		RISING	EQ 5MG BASE	A077660	001	Jul 31, 2007	Aug CAHN
	@			EQ 10MG BASE	A077660	002	Jul 31, 2007	Aug CAHN
	@			EQ 20MG BASE	A077660	003	Jul 31, 2007	Aug CAHN

SOLUTION;ORAL

ESCITALOPRAM OXALATE

	@		TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Aug DISC

TABLET;ORAL

ESCITALOPRAM OXALATE

AB			ASCENT PHARMS INC	EQ 5MG BASE	A215177	001	Jul 15, 2025	Jul NEWA
AB				EQ 10MG BASE	A215177	002	Jul 15, 2025	Jul NEWA
AB				EQ 20MG BASE	A215177	003	Jul 15, 2025	Jul NEWA

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

AB			APOTEX	200MG	A211236	001	Dec 07, 2023	Apr CMFD
AB				400MG	A211236	002	Dec 07, 2023	Apr CMFD
AB				600MG	A211236	003	Dec 07, 2023	Apr CMFD
AB				800MG	A211236	004	Dec 07, 2023	Apr CMFD
AB			JUBILANT GENERICS	200MG	A211219	001	Aug 04, 2025	Jul NEWA
AB				400MG	A211219	002	Aug 04, 2025	Jul NEWA
AB				600MG	A211219	003	Aug 04, 2025	Jul NEWA
AB				800MG	A211219	004	Aug 04, 2025	Jul NEWA
AB			LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar CMFD
AB				400MG	A211246	002	Mar 27, 2024	Mar CMFD
AB				600MG	A211246	003	Mar 27, 2024	Mar CMFD
AB				800MG	A211246	004	Mar 27, 2024	Mar CMFD
AB			TORRENT	200MG	A211227	001	Feb 27, 2024	May CMFD
AB				400MG	A211227	002	Feb 27, 2024	May CMFD
AB				600MG	A211227	003	Feb 27, 2024	May CMFD
AB				800MG	A211227	004	Feb 27, 2024	May CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	@		CIPLA	EQ 20MG BASE	A078003	001	Jan 26, 2015	Aug CAHN
	@			EQ 40MG BASE	A078003	002	Jan 26, 2015	Aug CAHN
AB			GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr CAHN

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr CAHN
	@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb DISC
	@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb DISC
	@	MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Jun DISC
	@		EQ 40MG BASE	A208511	002	Oct 23, 2024	Jun DISC
AB		SUN PHARM	EQ 20MG BASE	A209735	001	Apr 30, 2018	Jul CMFD
AB			EQ 40MG BASE	A209735	002	Apr 30, 2018	Jul CMFD

FOR SUSPENSION, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr NEWA
AB			EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr NEWA
AB			EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr NEWA
AB			EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr NEWA
AB		TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb NEWA
AB			EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb NEWA
AB			EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb NEWA
AB			EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb NEWA
AB			EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@	NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb CAHN
	@		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		EPIC PHARMA LLC	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jul CAHN
	@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul DISC
	@	PHARMOBEDIENT	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Jul CAHN
	@		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Jul CAHN
AP		YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan NEWA

ESTRADIOL

CREAM;VAGINAL
ESTRADIOL

AB		ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan CAHN

GEL;TRANSDERMAL
ESTRADIOL

AB		ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb NEWA
AB			0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb NEWA
AB			0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb NEWA
AB			0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb NEWA
AB			0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb NEWA

GEL, METERED;TRANSDERMAL
ELESTRIN

	+!	VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Feb CAHN

TABLET;ORAL
ESTRADIOL

	@	RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996	Apr CAHN
	@		1MG	A040114	001	Mar 14, 1996	Apr CAHN
	@		2MG	A040114	002	Mar 14, 1996	Apr CAHN

ESTRADIOL VALERATE

INJECTABLE;INJECTION
DELESTROGEN

AO	+!	PH HEALTH	10MG/ML	N009402	002		Aug CAHN
AO	+!		20MG/ML	N009402	004		Aug CAHN
	@ +		40MG/ML	N009402	003		Aug CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET;ORAL
MYFEMBREE

	+!	SUMITOMO PHARMA AM	1MG;0.5MG;40MG	N214846	001	May 26, 2021	Aug CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

	@	AVIV PHARMA	1MG		A203087	001	May 08, 2019	May CAHN
	@		2MG		A203087	002	May 08, 2019	May CAHN
	@		3MG		A203087	003	May 08, 2019	May CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>	AB	AMNEAL PHARMS	0.03MG;0.15MG		A203871	001	Nov 13, 2015	Sep CAHN
>D>	AB		0.03MG,0.01MG;0.15MG,N/A		A203872	001	Dec 22, 2015	Sep CAHN
>A>	AB	NAARI PTE	0.03MG;0.15MG		A203871	001	Nov 13, 2015	Sep CAHN
>A>	AB		0.03MG,0.01MG;0.15MG,N/A		A203872	001	Dec 22, 2015	Sep CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

GENCEPT 10/11-28

	@	BARR LABS	0.035MG,0.035MG;0.5MG,1MG		A072697	001	Feb 28, 1992	Mar CAHN

NORTREL 0.5/35-28

	AB	BARR LABS	0.035MG;0.5MG		A072695	001	Feb 28, 1992	Mar CAHN

NORTREL 1/35-28

	AB	!	BARR LABS	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar CAHN

TABLET, CHEWABLE;ORAL

KAITLIB FE

	AB	!	LUPIN LTD	0.025MG;0.8MG	A203448	001	Dec 17, 2015	Apr CHRS

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	@ +	TEVA BRANDED PHARM	0.025MG;0.8MG		N022573	001	Dec 22, 2010	Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	AB	BARR LABS	0.02MG;1MG		A090938	001	Dec 01, 2014	Mar CAHN

TABLET;ORAL-21

JUNEL 1/20

	AB	BARR LABS	0.02MG;1MG		A076380	001	May 30, 2003	Mar CAHN

TABLET;ORAL-28

BLISOVI FE 1.5/30

	AB	LUPIN LTD	0.03MG;1.5MG		A201585	001	Nov 18, 2015	Apr CTEC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>D>	@	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A203870	001	Nov 12, 2015	Sep CAHN
>D>	@		0.035MG;0.25MG		A203865	001	Oct 27, 2015	Sep CAHN
>D>	AB		0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		A203873	001	May 12, 2016	Sep CAHN
>A>	@	NAARI PTE	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A203870	001	Nov 12, 2015	Sep CAHN
>A>	@		0.035MG;0.25MG		A203865	001	Oct 27, 2015	Sep CAHN
>A>	AB		0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		A203873	001	May 12, 2016	Sep CAHN

ETHOSUXIMIDE

SYRUP;ORAL

ETHOSUXIMIDE

	AA	CHARTWELL RX	250MG/5ML		A040506	001	Dec 22, 2003	Aug CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

	@	SENORES PHARMS	400MG		A074839	001	Jul 11, 1997	Jul CAHN

ETOPOSIDE

CAPSULE;ORAL

VEPESID

	@ +	ONESOURCE SPECIALTY	50MG		N019557	001	Dec 30, 1986	Jun CAHN
	@ +		100MG		N019557	002	Dec 30, 1986	Jun CAHN

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

>A>	AB		BIONPHARMA	100MG	A219152	001	Oct 02, 2025	Sep NEWA
>A>	AB			200MG	A219152	002	Oct 02, 2025	Sep NEWA

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

	AB		BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar NEWA
	AB			0.5MG	A216140	002	Apr 09, 2025	Mar NEWA
	AB			0.75MG	A216140	003	Apr 09, 2025	Mar NEWA
	AB			1MG	A216140	004	Apr 09, 2025	Mar NEWA
	AB		BRECKENRIDGE	1MG	A205432	004	Sep 03, 2025	Aug NEWA
		@	MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar DISC
		@		5MG	A212936	002	Jun 08, 2020	Mar DISC
		@		7.5MG	A212936	003	Jun 08, 2020	Mar DISC
		@		10MG	A212936	004	Jun 08, 2020	Mar DISC

TABLET, FOR SUSPENSION;ORAL

EVEROLIMUS

	AB		AMNEAL	2MG	A218863	001	Jan 10, 2025	Jan NEWA
	AB			3MG	A218863	002	Jan 10, 2025	Jan NEWA
	AB			5MG	A218863	003	Jan 10, 2025	Jan NEWA
	AB		NATCO	2MG	A217640	001	Jan 28, 2025	Jan NEWA
	AB			3MG	A217640	002	Jan 28, 2025	Jan NEWA
	AB			5MG	A217640	003	Jan 28, 2025	Jan NEWA

EXEMESTANE

TABLET;ORAL

EXEMESTANE

>D>	AB		HIKMA	25MG	A077431	001	Apr 01, 2011	Sep DISC
>A>		@		25MG	A077431	001	Apr 01, 2011	Sep DISC

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

BYETTA

		@ +	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Apr DISC
		@ +		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Apr DISC

EXENATIDE SYNTHETIC

		!	AMNEAL	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr CTEC
	AP	!		300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr CHRS
		!		600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr CTEC
	AP	!		600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr CHRS

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

		@ +	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Mar DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

		@	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024	Jun DISC

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

		@	AMNEAL PHARMS CO	10MG;10MG	A208831	001	Nov 21, 2017	Jul DISC
		@		10MG;20MG	A208831	002	Nov 21, 2017	Jul DISC
		@		10MG;40MG	A208831	003	Nov 21, 2017	Jul DISC
		@		10MG;80MG	A208831	004	Nov 21, 2017	Jul DISC
		@	SCIEGEN PHARMS INC	10MG;10MG	A211663	001	Dec 10, 2024	Jun DISC
		@		10MG;20MG	A211663	002	Dec 10, 2024	Jun DISC
		@		10MG;40MG	A211663	003	Dec 10, 2024	Jun DISC
		@		10MG;80MG	A211663	004	Dec 10, 2024	Jun DISC
		@	TORRENT	10MG;10MG	A209461	001	Jan 27, 2025	Jun DISC
	AB			10MG;10MG	A209461	001	Jan 27, 2025	Jan NEWA
		@		10MG;20MG	A209461	002	Jan 27, 2025	Jun DISC
	AB			10MG;20MG	A209461	002	Jan 27, 2025	Jan NEWA
		@		10MG;40MG	A209461	003	Jan 27, 2025	Jun DISC
	AB			10MG;40MG	A209461	003	Jan 27, 2025	Jan NEWA
		@		10MG;80MG	A209461	004	Jan 27, 2025	Jun DISC
	AB			10MG;80MG	A209461	004	Jan 27, 2025	Jan NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Mar CAHN
AB		AURO BINDO PHARMA LTD	40MG/5ML	A219091	001	Jul 09, 2025	Jun NEWA
	@	BIONPHARMA	40MG/5ML	A219153	001	Jun 23, 2025	Jul DISC
AB			40MG/5ML	A219153	001	Jun 23, 2025	Jun NEWA
AB		LANNETT CO INC	40MG/5ML	A217982	001	Jun 02, 2025	May NEWA
AB		MSN	40MG/5ML	A219863	001	Jul 24, 2025	Jul NEWA
AB		NOVITIUM PHARMA	40MG/5ML	A201995	001	May 30, 2014	Jun CAHN

SOLUTION;INTRAVENOUS

FAMOTIDINE

	+!	SAGENT	20MG/5ML (4MG/ML)	N219935	001	Jul 16, 2025	Jul NEWA
	+!		40MG/10ML (4MG/ML)	N219935	002	Jul 16, 2025	Jul NEWA
	+!		200MG/50ML (4MG/ML)	N219935	003	Jul 16, 2025	Jul NEWA

TABLET;ORAL

FAMOTIDINE

	@	APOTEX	20MG	A075611	001	Jul 23, 2001	Mar DISC
	@		40MG	A075611	002	Jul 23, 2001	Mar DISC
AB		BEXIMCO PHARMS USA	20MG	A218631	001	Mar 25, 2025	Mar NEWA
AB			40MG	A218631	002	Mar 25, 2025	Mar NEWA
AB		RISING	20MG	A075704	001	Apr 16, 2001	Aug CMFD
AB			40MG	A075704	002	Apr 16, 2001	Aug CMFD

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB		AUROBINDO PHARMA LTD	26.6MG;800MG	A219538	001	Jun 30, 2025	Jun NEWA
AB		ENDO OPERATIONS	26.6MG;800MG	A203658	001	Mar 22, 2024	Feb CTNA
	@	TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Feb CTNA
AB		ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb NEWA

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB		MSN	40MG	A210461	001	Dec 30, 2019	Jan CTEC
AB			80MG	A210461	002	Dec 30, 2019	Jan CTEC

FELBAMATE

TABLET;ORAL

FELBAMATE

	@	ALVOGEN	400MG	A204595	001	Jan 11, 2016	May DISC
	@		600MG	A204595	002	Jan 11, 2016	May DISC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB		CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr CAHN
AB			130MG	A090859	002	Mar 01, 2012	Apr CAHN

TABLET;ORAL

FENOFIBRATE

	@	BAUSCH	48MG	A090715	001	Apr 05, 2012	Aug DISC
AB			48MG	A090715	001	Apr 05, 2012	Aug CAHN
	@		145MG	A090715	002	Apr 05, 2012	Aug DISC
AB			145MG	A090715	002	Apr 05, 2012	Aug CAHN
AB		BOSTAL	48MG	A208476	001	Feb 10, 2021	Aug CAHN
AB			54MG	A207803	001	Dec 19, 2017	Aug CAHN
AB			145MG	A208476	002	Feb 10, 2021	Aug CAHN
AB			160MG	A207803	002	Dec 19, 2017	Aug CAHN
AB		CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar CTEC
AB			120MG	A217732	002	Sep 07, 2023	Mar CTEC
	@	MYLAN	54MG	A076520	001	Oct 25, 2007	Feb DISC
	@		160MG	A076520	003	Oct 25, 2007	Feb DISC
	@	SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan DISC
	@		145MG	A200884	002	Sep 07, 2017	Apr DISC

>D>	FENOFIBRIC ACID							
>D>	TABLET;ORAL							
>D>	FIBRICOR							
>D>	+!	ATHENA	105MG	N022418	002	Aug 14, 2009	Sep DISC	
>A>	@ +		105MG	N022418	002	Aug 14, 2009	Sep DISC	
	+!		105MG	N022418	002	Aug 14, 2009	Jun CMFD	
	FIDAXOMICIN							
	TABLET;ORAL							
	DIFICID							
AB	+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul CTEC	
	FIDAXOMICIN							
AB		ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul CMFD	
	FINASTERIDE; TADALAFIL							
	CAPSULE;ORAL							
	FINASTERIDE AND TADALAFIL							
		NOVITIUM PHARMA	5MG;5MG	A218499	001	Mar 19, 2025	Mar NEWA	
	FINERENONE							
	TABLET;ORAL							
	KERENDIA							
	+	BAYER HLTHCARE	40MG	N215341	003	Jul 11, 2025	Jul NEWA	
	FITUSIRAN SODIUM							
	SOLUTION;SUBCUTANEOUS							
	QFITLIA							
	+!	GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025	Mar NEWA	
	+!		EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025	Mar NEWA	
	FLUCONAZOLE							
	TABLET;ORAL							
	FLUCONAZOLE							
	@	TARO	50MG	A076507	001	Jul 29, 2004	Aug DISC	
	@		100MG	A076507	002	Jul 29, 2004	Aug DISC	
	@		150MG	A076507	003	Jul 29, 2004	Aug DISC	
	@		200MG	A076507	004	Jul 29, 2004	Aug DISC	
	FLUCYTOSINE							
	CAPSULE;ORAL							
	FLUCYTOSINE							
AB		LAURUS	250MG	A218005	001	Jul 23, 2025	Jul NEWA	
AB			500MG	A218005	002	Jul 23, 2025	Jul NEWA	
	FLUDEOXYGLUCOSE F-18							
	INJECTABLE;INTRAVENOUS							
	FLUDEOXYGLUCOSE F18							
AP		BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA	
AP		SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN	
	@	WISCONSIN	20-500mCi/ML	A203709	001	Oct 23, 2013	Aug DISC	
	FLUOCINOLONE ACETONIDE							
	CREAM;TOPICAL							
	FLUOCINOLONE ACETONIDE							
	@	TARO	0.025%	A087104	001	Apr 27, 1982	Aug DISC	
	OIL;TOPICAL							
	FLUCINOLONE ACETONIDE							
	@	GLENMARK PHARMS LTD	0.01%	A210556	001	Oct 25, 2018	Jul DISC	
	FLUOCINONIDE ACETONIDE							
	@	GLENMARK PHARMS LTD	0.01%	A210539	001	Oct 26, 2018	Aug DISC	
	OIL/DROPS;OTIC							
	FLUOCINONIDE ACETONIDE							
	@	GLENMARK PHARMS LTD	0.01%	A211815	001	Dec 14, 2018	Aug DISC	
	OINTMENT;TOPICAL							
	FLUOCINOLONE ACETONIDE							
	@	TARO	0.025%	A040041	001	Sep 15, 1994	Aug DISC	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1		ENCUBE	0.05%	A211410	001	Oct 16, 2018	Feb	CMFD
	@	GLENMARK PHARMS LTD	0.1%	A091282	001	Jul 14, 2014	Aug	DISC
	@ +	SUN PHARMA CANADA	0.05%	N019117	001	Jun 26, 1984	Aug	CAHN

GEL;TOPICAL

FLUOCINONIDE

AB		PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Feb	CMFD

SOLUTION;TOPICAL

FLUOCINONIDE

AT		QUAGEN	0.05%	A216389	001	Feb 26, 2025	Feb	NEWA
>D>	@	SAPTALIS PHARMS	0.05%	A207554	001	Mar 18, 2019	Sep	CAHN
	@		0.05%	A207554	001	Mar 18, 2019	Feb	CAHN
>A>	@	SCIEGEN PHARMS INC	0.05%	A207554	001	Mar 18, 2019	Sep	CAHN

FLUORESCEIN SODIUM

INJECTABLE;INTRAVENOUS

AK-FLUOR 25%

	@ +	LONG GROVE PHARMS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	May	DISC

FLUORESCEIN SODIUM

AP		NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar	CAHN
	!		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May	CTEC
AP			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar	CAHN

FLUORODOPA F-18

SOLUTION;INTRAVENOUS

FLUORODOPA F18

	+!	FEINSTEIN	1-40mCi/ML	N200655	001	Oct 10, 2019	Feb	CPOT

FLUOROURACIL

CREAM;TOPICAL

FLUOROURACIL

AB		ENCUBE	5%	A216942	001	Feb 12, 2025	Jan	NEWA

INJECTABLE;INJECTION

FLUOROURACIL

AP		ACCORD HLTHCARE	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Jul	CHRS
AP			1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Jul	CHRS
	@		2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007	May	DISC
AP			5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007	Jul	CHRS
AP	!	ALEMBIC	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	May	CHRS
AP	!	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	Jul	CHRS
AP	!		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	Jul	CHRS
AP	!		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	Jul	CHRS
AP		KINDOS	5GM/100ML (50MG/ML)	A215699	001	Feb 06, 2025	Jan	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

	@	CHARTWELL RX	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jul	CAHN
	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Jul	CAHN
	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Jul	CAHN

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		SCIEGEN PHARMS INC	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002	Jun	CMFD
AA		SOLIS PHARMS	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr	CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	@	APPCO	EQ 10MG BASE	A211696	001	Jan 30, 2019	Feb	CAHN
	@		EQ 20MG BASE	A211696	002	Jan 30, 2019	Feb	CAHN
AB			EQ 60MG BASE	A211477	001	Nov 21, 2018	Jun	CAHN
AB	!	AUROBINDO PHARMA LTD	EQ 20MG BASE	A213286	002	Apr 08, 2020	Jun	CHRS
AB	!		EQ 60MG BASE	A213265	001	Jun 10, 2020	Apr	CHRS
	@	CHARTWELL RX	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar	CAHN
	@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar	CAHN
AB		DR REDDYS	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jun	CHRS
	@ +	TWI PHARMS	EQ 60MG BASE	N202133	001	Oct 06, 2011	Apr	DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

	AB		!	TEVA PHARMS	EQ 50MG BASE;EQ 6MG BASE	A077528	003	Jun 19, 2012	Jun CHRS

SYMBYAX

		@	+	LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520	001	Apr 09, 2007	Feb DISC
		@	+		EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003	Feb DISC
		@	+		EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003	Feb DISC
		@	+		EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003	Feb DISC
		@	+		EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003	Feb DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>A>	AB			CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Sep CAHN
>A>	AB				2.5MG	A215141	002	Oct 20, 2021	Sep CAHN
>A>	AB				5MG	A215141	003	Oct 20, 2021	Sep CAHN
>A>	AB				10MG	A215141	004	Oct 20, 2021	Sep CAHN
		@		TWI PHARMS	1MG	A215848	004	Dec 14, 2022	Jul DISC
		@			2.5MG	A215848	001	Apr 01, 2022	Jul DISC
		@			5MG	A215848	002	Apr 01, 2022	Jul DISC
		@			10MG	A215848	003	Apr 01, 2022	Jul DISC
>D>	AB			ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Sep CAHN
	AB				1MG	A215141	001	Oct 20, 2021	Feb CAHN
>D>	AB				2.5MG	A215141	002	Oct 20, 2021	Sep CAHN
	AB				2.5MG	A215141	002	Oct 20, 2021	Feb CAHN
>D>	AB				5MG	A215141	003	Oct 20, 2021	Sep CAHN
	AB				5MG	A215141	003	Oct 20, 2021	Feb CAHN
>D>	AB				10MG	A215141	004	Oct 20, 2021	Sep CAHN
	AB				10MG	A215141	004	Oct 20, 2021	Feb CAHN

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

		@	+	INA PHARMS	0.025%	N012806	003		May CAHN
		@	+		0.05%	N012806	002		May CAHN

LOTION;TOPICAL

CORDRAN

		@	+	INA PHARMS	0.05%	N013790	001		May CAHN

OINTMENT;TOPICAL

CORDRAN

		@	+	INA PHARMS	0.025%	N012806	004		May CAHN
		@	+		0.05%	N012806	001		May CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

		@		NOVITIUM PHARMA	15MG	A070444	001	Mar 20, 1986	Aug CAHN

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

			!	NEW HEIGHTSRX	100MG	A074431	001	May 31, 1995	Jul CAHN

FLUTICASONE PROPIONATE

LOTION;TOPICAL

FLUTICASONE PROPIONATE

		@		GLENMARK PHARMS LTD	0.05%	A090759	001	May 02, 2011	Aug DISC
			!	PADAGIS ISRAEL	0.05%	A091553	001	Jul 30, 2013	Aug CTEC
	AB		!		0.05%	A091553	001	Jul 30, 2013	Aug CHRS

OINTMENT;TOPICAL

FLUTICASONE PROPIONATE

		@		CHARTWELL RX	0.005%	A076300	001	May 14, 2004	Mar CAHN

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

	AB			RUBICON RESEARCH	0.05MG/SPRAY	A218321	001	Jun 05, 2025	May NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

	AB		ANNORA PHARMA	100MG	A217024	001	Jul 30, 2025	Jul NEWA
	AB			150MG	A217024	002	Jul 30, 2025	Jul NEWA

TABLET;ORAL

FLUVOXAMINE MALEATE

	AB		AIPING PHARM INC	25MG	A075888	001	Nov 29, 2000	Jul CAHN
	AB			50MG	A075888	002	Nov 29, 2000	Jul CAHN
	AB	!		100MG	A075888	003	Nov 29, 2000	Jul CAHN
>D>		@	NORVIUM BIOSCIENCE	25MG	A075889	001	Nov 29, 2000	Sep CAHN
>D>		@		50MG	A075889	002	Nov 29, 2000	Sep CAHN
>D>		@		100MG	A075889	003	Nov 29, 2000	Sep CAHN
>A>		@	QUAGEN	25MG	A075889	001	Nov 29, 2000	Sep CAHN
>A>		@		50MG	A075889	002	Nov 29, 2000	Sep CAHN
>A>		@		100MG	A075889	003	Nov 29, 2000	Sep CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

	AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Mar CAHN

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

FONDAPARINUX SODIUM

		@	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jul DISC
		@		5MG/0.4ML	A216493	002	Aug 19, 2024	Jul DISC
		@		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jul DISC
		@		10MG/0.8ML	A216493	004	Aug 19, 2024	Jul DISC

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

	AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025	Jan NEWA
	AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025	Jan NEWA

PERFOROMIST

	AN	+!	VIATRIS SPECIALTY	0.02MG/2ML	N022007	001	May 11, 2007	Feb CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

		@	PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr DISC
		@	PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan CAHN

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

>D>	AP		AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Sep CDFR
>D>	AP		AVET LIFESCIENCES	2.4GM/100ML	A213807	001	Jun 05, 2023	Sep CDFR
>D>	AP		FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Sep CDFR
>D>	AP		GLAND	2.4GM/100ML	A213001	001	Apr 21, 2021	Sep CDFR
>D>		@	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep CDFR
>D>	AP		SCIECURE	2.4GM/100ML	A213987	001	Nov 29, 2023	Sep CDFR

FOSCAVIR

>D>	AP	+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep CDFR

>A> SOLUTION;INTRAVENOUS

>A> FOSCARNET SODIUM

>A>	AP		AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Sep CDFR
>A>	AP			6GM/250ML (24MG/ML)	A216602	001	Mar 01, 2024	Sep CPOT
>A>	AP		AVET LIFESCIENCES	2.4GM/100ML	A213807	001	Jun 05, 2023	Sep CDFR
>A>	AP			6GM/250ML (24MG/ML)	A213807	001	Jun 05, 2023	Sep CPOT
>A>	AP		FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Sep CDFR
>A>	AP			6GM/250ML (24MG/ML)	A212483	001	Jan 29, 2021	Sep CPOT
>A>	AP		GLAND	2.4GM/100ML	A213001	001	Apr 21, 2021	Sep CDFR
>A>	AP			6GM/250ML (24MG/ML)	A213001	001	Apr 21, 2021	Sep CPOT
>A>		@	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep CDFR
>A>		@		6GM/250ML (24MG/ML)	A077174	001	May 31, 2005	Sep CPOT
>A>				12GM/500ML (24MG/ML)	A077174	002	May 31, 2005	Sep NEWA
>A>		@		12GM/500ML (24MG/ML)	A077174	002	May 31, 2005	Sep DISC
>A>	AP		SCIECURE	2.4GM/100ML	A213987	001	Nov 29, 2023	Sep CDFR
>A>	AP			6GM/250ML (24MG/ML)	A213987	001	Nov 29, 2023	Sep CPOT

>A>		SOLUTION;INTRAVENOUS							
>A>		FOSCAVIR							
>A>	AP	+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep	CDFR
>A>	AP	+!		6GM/250ML (24MG/ML)	N020068	001	Sep 27, 1991	Sep	CPOT
>A>		+		12GM/500ML (24MG/ML)	N020068	002	Sep 27, 1991	Sep	NEWA
>A>		@ +		12GM/500ML (24MG/ML)	N020068	002	Sep 27, 1991	Sep	DISC
		FOSFOMYCIN TROMETHAMINE							
		FOR SOLUTION;ORAL							
		FOSFOMYCIN TROMETHAMINE							
	AA		PRECISION DOSE INC	EQ 3GM BASE/PACKET	A217187	001	Jun 03, 2025	May	NEWA
		FOSINOPRIL SODIUM							
		TABLET;ORAL							
		FOSINOPRIL SODIUM							
		@	APOTEX	10MG	A076906	001	May 17, 2005	Mar	DISC
		@		20MG	A076906	002	May 17, 2005	Mar	DISC
		@		40MG	A076906	003	May 17, 2005	Mar	DISC
		FOSPHENYTOIN SODIUM							
		SOLUTION;INTRAVENOUS							
>D>		SESQUIENT							
>D>		+!	LUPIN	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Sep	DISC
>A>		@ +		EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Sep	DISC
		+!		EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Aug	CMFD
>D>		+!		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Sep	DISC
>A>		@ +		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Sep	DISC
		+!		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Aug	CMFD
		FROVATRIPTAN SUCCINATE							
		TABLET;ORAL							
		FROVATRIPTAN SUCCINATE							
	AB		LEADING	EQ 2.5MG BASE	A216998	001	Apr 16, 2025	Apr	NEWA
	AB		RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Aug	CAHN
		FULVESTRANT							
		SOLUTION;INTRAMUSCULAR							
		FULVESTRANT							
		@	EUGIA PHARMA	250MG/5ML (50MG/ML)	A208811	001	Jul 23, 2019	Aug	DISC
		FUROSEMIDE							
		TABLET;ORAL							
		FUROSEMIDE							
	AB		AUROBINDO PHARMA LTD	20MG	A218831	001	Jul 17, 2025	Jul	NEWA
	AB			40MG	A218831	002	Jul 17, 2025	Jul	NEWA
	AB			80MG	A218831	003	Jul 17, 2025	Jul	NEWA
	AB		HIKMA	20MG	N018823	001	Nov 10, 1983	Jun	CAHN
	AB			40MG	N018823	002	Nov 10, 1983	Jun	CAHN
		@	NORVIUM BIOSCIENCE	80MG	A070082	001	Oct 29, 1986	Feb	CAHN
		FUTIBATINIB							
		TABLET;ORAL							
		LYTGOBI							
		+	TAIHO ONCOLOGY	16MG	N214801	002	Jul 28, 2025	Aug	NEWA
		GABAPENTIN							
		CAPSULE;ORAL							
		GABAPENTIN							
>A>	AB		ANDA REPOSITORY	100MG	A219319	001	Aug 07, 2025	Sep	CAHN
>A>	AB			300MG	A219319	002	Aug 07, 2025	Sep	CAHN
>A>	AB			400MG	A219319	003	Aug 07, 2025	Sep	CAHN
>A>	AB		SENORES PHARMS	100MG	A219319	001	Aug 07, 2025	Sep	CAHN
>A>	AB			300MG	A219319	002	Aug 07, 2025	Sep	CAHN
>A>	AB			400MG	A219319	003	Aug 07, 2025	Sep	CAHN
>D>	AB		STALLION LABS	100MG	A219319	001	Aug 07, 2025	Sep	CAHN
	AB			100MG	A219319	001	Aug 07, 2025	Aug	NEWA
>D>	AB			300MG	A219319	002	Aug 07, 2025	Sep	CAHN

		CAPSULE;ORAL							
		GABAPENTIN							
	AB			300MG		A219319	002	Aug 07, 2025	Aug NEWA
>D>	AB			400MG		A219319	003	Aug 07, 2025	Sep CAHN
	AB			400MG		A219319	003	Aug 07, 2025	Aug NEWA
		@	TARO	100MG		A077261	001	Aug 02, 2013	Aug DISC
		@		300MG		A077261	002	Aug 02, 2013	Aug DISC
		@		400MG		A077261	003	Aug 02, 2013	Aug DISC
		SOLUTION;ORAL							
		GABAPENTIN							
	AA		AJENAT PHARMS	250MG/5ML		A091286	001	Mar 14, 2016	Jan CAHN
	AA		PAI HOLDINGS PHARM	250MG/5ML		A211330	001	Dec 03, 2019	Apr CMFD
		@	TARO	250MG/5ML		A076672	001	Jul 03, 2013	Aug DISC
		TABLET;ORAL							
		GABAPENTIN							
		@	ACTAVIS ELIZABETH	600MG		A075694	001	Oct 21, 2004	Jul DISC
		@		800MG		A075694	002	Oct 21, 2004	Jul DISC
>D>		@	ALLIED	600MG		A076877	001	Jul 06, 2006	Sep CAHN
		@		600MG		A076877	001	Jul 06, 2006	Jul CAHN
>D>		@		800MG		A076877	002	Jul 06, 2006	Sep CAHN
		@		800MG		A076877	002	Jul 06, 2006	Jul CAHN
		@	APOTEX	100MG		A077894	001	Oct 10, 2006	Mar DISC
		@		300MG		A077894	002	Oct 10, 2006	Mar DISC
		@		400MG		A077894	003	Oct 10, 2006	Mar DISC
			IVAX SUB TEVA PHARMS	300MG		A076017	002	Apr 28, 2004	Mar CTEC
>A>	AB2		SCIEGEN PHARMS INC	300MG		A218491	001	Sep 19, 2025	Sep NEWA
>A>	AB2			600MG		A218491	002	Sep 19, 2025	Sep NEWA
>A>		@	SENORES PHARMS	600MG		A076877	001	Jul 06, 2006	Sep CAHN
>A>		@		800MG		A076877	002	Jul 06, 2006	Sep CAHN
	AB		ZYDUS PHARMS	450MG		A203934	003	Aug 25, 2025	Aug NFTG
	AB			750MG		A203934	004	Aug 25, 2025	Aug NFTG
	AB			900MG		A203934	005	Aug 25, 2025	Aug NFTG
		GRALISE							
	AB	+	ALMATICA	450MG		N022544	003	Apr 18, 2023	Aug CFTG
	AB	+		750MG		N022544	004	Apr 18, 2023	Aug CFTG
	AB	+!		900MG		N022544	005	Apr 18, 2023	Aug CFTG
		GADOBUTROL							
		SOLUTION;INTRAVENOUS							
		GADOBUTROL							
	AP		HAINAN POLY PHARM	1.20944GM/2ML (604.72MG/ML)		A217480	003	Apr 16, 2025	Apr NEWA
	AP			6.0472GM/10ML (604.72MG/ML)		A217480	004	Apr 16, 2025	Apr NEWA
	AP			18.1416GM/30ML (604.72MG/ML)		A217480	005	Apr 16, 2025	Apr NEWA
	AP			39.3068GM/65ML (604.72MG/ML)		A217480	006	Apr 16, 2025	Apr NEWA
		GADOTERIDOL							
		INJECTABLE;INJECTION							
		GADOTERIDOL							
	AP		HAINAN POLY	279.3MG/ML		A218749	001	Feb 11, 2025	Jan NFTG
		PROHANCE							
	AP	+!	BRACCO	279.3MG/ML		N020131	001	Nov 16, 1992	Jan CFTG
		GALLIUM GA-68 GOZETOTIDE							
		POWDER;INTRAVENOUS							
		GOZELLIX							
		+!	TELIX INNOVATIONS	N/A		N219592	001	Mar 20, 2025	Mar NEWA
		GANCICLOVIR							
		SOLUTION;INTRAVENOUS							
		GANZYK-RTU							
		@ +	EXELA PHARMA	500MG/250ML (2MG/ML)		N209347	001	Feb 17, 2017	Apr DISC
		GANIRELIX ACETATE							
		INJECTABLE;INJECTION							
		GANIRELIX ACETATE							
	AP		QILU	250MCG/0.5ML		A218855	001	Apr 23, 2025	Apr NEWA
	AP		TRIS PHARMA INC	250MCG/0.5ML		A219454	001	Jun 27, 2025	Jun NEWA

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

>D>		@	CAPLIN	0.5%	A213542	001	Nov 03, 2021	Sep CMFD
>A>	AT			0.5%	A213542	001	Nov 03, 2021	Sep CMFD
		@		0.5%	A213542	001	Nov 03, 2021	May CAHN

GEFITINIB

TABLET;ORAL

GEFITINIB

	AB		CIPLA	250MG	A211826	001	May 16, 2025	May NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

		@	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	May DISC
		@		EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	May DISC

SOLUTION;INTRAVENOUS

AVGEMSI

		@ +	AVYXA HOLDINGS	EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Aug DISC
		+!		EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Jun NEWA
		+!		EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)	N219920	002	Jun 27, 2025	Jun NEWA
		+!		EQ 2GM BASE/52.6ML (EQ 38MG BASE/ML)	N219920	003	Jun 27, 2025	Jun NEWA
>A>			SYSTEM;INTRAVESICAL					
>A>			INLEXZO					
>A>		+!	JANSSEN BIOTECH	EQ 225MG BASE	N219683	001	Sep 09, 2025	Sep NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

		@	APOTEX	600MG	A075034	001	Jul 20, 1998	Mar DISC

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

			BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982	Aug CTEC
				EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982	Aug CTEC
				EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982	Aug CTEC
				EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982	Aug CTEC
		@	HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983	Aug DISC
		@		EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983	Aug DISC
		@		EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983	Aug DISC
		@		EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983	Aug DISC

OINTMENT;TOPICAL

GENTAMICIN SULFATE

		@	TARO	EQ 0.1% BASE	A062477	001	Dec 23, 1983	Jul DISC

SOLUTION/DROPS;OPHTHALMIC

GENTAK

>A>		@	PHARMOBEDIENT	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Sep CAHN
>D>		@	RENOVA PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Sep CAHN

GEPIRONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EXXUA

>D>		@ +	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Sep CMFD
>A>		+!		EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Sep CMFD
>D>		@ +		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Sep CMFD
>A>		+		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Sep CMFD
>D>		@ +		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Sep CMFD
>A>		+		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Sep CMFD
>D>		@ +		EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Sep CMFD
>A>		+!		EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Sep CMFD

GEPOTIDACIN MESYLATE

TABLET;ORAL

BLUJEPA

		+!	GLAXOSMITHKLINE	EQ 750MG BASE	N218230	001	Mar 25, 2025	Mar NEWA

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

GLATIRAMER ACETATE

	AP		CHEMI SPA	20MG/ML	A208468	001	May 07, 2025	Apr NEWA
	AP			40MG/ML	A208468	002	May 07, 2025	Apr NEWA

GLIMEPIRIDE

TABLET;ORAL

AMARYL

		@ +	SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995	Feb DISC
		@ +		2MG	N020496	002	Nov 30, 1995	Feb DISC
		@ +		4MG	N020496	003	Nov 30, 1995	Feb DISC

GLIMEPIRIDE

>A>		@	ANDA REPOSITORY	1MG	A076802	001	Oct 06, 2005	Sep CAHN
>A>		@		2MG	A076802	002	Oct 06, 2005	Sep CAHN
>A>		@		4MG	A076802	003	Oct 06, 2005	Sep CAHN
	AB	!	DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005	Feb CHRS
>D>		@	NORVIUM BIOSCIENCE	1MG	A077624	001	Nov 28, 2005	Sep CAHN
>D>		@		2MG	A077624	002	Nov 28, 2005	Sep CAHN
>D>		@		4MG	A077624	003	Nov 28, 2005	Sep CAHN
>A>		@	QUAGEN	1MG	A077624	001	Nov 28, 2005	Sep CAHN
>A>		@		2MG	A077624	002	Nov 28, 2005	Sep CAHN
>A>		@		4MG	A077624	003	Nov 28, 2005	Sep CAHN
>D>		@	TEVA	1MG	A076802	001	Oct 06, 2005	Sep CAHN
>D>		@		2MG	A076802	002	Oct 06, 2005	Sep CAHN
>D>		@		4MG	A076802	003	Oct 06, 2005	Sep CAHN

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

		@	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jan CAHN
		@		10MG	A074305	002	Apr 07, 1995	Jan CAHN
	AB		OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994	Apr CMFD
	AB			10MG	A074378	002	Nov 28, 1994	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL

GLUCOTROL XL

		@ +	PFIZER	2.5MG	N020329	003	Aug 10, 1999	Apr DISC
	AB	+		5MG	N020329	001	Apr 26, 1994	Apr CMFD
	AB	+		10MG	N020329	002	Apr 26, 1994	Apr CHRS

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>		@	ESJAY PHARMA	2.5MG;250MG	A078083	001	Apr 12, 2007	Sep CAHN
>D>		@		2.5MG;500MG	A078083	002	Apr 12, 2007	Sep CAHN
>D>		@		5MG;500MG	A078083	003	Apr 12, 2007	Sep CAHN
>A>		@	NOVITIUM PHARMA	2.5MG;250MG	A078083	001	Apr 12, 2007	Sep CAHN
>A>		@		2.5MG;500MG	A078083	002	Apr 12, 2007	Sep CAHN
>A>		@		5MG;500MG	A078083	003	Apr 12, 2007	Sep CAHN

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

>A>	AP		CIPLA	1MG/VIAL	A218813	001	Sep 15, 2025	Sep NEWA
	AP		LUPIN LTD	1MG/VIAL	A214457	001	Jul 22, 2025	Jul NEWA

SOLUTION;INTRAVENOUS

GVOKE VIALDX

		+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	Mar NEWA

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

		@	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Jan DISC

POWDER;INHALATION

SEEBRI NEOHALER

		@ +	NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	May CTNA

		SOLUTION;ORAL						
		GLYCOPYRROLATE						
	AA	MSN	1MG/5ML	A216084	001	Apr 08, 2025	Mar	NEWA
>D>	AA	SAPTALIS PHARMS	1MG/5ML	A216297	001	Oct 07, 2024	Sep	CAHN
>A>	AA	SCIEGEN PHARMS INC	1MG/5ML	A216297	001	Oct 07, 2024	Sep	CAHN
		TABLET;ORAL						
		GLYCOPYRROLATE						
>D>	AA	ADAPTIS	1MG	A091182	001	Feb 03, 2014	Sep	CAHN
>D>	AA		2MG	A091182	002	Feb 03, 2014	Sep	CAHN
	AA	CHARTWELL RX	1MG	A040847	001	Mar 21, 2008	Feb	CAHN
	AA		2MG	A040847	002	Mar 21, 2008	Feb	CAHN
>A>	AA	REGCON HOLDINGS	1MG	A091182	001	Feb 03, 2014	Sep	CAHN
>A>	AA		2MG	A091182	002	Feb 03, 2014	Sep	CAHN
		GLYCOPYRROLATE; INDACATEROL MALEATE						
		POWDER;INHALATION						
		UTIBRON NEOHALER						
	@ +	NOVARTIS	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	May	CTNA
		GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
		SOLUTION/DROPS;OPHTHALMIC						
		NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN						
>D>	AT	SAPTALIS PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005	Sep	CAHN
	AT		0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005	Feb	CAHN
>A>	AT	SCIEGEN PHARMS INC	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005	Sep	CAHN
		GRANISETRON HYDROCHLORIDE						
		SOLUTION;ORAL						
		GRANISETRON HYDROCHLORIDE						
		INTRA SANA LABS	EQ 2MG BASE/10ML	A219282	001	Mar 17, 2025	Mar	NEWA
		TABLET;ORAL						
		GRANISETRON HYDROCHLORIDE						
	@	APOTEX INC	EQ 1MG BASE	A078843	001	Feb 27, 2008	Mar	DISC
	@	TARO	EQ 1MG BASE	A090817	001	May 28, 2010	Aug	DISC
		GUANFACINE HYDROCHLORIDE						
		TABLET;ORAL						
		GUANFACINE HYDROCHLORIDE						
	AB	AIPING PHARM INC	EQ 1MG BASE	A216399	001	Jun 08, 2022	Jul	CAHN
	AB		EQ 2MG BASE	A216399	002	Jun 08, 2022	Jul	CAHN
	BX	RUBICON	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC
	BX		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC
		TABLET, EXTENDED RELEASE;ORAL						
		GUANFACINE HYDROCHLORIDE						
	AB	FOSUN WANBANG	EQ 1MG BASE	A217638	001	Jun 12, 2024	Mar	CMFD
	@		EQ 1MG BASE	A217638	001	Jun 12, 2024	Jan	CAHN
	AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	Mar	CMFD
	@		EQ 2MG BASE	A217638	002	Jun 12, 2024	Jan	CAHN
	AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	Mar	CMFD
	@		EQ 3MG BASE	A217638	003	Jun 12, 2024	Jan	CAHN
	AB		EQ 4MG BASE	A217638	004	Jun 12, 2024	Mar	CMFD
	@		EQ 4MG BASE	A217638	004	Jun 12, 2024	Jan	CAHN
	AB	RUBICON	EQ 1MG BASE	A219689	001	Apr 15, 2025	Apr	NEWA
	AB		EQ 2MG BASE	A219689	002	Apr 15, 2025	Apr	NEWA
	AB		EQ 3MG BASE	A219689	003	Apr 15, 2025	Apr	NEWA
	AB		EQ 4MG BASE	A219689	004	Apr 15, 2025	Apr	NEWA
		HALCINONIDE						
		CREAM;TOPICAL						
		HALOG						
	@ +	WESTWOOD SQUIBB	0.025%	N017818	001		Aug	CRLD
		OINTMENT;TOPICAL						
		HALOG						
	@ +	BRISTOL MYERS SQUIBB	0.025%	N018125	001		Aug	CRLD
		SOLUTION;TOPICAL						
		HALCINONIDE						
	!	ENCUBE	0.1%	A217671	001	May 29, 2024	Mar	CMFD
	@		0.1%	A217671	001	May 29, 2024	Jan	DISC

HALOBETASOL PROPIONATE

CREAM;TOPICAL

HALOBETASOL PROPIONATE

@	TARO	0.05%	A077227	001	Aug 04, 2005	Aug DISC	

LOTION;TOPICAL

ULTRAVATE

+!	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Apr CMFD	
@ +		0.05%	N208183	001	Nov 06, 2015	Jan CAHN	

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

@	TARO	0.05%	A076994	001	Dec 16, 2004	Aug DISC	

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

AB +!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr CFTG	

HALOBETASOL PROPIONATE AND TAZAROTENE

AB	TARO	0.01%;0.045%	A217190	001	May 02, 2025	Apr NFTG	

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	APPCO	0.5MG	A211061	001	Jan 08, 2020	Feb CAHN	
AB		1MG	A211061	002	Jan 08, 2020	Feb CAHN	
AB		2MG	A211061	003	Jan 08, 2020	Feb CAHN	
AB		5MG	A211061	004	Jan 08, 2020	Feb CAHN	
AB		10MG	A211061	005	Jan 08, 2020	Feb CAHN	
AB		20MG	A211061	006	Jan 08, 2020	Feb CAHN	

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO	CAPLIN	EQ 50MG BASE/ML	A219168	001	May 13, 2025	May NEWA	
AO		EQ 100MG BASE/ML	A219168	002	May 13, 2025	May NEWA	

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb DISC	

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

@	B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan DISC	
>A> AP	EMERGE BIOSCIENCE	1,000 UNITS/ML	A211005	001	Dec 14, 2018	Sep CAHN	
>A> AP		1,000 UNITS/ML	A211007	001	May 28, 2019	Sep CAHN	
>A> AP		5,000 UNITS/ML	A211007	002	May 28, 2019	Sep CAHN	
>A> AP		5,000 UNITS/ML	A212061	001	Jul 15, 2020	Sep CAHN	
>A> AP		10,000 UNITS/ML	A211007	003	May 28, 2019	Sep CAHN	
>A> AP		20,000 UNITS/ML	A211004	001	Feb 24, 2020	Sep CAHN	
	HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan CTEC	
>D> AP	NANJING KING-FRIEND	1,000 UNITS/ML	A211005	001	Dec 14, 2018	Sep CAHN	
>D> AP		1,000 UNITS/ML	A211007	001	May 28, 2019	Sep CAHN	
>D> AP		5,000 UNITS/ML	A211007	002	May 28, 2019	Sep CAHN	
>D> AP		5,000 UNITS/ML	A212061	001	Jul 15, 2020	Sep CAHN	
>D> AP		10,000 UNITS/ML	A211007	003	May 28, 2019	Sep CAHN	
>D> AP		20,000 UNITS/ML	A211004	001	Feb 24, 2020	Sep CAHN	
AP	NORVIUM BIOSCIENCE	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May CAHN	
AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	May CAHN	
AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	May CAHN	
AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	May CAHN	
@	PHARMOBEDIENT	20,000 UNITS/ML	A203852	001	Nov 30, 2017	Aug DISC	
AP	PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar CAHN	
AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar CAHN	
AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar CAHN	

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+!	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar NEWA	
+!		10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar NEWA	

HEPARIN SODIUM PRESERVATIVE FREE

>A> AP	EMERGE BIOSCIENCE	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Sep CAHN	
>D> AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Sep CAHN	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>D>		@	APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN
		@		1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Apr	CAHN
>A>		@	CHARTWELL	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Sep	CAHN
>D>		@	GENUS	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Sep	CAHN
		@	SANKALP LIFECARE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN
>A>		@	SCIEGEN PHARMS INC	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN
	AA		XTTRIUM LABS INC	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

>D>		@	ADRASTEA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN
		@		20MG/ML	A203110	001	Jun 29, 2015	Jun	DISC
	AP		BAXTER HLTHCARE CORP	20MG/ML	A219797	001	Jul 17, 2025	Jul	NEWA
	AP		KINDOS	20MG/ML	A217501	001	Jun 02, 2025	May	NEWA
>A>		@	PHARMOBEDIENT	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

		@	MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Jun	DISC
		@		25MG	A211010	002	Aug 21, 2024	Jun	DISC
		@		50MG	A211010	003	Aug 21, 2024	Jun	DISC
		@		100MG	A211010	004	Aug 21, 2024	Jun	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

>D>	AB		I3 PHARMS	37.5MG;20MG	A215988	001	Jan 17, 2024	Sep	CAHN
>A>	AB		MLV	37.5MG;20MG	A215988	001	Jan 17, 2024	Sep	CAHN
	AB		NOVAST LABS	37.5MG;20MG	A215586	001	Apr 06, 2022	Aug	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

>D>		@	NORVIUM BIOSCIENCE	12.5MG	A075640	001	Jan 28, 2000	Sep	CAHN
>A>		@	QUAGEN	12.5MG	A075640	001	Jan 28, 2000	Sep	CAHN

MICROZIDE

	AB	+!	TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Apr	CAHN

FOR SUSPENSION;ORAL

INZIRQO

		+!	NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan	NEWA

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	AB		UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

	AB		SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025	Jan	NEWA
	AB			25MG;100MG	A215789	002	Jan 08, 2025	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@	GLENMARK PHARMS	12.5MG;7.5MG	A090718	001	Mar 17, 2010	Aug	DISC
		@		12.5MG;15MG	A090718	002	Mar 17, 2010	Aug	DISC
		@		25MG;15MG	A090718	003	Mar 17, 2010	Aug	DISC
			TEVA	12.5MG;7.5MG	A076980	001	Mar 07, 2007	Aug	CTEC
				12.5MG;15MG	A076980	003	Mar 07, 2007	Aug	CTEC
		!		25MG;15MG	A076980	002	Mar 07, 2007	Aug	CTEC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

	AB		ALKEM LABS LTD	12.5MG;20MG	A207037	001	Jul 11, 2024	Aug	CTNA
	AB			12.5MG;40MG	A207037	002	Jul 11, 2024	Aug	CTNA
	AB			25MG;40MG	A207037	003	Jul 11, 2024	Aug	CTNA
>A>	AB		HANGZHOU BINJIANG	12.5MG;20MG	A214427	001	Aug 20, 2025	Sep	CAHN
>A>	AB			12.5MG;40MG	A214427	002	Aug 20, 2025	Sep	CAHN

TABLET;ORAL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A>	AB		25MG;40MG	A214427	003	Aug 20, 2025	Sep	CAHN
	AB	HETERO LABS LTD V	12.5MG;20MG	A209199	001	Jul 25, 2025	Aug	CTNA
	AB		12.5MG;20MG	A209199	001	Jul 25, 2025	Jul	NEWA
	AB		12.5MG;40MG	A209199	002	Jul 25, 2025	Aug	CTNA
	AB		12.5MG;40MG	A209199	002	Jul 25, 2025	Jul	NEWA
	AB		25MG;40MG	A209199	003	Jul 25, 2025	Aug	CTNA
	AB		25MG;40MG	A209199	003	Jul 25, 2025	Jul	NEWA
>A>	AB	MSN	12.5MG;20MG	A217398	001	Sep 26, 2025	Sep	NEWA
>A>	AB		12.5MG;40MG	A217398	002	Sep 26, 2025	Sep	NEWA
>A>	AB		25MG;40MG	A217398	003	Sep 26, 2025	Sep	NEWA
>D>	AB	ZHEJIANG NUODE	12.5MG;20MG	A214427	001	Aug 20, 2025	Sep	CAHN
	AB		12.5MG;20MG	A214427	001	Aug 20, 2025	Aug	NEWA
>D>	AB		12.5MG;40MG	A214427	002	Aug 20, 2025	Sep	CAHN
	AB		12.5MG;40MG	A214427	002	Aug 20, 2025	Aug	NEWA
>D>	AB		25MG;40MG	A214427	003	Aug 20, 2025	Sep	CAHN
	AB		25MG;40MG	A214427	003	Aug 20, 2025	Aug	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan	DISC
	@		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan	DISC
	@		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan	DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL
TELMISARTAN AND HYDROCHLOROTHIAZIDE

	@	MANKIND PHARMA	12.5MG;40MG	A218406	001	Mar 03, 2025	Aug	DISC
	AB		12.5MG;40MG	A218406	001	Mar 03, 2025	Feb	NEWA
	@		12.5MG;80MG	A218406	002	Mar 03, 2025	Aug	DISC
	AB		12.5MG;80MG	A218406	002	Mar 03, 2025	Feb	NEWA
	@		25MG;80MG	A218406	003	Mar 03, 2025	Aug	DISC
	AB		25MG;80MG	A218406	003	Mar 03, 2025	Feb	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@	MACLEODS PHARMS LTD	25MG;37.5MG	A214611	001	Jan 28, 2025	Jun	DISC
	AB		25MG;37.5MG	A214611	001	Jan 28, 2025	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL
HYDROCODONE

	@	STRIDES PHARMA	5MG;200MG	A077723	003	Nov 06, 2006	Apr	CAHN

HYDROCODONE BITARTRATE AND IBUPROFEN

	@	STRIDES PHARMA	7.5MG;200MG	A077723	001	Nov 06, 2006	Apr	CAHN
	@		10MG;200MG	A077723	002	Nov 06, 2006	Apr	CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	@	APOZEAL PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Sep	CAHN
	@		5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Apr	CAHN
>A>	@	SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Sep	CAHN

HYDROCORTISONE

GEL;TOPICAL
NUTRACORT

>D>	@	HEALTHPOINT	1%	A084698	001		Sep	CRLD
>A>	@ +		1%	A084698	001		Sep	CRLD

LOTION;TOPICAL
ALA-SCALP

	+	LEGACY PHARMA	2%	A083231	001		Mar	CRLD

HYDROCORTISONE

	@	TARO	2.5%	A040247	001	Jul 23, 1999	Aug	DISC

STIE-CORT

	!	PADAGIS US	2.5%	A089074	001	Nov 26, 1985	Aug	CTEC

OINTMENT;TOPICAL
HYDROCORTISONE

	@	TARO	1%	A086257	001		Aug	DISC

		SOLUTION;ORAL							
		KHINDIVI							
		+!	ETON	1MG/ML	N218980	001	May 28, 2025	May	NEWA
		TABLET;ORAL							
		HYDROCORTISONE							
	AB		NOVITIUM PHARMA	5MG	A217881	001	May 02, 2025	Apr	NEWA
	AB			10MG	A217881	002	May 02, 2025	Apr	NEWA
	AB			20MG	A217881	003	May 02, 2025	Apr	NEWA
		HYDROCORTISONE ACETATE							
		AEROSOL, METERED;RECTAL							
		CORTIFOAM							
		+!	VIATRIS	10%	N017351	001	Feb 10, 1982	Feb	CAHN
		CREAM;TOPICAL							
		MICORT-HC							
		@	LEGACY PHARMA	2%	A040398	001	Mar 29, 2002	Jan	CAHN
		HYDROCORTISONE BUTYRATE							
		CREAM;TOPICAL							
		HYDROCORTISONE BUTYRATE							
		@	GLENMARK PHARMS LTD	0.1%	A202145	001	Sep 27, 2013	Aug	DISC
		HYDROCORTISONE VALERATE							
		CREAM;TOPICAL							
		HYDROCORTISONE VALERATE							
		@	GLENMARK PHARMS LTD	0.2%	A211129	001	Oct 12, 2018	Jul	DISC
		OINTMENT;TOPICAL							
		HYDROCORTISONE VALERATE							
		@	GLENMARK PHARMS LTD	0.2%	A211750	001	Dec 14, 2018	Aug	DISC
		HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
		SOLUTION/DROPS;OTIC							
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
		@	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Feb	CAHN
		SUSPENSION/DROPS;OTIC							
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
>A>	AT		AMNEAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A217735	001	Sep 30, 2025	Sep	NEWA
>D>	AT		SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Sep	CAHN
	AT			1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Feb	CAHN
>A>	AT		SCIEGEN PHARMS INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Sep	CAHN
		HYDROMORPHONE HYDROCHLORIDE							
		SOLUTION;ORAL							
		HYDROMORPHONE HYDROCHLORIDE							
>A>		@	CHARTWELL	5MG/5ML	A207108	001	Apr 22, 2020	Sep	CAHN
>D>		@	GENUS LIFESCIENCES	5MG/5ML	A207108	001	Apr 22, 2020	Sep	CAHN
		TABLET;ORAL							
		HYDROMORPHONE HYDROCHLORIDE							
>A>		@	CHARTWELL	2MG	A077471	002	Dec 09, 2009	Sep	CAHN
>A>		@		4MG	A077471	003	Dec 09, 2009	Sep	CAHN
>A>		@		8MG	A077471	001	Dec 09, 2009	Sep	CAHN
>D>		@	GENUS LIFESCIENCES	2MG	A077471	002	Dec 09, 2009	Sep	CAHN
>D>		@		4MG	A077471	003	Dec 09, 2009	Sep	CAHN
>D>		@		8MG	A077471	001	Dec 09, 2009	Sep	CAHN
		@	MPP PHARMA	8MG	A076723	001	Oct 18, 2005	Jun	CAHN
		HYDROXYUREA							
		CAPSULE;ORAL							
		DROXIA							
>D>		@ +	CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998	Sep	CAHN
>D>		@ +		300MG	N016295	003	Feb 25, 1998	Sep	CAHN
>D>		@ +		400MG	N016295	004	Feb 25, 1998	Sep	CAHN
>A>		@ +	WAYLIS THERAP	200MG	N016295	002	Feb 25, 1998	Sep	CAHN
>A>		@ +		300MG	N016295	003	Feb 25, 1998	Sep	CAHN
>A>		@ +		400MG	N016295	004	Feb 25, 1998	Sep	CAHN
		HYDREA							
>D>	AB	+!	CHEPLAPHARM	500MG	N016295	001		Sep	CAHN
>A>	AB	+!	WAYLIS THERAP	500MG	N016295	001		Sep	CAHN

		HYDROXYZINE HYDROCHLORIDE						
		SYRUP;ORAL						
		HYDROXYZINE HYDROCHLORIDE						
	AA	BIONPHARMA	10MG/5ML	A219289	001	Apr 28, 2025	Apr	NEWA
	@	RISING	10MG/5ML	A086880	001		Aug	CAHN
		TABLET;ORAL						
		HYDROXYZINE HYDROCHLORIDE						
>D>	@	APPCO	10MG	A040812	001	Mar 12, 2008	Sep	CAHN
	@		10MG	A040812	001	Mar 12, 2008	Apr	CAHN
>D>	@		25MG	A040812	002	Mar 12, 2008	Sep	CAHN
	@		25MG	A040812	002	Mar 12, 2008	Apr	CAHN
>D>	@		50MG	A040812	003	Mar 12, 2008	Sep	CAHN
	@		50MG	A040812	003	Mar 12, 2008	Apr	CAHN
	AB !	GRAVITI PHARMS	50MG	A217652	003	Aug 17, 2023	Mar	CHRS
	AB +	PLIVA	50MG	A088619	001	Jan 10, 1986	Mar	CHRS
>A>	@	SOMERSET THERAPS LLC	10MG	A040812	001	Mar 12, 2008	Sep	CAHN
>A>	@		25MG	A040812	002	Mar 12, 2008	Sep	CAHN
>A>	@		50MG	A040812	003	Mar 12, 2008	Sep	CAHN
	@ +	STRIDES PHARMA	50MG	A087604	001	Jan 22, 1982	Mar	CRLD
		HYDROXYZINE PAMOATE						
		CAPSULE;ORAL						
		HYDROXYZINE PAMOATE						
	AB	BARR LABS	EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984	Mar	CAHN
			EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984	Mar	CAHN
		SUSPENSION;ORAL						
		VISTARIL						
	@ +	PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001		Jul	CRLD
		ICATIBANT ACETATE						
		INJECTABLE;SUBCUTANEOUS						
		ICATIBANT ACETATE						
	@	CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	Apr	CAHN
		ICODEXTRIN						
		SOLUTION;INTRAPERITONEAL						
		EXTRANEAL						
	+!	VANTIVE US HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002	Feb	CAHN
		ICOSAPENT ETHYL						
		CAPSULE;ORAL						
		ICOSAPENT ETHYL						
>A>	AB	PHARMOBEDIENT	1GM	A218994	001	Dec 20, 2024	Sep	CAHN
>D>	AB	SPRIASO LLC	1GM	A218994	001	Dec 20, 2024	Sep	CAHN
	AB	XIAMEN LP PHARM CO	1GM	A219156	001	Aug 06, 2025	Jul	NEWA
		IMATINIB MESYLATE						
		TABLET;ORAL						
		IMATINIB MESYLATE						
	AB	CSPC OUYI	EQ 100MG BASE	A212193	001	Apr 21, 2025	Apr	NEWA
	AB		EQ 400MG BASE	A212193	002	Apr 21, 2025	Apr	NEWA
	AB	HETERO LABS LTD V	EQ 100MG BASE	A212975	001	Apr 14, 2025	Apr	NEWA
	AB		EQ 400MG BASE	A212975	002	Apr 14, 2025	Apr	NEWA
		IMIQUIMOD						
		CREAM;TOPICAL						
		IMIQUIMOD						
	@	APOTEX INC	5%	A091308	001	Apr 06, 2012	Mar	DISC
>A>		IMLUNESTRANT TOSYLATE						
>A>		TABLET;ORAL						
>A>		INLURIYO						
>A>	+!	ELI LILLY AND CO	EQ 200MG BASE	N218881	001	Sep 25, 2025	Sep	NEWA
		INDOCYANINE GREEN						
		INJECTABLE;INJECTION						
		IC-GREEN						
	AP +	RENEW PHARMS	25MG/VIAL	N011525	001		May	CMFD
		INDOCYANINE GREEN						
	AP !	RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	May	CTEC

INDOMETHACIN

SUPPOSITORY;RECTAL

INDOMETHACIN

AB	AMNEAL	50MG	A215399	001	Feb 24, 2025	Feb	NEWA
AB	ANNORA PHARMA	50MG	A216905	001	Jul 03, 2025	Jun	NEWA

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS

ADREVIEW

+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008	Jun	CTEC

IOBENGUANE I-123

@	BWXT MEDCL	10mCi/5ML (2mCi/ML)	A213637	001	Dec 09, 2024	Jun	DISC

IOMEPROL

SOLUTION;INTRA-ARTERIAL

IOMERVU

@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216016	002	Nov 27, 2024	Mar	DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216016	006	Nov 27, 2024	Mar	DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216016	010	Nov 27, 2024	Mar	DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216016	001	Nov 27, 2024	Mar	DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216016	003	Nov 27, 2024	Mar	DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Mar	DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216016	012	Nov 27, 2024	Mar	DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216016	004	Nov 27, 2024	Mar	DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML	N216016	008	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024	Mar	DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Mar	DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Mar	DISC

SOLUTION;INTRAVENOUS

IOMERVU

@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Mar	DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Mar	DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Mar	DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Mar	DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar	DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar	DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar	DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar	DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar	DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar	DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar	DISC

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 300

@ +	LIEBEL-FLARSHEIM	64%	N020923	004	May 13, 1999	Jul	DISC

IPRATROPIUM BROMIDE

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

	@	PHARMOBEDIENT	0.02%	A074755	001	Jan 10, 1997	Jun	CAHN
	@	SUN PHARM	0.02%	A207903	001	Jan 03, 2017	Aug	DISC

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB		LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan	NEWA
AB			0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan	NEWA
AB		RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan	NEWA

IRBESARTAN

TABLET;ORAL

IRBESARTAN

>D>	@	APPCO	75MG	A200461	001	Sep 27, 2012	Sep	CAHN
>D>	@		150MG	A200461	002	Sep 27, 2012	Sep	CAHN
>D>	@		300MG	A200461	003	Sep 27, 2012	Sep	CAHN
>A>	@	YILING	75MG	A200461	001	Sep 27, 2012	Sep	CAHN
>A>	@		150MG	A200461	002	Sep 27, 2012	Sep	CAHN
>A>	@		300MG	A200461	003	Sep 27, 2012	Sep	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

>D> AP		HENGRUI PHARMA	40MG/2ML (20MG/ML)	A090675	002	Dec 16, 2011	Sep	DISC
>A>	@		40MG/2ML (20MG/ML)	A090675	002	Dec 16, 2011	Sep	DISC
>D> AP			100MG/5ML (20MG/ML)	A090675	001	Dec 16, 2011	Sep	DISC
>A>	@		100MG/5ML (20MG/ML)	A090675	001	Dec 16, 2011	Sep	DISC
AP		PHARMOBEDIENT	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Aug	CAHN
AP			100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Aug	CAHN

IRON DEXTRAN

INJECTABLE;INJECTION

DEXFERRUM

	@	AM REGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Aug	CAIN

INFED

BP	+!	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001		Aug	CAIN

IRON DEXTRAN

	@	SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002		Aug	CAIN

PROFERDEX

	@	NEW RIVER	EQ 50MG IRON/ML	N017807	001		Aug	CAIN

IRON SUCROSE

INJECTABLE;INTRAVENOUS

IRON SUCROSE

AB		INTL MEDICATION SYS	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A208977	001	Aug 08, 2025	Aug	NFTG
AB			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A208977	002	Aug 08, 2025	Aug	NFTG
AB			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A208977	003	Aug 08, 2025	Aug	NFTG
AB		MYLAN LABS LTD	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A212559	001	Aug 08, 2025	Aug	NFTG
AB			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A212559	002	Aug 08, 2025	Aug	NFTG
AB			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A212559	003	Aug 08, 2025	Aug	NFTG
AB		SANDOZ	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A212340	001	Aug 08, 2025	Aug	NFTG
AB			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A212340	002	Aug 08, 2025	Aug	NFTG
AB			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A212340	003	Aug 08, 2025	Aug	NFTG

VENOFER

AB	+	AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005	Aug	CFTG
	+		EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005	Aug	CAIN
	@		EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013	Aug	CAIN
	@		EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005	Aug	CAIN
AB	+!		EQ 100MG IRON/5ML (EQ 20MG	N021135	001	Nov 06, 2000	Aug	CFTG

		INJECTABLE;INTRAVENOUS							
		VENOFER							
				IRON/ML)					
		+!		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000		Aug CAIN
	AB	+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007		Aug CFTG
		+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007		Aug CAIN
		ISOCARBOXAZID							
		TABLET;ORAL							
		MARPLAN							
		+!	LIFSA DRUGS	10MG	N011961	001			Jun CAHN
		ISONIAZID							
		SYRUP;ORAL							
		ISONIAZID							
	AA		CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997		Feb CMFD
	AA	+!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983		Feb CTEC
		TABLET;ORAL							
		ISONIAZID							
		@	GENUS	100MG	A080936	001			Aug DISC
		@		300MG	A080937	002			Aug DISC
	AA	!	OMNIVIUM PHARMS	100MG	A040090	001	Jun 26, 1997		Aug CHRS
	AA	!		300MG	A040090	002	Jun 26, 1997		Aug CHRS
		ISOSORBIDE DINITRATE							
		TABLET;ORAL							
		ISOSORBIDE DINITRATE							
	AB		HIKMA INTL PHARMS	5MG	A088088	003	Oct 29, 1987		Jul CMS1
	AB			10MG	A088088	002	Oct 29, 1987		Jul CMS1
		TABLET;SUBLINGUAL							
		ISOSORBIDE DINITRATE							
		@	HIKMA INTL PHARMS	2.5MG	A086055	002	Oct 29, 1987		Jul CMS1
		ISOSULFAN BLUE							
		SOLUTION;SUBCUTANEOUS							
		ISOSULFAN BLUE							
		@	SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019		Jun CAHN
		ISOTRETINOIN							
		CAPSULE;ORAL							
		AMNESTEEM							
	AB1		MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025		Mar NEWA
		ISOTRETINOIN							
>A>	AB2		AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025		Sep NEWA
>A>	AB2			20MG	A216097	002	Oct 07, 2025		Sep NEWA
>A>	AB2			25MG	A216097	003	Oct 07, 2025		Sep NEWA
>A>	AB2			30MG	A216097	004	Oct 07, 2025		Sep NEWA
>A>	AB2			35MG	A216097	005	Oct 07, 2025		Sep NEWA
>A>	AB2			40MG	A216097	006	Oct 07, 2025		Sep NEWA
	AB2		ZYDUS PHARMS	10MG	A216633	001	May 22, 2025		May NEWA
	AB2			20MG	A216633	002	May 22, 2025		May NEWA
	AB2			25MG	A216633	003	May 22, 2025		May NEWA
	AB2			30MG	A216633	004	May 22, 2025		May NEWA
	AB2			35MG	A216633	005	May 22, 2025		May NEWA
	AB2			40MG	A216633	006	May 22, 2025		May NEWA
		ITRACONAZOLE							
		CAPSULE;ORAL							
		ITRACONAZOLE							
	AB		RISING	100MG	A205724	001	Dec 13, 2016		Feb CMFD
		SOLUTION;ORAL							
		ITRACONAZOLE							
	AA	!	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015		Aug CHRS
		SPORANOX							
		@ +	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997		Aug DISC

IVABRADINE HYDROCHLORIDE

TABLET;ORAL
IVABRADINE HYDROCHLORIDE

	AB		MSN	EQ 5MG BASE	A213483	001	Apr 28, 2025	Apr NEWA
	AB			EQ 7.5MG BASE	A213483	002	Apr 28, 2025	Apr NEWA

IVERMECTIN

TABLET;ORAL
IVERMECTIN

	AB		EPIC PHARMA LLC	3MG	A218805	001	Sep 09, 2025	Aug NEWA
	AB		RUBICON	3MG	A215922	001	Jan 22, 2025	Jan NEWA
				6MG	A215922	002	Jan 22, 2025	Jan NFTG

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
KETAMINE HYDROCHLORIDE

>A>	AP		CAPLIN	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Sep CAHN
	AP		FRESENIUS KABI USA	EQ 100MG BASE/ML	A215808	003	Apr 18, 2025	Apr NEWA
>D>	AP		PHARMATHER	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Sep CAHN
	AP			EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Aug NEWA

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
KETAMINE HYDROCHLORIDE

>A>		!	BAXTER HLTHCARE CORP	EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A219684	001	Sep 17, 2025	Sep NEWA

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL
EXTINA

		@ +	RISING	2%	N021738	001	Jun 12, 2007	Aug CAHN

CREAM;TOPICAL
KETOCONAZOLE

>D>	AB		ENCUBE	2%	A212443	001	May 20, 2021	Sep CHRS
>A>	AB	!		2%	A212443	001	May 20, 2021	Sep CHRS
>A>	AB		PADAGIS US	2%	A215185	001	Nov 17, 2021	Sep CAHN
>D>	AB	!	TEVA	2%	A075581	001	Apr 25, 2000	Sep CHRS
>A>	AB			2%	A075581	001	Apr 25, 2000	Sep CHRS
>A>	AB		TP ANDA HOLDINGS	2%	A215185	001	Nov 17, 2021	Sep CAHN
>D>	AB		TRUPHARMA	2%	A215185	001	Nov 17, 2021	Sep CAHN

GEL;TOPICAL
XOLEGEL

		@ +	INA PHARMS	2%	N021946	001	Jul 28, 2006	May CAHN

SHAMPOO;TOPICAL
KETOCONAZOLE

	AB		ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025	Feb NEWA

TABLET;ORAL
KETOCONAZOLE

	AB		ESJAY PHARMA	200MG	A219129	001	Jul 03, 2025	Jun NEWA
	AB		NOVITIUM PHARMA	200MG	A219129	001	Jul 03, 2025	Aug CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

		@	FRESENIUS KABI USA	15MG/ML	A203242	001	Oct 07, 2015	Jul DISC
		@	HOSPIRA	30MG/ML	A074993	002	Jan 27, 1999	Jul DISC
		@	SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008	Jul DISC
		@		30MG/ML	A078737	002	Oct 06, 2008	Jul DISC

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

>A>	AP		AMNEAL	5MG/ML	A218870	001	Oct 02, 2025	Sep NEWA

TABLET;ORAL
LABETALOL HYDROCHLORIDE

>A>	AB		MACLEODS PHARMS LTD	100MG	A217949	001	Sep 23, 2025	Sep NEWA
>A>	AB			200MG	A217949	002	Sep 23, 2025	Sep NEWA
>A>	AB			300MG	A217949	003	Sep 23, 2025	Sep NEWA
	AB		RUBICON RESEARCH	100MG	A211953	001	Aug 18, 2021	Jul CAHN
	AB			200MG	A211953	002	Aug 18, 2021	Jul CAHN
	AB			300MG	A211953	003	Aug 18, 2021	Jul CAHN

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE

	AP		WESTMINSTER PHARMS	200MG/20ML (10MG/ML)	A218706	001	May 23, 2025	May NEWA

SOLUTION;ORAL

LACOSAMIDE

	AA		AJENAT PHARMS	10MG/ML	A219699	001	Jun 26, 2025	Jun NEWA
	AA		APOTEX	10MG/ML	A206355	001	Sep 26, 2022	May CMFD
		@		10MG/ML	A206355	001	Sep 26, 2022	Feb DISC
>A>	AA		KANCHAN HLTHCARE	10MG/ML	A216461	001	Feb 06, 2023	Sep CAHN
>D>	AA		MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Sep CAHN

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

	AA	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Mar CTEC
	AA	!		20GM/PACKET	A074712	002	Dec 10, 1997	Mar CTEC
	AA		PAI HOLDINGS	10GM/PACKET	A217914	001	Mar 14, 2025	Mar NEWA
	AA			20GM/PACKET	A217914	002	Mar 14, 2025	Mar NEWA

SOLUTION;ORAL

LACTULOSE

		@	VISTAPHARM LLC	10GM/15ML	A074138	001	Sep 30, 1992	Jan CAHN

SOLUTION;ORAL, RECTAL

LACTULOSE

>D>	AA		APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Sep CAHN
>A>	AA		SCIEGEN PHARMS INC	10GM/15ML	A203762	001	Mar 27, 2015	Sep CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

	AB		APPCO	150MG	A206974	001	Nov 21, 2016	Mar CAHN
	AB			300MG	A206974	002	Nov 21, 2016	Mar CAHN
		@	NORVIUM BIOSCIENCE	150MG	A078545	001	Mar 05, 2019	Feb CAHN
		@		300MG	A078545	002	Mar 05, 2019	Feb CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

	AB		NORVIUM BIOSCIENCE	150MG;300MG	A079128	001	May 13, 2015	May CAHN

LAMOTRIGINE

>A>			SUSPENSION;ORAL					
>A>			SUBVENITE					
>A>		+!	OWP PHARMS	10MG/ML	N218879	001	Sep 16, 2025	Sep NEWA

TABLET;ORAL

LAMOTRIGINE

		@	AIPING PHARM INC	25MG	A078645	001	Jan 27, 2009	Jan CAHN
		@		100MG	A078645	002	Jan 27, 2009	Jan CAHN
		@		150MG	A078645	003	Jan 27, 2009	Jan CAHN
		@		200MG	A078645	004	Jan 27, 2009	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>D>		@	PH HEALTH	25MG	A201374	001	Dec 26, 2012	Sep CMFD
>A>	AB			25MG	A201374	001	Dec 26, 2012	Sep CMFD
>D>		@		50MG	A201374	002	Dec 26, 2012	Sep CMFD
>A>	AB			50MG	A201374	002	Dec 26, 2012	Sep CMFD
>D>		@		100MG	A201374	003	Dec 26, 2012	Sep CMFD
>A>	AB			100MG	A201374	003	Dec 26, 2012	Sep CMFD
>D>		@		200MG	A201374	004	Dec 26, 2012	Sep CMFD
>A>	AB			200MG	A201374	004	Dec 26, 2012	Sep CMFD
>D>		@		250MG	A201374	005	Dec 26, 2012	Sep CMFD
>A>	AB			250MG	A201374	005	Dec 26, 2012	Sep CMFD
>D>		@		300MG	A201374	006	Dec 26, 2012	Sep CMFD
>A>	AB			300MG	A201374	006	Dec 26, 2012	Sep CMFD

TABLET, FOR SUSPENSION;ORAL

LAMOTRIGINE

		@	TARO	5MG	A079204	001	Feb 04, 2009	Aug DISC
		@		25MG	A079204	002	Feb 04, 2009	Aug DISC

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

>A>	AB		TARO	25MG	A219677	001	Oct 07, 2025	Sep NEWA
>A>	AB			50MG	A219677	002	Oct 07, 2025	Sep NEWA
>A>	AB			100MG	A219677	003	Oct 07, 2025	Sep NEWA
>A>	AB			200MG	A219677	004	Oct 07, 2025	Sep NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

	@		MACLEODS PHARMS LTD	15MG	A208671	001	Nov 04, 2024	Jun DISC
	@			30MG	A208671	002	Nov 04, 2024	Jun DISC

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

AB			ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar NEWA
AB				EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar NEWA
AB				EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

	@		CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Apr CAHN
AT			MICRO LABS	0.005%	A219306	001	Apr 14, 2025	Apr NEWA

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC
LATANOPROSTENE BUNOD

AB			GLAND	0.024%	A217387	001	Apr 29, 2025	Apr NFTG
	VYZULTA							
AB		+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Apr CFTG

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE

AB			FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan CAHN
AB				20MG	A077087	002	Sep 13, 2005	Jan CAHN

LENACAPAVIR SODIUM

SOLUTION;SUBCUTANEOUS
YEZTUGO

		+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N220018	001	Jun 18, 2025	Jun NEWA

TABLET;ORAL
YEZTUGO

		+!	GILEAD SCIENCES INC	EQ 300MG BASE	N220020	001	Jun 18, 2025	Jun NEWA

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

	@		AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Jun DISC
AB				2.5MG	A216213	001	Jan 31, 2025	Jan NEWA
	@			5MG	A216213	002	Jan 31, 2025	Jun DISC
AB				5MG	A216213	002	Jan 31, 2025	Jan NEWA
	@			10MG	A216213	003	Jan 31, 2025	Jun DISC
AB				10MG	A216213	003	Jan 31, 2025	Jan NEWA
	@			15MG	A216213	004	Jan 31, 2025	Jun DISC
AB				15MG	A216213	004	Jan 31, 2025	Jan NEWA
	@			20MG	A216213	005	Jan 31, 2025	Jun DISC
AB				20MG	A216213	005	Jan 31, 2025	Jan NEWA
	@			25MG	A216213	006	Jan 31, 2025	Jun DISC
AB				25MG	A216213	006	Jan 31, 2025	Jan NEWA
AB			BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb NEWA
AB				5MG	A215759	002	Mar 03, 2025	Feb NEWA
AB				10MG	A215759	003	Mar 03, 2025	Feb NEWA
AB				15MG	A215759	004	Mar 03, 2025	Feb NEWA
AB				20MG	A215759	005	Mar 03, 2025	Feb NEWA
AB				25MG	A215759	006	Mar 03, 2025	Feb NEWA
AB			DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025	May NEWA
AB				5MG	A217554	002	May 22, 2025	May NEWA
AB				10MG	A217554	003	May 22, 2025	May NEWA

CAPSULE;ORAL
LENALIDOMIDE

	AB		15MG	A217554	004	May 22, 2025	May	NEWA
	AB		20MG	A217554	005	May 22, 2025	May	NEWA
	AB		25MG	A217554	006	May 22, 2025	May	NEWA
>A>	AB	LUPIN LTD	2.5MG	A214398	001	Sep 16, 2025	Sep	NEWA
>A>	AB		5MG	A214398	002	Sep 16, 2025	Sep	NEWA
>A>	AB		10MG	A214398	003	Sep 16, 2025	Sep	NEWA
>A>	AB		15MG	A214398	004	Sep 16, 2025	Sep	NEWA
>A>	AB		20MG	A214398	005	Sep 16, 2025	Sep	NEWA
>A>	AB		25MG	A214398	006	Sep 16, 2025	Sep	NEWA

LETROZOLE
TABLET;ORAL
LETROZOLE

>A>		@ CARNEGIE	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN
>D>		@ RYAN LABS	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN

LEUPROLIDE ACETATE
SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

	AP	ENDO OPERATIONS	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	May	NEWA
		@ PH HEALTH	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	Aug	DISC

LEUPROLIDE MESYLATE
EMULSION;SUBCUTANEOUS
CAMCEVI ETM

		+! FORESEE PHARMS	EQ 21MG BASE	N219745	001	Aug 25, 2025	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE
SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

		@ MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr	DISC
		@	EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr	DISC
		@	EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr	DISC

LEVETIRACETAM
INJECTABLE;INTRAVENOUS
LEVETIRACETAM IN SODIUM CHLORIDE

	AP	CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan	NEWA
	AP		1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan	NEWA
	AP		1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan	NEWA

SOLUTION;ORAL
LEVETIRACETAM

	AA	AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan	CAHN
	AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	May	CMFD

TABLET;ORAL
LEVETIRACETAM

>A>	AB	ANDA REPOSITORY	250MG	A076920	001	Jan 15, 2009	Sep	CAHN
>A>	AB		500MG	A076920	002	Jan 15, 2009	Sep	CAHN
>A>	AB		750MG	A076920	003	Jan 15, 2009	Sep	CAHN
		@ CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015	Jan	CAHN
		@	1GM	A205102	003	Dec 16, 2015	Jan	CAHN
		@ MPP PHARMA	250MG	A090511	001	Aug 18, 2011	Jun	CAHN
		@	500MG	A090511	002	Aug 18, 2011	Jun	CAHN
		@	750MG	A090511	003	Aug 18, 2011	Jun	CAHN
		@	1GM	A090511	004	Aug 18, 2011	Jun	CAHN
>D>	AB	SENORES PHARMS	250MG	A076920	001	Jan 15, 2009	Sep	CAHN
>D>	AB		500MG	A076920	002	Jan 15, 2009	Sep	CAHN
>D>	AB		750MG	A076920	003	Jan 15, 2009	Sep	CAHN
		@ TARO	250MG	A078960	004	Feb 01, 2010	Aug	DISC
		@	500MG	A078960	003	Feb 01, 2010	Aug	DISC
		@	750MG	A078960	002	Feb 01, 2010	Aug	DISC
		@	1GM	A078960	001	Feb 01, 2010	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

		@ APOTEX	1GM	A202958	001	Feb 25, 2015	Mar	DISC

TABLET, FOR SUSPENSION;ORAL
SPRITAM

		+! APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr	CHRS
		@ +	750MG	N207958	003	Jul 31, 2015	Apr	DISC
		@ +	1GM	N207958	004	Jul 31, 2015	Apr	DISC

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

AP		DEVA HOLDING AS	200MG/ML	A217430	001	Jun 30, 2025	Jun NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	@	TARO	2.5MG/5ML	A202673	001	Jul 26, 2013	Aug DISC

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb CAHN

LEVODOPA

POWDER;INHALATION

INBRIJA

	+!	MERZ	42MG	N209184	001	Dec 21, 2018	Feb CAHN

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

>D>	@	ANDA REPOSITORY	250MG	A090367	001	Jun 20, 2011	Sep CAHN
>D>	@		500MG	A090367	002	Jun 20, 2011	Sep CAHN
>D>	@		750MG	A090367	003	Jun 20, 2011	Sep CAHN
	@	APOTEX INC	250MG	A090787	001	Sep 29, 2011	Mar DISC
	@		500MG	A090787	002	Sep 29, 2011	Mar DISC
	@		750MG	A090787	003	Sep 29, 2011	Mar DISC
>A>	@	CHARTWELL RX	250MG	A090367	001	Jun 20, 2011	Sep CAHN
>A>	@		500MG	A090367	002	Jun 20, 2011	Sep CAHN
>A>	@		750MG	A090367	003	Jun 20, 2011	Sep CAHN

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB		ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr CAHN
BX		NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar CTEC
BX			2MG	A213479	001	Jul 01, 2020	Mar CTEC
BX			3MG	A213479	002	Jan 12, 2021	Mar CTEC
AB			3MG	A213479	002	Jan 12, 2021	Mar CHRS
	!	SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar CTEC
AB	!		3MG	A213906	002	Apr 25, 2023	Mar CHRS

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

	@	ANI PHARMS	0.075MG	A211369	001	Oct 28, 2020	Jun CAHN
	@		0.088MG	A213256	001	Jan 06, 2021	Jun CAHN
	@		0.1MG	A213256	002	Jan 06, 2021	Jun CAHN
	@		0.112MG	A211369	003	Apr 16, 2021	Jun CAHN
	@		0.125MG	A213256	003	Jan 06, 2021	Jun CAHN
	@		0.137MG	A211369	005	May 02, 2023	Jun CAHN
	@		0.15MG	A211369	002	Oct 28, 2020	Jun CAHN
	@		0.175MG	A211369	006	May 02, 2023	Jun CAHN
	@		0.2MG	A211369	004	Nov 09, 2022	Jun CAHN

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP		ONESOURCE SPECIALTY	100MCG/VIAL	A216729	001	Mar 05, 2025	May CAHN
AP			200MCG/VIAL	A216729	002	Mar 05, 2025	May CAHN
AP			500MCG/VIAL	A216729	003	Mar 05, 2025	May CAHN
AP		STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	Feb NEWA
AP			200MCG/VIAL	A216729	002	Mar 05, 2025	Feb NEWA
AP			500MCG/VIAL	A216729	003	Mar 05, 2025	Feb NEWA

SOLUTION;ORAL

THYQUIDITY

	+!	STEVENS J	100MCG/5ML	N214047	001	Nov 30, 2020	Apr CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr CAHN
AB2		0.05MG	N021292	002	May 31, 2002	Apr CAHN
AB2		0.075MG	N021292	003	May 31, 2002	Apr CAHN
AB2		0.088MG	N021292	004	May 31, 2002	Apr CAHN
AB2		0.1MG	N021292	005	May 31, 2002	Apr CAHN
AB2		0.112MG	N021292	006	May 31, 2002	Apr CAHN
AB2		0.125MG	N021292	007	May 31, 2002	Apr CAHN
AB2		0.137MG	N021292	008	May 31, 2002	Apr CAHN
AB2		0.15MG	N021292	009	May 31, 2002	Apr CAHN
AB2		0.175MG	N021292	010	May 31, 2002	Apr CAHN
AB2		0.2MG	N021292	011	May 31, 2002	Apr CAHN
@		0.3MG	N021292	012	May 31, 2002	Apr CAHN

LEVOTHYROXINE SODIUM

@	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan DISC
@		0.15MG	A216414	002	Jul 16, 2024	Jan DISC
@		0.175MG	A216414	003	Jul 16, 2024	Jan DISC
@		0.2MG	A216414	004	Jul 16, 2024	Jan DISC
@		0.3MG	A216414	005	Jul 16, 2024	Jan DISC
AB1,AB2, AB3,AB4	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.025MG	A211417	001	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4		0.3MG	A211417	012	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4		0.3MG	A211417	012	Dec 21, 2022	Feb CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

BX	ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar CTEC
AT	CHARTWELL RX	5%	A208660	001	Jan 05, 2021	Apr CAHN

PATCH;TOPICAL
LIDOCAINE

>A>	AB		ALKEM LABS LTD	5%	A216484	001	Oct 06, 2025	Sep NEWA
>D>	AB		AVEVA	1.8%	A217221	001	Mar 25, 2025	Sep CAHN
	AB			1.8%	A217221	001	Mar 25, 2025	Mar NFTG
>A>	AB		DIFGEN PHARMS	1.8%	A217221	001	Mar 25, 2025	Sep CAHN

ZTLIDO

	AB	+!	SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar CFTG

SYSTEM;TOPICAL
BONDLIDO

>A>		+!	MEDRX USA	10%	N215029	001	Sep 24, 2025	Sep NEWA

LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

		@	AFAXYS	1%	A215132	001	Jun 09, 2022	Jul DISC
>D>	AP		ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Sep CAHN
	AP			1%	A219535	001	Apr 02, 2025	Mar NEWA
>A>	AP		NEOCUBES PHARMA	1%	A219535	001	Apr 02, 2025	Sep CAHN
>D>	AP		SINTETICA US	1%	A214267	001	Sep 19, 2022	Sep CAHN
>D>	AP			2%	A214267	002	Sep 19, 2022	Sep CAHN
>D>	AP			4%	A214269	001	May 05, 2022	Sep CAHN
>A>	AP		YILING	1%	A214267	001	Sep 19, 2022	Sep CAHN
>A>	AP			2%	A214267	002	Sep 19, 2022	Sep CAHN
>A>	AP			4%	A214269	001	May 05, 2022	Sep CAHN

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

		@	EUGIA PHARMA	1%	A203040	001	Mar 14, 2013	Jul DISC
		@		2%	A203040	002	Mar 14, 2013	Jul DISC

SOLUTION;ORAL
LIDOCAINE HYDROCHLORIDE

	AT		AUROBINDO PHARMA LTD	2%	A219759	001	Jul 29, 2025	Jul NEWA
	AT		XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb CAHN

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

	AT		XTTRIUM LABS INC	4%	A087881	001	Nov 18, 1982	Feb CAHN

LIDOCAINE; TETRACAINE
CREAM;TOPICAL
PLIAGLIS

>D>		@ +	CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Sep CMFD
>A>		+!		7%;7%	N021717	001	Jun 29, 2006	Sep CMFD

LINAGLIPTIN
TABLET;ORAL
LINAGLIPTIN

>D>		@	ZYDUS PHARMS	5MG	A208448	001	Mar 30, 2023	Sep CMFD
>A>	AB			5MG	A208448	001	Mar 30, 2023	Sep CMFD

LINAGLIPTIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

>D>		@	ZYDUS PHARMS	2.5MG;500MG	A208449	001	Mar 30, 2023	Sep CMFD
>A>	AB			2.5MG;500MG	A208449	001	Mar 30, 2023	Sep CMFD
>D>		@		2.5MG;850MG	A208449	002	Mar 30, 2023	Sep CMFD
>A>	AB			2.5MG;850MG	A208449	002	Mar 30, 2023	Sep CMFD
>D>		@		2.5MG;1GM	A208449	003	Mar 30, 2023	Sep CMFD
>A>	AB			2.5MG;1GM	A208449	003	Mar 30, 2023	Sep CMFD

LINEZOLID
SOLUTION;INTRAVENOUS
LINEZOLID

	AP		NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Feb CAHN
	AP			600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Feb CAHN

TABLET;ORAL
LINEZOLID

		@	MACLEODS PHARMS LTD	600MG	A210378	001	Oct 10, 2024	Jun DISC

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

TRIOSTAT

@ +	PH HEALTH	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jul	CAHN

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

LIRAGLUTIDE

AP1	HIKMA	18MG/3ML (6MG/ML)	A215503	001	Dec 23, 2024	Aug	CTEC
AP1	LUPIN LTD	18MG/3ML (6MG/ML)	A215421	001	Jul 22, 2025	Aug	CTEC
AP		18MG/3ML (6MG/ML)	A215421	001	Jul 22, 2025	Jul	NEWA
AP1	NANJING KING FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Aug	CTEC
AP	NANJING KING-FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Mar	NEWA
AP2	TEVA PHARMS	18MG/3ML (6MG/ML)	A214568	001	Aug 27, 2025	Aug	NFTG

SAXENDA

AP2 +!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Aug	CFTG

VICTOZA

AP1 +!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Aug	CTEC

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	GRANULES	10MG	A218987	001	Jan 29, 2025	Jan	NEWA
AB		20MG	A218987	002	Jan 29, 2025	Jan	NEWA
AB		30MG	A218987	003	Jan 29, 2025	Jan	NEWA
AB		40MG	A218987	004	Jan 29, 2025	Jan	NEWA
AB		50MG	A218987	005	Jan 29, 2025	Jan	NEWA
AB		60MG	A218987	006	Jan 29, 2025	Jan	NEWA
AB		70MG	A218987	007	Jan 29, 2025	Jan	NEWA
AB	SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan	CMFD
AB		30MG	A202836	002	Jul 26, 2024	Jan	CMFD
AB		40MG	A202836	003	Jul 26, 2024	Jan	CMFD
AB		50MG	A202836	004	Jul 26, 2024	Jan	CMFD
AB		60MG	A202836	005	Jul 26, 2024	Jan	CMFD
AB		70MG	A202836	006	Jul 26, 2024	Jan	CMFD

SOLUTION;ORAL

ARYNTA

+!	AZURITY	10MG/ML	N219847	001	Jun 16, 2025	Jun	NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

@	NORVIUM BIOSCIENCE	300MG	A202288	001	Jun 29, 2012	Jul	DISC
@		450MG	A202219	001	Aug 08, 2012	Mar	DISC
AB		450MG	A202219	001	Aug 08, 2012	Feb	CAHN

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

@ +	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993	May	DISC

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

AB	MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb	NEWA

LUCEMYRA

AB +!	BIOCORRX PHARMS	EQ 0.18MG BASE	N209229	001	May 16, 2018	May	CAHN

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

@ +	AZURITY	5MG	N017588	004	Dec 19, 2014	Aug	CAHN
+		10MG	N017588	001		Aug	CAHN
+!		40MG	N017588	002		Aug	CAHN
+		100MG	N017588	003		Aug	CAHN

LORAZEPAM

INJECTABLE;INJECTION

LORAZEPAM

	@		AVIV PHARMA	1MG/0.5ML	A074551	003	Sep 12, 1996	May CAHN
	@			2MG/ML	A074535	001	Sep 12, 1996	Apr CAHN
	@			2MG/ML	A074551	001	Sep 12, 1996	May CAHN
	@			4MG/ML	A074535	002	Sep 12, 1996	Apr CAHN
	@			4MG/ML	A074551	002	Sep 12, 1996	May CAHN
	@		HOSPIRA	2MG/ML	A074282	001	May 27, 1994	Apr DISC
	@			4MG/ML	A074282	002	May 27, 1994	Apr DISC

TABLET;ORAL

LORAZEPAM

	AB		AUROBINDO PHARMA	0.5MG	A203572	001	Dec 22, 2017	Aug CAHN
	AB			1MG	A203572	002	Dec 22, 2017	Aug CAHN
	AB			2MG	A203572	003	Dec 22, 2017	Aug CAHN
	AB		GRAVITI PHARMS	0.5MG	A218597	001	Jul 24, 2025	Jul NEWA
	AB			1MG	A218597	002	Jul 24, 2025	Jul NEWA
	AB			2MG	A218597	003	Jul 24, 2025	Jul NEWA

LOSARTAN POTASSIUM

SUSPENSION;ORAL

ARBLI

		+!	SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025	Mar NEWA

TABLET;ORAL

LOSARTAN POTASSIUM

	AB		AIPING PHARM INC	25MG	A090544	001	Oct 06, 2010	Jul CMFD
	AB			50MG	A090544	002	Oct 06, 2010	Jul CMFD
	AB			100MG	A090544	003	Oct 06, 2010	Jul CMFD
	@		APOTEX	25MG	A218551	001	Jun 04, 2024	Jan DISC
	@			50MG	A218551	002	Jun 04, 2024	Jan DISC
	@			100MG	A218551	003	Jun 04, 2024	Jan DISC
>A>	AB		GRAVITI PHARMS	25MG	A219859	001	Sep 19, 2025	Sep NEWA
>A>	AB			50MG	A219859	002	Sep 19, 2025	Sep NEWA
>A>	AB			100MG	A219859	003	Sep 19, 2025	Sep NEWA

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX SM

	AB	+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Jun CFTG

LOTEPREDNOL ETABONATE

>D>		@	HIKMA	0.5%	A213956	001	Nov 29, 2023	Sep CMFD
>A>	AB			0.5%	A213956	001	Nov 29, 2023	Sep CMFD
	AB		LUPIN LTD	0.38%	A218087	001	Jun 30, 2025	Jun NFTG

SUSPENSION/DROPS;OPHTHALMIC

LOTEPREDNOL ETABONATE

	AB		AMNEAL	0.5%	A217484	001	May 20, 2025	May NEWA
	AB		PADAGIS US	0.5%	A215204	001	Jan 29, 2025	Jan NEWA

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

	@	+	COVIS	20MG	N021316	002	Jun 26, 2002	May DISC
	@	+		40MG	N021316	003	Jun 26, 2002	May DISC
	@	+		60MG	N021316	004	Jun 26, 2002	May DISC

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

>D>	AB		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Sep DISC
>A>		@		8MCG	A209450	001	Nov 30, 2021	Sep DISC
>D>	AB			24MCG	A209450	002	Nov 30, 2021	Sep DISC
>A>		@		24MCG	A209450	002	Nov 30, 2021	Sep DISC

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

	AB		CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar CAHN
	AB			40MG	A212091	002	Dec 28, 2020	Mar CAHN
	AB			60MG	A212091	003	Dec 28, 2020	Mar CAHN
	AB			80MG	A212091	004	Dec 28, 2020	Mar CAHN
	AB			120MG	A212091	005	Dec 28, 2020	Mar CAHN

TABLET;ORAL
LURASIDONE HYDROCHLORIDE

AB		TORRENT	60MG	A208055	005	Jan 13, 2025	Jan	NEWA

MACITENTAN

TABLET;ORAL
MACITENTAN

AB		ALEMBIC	10MG	A211128	001	Aug 18, 2025	Aug	NEWA
AB		MSN	10MG	A211136	001	Aug 20, 2025	Aug	NEWA
AB		SUN PHARM	10MG	A211123	001	Aug 26, 2025	Aug	NEWA

OPSUMIT

AB	+!	ACTELION	10MG	N204410	001	Oct 18, 2013	Aug	CTEC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

@		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun	DISC

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001		Jun	CTEC

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP		ASPIRO	1GM/2ML (500MG/ML)	A219777	001	May 28, 2025	May	NFTG
AP			5GM/10ML (500MG/ML)	A219777	002	May 28, 2025	May	NEWA
AP			10GM/20ML (500MG/ML)	A219777	003	May 28, 2025	May	NEWA
AP			25GM/50ML (500MG/ML)	A219777	004	May 28, 2025	May	NFTG
AP	+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	May	CFTG
AP	+!		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	May	CFTG

MANGANESE CHLORIDE

INJECTABLE;INJECTION
MANGANESE CHLORIDE

AP		FRESENIUS KABI USA	EQ 0.1MG MANGANESE/ML	A217583	001	Jul 07, 2025	Jun	NFTG

MANGANESE CHLORIDE IN PLASTIC CONTAINER

AP	+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Jun	CFTG

MARALIXIBAT CHLORIDE

TABLET;ORAL
LIVMARLI

	+	MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Apr	NEWA
	+		EQ 15MG BASE	N219485	002	Apr 10, 2025	Apr	NEWA
	+		EQ 20MG BASE	N219485	003	Apr 10, 2025	Apr	NEWA
	+!		EQ 30MG BASE	N219485	004	Apr 10, 2025	Apr	NEWA

MARAVIROC

TABLET;ORAL
MARAVIROC

AB		NAVINTA LLC	150MG	A217880	001	May 13, 2025	May	NEWA
AB			300MG	A217880	002	May 13, 2025	May	NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
MECLIZINE HYDROCHLORIDE

>D> AA		ALLIED	25MG	A084092	003	May 22, 1989	Sep	CAHN
AA			25MG	A084092	003	May 22, 1989	Jul	CAHN
	@	HERITAGE	12.5MG	A205136	001	Feb 22, 2019	Jul	CAHN
	@		25MG	A205136	002	Feb 22, 2019	Jul	CAHN
	@		50MG	A205136	003	Feb 22, 2019	Jul	CAHN
	@	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Jun	CAHN
	@		25MG	A205136	002	Feb 22, 2019	Jun	CAHN
	@		50MG	A205136	003	Feb 22, 2019	Jun	CAHN
>A> AA		SCIEGEN PHARMS INC	25MG	A084092	003	May 22, 1989	Sep	CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

	AB		AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan CAHN
		@	MPP PHARMA	250MG	A090359	001	Feb 05, 2013	Jun CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

	AB		CHARTWELL RX	250MG	A076175	001	Feb 20, 2002	Jun CMFD
>D>	AB		HIKMA	250MG	A076523	001	Oct 01, 2004	Sep DISC
>A>		@		250MG	A076523	001	Oct 01, 2004	Sep DISC

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE ES

		@ +	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	Feb DISC

MEGESTROL ACETATE

		!	TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014	Feb CTEC
	AB	!		125MG/ML	A203139	001	Aug 27, 2014	Feb CHRS
	AB		XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Apr CMFD

MELOXICAM

SOLUTION;INTRAVENOUS

QAMZOVA

		+!	NANJING DELOVA	30MG/ML (30MG/ML)	N217593	001	Apr 22, 2025	Apr NEWA

XIFYRM

		+!	AZURITY	30MG/ML (30MG/ML)	N218395	001	Jun 05, 2025	Jun NEWA

TABLET;ORAL

MELOXICAM

	AB		GRAVITI PHARMS	7.5MG	A077931	001	Jul 25, 2006	Feb CAHN
	AB			15MG	A077931	002	Jul 25, 2006	Feb CAHN
		@	TARO	7.5MG	A078102	001	Nov 07, 2006	Aug DISC
		@		15MG	A078102	002	Nov 07, 2006	Aug DISC

MELOXICAM; RIZATRIPTAN BENZOATE

TABLET;ORAL

SYMBRAVO

		+!	AXSOME	20MG;EQ 10MG BASE	N215431	001	Jan 30, 2025	Jan NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

>D>	AP		NOVAST LABS	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Sep DISC
>A>		@		EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Sep DISC
	AP			EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Aug CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

		@	APOTEX	7MG	A206135	001	Nov 22, 2016	Mar DISC
		@		14MG	A206135	002	Nov 22, 2016	Mar DISC
		@		21MG	A206135	003	Nov 22, 2016	Mar DISC
		@		28MG	A206135	004	Nov 22, 2016	Mar DISC
	AB		MACLEODS PHARMS LTD	7MG	A206310	001	Aug 28, 2025	Aug NEWA
	AB			14MG	A206310	002	Aug 28, 2025	Aug NEWA
	AB			21MG	A206310	003	Aug 28, 2025	Aug NEWA
	AB			28MG	A206310	004	Aug 28, 2025	Aug NEWA
	AB		RISING	7MG	A206032	001	Sep 28, 2016	May CMFD
	AB			14MG	A206032	002	Sep 28, 2016	May CMFD
	AB			21MG	A206032	003	Sep 28, 2016	May CMFD
	AB			28MG	A206032	004	Sep 28, 2016	May CMFD
>A>	AB		VITRUVIAS	7MG	A213985	001	Oct 11, 2022	Sep CAHN
>A>	AB			14MG	A213985	002	Oct 11, 2022	Sep CAHN
>A>	AB			21MG	A213985	004	Feb 06, 2024	Sep CAHN
>A>	AB			28MG	A213985	003	Oct 11, 2022	Sep CAHN
>D>	AB		XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Sep CAHN
>D>	AB			14MG	A213985	002	Oct 11, 2022	Sep CAHN
>D>	AB			21MG	A213985	004	Feb 06, 2024	Sep CAHN
>D>	AB			28MG	A213985	003	Oct 11, 2022	Sep CAHN

		SOLUTION;ORAL							
		MEMANTINE HYDROCHLORIDE							
>D>		@	APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Sep	CAHN
		@		2MG/ML	A205446	001	Dec 07, 2015	Apr	CAHN
>A>		@	SCIEGEN PHARMS INC	2MG/ML	A205446	001	Dec 07, 2015	Sep	CAHN
		TABLET;ORAL							
		MEMANTINE HYDROCHLORIDE							
		@	POINTVIEW HLDINGS	5MG	A090073	001	Sep 04, 2015	Apr	CAHN
		@		10MG	A090073	002	Sep 04, 2015	Apr	CAHN
>D>	AB		RENATA	5MG	A209527	001	May 07, 2018	Sep	CAHN
	AB			5MG	A209527	001	May 07, 2018	Aug	CAHN
>D>	AB			10MG	A209527	002	May 07, 2018	Sep	CAHN
	AB			10MG	A209527	002	May 07, 2018	Aug	CAHN
>A>	AB		SOMERSET THERAPS LLC	5MG	A209527	001	May 07, 2018	Sep	CAHN
>A>	AB			10MG	A209527	002	May 07, 2018	Sep	CAHN
	AB		YILING	5MG	A212947	001	Apr 03, 2020	Apr	CMFD
	AB			10MG	A212947	002	Apr 03, 2020	Apr	CMFD
		MEPIVACAINE HYDROCHLORIDE							
		INJECTABLE;INJECTION							
		CARBOCAINE							
		@ +	HOSPIRA	1%	N012250	001		Jul	DISC
		@ +		1.5%	N012250	005		Jul	DISC
		@ +		2%	N012250	002		Jul	DISC
		POLOCAINE							
			FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jul	CTEC
				2%	A089410	001	Dec 01, 1986	Jul	CTEC
		POLOCAINE-MPF							
			FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jul	CTEC
				1.5%	A089408	001	Dec 01, 1986	Jul	CTEC
				2%	A089409	001	Dec 01, 1986	Jul	CTEC
		MERCAPTOPURINE							
		SUSPENSION;ORAL							
		MERCAPTOPURINE							
	AB		HIKMA	20MG/ML	A216418	001	Feb 26, 2025	Feb	NFTG
		PURIXAN							
	AB	+!	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Feb	CFTG
		MEROPENEM							
		INJECTABLE;INJECTION							
		MEROPENEM							
	AP	!	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Apr	CHRS
	AP	!		1GM/VIAL	A091404	002	Oct 26, 2011	Apr	CHRS
		MERREM IV							
		@ +	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Apr	DISC
		@ +		1GM/VIAL	N050706	001	Jun 21, 1996	Apr	DISC
		POWDER;INTRAVENOUS							
		MEROPENEM							
	AP		BROOKS STERISCIENCE	2GM/VIAL	A219084	001	Jun 23, 2025	Jun	NFTG
	AP	+!	HQ SPCLT PHARMA	2GM/VIAL	N215212	001	Jul 26, 2023	Jun	CFTG
		MESALAMINE							
		CAPSULE, EXTENDED RELEASE;ORAL							
		MESALAMINE							
	AB		ANNORA PHARMA	375MG	A219864	001	Aug 13, 2025	Aug	NEWA
>D>	AB		NOVAST LABS	375MG	A218410	001	Aug 22, 2024	Sep	CAHN
>A>	AB			375MG	A218410	001	Aug 22, 2024	Sep	CAHN
		ENEMA;RECTAL							
		MESALAMINE							
	AB		NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr	NEWA
		SUPPOSITORY;RECTAL							
		MESALAMINE							
>D>	AB		NORVIUM BIOSCIENCE	1GM	A204354	001	Nov 24, 2015	Sep	CAHN
	AB			1GM	A204354	001	Nov 24, 2015	May	CAHN
>A>	AB		QUAGEN	1GM	A204354	001	Nov 24, 2015	Sep	CAHN
	AB		RISING	1GM	A219028	001	Apr 14, 2025	Apr	NEWA
		TABLET, DELAYED RELEASE;ORAL							
		MESALAMINE							
	AB		AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb	NEWA

MESNA

TABLET;ORAL

MESNA

	AB		NOVAST LABS	400MG	A218871	001	Jan 13, 2025	Aug CAHN
	AB		RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan NFTG

MESNEX

	AB	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan CFTG

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

>A>		!	CHARTWELL	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN
>D>		!	GENUS LIFESCIENCES	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN

METAXALONE

TABLET;ORAL

METAXALONE

>D>		@	INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020	Sep CAHN
>A>		@	NOVAST LABS	800MG	A213836	001	Oct 21, 2020	Sep CAHN

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

	AB		ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar NEWA
	AB		BIONPHARMA	500MG/5ML	A219151	001	Apr 14, 2025	Apr NEWA
	AB		VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>A>	AB		ANDA REPOSITORY	500MG	A076033	001	Jan 24, 2002	Sep CAHN
>A>	AB			850MG	A076033	002	Jan 24, 2002	Sep CAHN
>A>	AB			1GM	A076033	003	Jan 24, 2002	Sep CAHN
		@	APOTEX	500MG	A075984	001	Apr 23, 2002	Mar DISC
		@		500MG	A090666	001	Dec 07, 2011	Mar DISC
		@		850MG	A075984	002	Apr 23, 2002	Mar DISC
		@		850MG	A090666	002	Dec 07, 2011	Mar DISC
		@		1GM	A075984	003	Apr 23, 2002	Mar DISC
		@		1GM	A090666	003	Dec 07, 2011	Mar DISC
>D>	AB		ATLAS PHARMS LLC	500MG	A076033	001	Jan 24, 2002	Sep CAHN
>D>	AB			850MG	A076033	002	Jan 24, 2002	Sep CAHN
>D>	AB			1GM	A076033	003	Jan 24, 2002	Sep CAHN
		@	GLENMARK PHARMS LTD	500MG	A078170	001	May 23, 2008	Aug DISC
		@		850MG	A078170	002	May 23, 2008	Aug DISC
		@		1GM	A078170	003	May 23, 2008	Aug DISC

TABLET, EXTENDED RELEASE;ORAL

FORTAMET

		@ +	ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Jul DISC

METFORMIN HYDROCHLORIDE

	AB1		MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Feb CAHN
	AB			750MG	A202306	002	Feb 23, 2017	Feb CAHN
	AB2		MPP PHARMA	500MG	A203832	001	Dec 26, 2017	May CAHN
	AB2			1GM	A203832	002	Dec 26, 2017	May CAHN
		@	SUN PHARM	500MG	A202917	001	Aug 01, 2016	Jan DISC
		@		1GM	A202917	002	Aug 01, 2016	Jan DISC
>D>	AB		SUN PHARM INDS (IN)	750MG	A077336	002	Feb 09, 2006	Sep DISC
>A>		@		750MG	A077336	002	Feb 09, 2006	Sep DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

	AB		TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	May CMFD
	AB			850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	May CMFD

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

	AB		DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jan CTNA
	AB			1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jan CTNA
	AB	!		1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jan CTNA
		@	SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul DISC
		@		1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul DISC
		@		1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul DISC

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Jun	CTEC
AB	+		500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May	CFTG
	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Jun	CTEC
AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May	CFTG
	+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Jun	CTEC
AB	+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May	CFTG

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

	@	ENDO OPERATIONS	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	Jun	DISC
AB			500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May	NFTG
	@		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	Jun	DISC
AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May	NFTG
	@		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	Jun	DISC
AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May	NFTG

METHADONE HYDROCHLORIDE

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		HIKMA	10MG/ML	A218609	001	May 05, 2025	Apr	NEWA

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA		HIKMA	5MG	A088109	002	Mar 08, 1983	Jul	CMS1
	@	VISTAPHARM LLC	10MG	A040241	002	May 29, 1998	Aug	DISC

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA		VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan	CAHN

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

>A> AB		ANDA REPOSITORY	25MG	A040062	001	Jan 27, 1994	Sep	CAHN
>A> AB	!		50MG	A040062	002	Jan 27, 1994	Sep	CAHN
>D> AB		MIKART	25MG	A040062	001	Jan 27, 1994	Sep	CAHN
>D> AB	!		50MG	A040062	002	Jan 27, 1994	Sep	CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+	ESJAY PHARMA	1GM	N017681	001		Jul	CMFD
	@ +		1GM	N017681	001		May	DISC

METHENAMINE HIPPURATE

AB		ZYDUS LIFESCIENCES	1GM	A219661	001	Mar 10, 2025	Feb	NEWA

UREX

AB		QUAGEN	1GM	N016151	001		Jul	CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		AIPING PHARM INC	5MG	A040547	001	Feb 18, 2005	Mar	CAHN
AB			10MG	A040547	002	Feb 18, 2005	Mar	CAHN
	@		20MG	A040547	004	Feb 18, 2005	Mar	CAHN
AB		SQUARE PHARMS PLC	5MG	A218830	001	Feb 05, 2025	Aug	CMFD
	@		5MG	A218830	001	Feb 05, 2025	Jul	DISC
AB			5MG	A218830	001	Feb 05, 2025	Jan	NEWA
AB			10MG	A218830	002	Feb 05, 2025	Aug	CMFD
	@		10MG	A218830	002	Feb 05, 2025	Jul	DISC
AB			10MG	A218830	002	Feb 05, 2025	Jan	NEWA

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

	@	PHARMOBEDIENT	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jun	CAHN

SUSPENSION;ORAL

ATMEKSI

	+!	ROSEMONT PHARMS	750MG/5ML	N219843	001	Jul 30, 2025	Jul	NEWA

TABLET;ORAL

METHOCARBAMOL

AA		BOSTAL	500MG	A200958	001	Oct 21, 2011	May	CAHN
AA			750MG	A200958	002	Oct 21, 2011	May	CAHN

TABLET;ORAL
METHOCARBAMOL

	AB	!		1GM	A200958	003	Dec 06, 2021	May CAHN
>D>	AA		HLTHCARE	500MG	A203550	001	Feb 08, 2017	Sep CAHN
>D>	AA			750MG	A203550	002	Feb 08, 2017	Sep CAHN
>A>	AA		PHARMOBEDIENT	500MG	A203550	001	Feb 08, 2017	Sep CAHN
>A>	AA			750MG	A203550	002	Feb 08, 2017	Sep CAHN
	AA		POINTVIEW HLDINGS	500MG	A212623	001	Apr 30, 2021	Apr CAHN
	AA			750MG	A212623	002	Apr 30, 2021	Apr CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS
OTREXUP

	@ +		ASSERTIO SPECLTY	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Aug CAHN
	@ +			10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Aug CAHN
	@ +			12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Aug CAHN
	@ +			15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Aug CAHN
	@ +			17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Aug CAHN
	@ +			20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Aug CAHN
	@ +			22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Aug CAHN
	@ +			25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Aug CAHN
	@ +		OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Jul DISC
	@ +			12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Jul DISC
	@ +			15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Jul DISC
	@ +			17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Jul DISC
	@ +			20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Jul DISC
	@ +			22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Jul DISC
	@ +			25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Jul DISC

OTREXUP PFS

	@ +		ASSERTIO SPECLTY	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Aug CAHN
	@ +			15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Aug CAHN
	@ +			17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Aug CAHN
	@ +			20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Aug CAHN
	@ +			22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Aug CAHN
	@ +			25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Aug CAHN

METHYLENE BLUE

SOLUTION;INTRAVENOUS
METHYLENE BLUE

	AP		HIKMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Jan CAHN
	AP		MEITHEAL	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan CAHN
	AP		NANJING KING-FRIEND	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan NEWA
	AP		XIROMED	50MG/10ML (5MG/ML)	A219363	001	Jul 30, 2025	Jul NEWA

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS
METHYLNALTREXONE BROMIDE

	@		ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar DISC
	@			12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar DISC
	@		MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	Jun DISC
	AP			12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	May NFTG

RELISTOR

	+!		SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar CTEC
	+!			12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	Jun CTEC
	AP +!			12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	May CFTG
	+!			12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar CTEC

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

	@ +		NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Jun DISC
	+			34.6MG	N205489	004	Aug 19, 2024	Apr CMFD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL
METHYLPHENIDATE HYDROCHLORIDE

	@		ESJAY PHARMA	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
	@			10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN
>A>	AA		HIBROW HLTHCARE	5MG/5ML	A210139	001	Oct 03, 2018	Sep CAHN
>A>	AA			10MG/5ML	A210139	002	Oct 03, 2018	Sep CAHN
>D>	AA		WES PHARMA INC	5MG/5ML	A210139	001	Oct 03, 2018	Sep CAHN
>D>	AA			10MG/5ML	A210139	002	Oct 03, 2018	Sep CAHN

TABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

	@	MPP PHARMA	5MG	A207587	001	Mar 03, 2017	Jun CAHN
	@		10MG	A207587	002	Mar 03, 2017	Jun CAHN
	@		20MG	A207587	003	Mar 03, 2017	Jun CAHN

TABLET, CHEWABLE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

	@	STRIDES PHARMA	2.5MG	A204954	001	Jan 26, 2017	Apr CAHN
	@		5MG	A204954	002	Jan 26, 2017	Apr CAHN
	@		10MG	A204954	003	Jan 26, 2017	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D> AB		DR REDDYS	18MG	A213473	001	Jul 29, 2020	Sep CAHN
>D> AB			27MG	A213473	002	Jul 29, 2020	Sep CAHN
>D> AB			36MG	A213473	003	Jul 29, 2020	Sep CAHN
>D> AB			54MG	A213473	004	Jul 29, 2020	Sep CAHN
>A> AB		GRANULES	18MG	A213473	001	Jul 29, 2020	Sep CAHN
>A> AB			27MG	A213473	002	Jul 29, 2020	Sep CAHN
>A> AB			36MG	A213473	003	Jul 29, 2020	Sep CAHN
>A> AB			54MG	A213473	004	Jul 29, 2020	Sep CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

AB		HIKMA	80MG/ML	A219145	001	Apr 16, 2025	Apr NEWA

METHYLTESTOSTERONE

TABLET;ORAL
ANDROID 25

	@	BAUSCH	25MG	A087147	001		Apr DISC
BP			25MG	A087147	001		Mar CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

	@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jul DISC

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

	@	VISTAPHARM LLC	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001	Jan CAHN

TABLET;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

	@	IMPAX LABS INC	EQ 5MG BASE	A071250	002	Dec 28, 1995	Jul DISC
	@		EQ 10MG BASE	A071250	001	Feb 03, 1988	Jul DISC

METOLAZONE

TABLET;ORAL
METOLAZONE

AB		IXORA LIFESCIENCE	2.5MG	A218606	001	Apr 17, 2024	Aug CAHN
AB			5MG	A218606	002	Apr 17, 2024	Aug CAHN
AB			10MG	A218606	003	Apr 17, 2024	Aug CAHN
AB		LEADING	2.5MG	A218606	001	Apr 17, 2024	Jun CAHN
AB			5MG	A218606	002	Apr 17, 2024	Jun CAHN
AB			10MG	A218606	003	Apr 17, 2024	Jun CAHN
AB		RENATA	2.5MG	A215616	001	Oct 24, 2022	Aug CAHN
AB			5MG	A215616	002	Oct 24, 2022	Aug CAHN
AB			10MG	A215616	003	Oct 24, 2022	Aug CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

AB		IPCA LABS LTD	EQ 25MG TARTRATE	A206980	001	Jun 25, 2025	Jun NEWA
AB			EQ 50MG TARTRATE	A206980	002	Jun 25, 2025	Jun NEWA
AB			EQ 100MG TARTRATE	A206980	003	Jun 25, 2025	Jun NEWA
AB			EQ 200MG TARTRATE	A206980	004	Jun 25, 2025	Jun NEWA

METOPROLOL TARTRATE

SOLUTION;ORAL
LOPRESSOR

	+!	RUBICON	10MG/ML	N219373	001	Apr 10, 2025	Apr NEWA

		TABLET;ORAL							
		LOPRESSOR							
		+!	XTM CONSULTING	12.5MG	N218698	001	Aug 28, 2025	Aug	NEWA
		METOPROLOL TARTRATE							
		@	PHARMOBEDIENT	50MG	A073666	001	Dec 21, 1993	Jun	CAHN
		@		100MG	A073666	002	Dec 21, 1993	Jun	CAHN
	AB		RENATA	50MG	A074453	001	Apr 27, 1995	Aug	CAHN
	AB			100MG	A074453	002	Apr 27, 1995	Aug	CAHN
	AB		SCIEGEN PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	CAHN
	AB			50MG	A208955	002	Feb 05, 2020	Jan	CAHN
	AB			100MG	A208955	003	Feb 05, 2020	Jan	CAHN
		@	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Apr	DISC
		METRONIDAZOLE							
		CREAM;TOPICAL							
		METROCREAM							
	AB	+	GALDERMA LABS LP	0.75%	N020531	001	Sep 20, 1995	Jun	CHRS
		METRONIDAZOLE							
	AB		AUROBINDO PHARMA LTD	0.75%	A219295	001	Jul 09, 2025	Jun	NEWA
	AB	!	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jun	CHRS
	BX		ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Mar	CTEC
		GEL;VAGINAL							
		METROGEL-VAGINAL							
		@ +	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Aug	DISC
		METRONIDAZOLE							
	AB	!	ENCUBE	0.75%	A215610	001	Jun 16, 2023	Aug	CHRS
		@		1.3%	A216795	001	Mar 18, 2024	Jan	DISC
>D>	AB		SAPTALIS PHARMS	0.75%	A216750	001	Dec 31, 2024	Sep	CAHN
>A>	AB		SCIEGEN PHARMS INC	0.75%	A216750	001	Dec 31, 2024	Sep	CAHN
		NUVESSA							
		+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Jan	CTEC
		METYRAPONE							
		CAPSULE;ORAL							
		METOPIRONE							
		+!	ESTEVE	250MG	N012911	002	Aug 09, 1996	Jul	CAHN
		TABLET;ORAL							
		METOPIRONE							
		@	ESTEVE	250MG	N012911	001		Jul	CAHN
		METYROSINE							
		CAPSULE;ORAL							
		METYROSINE							
>D>	AB		CEROVENE INC	250MG	A218620	001	Apr 09, 2025	Sep	CAHN
	AB			250MG	A218620	001	Apr 09, 2025	Mar	NEWA
>A>	AB		DR REDDYS LABS SA	250MG	A218620	001	Apr 09, 2025	Sep	CAHN
		MEXILETINE HYDROCHLORIDE							
		CAPSULE;ORAL							
		MEXILETINE HYDROCHLORIDE							
	AB		IXORA LIFESCIENCE	150MG	A215876	001	Feb 27, 2023	Aug	CAHN
	AB			200MG	A215876	002	Feb 27, 2023	Aug	CAHN
	AB			250MG	A215876	003	Feb 27, 2023	Aug	CAHN
		MICAFUNGIN SODIUM							
		INJECTABLE;INTRAVENOUS							
		MICAFUNGIN SODIUM							
	AP		QILU PHARM HAINAN	EQ 50MG BASE/VIAL	A219273	001	Apr 03, 2025	Mar	NEWA
	AP			EQ 100MG BASE/VIAL	A219273	002	Apr 03, 2025	Mar	NEWA
		MIDAZOLAM							
		SOLUTION;INTRAVENOUS							
		MIDAZOLAM IN 0.8% SODIUM CHLORIDE							
		!	B BRAUN MEDICAL	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Jul	CHRS
				50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	May	CAHN
		!		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Jul	CHRS
				100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	May	CAHN
			STERINOVA INC	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Apr	NFTG
				100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Apr	NFTG

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

	@	EPIC PHARMA LLC	EQ 5MG BASE/ML	A	075481	001	Jun 30, 2000	Jun CAHN
AP		HIKMA	EQ 1MG BASE/ML	A	212847	001	Dec 11, 2020	Jun CAHN
AP			EQ 5MG BASE/ML	A	212847	002	Dec 11, 2020	Jun CAHN
AP		RISING	EQ 1MG BASE/ML	A	075494	001	Jun 30, 2000	Jun CAHN
AP			EQ 5MG BASE/ML	A	075494	002	Jun 30, 2000	Jun CAHN

SOLUTION;INTRAMUSCULAR

SEIZALAM

	@ +	MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N	209566	001	Sep 14, 2018	Jul DISC

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

ORVATEN

AB		BEIJING YILING	2.5MG	A	076725	001	Nov 03, 2004	Jun CAHN
AB	!		5MG	A	076725	002	Nov 03, 2004	Jun CAHN
AB			10MG	A	076725	003	Nov 03, 2004	Jun CAHN

MIFEPRISTONE

TABLET;ORAL

MIFEPRISTONE

>A> AB		EVITA SOLUTIONS	200MG	A	216616	001	Sep 30, 2025	Sep NEWA

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

	@	CHARTWELL RX	100MG	A	209325	001	Feb 03, 2022	Mar CAHN
AB		NAVINTA LLC	100MG	A	219111	001	Mar 14, 2025	Mar NEWA
	@	VERANOVA	100MG	A	209325	001	Feb 03, 2022	Feb CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

>A>	@	BRECKENRIDGE	12.5MG	A	205071	001	Jan 27, 2016	Sep CAHN
>A>	@		25MG	A	205071	002	Jan 27, 2016	Sep CAHN
>A>	@		50MG	A	205071	003	Jan 27, 2016	Sep CAHN
>A>	@		100MG	A	205071	004	Jan 27, 2016	Sep CAHN
>A>	@	CENTAUR PHARMS PVT	12.5MG	A	205071	001	Jan 27, 2016	Sep CAHN
>A>	@		25MG	A	205071	002	Jan 27, 2016	Sep CAHN
>A>	@		50MG	A	205071	003	Jan 27, 2016	Sep CAHN
>A>	@		100MG	A	205071	004	Jan 27, 2016	Sep CAHN
>D>	@	FIRST TIME US	12.5MG	A	205071	001	Jan 27, 2016	Sep CAHN
>D>	@		25MG	A	205071	002	Jan 27, 2016	Sep CAHN
>D>	@		50MG	A	205071	003	Jan 27, 2016	Sep CAHN
>D>	@		100MG	A	205071	004	Jan 27, 2016	Sep CAHN
	@	HETERO LABS LTD V	12.5MG	A	205147	001	Oct 03, 2024	Apr DISC
	@		25MG	A	205147	002	Oct 03, 2024	Apr DISC
	@		50MG	A	205147	003	Oct 03, 2024	Apr DISC
	@		100MG	A	205147	004	Oct 03, 2024	Apr DISC

SAVELLA

	+	ABBVIE	12.5MG	N	022256	001	Jan 14, 2009	Apr CTEC
	+		25MG	N	022256	002	Jan 14, 2009	Apr CTEC
	+!		50MG	N	022256	003	Jan 14, 2009	Apr CTEC
	+		100MG	N	022256	004	Jan 14, 2009	Apr CTEC

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

AP		CAPLIN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A	219170	001	Sep 02, 2025	Aug NEWA
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A	219170	002	Sep 02, 2025	Aug NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMROSI

	+!	JOURNEY	EQ 40MG BASE	N	219015	001	Nov 01, 2024	Mar CPOT

		INJECTABLE;INJECTION						
		MINOCIN						
		+! REMPEX	EQ 100MG BASE/VIAL	N050444	001			May CTEC
		MINOCYCLINE HYDROCHLORIDE						
	AP	NEXUS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024		Mar CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		MINOCYCLINE HYDROCHLORIDE						
		@ SUN PHARM	EQ 45MG BASE	A204394	001	Dec 30, 2015		Aug DISC
		@	EQ 55MG BASE	A204394	002	Oct 07, 2022		Aug DISC
		@	EQ 65MG BASE	A204394	003	Oct 07, 2022		Aug DISC
		@	EQ 80MG BASE	A204394	004	Dec 30, 2015		Aug DISC
		@	EQ 105MG BASE	A204394	005	Dec 30, 2015		Aug DISC
		@	EQ 115MG BASE	A204394	006	Oct 07, 2022		Aug DISC
		@	EQ 135MG BASE	A204394	007	Dec 30, 2015		Aug DISC
		MIRABEGRON						
		TABLET, EXTENDED RELEASE;ORAL						
		MIRABEGRON						
		@ APOTEX	25MG	A209434	001	Jan 02, 2025		May DISC
		@	50MG	A209434	002	Jan 02, 2025		May DISC
>A>	AB	ASCENT PHARMS INC	25MG	A218172	001	Sep 24, 2025		Sep NEWA
>A>	AB		50MG	A218172	002	Sep 24, 2025		Sep NEWA
	AB	QILU	25MG	A217989	001	Jun 30, 2025		Jun NEWA
	AB		50MG	A217989	002	Jun 30, 2025		Jun NEWA
		@ SAWAI USA	50MG	A217061	001	May 06, 2025		Jun DISC
	AB		50MG	A217061	001	May 06, 2025		Apr NEWA
		MIRDAMETINIB						
		CAPSULE;ORAL						
		GOMEKLI						
		+ SPRINGWORKS	1MG	N219389	001	Feb 11, 2025		Feb NEWA
		+!	2MG	N219389	002	Feb 11, 2025		Feb NEWA
		TABLET, FOR SUSPENSION;ORAL						
		GOMEKLI						
		+! SPRINGWORKS	1MG	N219379	001	Feb 11, 2025		Feb NEWA
		MIRTAZAPINE						
		TABLET;ORAL						
		MIRTAZAPINE						
>A>	AB	ANNORA PHARMA	7.5MG	A219721	001	Oct 02, 2025		Sep NEWA
>A>	AB		15MG	A219721	002	Oct 02, 2025		Sep NEWA
>A>	AB		30MG	A219721	003	Oct 02, 2025		Sep NEWA
>A>	AB		45MG	A219721	004	Oct 02, 2025		Sep NEWA
		TABLET, ORALLY DISINTEGRATING;ORAL						
		MIRTAZAPINE						
>A>	AB	ACME LABS	15MG	A205798	001	Jun 01, 2017		Sep CAHN
>A>	AB		30MG	A205798	002	Jun 01, 2017		Sep CAHN
>A>	AB		45MG	A205798	003	Jun 01, 2017		Sep CAHN
>D>	AB	SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017		Sep CAHN
>D>	AB		30MG	A205798	002	Jun 01, 2017		Sep CAHN
>D>	AB		45MG	A205798	003	Jun 01, 2017		Sep CAHN
		MITOMYCIN						
		FOR SOLUTION;TOPICAL						
		MITOSOL						
		+! GLAUKOS	0.2MG/VIAL	N022572	001	Feb 07, 2012		Aug CAHN
		INJECTABLE;INJECTION						
		MITOMYCIN						
	AP	ACCORD HLTHCARE	20MG/VIAL	A064144	002	Apr 30, 1998		Apr CMFD
		@	20MG/VIAL	A064144	002	Apr 30, 1998		Jan DISC
		@ EUGIA PHARMA	5MG/VIAL	A216732	001	Oct 30, 2023		Aug DISC
		@	20MG/VIAL	A216732	002	Oct 30, 2023		Aug DISC
		@	40MG/VIAL	A216732	003	Oct 30, 2023		Aug DISC
	AP	! MEITHEAL	20MG/VIAL	A214505	002	Sep 08, 2022		Jan CHRS
		POWDER;INTRAVESICAL						
		ZUSDURI						
		+! UROGEN PHARMA	40MG/VIAL	N215793	001	Jun 12, 2025		Jun NEWA

MITOTANE
TABLET;ORAL
LYSODREN

		+!	ESTEVE	500MG	N016885	001		Jul CAHN

MODAFINIL
TABLET;ORAL
MODAFINIL

		@	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jun DISC
		@		200MG	A076715	002	Nov 01, 2012	Jun DISC

PROVIGIL

	AB	+	NUVO PHARMS	100MG	N020717	001	Dec 24, 1998	Jan CAHN
	AB	+!		200MG	N020717	002	Dec 24, 1998	Jan CAHN

MOEXIPRIL HYDROCHLORIDE
TABLET;ORAL
MOEXIPRIL HYDROCHLORIDE

		@	APOTEX INC	7.5MG	A078454	001	Jun 02, 2008	Mar DISC
		@		15MG	A078454	002	Jun 02, 2008	Mar DISC

MOMETASONE FUROATE
CREAM;TOPICAL
MOMETASONE FUROATE

		@	CHARTWELL MOLECULAR	0.1%	A076591	001	Apr 18, 2007	Feb CAHN
	AB	!	COSETTE	0.1%	A077447	001	May 22, 2006	Jun CHRS
		@	GLENMARK PHARMS INC	0.1%	A078541	001	May 28, 2008	Jun DISC

LOTION;TOPICAL
MOMETASONE FUROATE

		@	GLENMARK PHARMS LTD	0.1%	A090506	001	Aug 09, 2010	Jul DISC
>A>		@	SUN PHARMA CANADA	0.1%	A076788	001	Mar 15, 2006	Sep CAHN
>D>		@	TARO	0.1%	A076788	001	Mar 15, 2006	Sep CAHN
		@		0.1%	A076788	001	Mar 15, 2006	Aug DISC

OINTMENT;TOPICAL
MOMETASONE FUROATE

		@	GLENMARK PHARMS INC	0.1%	A078571	001	May 28, 2008	Jun DISC
	AB	!	PADAGIS US	0.1%	A076067	001	Mar 18, 2002	Jun CHRS

SPRAY, METERED;NASAL
MOMETASONE FUROATE

	AB		NASPRESS	0.05MG/SPRAY	A211706	001	May 15, 2025	May NEWA

MONTELUKAST SODIUM
TABLET;ORAL
MONTELUKAST SODIUM

>A>	AB		PHARMOBEDIENT	EQ 10MG BASE	A202859	001	Oct 30, 2014	Sep CAHN
>D>		@	SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Sep CMFD
>A>	AB			EQ 10MG BASE	A200889	001	Aug 03, 2012	Sep CMFD
>D>	AB		UNIMARK REMEDIES LTD	EQ 10MG BASE	A202859	001	Oct 30, 2014	Sep CAHN

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

>D>		@	NEW HEIGHTSRX	EQ 4MG BASE	A091588	001	Aug 03, 2012	Sep CAHN
		@		EQ 4MG BASE	A091588	001	Aug 03, 2012	Aug CAHN
>D>		@		EQ 5MG BASE	A091588	002	Aug 03, 2012	Sep CAHN
		@		EQ 5MG BASE	A091588	002	Aug 03, 2012	Aug CAHN
>A>		@	PHARMACO	EQ 4MG BASE	A091588	001	Aug 03, 2012	Sep CAHN
>A>		@		EQ 5MG BASE	A091588	002	Aug 03, 2012	Sep CAHN
>A>	AB		PHARMOBEDIENT	EQ 4MG BASE	A203037	001	Oct 30, 2014	Sep CAHN
>A>	AB			EQ 5MG BASE	A203037	002	Oct 30, 2014	Sep CAHN
	AB		UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug CMFD
	AB			EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug CMFD
>D>	AB		UNIMARK REMEDIES LTD	EQ 4MG BASE	A203037	001	Oct 30, 2014	Sep CAHN
>D>	AB			EQ 5MG BASE	A203037	002	Oct 30, 2014	Sep CAHN

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>A>		@	ANDA REPOSITORY	20MG	A203158	001	Aug 04, 2021	Sep CAHN
>A>		@		30MG	A203158	002	Aug 04, 2021	Sep CAHN
>A>		@		50MG	A203158	003	Aug 04, 2021	Sep CAHN
>A>		@		60MG	A203158	004	Aug 04, 2021	Sep CAHN
>A>		@		80MG	A203158	005	Aug 04, 2021	Sep CAHN
>A>		@		100MG	A203158	006	Aug 04, 2021	Sep CAHN

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>D>		@	NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Sep	CAHN
>D>		@		30MG	A203158	002	Aug 04, 2021	Sep	CAHN
>D>		@		50MG	A203158	003	Aug 04, 2021	Sep	CAHN
>D>		@		60MG	A203158	004	Aug 04, 2021	Sep	CAHN
>D>		@		80MG	A203158	005	Aug 04, 2021	Sep	CAHN
>D>		@		100MG	A203158	006	Aug 04, 2021	Sep	CAHN

SOLUTION;ORAL
MORPHINE SULFATE

	AA	+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Apr	CTEC
		+		20MG/5ML	N022195	002	Mar 17, 2008	Feb	CTEC
	AA		PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Jun	CMFD
	AA			100MG/5ML	A206573	001	Nov 14, 2016	Jun	CMFD
		@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan	DISC
		@		20MG/5ML	A206420	001	Jul 12, 2016	Jan	DISC
		@		100MG/5ML	A206308	002	Jun 22, 2017	Jan	DISC
		@	SANKALP LIFECARE	10MG/5ML	A201011	001	Feb 05, 2014	Apr	CAHN
		@		20MG/5ML	A201011	002	Feb 05, 2014	Apr	CAHN
		@		100MG/5ML	A201011	003	Oct 06, 2016	Apr	CAHN
	AA		WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Apr	CMFD
		@		10MG/5ML	A211454	001	Feb 12, 2021	Feb	DISC
	AA			20MG/5ML	A211454	002	Feb 12, 2021	Apr	CMFD
		@		20MG/5ML	A211454	002	Feb 12, 2021	Feb	DISC
	AA			100MG/5ML	A211454	003	Feb 12, 2021	Apr	CMFD
		@		100MG/5ML	A211454	003	Feb 12, 2021	Feb	DISC

TABLET;ORAL
MORPHINE SULFATE

	AB	+	HIKMA	15MG	N022207	001	Mar 17, 2008	Jun	CAHN
	AB	+!		30MG	N022207	002	Mar 17, 2008	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

		@	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Feb	DISC
		@		30MG	A203602	002	Dec 16, 2015	Feb	DISC
		@		60MG	A203602	003	Dec 16, 2015	Feb	DISC
		@		100MG	A203602	004	Dec 16, 2015	Feb	DISC
		@		200MG	A203602	005	Dec 16, 2015	Feb	DISC

MOTIXAFORTIDE ACETATE

POWDER;SUBCUTANEOUS
APHEXDA

		+!	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

>D>	AT1		ADAPTIS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Sep	CAHN
	AT1		FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Jul	NEWA
	AT1		MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan	NEWA
		@	NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb	CAHN
>A>	AT1		REGCON HOLDINGS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Sep	CAHN

TABLET;ORAL
MOXIFLOXACIN HYDROCHLORIDE

>D>		@	TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Sep	CMFD
>A>	AB			EQ 400MG BASE	A200160	001	Apr 03, 2014	Sep	CMFD

MUPIROCIN

OINTMENT;TOPICAL
MUPIROCIN

	AB		ENCUBE	2%	A217943	001	May 13, 2025	May	NEWA
>A>	AB		SUN PHARMA CANADA	2%	A065170	001	Sep 23, 2005	Sep	CAHN
>D>	AB		TARO	2%	A065170	001	Sep 23, 2005	Sep	CAHN

MUPIROCIN CALCIUM

CREAM;TOPICAL
MUPIROCIN

	BX		ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Mar	CTEC

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

	@	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Apr DISC
AB		VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan CAHN

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLATE SODIUM

AB		ACCORD HLTHCARE	EQ 180MG BASE	A202555	001	Aug 23, 2017	Aug CAIN
AB			EQ 360MG BASE	A202555	002	Aug 23, 2017	Aug CAIN
AB		ALKEM LABS LTD	EQ 180MG BASE	A208315	001	Sep 23, 2021	Aug CAIN
AB			EQ 360MG BASE	A208315	002	Sep 23, 2021	Aug CAIN
AB		APOTEX INC	EQ 180MG BASE	A091558	001	Aug 21, 2012	Aug CAIN
AB			EQ 360MG BASE	A091558	002	Aug 19, 2014	Aug CAIN
AB		AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Aug CAIN
AB			EQ 360MG BASE	A218603	002	Feb 27, 2024	Aug CAIN
AB		BIOCON PHARMA	EQ 180MG BASE	A214630	001	Nov 29, 2021	Aug CAIN
AB			EQ 180MG BASE	A217031	001	Nov 29, 2023	Aug CAIN
AB			EQ 360MG BASE	A214630	002	Nov 29, 2021	Aug CAIN
AB			EQ 360MG BASE	A217031	002	Nov 29, 2023	Aug CAIN
AB		CONCORD BIOTECH LTD	EQ 180MG BASE	A211173	001	Dec 13, 2019	Aug CAIN
AB			EQ 360MG BASE	A211173	002	Dec 13, 2019	Aug CAIN
AB		FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Aug CAIN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Aug CAIN
AB		RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Aug CAIN
AB			EQ 360MG BASE	A091248	001	Jan 08, 2014	Aug CAIN
	@	TEVA PHARMS USA	EQ 180MG BASE	A202720	001	Oct 30, 2014	Aug CAIN
	@		EQ 360MG BASE	A202720	002	Oct 30, 2014	Aug CAIN
AB		TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Aug CAIN
AB			EQ 360MG BASE	A214289	002	Nov 03, 2021	Aug CAIN
AB		YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Aug CAIN
AB			EQ 360MG BASE	A214376	002	Feb 10, 2021	Aug CAIN

MYFORTIC

AB	+	NOVARTIS	EQ 180MG BASE	N050791	001	Feb 27, 2004	Aug CAIN
AB	+!		EQ 360MG BASE	N050791	002	Feb 27, 2004	Aug CAIN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB		FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan CAHN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Jan CAHN
AB		YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Jul CAHN
AB			EQ 360MG BASE	A214376	002	Feb 10, 2021	Jul CAHN

NABUMETONE

TABLET;ORAL

NABUMETONE

	@	MPP PHARMA	500MG	A090427	001	Dec 30, 2011	Jun CAHN
	@		750MG	A090427	002	Dec 30, 2011	Jun CAHN

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

	@	FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	Apr DISC

NALBUPHINE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALBUPHINE

	@	ABRAXIS PHARM	10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986	Mar CPOT
	@		10MG/ML	A070751	001	Jul 02, 1986	Mar CDFR
	@		20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986	Mar CPOT
	@		20MG/ML	A070752	001	Sep 24, 1986	Mar CDFR
	@		200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986	Mar NEWA

NALBUPHINE HYDROCHLORIDE

	@	ABBOTT	20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989	Mar CPOT
	@		20MG/ML	A070917	001	Feb 03, 1989	Mar CDFR
	@	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986	Mar NEWA
	@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar CDFR
	@		20MG/ML	A074471	002	Mar 19, 1998	Mar CDFR
	@		100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998	Mar CPOT
	@		200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998	Mar CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALBUPHINE HYDROCHLORIDE

AP	!	HOSPIRA	10MG/ML (10MG/ML)	A070914	001	Feb 03, 1989	Mar CPOT
AP	!		10MG/ML	A070914	001	Feb 03, 1989	Mar CDFR
AP	!		10MG/ML	A070915	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML (20MG/ML)	A070916	001	Feb 03, 1989	Mar CPOT
AP	!		20MG/ML	A070916	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML	A070918	001	Feb 03, 1989	Mar CDFR
AP	!		100MG/10ML (10MG/ML)	A070915	001	Feb 03, 1989	Mar CPOT
AP	!		200MG/10ML (20MG/ML)	A070918	001	Feb 03, 1989	Mar CPOT
	@	IGI LABS INC	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989	Mar CPOT
	@		10MG/ML	A072070	001	Apr 10, 1989	Mar CDFR
	@		10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989	Mar CPOT
	@		10MG/ML	A072071	001	Apr 10, 1989	Mar CDFR
	@		10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989	Mar CPOT
	@		10MG/ML	A072072	001	Apr 10, 1989	Mar CDFR
	@		20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989	Mar CPOT
	@		20MG/ML	A072073	001	Apr 10, 1989	Mar CDFR
	@		20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989	Mar CPOT
	@		20MG/ML	A072074	001	Apr 10, 1989	Mar CDFR
	@		20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989	Mar CPOT
	@		20MG/ML	A072075	001	Apr 10, 1989	Mar CDFR
	@		100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989	Mar NEWA
	@		200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989	Mar NEWA
	@	RISING	10MG/ML	A206506	001	Feb 06, 2019	Mar CDFR
	@		10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019	Mar CPOT
	@		10MG/ML	A207595	001	Jan 11, 2019	Mar CDFR
	@		20MG/ML	A206506	002	Feb 06, 2019	Mar CDFR
	@		20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019	Mar CPOT
	@		20MG/ML	A207595	002	Jan 11, 2019	Mar CDFR
	@		100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019	Mar CPOT
	@		200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019	Mar CPOT
AP		SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Mar CDFR
AP			10MG/ML (10MG/ML)	A216050	001	Sep 19, 2024	Mar CPOT
AP			10MG/ML	A216050	001	Sep 19, 2024	Mar CDFR
AP			20MG/ML	A216049	002	Sep 19, 2024	Mar CDFR
AP			20MG/ML (20MG/ML)	A216050	002	Sep 19, 2024	Mar CPOT
AP			20MG/ML	A216050	002	Sep 19, 2024	Mar CDFR
AP			100MG/10ML (10MG/ML)	A216049	001	Sep 19, 2024	Mar CPOT
AP			200MG/10ML (20MG/ML)	A216049	002	Sep 19, 2024	Mar CPOT

NUBAIN

	@ +	ENDO OPERATIONS	10MG/ML	N018024	001		Mar CDFR
	@ +		10MG/ML (10MG/ML)	N018024	001		Mar CPOT
	@ +		20MG/ML	N018024	002	May 27, 1982	Mar CDFR
	@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Mar CPOT
	@ +		20MG/2ML (10MG/ML)	N018024	004		Mar NEWA
	@ +		100MG/10ML (10MG/ML)	N018024	003		Mar NEWA
	@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar NEWA
	@ +	PH HEALTH	10MG/ML (10MG/ML)	N018024	001		Jul CAHN
	@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Jul CAHN
	@ +		20MG/2ML (10MG/ML)	N018024	004		Jul CAHN
	@ +		100MG/10ML (10MG/ML)	N018024	003		Jul CAHN
	@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Jul CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZURNAI (AUTOINJECTOR)

>D>	@ +	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Sep CMFD
>A>	+!		EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Sep CMFD
	@ +		EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan DISC

NALOXEGOL OXALATE

TABLET;ORAL
MOVANTIK

>A>	+	AVERITAS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep CAHN
>A>	+!		EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep CAHN
>D>	+	VALINOR	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep CAHN
>D>	+!		EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

	AP		BAXTER HLTHCARE CORP	1MG/ML	A214785	002	Jun 03, 2025	May NEWA
		@	PH HEALTH	0.4MG/ML	A211286	001	Jan 17, 2020	Jul CAHN
	AP		STERINOVA INC	0.4MG/ML	A214211	001	Aug 21, 2025	Aug NEWA

SPRAY;NASAL

KLOXXADO

		+	HIKMA	4MG/SPRAY	N212045	002	Aug 25, 2025	Aug NEWA
		+!		8MG/SPRAY	N212045	001	Apr 29, 2021	May CTEC
	AB	+!		8MG/SPRAY	N212045	001	Apr 29, 2021	Apr CFTG

NALOXONE HYDROCHLORIDE

		@	PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025	May DISC
	AB			8MG/SPRAY	A216719	001	Apr 24, 2025	Apr NFTG

REZENOPY

		@ +	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Aug CAHN
		@ +	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Jul DISC

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

		@	ALLIED	50MG	A075434	001	Mar 08, 2000	Jul CAHN
		@	ESJAY PHARMA	50MG	A075434	001	Mar 08, 2000	Jul CAHN

NAPROXEN

SUSPENSION;ORAL

NAPROXEN

>A>	AB		AUROBINDO PHARMA	25MG/ML	A216504	001	Oct 03, 2025	Sep NEWA

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

	AB		AUROBINDO PHARMA USA	375MG	A075390	001	Apr 19, 2001	Aug CMFD
	AB			500MG	A075390	002	Apr 19, 2001	Aug CMFD

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

	AB		MACLEODS PHARMS LTD	EQ 2.5MG BASE	A212661	001	Jan 28, 2025	Jan NEWA
	AB			EQ 5MG BASE	A212661	002	Jan 28, 2025	Jan NEWA
	AB			EQ 10MG BASE	A212661	003	Jan 28, 2025	Jan NEWA
	AB			EQ 20MG BASE	A212661	004	Jan 28, 2025	Jan NEWA

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

		!	SHORLA	375MG/75ML (5MG/ML)	A214809	002	Jul 16, 2025	Jul NFTG

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

>A>	AA		AARXION ANDA HLDING	500MG	A065220	001	Jul 28, 2006	Sep CAHN
>D>	AA		ADRASTEA PHARMA	500MG	A065220	001	Jul 28, 2006	Sep CAHN
		@	AVIV PHARMA	500MG	A065468	001	Mar 29, 2010	May CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

>D>	AP		ADAPTIS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Sep CAHN
>D>	AP			10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Sep CAHN
	AP		AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)	A208230	001	Nov 25, 2022	May CTNA
	AP			10MG/10ML (1MG/ML)	A208230	002	Nov 25, 2022	May CTNA
>A>	AP		REGCON HOLDINGS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Sep CAHN
>A>	AP			10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Sep CAHN

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

>D>		@	NORVIUM BIOSCIENCE	200MG	A078864	001	May 22, 2012	Sep CAHN
>A>		@	PHARMOBEDIENT	200MG	A078864	001	May 22, 2012	Sep CAHN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

	AB		MPP PHARMA	500MG	A207726	001	Jul 25, 2025	Jul NEWA
	AB			750MG	A207726	002	Jul 25, 2025	Jul NEWA
	AB			1GM	A207726	003	Jul 25, 2025	Jul NEWA
>D>	AB		ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025	Sep DISC
>A>		@		500MG	A203285	001	Apr 28, 2025	Sep DISC
	AB			500MG	A203285	001	Apr 28, 2025	Apr NEWA
>D>	AB			750MG	A203285	002	Apr 28, 2025	Sep DISC
>A>		@		750MG	A203285	002	Apr 28, 2025	Sep DISC
	AB			750MG	A203285	002	Apr 28, 2025	Apr NEWA
>D>	AB			1GM	A203285	003	Apr 28, 2025	Sep DISC
>A>		@		1GM	A203285	003	Apr 28, 2025	Sep DISC
	AB			1GM	A203285	003	Apr 28, 2025	Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

>A>	AB		AMNEAL	20MG	A218202	001	Apr 10, 2024	Sep CAHN
>A>	AB			30MG	A218202	002	Apr 10, 2024	Sep CAHN
	AB		NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Jun NEWA
	AB			30MG	A218638	002	Jun 25, 2025	Jun NEWA
>D>	AB		SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Sep CAHN
>D>	AB			30MG	A218202	002	Apr 10, 2024	Sep CAHN

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

		@	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan DISC
	AP		MANKIND PHARMA	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Jun CAHN
	AP		NANJING KING FRIEND	25MG/10ML (2.5MG/ML)	A216819	001	Aug 20, 2025	Aug NEWA

NILOTINIB D-TARTRATE

CAPSULE;ORAL

NILOTINIB D-TARTRATE

		+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb NEWA
		+		EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb NEWA
		+!		EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

	AB		APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr CMFD
	AB			EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr CMFD
	AB			EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr CMFD

TASIGNA

	AB	+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
	AB	+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
	AB	+!		EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

	AB		ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan NFTG

NYMALIZE

	AB	+!	AZURITY	6MG/ML	N203340	002	Apr 08, 2020	Jan CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

	AB		ANI PHARMS	500MG	A214844	001	Feb 03, 2025	Apr CAHN
	AB		ANNORA PHARMA	500MG	A218701	001	Apr 15, 2025	Apr NEWA
	AB	!	RISING	500MG	A213820	001	Nov 27, 2020	Jan CTEC
	AB		ZENARA	500MG	A214844	001	Feb 03, 2025	Jan NEWA

NITISINONE

TABLET;ORAL

HARLIKU

		+!	CYCLE	2MG	N209449	004	Jun 10, 2025	Jul NEWA

NITRIC OXIDE

GAS;INHALATION

INOMAX

	@ +	MALLINCKRODT IRELAND	100PPM	N020845	002	Dec 23, 1999	Jul	CAHN
AA	+!		800PPM	N020845	003	Dec 23, 1999	Jul	CAHN
	+!		4880PPM	N020845	004	Jan 17, 2023	Jul	CAHN

NOXIVENT

	@	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr	DISC

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

AB		ANNORA PHARMA	25MG/5ML	A219495	001	Jul 02, 2025	Jun	NEWA
AB		APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan	NEWA
AB		STRIDES PHARMA	25MG/5ML	A201355	001	Aug 14, 2013	Apr	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

	@	AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	Jul	DISC
>A> AB		MICRO LABS	75MG;25MG	A217073	001	Nov 03, 2023	Sep	CAHN
>D> AB		OMSAV PHARMA	75MG;25MG	A217073	001	Nov 03, 2023	Sep	CAHN

NITROGLYCERIN

OINTMENT;INTRA-ANAL

NITROGLYCERIN

AB		TP ANDA HOLDINGS	0.4%	A212222	001	Nov 29, 2024	Aug	CAHN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

AB		ENCUBE	2%	A218235	001	Apr 15, 2025	Apr	NFTG
AB	+!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Apr	CFTG

TABLET;SUBLINGUAL

NITROGLYCERIN

AB		RUBICON RESEARCH	0.3MG	A209779	001	May 03, 2021	Jul	CAHN
AB			0.4MG	A209779	002	May 03, 2021	Jul	CAHN
AB			0.6MG	A209779	003	May 03, 2021	Jul	CAHN

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

	@	GLENMARK PHARMS INC	150MG	A090618	001	Jul 15, 2011	Jul	DISC
	@		300MG	A090618	002	Jul 15, 2011	Jul	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP		ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan	NEWA
AP		BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar	NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

AP	+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Aug	CFTG
AP	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Aug	CFTG
AP		SAGENT	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	A219692	001	Aug 11, 2025	Aug	NFTG
AP			EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	A219692	002	Aug 11, 2025	Aug	NFTG

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar	NEWA
	@	CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr	CAHN

POWDER;TOPICAL

NYSTATIN

>D>	@	ADRASTEA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Sep	CAHN
	@		100,000 UNITS/GM	A065175	001	Dec 17, 2004	Jun	DISC
>A>	@	PHARMOBEDIENT	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Sep	CAHN

SUSPENSION;ORAL
NYSTATIN

>D>	AA	!	MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Sep	CAHN
	AA		MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Aug	CMFD
	AA		PHARMOBEDIENT	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Aug	CAHN
>A>	AA	!	SENORES PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Sep	CAHN
		@	TARO	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Aug	DISC
	AA		XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

	AT		CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr	CAHN
		@	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208136	001	Oct 24, 2016	Jul	DISC

OINTMENT;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

		@	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jul	DISC

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

		@	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	DISC

SOLUTION/DROPS;OTIC
OFLOXACIN

	AT		FDC LTD	0.3%	A215038	001	Jan 19, 2022	Aug	CMFD

OLANZAPINE

INJECTABLE;INTRAMUSCULAR
OLANZAPINE

	AP		QILU	10MG/VIAL	A218116	001	May 16, 2025	May	NEWA
	AP		UBI	10MG/VIAL	A211072	001	Jun 11, 2025	May	NEWA

OLICERIDINE

SOLUTION;INTRAVENOUS
OLINVYK

		@ +	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan	DISC
		@ +		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan	DISC

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS
CLINOLIPID 20%

		+!	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun	CMFD

OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL

	AB		JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Mar	CMFD
	AB			20MG	A205482	002	Apr 24, 2017	Mar	CMFD
	AB			40MG	A205482	003	Apr 24, 2017	Mar	CMFD

OMAVELOXOLONE

CAPSULE;ORAL
SKYCLARYS

		+!	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan	CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
LOVAZA

	AB	+!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN

OMEGA-3-ACID ETHYL ESTERS

		@	SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020	Jul	DISC

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

	+!	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022	Jun CMFD

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	May CMFD
AB			8MG	A209389	002	Oct 30, 2023	May CMFD
	@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb CAHN
	@		8MG	A078139	002	Jun 25, 2007	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	@	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

	@	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar DISC
	@		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar DISC
AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	May CMFD
AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	May CMFD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

>A> AB		BEIJING JIALIN	EQ 30MG BASE	A217133	001	Oct 30, 2024	Sep CAHN
>A> AB			EQ 75MG BASE	A217133	002	Oct 30, 2024	Sep CAHN
>D> AB		NANJING DAOQUN	EQ 30MG BASE	A217133	001	Oct 30, 2024	Sep CAHN
>D> AB			EQ 75MG BASE	A217133	002	Oct 30, 2024	Sep CAHN
AB		SHANDONG	EQ 30MG BASE	A217274	001	Jul 09, 2025	Jun NEWA
AB			EQ 45MG BASE	A217274	002	Jul 09, 2025	Jun NEWA
AB			EQ 75MG BASE	A217274	003	Jul 09, 2025	Jun NEWA
>A> AB		ZHEJIANG POLY PHARM	EQ 30MG BASE	A218009	002	Oct 02, 2025	Sep NEWA
>A> AB			EQ 45MG BASE	A218009	003	Oct 02, 2025	Sep NEWA
AB			EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar CAHN

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb NEWA
>D> AB		ORYZA	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Sep CAHN
>A> AB		PHARMOBEDIENT	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Sep CAHN

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

	@	HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Apr DISC

OSPHENA

	+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Apr CTEC

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

	@	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Aug DISC
	@		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Aug DISC
AP		HETERO LABS LTD VI	50MG/10ML (5MG/ML)	A217925	001	Jan 27, 2025	Jan NEWA
AP			100MG/20ML (5MG/ML)	A217925	002	Jan 27, 2025	Jan NEWA

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB		EPIC PHARMA LLC	10MG	A071756	002	Apr 19, 1988	Jul CMS1
AB			30MG	A071756	003	Apr 19, 1988	Jul CMS1
AB		LEADING	10MG	A218261	001	Mar 03, 2025	Feb NEWA
AB			15MG	A218261	002	Mar 03, 2025	Feb NEWA
AB			30MG	A218261	003	Mar 03, 2025	Feb NEWA

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB		MACLEODS PHARMS LTD	300MG/5ML	A207300	001	Jul 11, 2025	Jul NEWA
	@	PAI HOLDINGS	300MG/5ML	A211420	001	Jul 09, 2021	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB		AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Apr CMFD
AB			300MG	A217659	002	Feb 22, 2024	Apr CMFD
AB			600MG	A217659	003	Feb 22, 2024	Apr CMFD
	@	AUROBINDO PHARMA LTD	150MG	A219241	001	Apr 30, 2025	May DISC
AB			150MG	A219241	001	Apr 30, 2025	Apr NEWA
	@		300MG	A219241	002	Apr 30, 2025	May DISC
AB			300MG	A219241	002	Apr 30, 2025	Apr NEWA
	@		600MG	A219241	003	Apr 30, 2025	May DISC
AB			600MG	A219241	003	Apr 30, 2025	Apr NEWA
AB		RICONPHARMA LLC	150MG	A215796	001	Nov 22, 2024	Apr CMFD
AB			300MG	A215796	002	Nov 22, 2024	Apr CMFD
AB			600MG	A215796	003	Nov 22, 2024	Apr CMFD

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		AIPING PHARM INC	5MG	A074625	001	Jul 31, 1996	Jul CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

>A> AA		HIBROW HLTHCARE	5MG/5ML	A207511	001	Nov 23, 2016	Sep CAHN
>A> AA			100MG/5ML	A209897	001	Sep 06, 2017	Sep CAHN
	@	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Apr DISC
	@	PHARMOBEDIENT	5MG/5ML	A206456	001	Jun 16, 2015	Aug CAHN
	@	VISTAPHARM LLC	100MG/5ML	A202537	001	Jul 30, 2012	Jan CAHN
>D> AA		WES PHARMA INC	5MG/5ML	A207511	001	Nov 23, 2016	Sep CAHN
>D> AA			100MG/5ML	A209897	001	Sep 06, 2017	Sep CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

	@	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	Feb DISC
	@		10MG	A204021	002	Jun 12, 2017	Feb DISC
	@		15MG	A204021	003	Jun 12, 2017	Feb DISC
	@		20MG	A204021	004	Jun 12, 2017	Feb DISC
	@		30MG	A204021	005	Jun 12, 2017	Feb DISC

PACLITAXEL

POWDER;INTRAVENOUS

PACLITAXEL

AB		CIPLA	100MG/VIAL	A209657	001	Apr 10, 2025	Mar NEWA
AB		MYLAN	100MG/VIAL	A217877	001	Aug 19, 2025	Aug NEWA
AB		SHUANGCHENG	100MG/VIAL	A216355	001	May 15, 2025	May NEWA

PALBOCICLIB

TABLET;ORAL

PALBOCICLIB

	@	ZYDUS LIFESCIENCES	75MG	A215570	001	Jun 05, 2024	Apr CAHN
	@		100MG	A215570	002	Jun 05, 2024	Apr CAHN
	@		125MG	A215570	003	Jun 05, 2024	Apr CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB		DR REDDYS	3MG	A205559	001	Feb 19, 2025	Feb NEWA
AB			6MG	A205559	002	Feb 19, 2025	Feb NEWA
AB			9MG	A205559	003	Feb 19, 2025	Feb NEWA
>D> AB		ESKAYEF	1.5MG	A218755	001	Sep 04, 2025	Sep CAHN
AB			1.5MG	A218755	001	Sep 04, 2025	Aug NEWA
>D> AB			3MG	A218755	002	Sep 04, 2025	Sep CAHN
AB			3MG	A218755	002	Sep 04, 2025	Aug NEWA
>D> AB			6MG	A218755	003	Sep 04, 2025	Sep CAHN
AB			6MG	A218755	003	Sep 04, 2025	Aug NEWA
>D> AB			9MG	A218755	004	Sep 04, 2025	Sep CAHN
AB			9MG	A218755	004	Sep 04, 2025	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL
PALIPERIDONE

>A>	AB		EVEREST LIFESCIENCES	1.5MG	A218755	001	Sep 04, 2025	Sep CAHN
>A>	AB			3MG	A218755	002	Sep 04, 2025	Sep CAHN
>A>	AB			6MG	A218755	003	Sep 04, 2025	Sep CAHN
>A>	AB			9MG	A218755	004	Sep 04, 2025	Sep CAHN

PALONOSETRON HYDROCHLORIDE
INJECTABLE;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

>D>		@	NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Sep CAHN
>A>		@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Sep CAHN

>A> PALTUSOTINE HYDROCHLORIDE
>A> TABLET;ORAL
>A> PALSONIFY

>A>		+	CRINETICS	EQ 20MG BASE	N219070	001	Sep 25, 2025	Sep NEWA
>A>		+!		EQ 30MG BASE	N219070	002	Sep 25, 2025	Sep NEWA

PANTOPRAZOLE SODIUM
FOR SUSPENSION, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

	AB		AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar NEWA
	AB		CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar NEWA

INJECTABLE;INTRAVENOUS
PANTOPRAZOLE SODIUM

	AP		ALEMBIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar NEWA
	AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A215074	001	May 16, 2025	May NEWA

POWDER;INTRAVENOUS
PANTOPRAZOLE SODIUM

	AP		FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	May CMFD
		@		EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb DISC
	AP	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	May CTEC
		+!		EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb CTEC

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

	AB		GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan NEWA
	AB			EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan NEWA
		@	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Jan DISC

PARICALCITOL
CAPSULE;ORAL
PARICALCITOL

	AB		CHARTWELL RX	1MCG	A091412	001	Jun 24, 2014	Apr CAHN
	AB			2MCG	A091412	002	Jun 24, 2014	Apr CAHN
	AB			4MCG	A091412	003	Jun 24, 2014	Apr CAHN

SOLUTION;INTRAVENOUS
PARICALCITOL

	AP		CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr CAHN
	AP			0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr CAHN
	AP			0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr CAHN
		@	HIKMA PHARMS	0.002MG/ML (0.002MG/ML)	N205917	001	Nov 18, 2014	Jul DISC
		@		0.005MG/ML (0.005MG/ML)	N205917	002	Nov 18, 2014	Jul DISC
		@		0.01MG/2ML (0.005MG/ML)	N205917	003	Nov 18, 2014	Jul DISC

PAROXETINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

>A>	AB		ALEMBIC	EQ 25MG BASE	A217280	001	Sep 24, 2025	Sep NEWA
>A>	AB			EQ 37.5MG BASE	A217280	002	Sep 24, 2025	Sep NEWA

PAZOPANIB HYDROCHLORIDE
TABLET;ORAL
PAZOPANIB HYDROCHLORIDE

			TORRENT	EQ 400MG BASE	A219922	001	Sep 04, 2025	Aug NFTG

PEGULICIANINE ACETATE

POWDER;INTRAVENOUS

LUMISIGHT

		+!	LUMICELL	EQ 39MG BASE/VIAL	N214511	001	Apr 17, 2024	Aug CPOT

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

		@	BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	May DISC
		@		EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	May DISC

SOLUTION;INTRAVENOUS

PEMETREXED DISODIUM

		@ +	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jun DISC
		@ +		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jun DISC
		@ +		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jun DISC
		@ +		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jun DISC

PENCICLOVIR

CREAM;TOPICAL

PENCICLOVIR

	AB		AMNEAL	1%	A214100	001	Aug 22, 2025	Aug NEWA
	BX		TORRENT	1%	A216981	001	Aug 07, 2023	Mar CTEC

PENICILLAMINE

CAPSULE;ORAL

PENICILLAMINE

>D>	AB		APOTEX	250MG	A213310	001	Apr 28, 2020	Sep DISC
>A>		@		250MG	A213310	001	Apr 28, 2020	Sep DISC

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAMIDINE ISETHIONATE

>A>	AP		PHARMOBEDIENT	300MG/VIAL	A206982	001	Mar 17, 2022	Sep CAHN
>D>	AP		XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Sep CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

>A>	AB		BAUSCH	400MG	A075028	001	Jul 20, 1998	Sep CAHN
>A>		@		400MG	A075028	001	Jul 20, 1998	Sep DISC
>D>	AB		VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Sep CAHN

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

	AB	+!	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Jul CFTG

PERAMPANEL

	AB		MSN	0.5MG/ML	A218152	001	Jul 11, 2025	Jul NFTG

TABLET;ORAL

FYCOMPA

	AB	+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	May CFTG
	AB	+		4MG	N202834	002	Oct 22, 2012	May CFTG
	AB	+		6MG	N202834	003	Oct 22, 2012	May CFTG
	AB	+		8MG	N202834	004	Oct 22, 2012	May CFTG
	AB	+		10MG	N202834	005	Oct 22, 2012	May CFTG
	AB	+!		12MG	N202834	006	Oct 22, 2012	May CFTG

PERAMPANEL

	AB		TEVA PHARMS USA INC	2MG	A209801	001	May 23, 2025	May NFTG
	AB			4MG	A209801	002	May 23, 2025	May NFTG
	AB			6MG	A209801	003	May 23, 2025	May NFTG
	AB			8MG	A209801	004	May 23, 2025	May NFTG
	AB			10MG	A209801	005	May 23, 2025	May NFTG
	AB			12MG	A209801	006	May 23, 2025	May NFTG

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar NEWA
AB			4MG	A213694	002	Mar 18, 2025	Mar NEWA
AB			8MG	A213694	003	Mar 18, 2025	Mar NEWA
AB			16MG	A213694	004	Mar 18, 2025	Mar NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENDIMETRAZINE TARTRATE

	+!	ACERTIS PHARMS	105MG	N018074	001		May CAHN

TABLET;ORAL

BONTRIL PDM

AA	+!	BAUSCH	35MG	A085272	001		Mar CAHN

PHENDIMETRAZINE TARTRATE

AA		ACERTIS PHARMS	35MG	A085588	001		May CAHN
	@	MPP PHARMA	35MG	A203600	001	Dec 27, 2017	May CAHN

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB		DR REDDYS LABS SA	EQ 7.5MG BASE;46MG	A208175	002	Jun 12, 2025	Jun NEWA
AB			EQ 11.25MG BASE;69MG	A208175	003	Jun 12, 2025	Jun NEWA
AB			EQ 15MG BASE;92MG	A208175	004	Jun 12, 2025	Jun NEWA
AB			EQ 3.75MG BASE;23MG	A208175	001	Jun 12, 2025	Jun NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

AP	+!	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb CFTG

PHENYLEPHRINE HYDROCHLORIDE

>A> AP1		MILLA PHARMS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Sep CAHN
>A> AP1			50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Sep CAHN
>A> AP1			100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Sep CAHN
>D> AP1		PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Sep CAHN
>D> AP1			50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Sep CAHN
>D> AP1			100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Sep CAHN
	@	SANDOZ	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Aug CHRS
	@		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Aug CHRS
	@		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Aug CHRS
AP		SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025	Feb NFTG

PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

	+!	DR REDDYS LABS SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	Jun CAHN
	+!	SINTETICA SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	May NEWA

VAZCULEP

	@ +	EXELA PHARMA	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Aug DISC
	@ +		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Aug DISC
	@ +		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Aug DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

	@	VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001	Jan CAHN
	@		125MG/5ML	A040342	002	Aug 18, 2005	Jan CAHN

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

AB		ALEMBIC	1MG/0.5ML	A216444	001	Sep 08, 2025	Aug NEWA
AB1		CAPLIN	10MG/ML	A219212	001	Apr 17, 2025	Apr NEWA

TABLET;ORAL

PHYTONADIONE

	@	HIKMA	5MG	A212112	001	Dec 19, 2024	Feb DISC

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

AB		AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr NFTG
>A> AT		FDC LTD	1%	A217052	001	Oct 02, 2025	Sep NEWA
>A> AT			2%	A217052	002	Oct 02, 2025	Sep NEWA

SOLUTION;OPHTHALMIC
PILOCARPINE HYDROCHLORIDE

>A>	AT			4%	A217052	003	Oct 02, 2025	Sep NEWA

VUITY

AB		+!	ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr CFTG

PINDOLOL

TABLET;ORAL
PINDOLOL

AB			MPP PHARMA	5MG	A205415	001	Jan 13, 2016	May CAHN
AB				10MG	A205415	002	Jan 13, 2016	May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE

		@	AVIV PHARMA	EQ 15MG BASE	A078472	001	Feb 13, 2013	May CAHN
		@		EQ 30MG BASE	A078472	002	Feb 13, 2013	May CAHN
		@		EQ 45MG BASE	A078472	003	Feb 13, 2013	May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM

>A>	AP		MILLA PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Sep CAHN
>A>	AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Sep CAHN
>A>	AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Sep CAHN
>A>	AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Sep CAHN
>A>	AP			EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Sep CAHN
>D>	AP		PROVEPHARM SAS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Sep CAHN
>D>	AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Sep CAHN
>D>	AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Sep CAHN
>D>	AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Sep CAHN
>D>	AP			EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Sep CAHN

POWDER;INTRAVENOUS
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		+!	B BRAUN MEDICAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025	Apr NEWA
		+!		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025	Apr NEWA
		+!		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025	Apr NEWA

PIRFENIDONE

TABLET;ORAL
PIRFENIDONE

AB			AUROBINDO PHARMA	267MG	A212596	001	Aug 11, 2025	Aug NEWA
AB				801MG	A212596	002	Aug 11, 2025	Aug NEWA

PIROXICAM

CAPSULE;ORAL
PIROXICAM

AB			SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr CAHN
AB				20MG	A074118	001	Jun 15, 1993	Apr CAHN

PITOLISANT HYDROCHLORIDE

TABLET;ORAL
WAKIX

		+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb CAHN
		+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb CAHN

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

AP		HETERO LABS LTD VI	24MG/1.2ML (20MG/ML)	A217560	001	Jun 16, 2025	Jun	NEWA	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@	SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr	CAHN	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

>D>	@	NORVIUM BIOSCIENCE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Sep	CAHN	
>D>	@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Sep	CAHN	
>D>	@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Sep	CAHN	
>D>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Sep	CAHN	
>D>	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Sep	CAHN	
>A>	@	QUAGEN	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Sep	CAHN	
>A>	@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Sep	CAHN	
>A>	@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Sep	CAHN	
>A>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Sep	CAHN	
>A>	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Sep	CAHN	

COLYTE WITH FLAVOR PACKS

>D>	@	NORVIUM BIOSCIENCE	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Sep	CAHN	
>A>	@	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Sep	CAHN	

COLYTE-FLAVORED

>D>	@	NORVIUM BIOSCIENCE	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Sep	CAHN	
>D>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Sep	CAHN	
>A>	@	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Sep	CAHN	
>A>	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Sep	CAHN	

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

>D>	@	ADRASTEA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Sep	CAHN	
	@		EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Jun	DISC	
>A>	@	PHARMOBEDIENT	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Sep	CAHN	

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

	@	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	DISC	
	@		2MG	A210164	002	Jun 11, 2024	Jan	DISC	
	@		3MG	A210164	003	Jun 11, 2024	Jan	DISC	
	@		4MG	A210164	004	Jun 11, 2024	Jan	DISC	
	@	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr	DISC	
	@		2MG	A210236	002	Sep 26, 2024	Apr	DISC	
	@		3MG	A210236	003	Sep 26, 2024	Apr	DISC	
	@		4MG	A210236	004	Sep 26, 2024	Apr	DISC	

POMALYST

	+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr	CTEC	

CAPSULE;ORAL
POMALYST

	+	2MG	N204026	002	Feb 08, 2013	Apr CTEC
	+	3MG	N204026	003	Feb 08, 2013	Apr CTEC
	+!	4MG	N204026	004	Feb 08, 2013	Apr CTEC

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB		MSN	100MG	A218434	001	Feb 24, 2025	Feb NEWA
AB		QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr NEWA

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL
POTASSIUM CHLORIDE

AA		AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan CAHN
>A> AA		ANDA REPOSITORY	20MEQ	A219009	001	Jul 11, 2025	Sep CAHN
AA	+!	GENUS	20MEQ	N208019	001	Aug 19, 2015	Jan CHRS
	@ +		40MEQ	N208019	003	Aug 25, 2023	Jan DISC
>D> AA		GUARDIAN DRUG	20MEQ	A219009	001	Jul 11, 2025	Sep CAHN
AA			20MEQ	A219009	001	Jul 11, 2025	Jul NEWA

INJECTABLE;INJECTION
POTASSIUM CHLORIDE

AP		NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar CAHN

SOLUTION;ORAL
POTASSIUM CHLORIDE

AA		AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan CAHN
AA			40MEQ/15ML	A216156	002	Mar 07, 2023	Jan CAHN
AA		ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar NEWA
AA			40MEQ/15ML	A211992	002	Apr 09, 2025	Mar NEWA
AA		MACLEODS PHARMS LTD	20MEQ/15ML	A218733	001	Sep 10, 2025	Aug NEWA
AA			40MEQ/15ML	A218733	002	Sep 10, 2025	Aug NEWA
AA		TARO	20MEQ/15ML	A218960	001	Jul 22, 2025	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1		GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr CAHN
AB1			20MEQ	A214395	002	Jan 28, 2021	Apr CAHN
AB2		NORVIUM BIOSCIENCE	8MEQ	A204662	001	Aug 21, 2014	May CAHN
AB2			10MEQ	A204662	002	Aug 21, 2014	May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		OTSUKA ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	May CAHN

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES

AP		CIPLA	1.18GM/5ML(236MG/ML); 1.12GM/5ML(224MG/ML)	A217892	001	Jan 24, 2025	Jan NEWA
AP			3.54GM/15ML(236MG/ML); 3.36GM/15ML(224MG/ML)	A217892	002	Jan 24, 2025	Jan NEWA
AP			11.8GM/50ML(236MG/ML); 11.2GM/50ML(224MG/ML)	A217892	003	Jan 24, 2025	Jan NEWA
>A> AP		HOSPIRA	3.54GM/15ML (236MG/ML);3.36GM/15ML	A217459	001	Sep 11, 2025	Sep NEWA

POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE

	+!	FRESENIUS KABI USA	1.18GM/100ML(11.8MG/ML); 1.12GM/100ML(11.2MG/ML)	N212832	004	May 09, 2025	May NEWA
	+!		1.18GM/250ML(4.72MG/ML); 1.12GM/250ML(4.48MG/ML)	N212832	005	May 09, 2025	May NEWA

PRALATREXATE

SOLUTION;INTRAVENOUS
FOLOTYN

AP	+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb CFTG
AP	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb CFTG

PRALATREXATE

AP		DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb NFTG
AP			40MG/2ML (20MG/ML)	A206183	002	Mar 10, 2025	Feb NFTG

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@	AVIV PHARMA	0.125MG	A091450	001	Oct 08, 2010	May	CAHN
	@		0.25MG	A091450	002	Oct 08, 2010	May	CAHN
	@		0.5MG	A091450	003	Oct 08, 2010	May	CAHN
	@		1MG	A091450	004	Oct 08, 2010	May	CAHN
	@		1.5MG	A091450	005	Oct 08, 2010	May	CAHN
AB		PHARMOBEDIENT	0.125MG	A090151	001	Apr 30, 2012	Aug	CAHN
AB			0.25MG	A090151	002	Apr 30, 2012	Aug	CAHN
AB			0.5MG	A090151	003	Apr 30, 2012	Aug	CAHN
AB			0.75MG	A090151	006	Apr 30, 2012	Aug	CAHN
AB			1MG	A090151	004	Apr 30, 2012	Aug	CAHN
AB			1.5MG	A090151	005	Apr 30, 2012	Aug	CAHN

PREDNISOLONE

SOLUTION;ORAL

PREDNISOLONE

AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun	CDFR
	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Jun	CDFR
	@	IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999	Jun	CDFR
AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	Jun	CDFR
	@	NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002	Jun	CDFR
	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Jun	CDFR
AA			15MG/5ML	A040571	001	Aug 25, 2005	Jun	CDFR
	@	PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Jun	CDFR
	@	TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000	Jun	CDFR
AA		TP ANDA HOLDINGS	15MG/5ML	A219509	001	Jun 23, 2025	Aug	CAHN
AA		TULEX PHARMS INC	15MG/5ML	A219509	001	Jun 23, 2025	Jun	NEWA
	@	WE PHARMS	15MG/5ML	A040192	001	May 28, 1998	Jun	CDFR

PRELONE

AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986	Jun	CDFR

PREDNISOLONE ACETATE

SUSPENSION;ORAL

FLO-PRED

	@	SUN PHARMA CANADA	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008	Aug	CAHN
	@		EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008	Aug	CAHN

SUSPENSION/DROPS;OPHTHALMIC

PREDNISOLONE ACETATE

AB		AMNEAL	1%	A218256	001	Jun 11, 2025	May	NEWA

PREDNISONE

TABLET;ORAL

PREDNISONE

	@	AIPING PHARM INC	5MG	A080336	002			Jan CAHN
AB	+!	HIKMA	1MG	A080352	002	Apr 22, 1982	Apr	CMS1
AB	+!		2.5MG	A080352	003	Apr 22, 1982	Apr	CMS1
AB	+!		10MG	A080352	004		Apr	CMS1
AB	+!		20MG	A080352	005		Apr	CMS1
AB	+!		50MG	A080352	006		Apr	CMS1
AB		MYLAN	5MG	A083677	002		Aug	CMS1
AB			10MG	A083677	003	Dec 04, 1985	Aug	CMS1
AB		POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr	CAHN
AB			10MG	A212629	002	Dec 05, 2023	Apr	CAHN
AB			20MG	A212629	003	Dec 05, 2023	Apr	CAHN

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

>A>	!	DR REDDYS	1MG	A219477	001	Oct 01, 2025	Sep	NEWA
>A>			2MG	A219477	002	Oct 01, 2025	Sep	NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

	@	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Apr	DISC
	@		50MG	A091025	002	Jul 09, 2020	Apr	DISC
	@		75MG	A091025	003	Jul 09, 2020	Apr	DISC
	@		100MG	A091025	004	Jul 09, 2020	Apr	DISC
	@		150MG	A091025	005	Jul 09, 2020	Apr	DISC
	@		200MG	A091025	006	Jul 09, 2020	Apr	DISC
	@		225MG	A091025	007	Jul 09, 2020	Apr	DISC
	@		300MG	A091025	008	Jul 09, 2020	Apr	DISC

CAPSULE;ORAL
PREGABALIN

>D>	AB		ADAPTIS	25MG	A208113	001	May 17, 2024	Sep CAHN
>D>	AB			50MG	A208113	002	May 17, 2024	Sep CAHN
>D>	AB			75MG	A208113	004	May 17, 2024	Sep CAHN
>D>	AB			100MG	A208113	005	May 17, 2024	Sep CAHN
>D>	AB			150MG	A208113	003	May 17, 2024	Sep CAHN
>D>	AB			200MG	A208113	006	May 17, 2024	Sep CAHN
>D>	AB			225MG	A208113	007	May 17, 2024	Sep CAHN
>D>	AB			300MG	A208113	008	May 17, 2024	Sep CAHN
		@	APOTEX	25MG	A211685	001	Jul 07, 2021	Apr DISC
		@		50MG	A211685	002	Jul 07, 2021	Apr DISC
		@		75MG	A211685	003	Jul 07, 2021	Apr DISC
		@		100MG	A211685	004	Jul 07, 2021	Apr DISC
		@		150MG	A211685	005	Jul 07, 2021	Apr DISC
		@		200MG	A211685	006	Jul 07, 2021	Apr DISC
		@		225MG	A211685	007	Jul 07, 2021	Apr DISC
		@		300MG	A211685	008	Jul 07, 2021	Apr DISC
>D>	AB		HLTHCARE	25MG	A091222	001	Feb 21, 2025	Sep CAHN
	AB			25MG	A091222	001	Feb 21, 2025	Feb NEWA
>D>	AB			50MG	A091222	002	Feb 21, 2025	Sep CAHN
	AB			50MG	A091222	002	Feb 21, 2025	Feb NEWA
>D>	AB			75MG	A091222	003	Feb 21, 2025	Sep CAHN
	AB			75MG	A091222	003	Feb 21, 2025	Feb NEWA
>D>	AB			100MG	A091222	004	Feb 21, 2025	Sep CAHN
	AB			100MG	A091222	004	Feb 21, 2025	Feb NEWA
>D>	AB			150MG	A091222	005	Feb 21, 2025	Sep CAHN
	AB			150MG	A091222	005	Feb 21, 2025	Feb NEWA
>D>	AB			200MG	A091222	006	Feb 21, 2025	Sep CAHN
	AB			200MG	A091222	006	Feb 21, 2025	Feb NEWA
>D>	AB			225MG	A091222	007	Feb 21, 2025	Sep CAHN
	AB			225MG	A091222	007	Feb 21, 2025	Feb NEWA
>D>	AB			300MG	A091222	008	Feb 21, 2025	Sep CAHN
	AB			300MG	A091222	008	Feb 21, 2025	Feb NEWA
	AB		JUBILANT GENERICS	25MG	A209530	001	May 20, 2025	May NEWA
	AB			50MG	A209530	002	May 20, 2025	May NEWA
	AB			75MG	A209530	003	May 20, 2025	May NEWA
	AB			100MG	A209530	004	May 20, 2025	May NEWA
	AB			150MG	A209530	005	May 20, 2025	May NEWA
	AB			200MG	A209530	006	May 20, 2025	May NEWA
	AB			225MG	A209530	007	May 20, 2025	May NEWA
	AB			300MG	A209530	008	May 20, 2025	May NEWA
		@	MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024	Jun DISC
		@		50MG	A205924	002	Nov 12, 2024	Jun DISC
		@		75MG	A205924	003	Nov 12, 2024	Jun DISC
		@		100MG	A205924	004	Nov 12, 2024	Jun DISC
		@		150MG	A205924	005	Nov 12, 2024	Jun DISC
		@		200MG	A205924	006	Nov 12, 2024	Jun DISC
		@		225MG	A205924	007	Nov 12, 2024	Jun DISC
		@		300MG	A205924	008	Nov 12, 2024	Jun DISC
>A>	AB		PHARMOBEDIENT	25MG	A091222	001	Feb 21, 2025	Sep CAHN
>A>	AB			50MG	A091222	002	Feb 21, 2025	Sep CAHN
>A>	AB			75MG	A091222	003	Feb 21, 2025	Sep CAHN
>A>	AB			100MG	A091222	004	Feb 21, 2025	Sep CAHN
>A>	AB			150MG	A091222	005	Feb 21, 2025	Sep CAHN
>A>	AB			200MG	A091222	006	Feb 21, 2025	Sep CAHN
>A>	AB			225MG	A091222	007	Feb 21, 2025	Sep CAHN
>A>	AB			300MG	A091222	008	Feb 21, 2025	Sep CAHN
>A>	AB		REGCON HOLDINGS	25MG	A208113	001	May 17, 2024	Sep CAHN
>A>	AB			50MG	A208113	002	May 17, 2024	Sep CAHN
>A>	AB			75MG	A208113	004	May 17, 2024	Sep CAHN
>A>	AB			100MG	A208113	005	May 17, 2024	Sep CAHN
>A>	AB			150MG	A208113	003	May 17, 2024	Sep CAHN
>A>	AB			200MG	A208113	006	May 17, 2024	Sep CAHN
>A>	AB			225MG	A208113	007	May 17, 2024	Sep CAHN
>A>	AB			300MG	A208113	008	May 17, 2024	Sep CAHN
>D>	AB		RENATA	50MG	A210585	001	Dec 26, 2019	Sep CAHN
	AB			50MG	A210585	001	Dec 26, 2019	Aug CAHN
>D>	AB			75MG	A210585	002	Dec 26, 2019	Sep CAHN
	AB			75MG	A210585	002	Dec 26, 2019	Aug CAHN
>D>	AB			100MG	A210585	003	Dec 26, 2019	Sep CAHN
	AB			100MG	A210585	003	Dec 26, 2019	Aug CAHN
>D>	AB			150MG	A210585	004	Dec 26, 2019	Sep CAHN
	AB			150MG	A210585	004	Dec 26, 2019	Aug CAHN

CAPSULE;ORAL
PREGABALIN

>D>	AB			200MG	A210585	005	Dec 26, 2019	Sep CAHN
	AB			200MG	A210585	005	Dec 26, 2019	Aug CAHN
>D>	AB			300MG	A210585	006	Dec 26, 2019	Sep CAHN
	AB			300MG	A210585	006	Dec 26, 2019	Aug CAHN
>A>	AB		SOMERSET THERAPS LLC	50MG	A210585	001	Dec 26, 2019	Sep CAHN
>A>	AB			75MG	A210585	002	Dec 26, 2019	Sep CAHN
>A>	AB			100MG	A210585	003	Dec 26, 2019	Sep CAHN
>A>	AB			150MG	A210585	004	Dec 26, 2019	Sep CAHN
>A>	AB			200MG	A210585	005	Dec 26, 2019	Sep CAHN
>A>	AB			300MG	A210585	006	Dec 26, 2019	Sep CAHN
	AB		TORRENT	25MG	A206942	001	Feb 21, 2025	Feb NEWA
	AB			50MG	A206942	002	Feb 21, 2025	Feb NEWA
	AB			75MG	A206942	003	Feb 21, 2025	Feb NEWA
	AB			100MG	A206942	004	Feb 21, 2025	Feb NEWA
	AB			150MG	A206942	005	Feb 21, 2025	Feb NEWA
	AB			200MG	A206942	006	Feb 21, 2025	Feb NEWA
	AB			225MG	A206942	007	Feb 21, 2025	Feb NEWA
	AB			300MG	A206942	008	Feb 21, 2025	Feb NEWA
	AB		WESTMINSTER PHARMS	25MG	A212988	001	Mar 08, 2022	Aug CAHN
	AB			50MG	A212988	002	Mar 08, 2022	Aug CAHN
	AB			75MG	A212988	003	Mar 08, 2022	Aug CAHN
	AB			100MG	A212988	004	Mar 08, 2022	Aug CAHN
	AB			150MG	A212988	005	Mar 08, 2022	Aug CAHN
	AB			200MG	A212988	006	Mar 08, 2022	Aug CAHN
	AB			225MG	A212988	007	Mar 08, 2022	Aug CAHN
	AB			300MG	A212988	008	Mar 08, 2022	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

>A>	AB		AIPING PHARM INC	330MG	A217857	001	Jan 28, 2025	Sep CAHN
		@	ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb DISC
		@		165MG	A211593	002	Apr 13, 2021	Feb DISC
		@		330MG	A211593	003	Apr 13, 2021	Feb DISC
		@	APOTEX	165MG	A213313	001	Apr 13, 2021	Jan DISC
		@		330MG	A213313	002	Apr 13, 2021	Jan DISC
>D>	AB		HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Sep CAHN
	AB			330MG	A217857	001	Jan 28, 2025	Jan NEWA

PRIMIDONE

TABLET;ORAL
PRIMIDONE

		@	CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr CAHN
		@		250MG	A040862	002	Oct 03, 2008	Apr CAHN

PROBENECID; SULOPENEM ETZADROXIL

TABLET;ORAL
ORLYNVAH

		@ +	ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Apr DISC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

	AP		CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan NEWA
	AP			500MG/ML	A218674	002	Feb 04, 2025	Jan NEWA

PROCHLORPERAZINE

SUPPOSITORY;RECTAL
COMPAZINE

		@ +	GLAXOSMITHKLINE	2.5MG	N011127	003		Mar CRLD
		@ +		5MG	N011127	001		Mar CMS1
		@ +		5MG	N011127	001		Mar CRLD
		@ +		25MG	N011127	002		Mar CMS1
		@ +		25MG	N011127	002		Mar CRLD

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

		@	NEXUS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Apr DISC

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

	AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A218734	001	Sep 08, 2025	Aug NEWA
	AB			EQ 10MG BASE	A218734	002	Sep 08, 2025	Aug NEWA
>D>	AB		CEROVENE INC	EQ 5MG BASE	A217847	001	May 19, 2025	Sep CAHN
	AB			EQ 5MG BASE	A217847	001	May 19, 2025	May NEWA
>D>	AB			EQ 10MG BASE	A217847	002	May 19, 2025	Sep CAHN
	AB			EQ 10MG BASE	A217847	002	May 19, 2025	May NEWA
>A>	AB		DR REDDYS LABS SA	EQ 5MG BASE	A217847	001	May 19, 2025	Sep CAHN
>A>	AB			EQ 10MG BASE	A217847	002	May 19, 2025	Sep CAHN

PROGESTERONE

CAPSULE;ORAL

PROMETRIUM

	AB	+	ACERTIS PHARMS	100MG	N019781	001	May 14, 1998	May CAHN
	AB	+!		200MG	N019781	002	Oct 15, 1999	May CAHN
		@		300MG	N019781	003	Oct 15, 1999	May CAHN

INSERT;VAGINAL

ENDOMETRIN

>D>		+!	FERRING	100MG	N022057	001	Jun 21, 2007	Sep CFTG
>A>	AB	+!		100MG	N022057	001	Jun 21, 2007	Sep CFTG

>A> PROGESTERONE

>A>	AB		XIROMED	100MG	A218391	001	Sep 19, 2025	Sep NFTG

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

		@	TARO	12.5MG	A040603	001	Oct 26, 2006	Aug DISC
		@		25MG	A040603	002	Oct 26, 2006	Aug DISC

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

	AA		COSETTE	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun CAHN
	AA		PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006	Aug CMFD
	AA		STRIDES PHARMA	6.25MG/5ML	A040891	001	Mar 13, 2009	Apr CAHN
		@	TARO	6.25MG/5ML	A040718	001	Apr 04, 2007	Aug DISC

PROMETHAZINE PLAIN

	AA	+!	XTTRIUM LABS INC	6.25MG/5ML	A087953	001	Nov 15, 1982	Feb CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PROPARACAINE HYDROCHLORIDE

	AT		MANKIND PHARMA	0.5%	A219136	001	May 21, 2025	May NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB		ANDA REPOSITORY	60MG	A078065	001	Jan 26, 2007	Sep CAHN
>A>	AB			80MG	A078065	002	Jan 26, 2007	Sep CAHN
>A>	AB			120MG	A078065	003	Jan 26, 2007	Sep CAHN
>A>	AB			160MG	A078065	004	Jan 26, 2007	Sep CAHN
>D>	AB		NORTEC DEV ASSOC	60MG	A078065	001	Jan 26, 2007	Sep CAHN
>D>	AB			80MG	A078065	002	Jan 26, 2007	Sep CAHN
>D>	AB			120MG	A078065	003	Jan 26, 2007	Sep CAHN
>D>	AB			160MG	A078065	004	Jan 26, 2007	Sep CAHN

PROTAMINE SULFATE

POWDER;INTRAVENOUS

PROTAMINE SULFATE

		@	PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001		Aug CDFR
		@		250MG/VIAL	N007413	002	Aug 02, 1984	Aug CDFR

SOLUTION;INTRAVENOUS

PROTAMINE SULFATE

		!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987	Aug CDFR
		!		50MG/5ML (10MG/ML)	A089454	001	Apr 07, 1987	Aug CPOT
		!		250MG/25ML (10MG/ML)	A089454	002	Apr 07, 1987	Aug NEWA
		@	HIKMA	10MG/ML	A089474	001	Nov 05, 1986	Aug CDFR
		@		10MG/ML	A089475	001	Nov 05, 1986	Aug CDFR
		@		50MG/5ML (10MG/ML)	A089474	001	Nov 05, 1986	Aug CPOT
		@		50MG/5ML (10MG/ML)	A089475	002	Jun 07, 1988	Aug NEWA
		@		250MG/25ML (10MG/ML)	A089475	001	Nov 05, 1986	Aug CPOT

SOLUTION;INTRAVENOUS
PROTAMINE SULFATE

	@ +	LILLY	10MG/ML	N006460	002			Aug CDFR
	@ +		50MG/5ML (10MG/ML)	N006460	002			Aug CPOT
	@ +		250MG/25ML (10MG/ML)	N006460	003			Aug DISC
	+		250MG/25ML (10MG/ML)	N006460	003			Aug NEWA

PROTRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
PROTRIPTYLINE HYDROCHLORIDE

AB	!	EPIC PHARMA LLC	10MG	A202220	002	Nov 19, 2012	Apr	CHRS
	@	HIKMA	5MG	A078913	001	Sep 16, 2008	Apr	DISC
	@		10MG	A078913	002	Sep 16, 2008	Apr	DISC

PRUCALOPRIDE SUCCINATE
TABLET;ORAL
PRUCALOPRIDE SUCCINATE

AB		AGGREGA	EQ 1MG BASE	A219193	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A219193	002	Jun 24, 2025	Jun	NEWA
AB		ALKEM LABS LTD	EQ 1MG BASE	A218295	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A218295	002	Jun 24, 2025	Jun	NEWA
>A> AB		AMNEAL	EQ 1MG BASE	A218812	001	Jun 24, 2025	Sep	CAHN
>A> AB			EQ 2MG BASE	A218812	002	Jun 24, 2025	Sep	CAHN
AB		ANNORA PHARMA	EQ 1MG BASE	A219160	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A219160	002	Jun 24, 2025	Jun	NEWA
AB		APOTEX	EQ 1MG BASE	A218977	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A218977	002	Jun 24, 2025	Jun	NEWA
AB		APPCO	EQ 1MG BASE	A218963	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A218963	002	Jun 24, 2025	Jun	NEWA
AB		H2-PHARMA	EQ 1MG BASE	A219216	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A219216	002	Jun 24, 2025	Jun	NEWA
AB		HIKMA	EQ 1MG BASE	A217662	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A217662	002	Jun 24, 2025	Jun	NEWA
AB		LUPIN LTD	EQ 1MG BASE	A218847	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A218847	002	Jun 24, 2025	Jun	NEWA
AB		MSN	EQ 1MG BASE	A218177	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A218177	002	Jun 24, 2025	Jun	NEWA
>D> AB		SKG PHARMA	EQ 1MG BASE	A218812	001	Jun 24, 2025	Sep	CAHN
AB			EQ 1MG BASE	A218812	001	Jun 24, 2025	Jun	NEWA
>D> AB			EQ 2MG BASE	A218812	002	Jun 24, 2025	Sep	CAHN
AB			EQ 2MG BASE	A218812	002	Jun 24, 2025	Jun	NEWA
AB		SOMERSET THERAP	EQ 1MG BASE	A219078	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A219078	002	Jun 24, 2025	Jun	NEWA
AB		SPECGX LLC	EQ 1MG BASE	A219193	001	Jun 24, 2025	Aug	CAHN
AB			EQ 2MG BASE	A219193	002	Jun 24, 2025	Aug	CAHN
	@	TORRENT	EQ 1MG BASE	A218778	001	Jun 24, 2025	Jul	DISC
AB			EQ 1MG BASE	A218778	001	Jun 24, 2025	Jun	NEWA
	@		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jul	DISC
AB			EQ 2MG BASE	A218778	002	Jun 24, 2025	Jun	NEWA
AB		ZENARA	EQ 1MG BASE	A218795	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A218795	002	Jun 24, 2025	Jun	NEWA
>A> AB		ZYDUS LIFESCIENCES	EQ 1MG BASE	A218056	001	Aug 07, 2025	Sep	CAHN
>A> AB			EQ 2MG BASE	A218056	002	Aug 07, 2025	Sep	CAHN
>D> AB		ZYDUS PHARMS	EQ 1MG BASE	A218056	001	Aug 07, 2025	Sep	CAHN
AB			EQ 1MG BASE	A218056	001	Aug 07, 2025	Aug	NEWA
>D> AB			EQ 2MG BASE	A218056	002	Aug 07, 2025	Sep	CAHN
AB			EQ 2MG BASE	A218056	002	Aug 07, 2025	Aug	NEWA

PYRIMETHAMINE
TABLET;ORAL
PYRIMETHAMINE

	@	ALVOGEN	25MG	A211271	001	Jul 27, 2021	May	DISC

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

AB		GRAVITI PHARMS	EQ 25MG BASE	A077380	001	Mar 27, 2012	Feb	CAHN
AB			EQ 50MG BASE	A077380	002	Mar 27, 2012	Feb	CAHN
AB			EQ 100MG BASE	A077380	003	Mar 27, 2012	Feb	CAHN
AB			EQ 150MG BASE	A077380	004	Mar 27, 2012	Feb	CAHN
AB			EQ 200MG BASE	A077380	005	Mar 27, 2012	Feb	CAHN
AB			EQ 300MG BASE	A077380	006	Mar 27, 2012	Feb	CAHN
AB			EQ 400MG BASE	A077380	007	Mar 27, 2012	Feb	CAHN

TABLET;ORAL
QUETIAPINE FUMARATE

>D>	AB		SUN PHARM	EQ 200MG BASE	A201190	004	Mar 27, 2012	Sep DISC
>A>		@		EQ 200MG BASE	A201190	004	Mar 27, 2012	Sep DISC

SEROQUEL

	AB	+!	CHEPLAPHARM	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar CAHN
	AB	+		EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar CAHN
	AB	+		EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar CAHN
		@ +		EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar CAHN
	AB	+		EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar CAHN
	AB	+!		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar CAHN
	AB	+		EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

	AB		MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Feb CAHN
	AB			EQ 150MG BASE	A202939	002	May 09, 2017	Feb CAHN
	AB			EQ 200MG BASE	A202939	003	May 09, 2017	Feb CAHN
	AB			EQ 300MG BASE	A202939	004	May 09, 2017	Feb CAHN
	AB			EQ 400MG BASE	A202939	005	May 09, 2017	Feb CAHN

SEROQUEL XR

	AB	+	CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar CAHN
	AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar CAHN
	AB	+!		EQ 200MG BASE	N022047	002	May 17, 2007	Mar CAHN
	AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Mar CAHN
	AB	+		EQ 400MG BASE	N022047	004	May 17, 2007	Mar CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL
ISENTRESS

		+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan CTEC

ISENTRESS HD

	AB	+!	MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Apr CFTG

RALTEGRAVIR POTASSIUM

		@	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan DISC
	AB		LUPIN LTD	EQ 600MG BASE	A217990	001	May 06, 2025	Apr NFTG

RAMELTEON

TABLET;ORAL
RAMELTEON

	AB		APPCO	8MG	A213815	001	Oct 26, 2020	Mar CAHN
	BX		AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar CTEC
	BX		I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar CTEC
	BX		XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RAMIPRIL

CAPSULE;ORAL
ALTACE

		@ +	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul DISC
		@ +		2.5MG	N019901	002	Jan 28, 1991	Jul DISC
		@ +		5MG	N019901	003	Jan 28, 1991	Jul DISC
		@ +		10MG	N019901	004	Jan 28, 1991	Jul DISC

RAMIPRIL

	AB	!	LUPIN	10MG	A077626	004	Jun 09, 2008	Jul CHRS

SOLUTION;ORAL
VOSTALLY

		+!	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Jul NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

		@	APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar DISC
		@		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar DISC
		@	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	Aug DISC
		@		EQ 300MG BASE	A078542	002	Nov 19, 2008	Aug DISC
		@	MPP PHARMA	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jun CAHN
		@		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jun CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

	AB		ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan CAHN
	AB			1GM	A212781	002	Mar 23, 2020	Jan CAHN
	AB	!	CADILA	1GM	A210188	002	Aug 19, 2019	Mar CHRS
	AB		JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr NEWA
	AB			1GM	A211361	002	Apr 15, 2025	Apr NEWA
		@	SUN PHARM	500MG	A211707	001	May 28, 2019	Mar DISC
		@		1GM	A211707	002	May 28, 2019	Mar DISC
		@	TORRENT	500MG	A210407	001	Feb 04, 2025	Jun DISC
	AB			500MG	A210407	001	Feb 04, 2025	Jan NEWA
		@		1GM	A210407	002	Feb 04, 2025	Jun DISC
	AB			1GM	A210407	002	Feb 04, 2025	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

		@	CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr CAHN
		@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr CAHN
>A>	AB		RISING	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Sep CAHN
>A>	AB			EQ 1MG BASE	A218163	002	Apr 09, 2024	Sep CAHN
>D>	AB		SKG PHARMA	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Sep CAHN
>D>	AB			EQ 1MG BASE	A218163	002	Apr 09, 2024	Sep CAHN
	AB		TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr NEWA
	AB			EQ 1MG BASE	A210150	002	May 05, 2025	Apr NEWA

REGORAFENIB

TABLET;ORAL

REGORAFENIB

		@	ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jul DISC
	AB			40MG	A209728	001	Jan 13, 2025	Jan NFTG

STIVARGA

		+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jul CTEC
	AB	+!		40MG	N203085	001	Sep 27, 2012	Jan CFTG

RELUGOLIX

TABLET;ORAL

ORGOVYX

		+!	SUMITOMO PHARMA AM	120MG	N214621	001	Dec 18, 2020	Aug CAHN

REMDESIVIR

SOLUTION;INTRAVENOUS

VEKLURY

		@ +	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020	Jun DISC

>A> REMIBRUTINIB

>A> TABLET;ORAL

>A> RHAPSIDO

>A>		+!	NOVARTIS	25MG	N218436	001	Sep 30, 2025	Sep NEWA

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

>D>		@	NORVIUM BIOSCIENCE	0.5MG	A090252	001	Aug 23, 2013	Sep CAHN
>D>		@		1MG	A090252	002	Jan 22, 2014	Sep CAHN
>D>		@		2MG	A090252	003	Jan 22, 2014	Sep CAHN
>A>		@	QUAGEN	0.5MG	A090252	001	Aug 23, 2013	Sep CAHN
>A>		@		1MG	A090252	002	Jan 22, 2014	Sep CAHN
>A>		@		2MG	A090252	003	Jan 22, 2014	Sep CAHN
		@	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb DISC
		@		2MG	A077571	003	Jul 11, 2013	Feb DISC

REPOTRECTINIB

CAPSULE;ORAL

AUGTYRO

		+!	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul CHRS

RIBAVIRIN
FOR SOLUTION;INHALATION
RIBAVIRIN
! NAVINTA LLC 6GM/VIAL A207366 001 Oct 06, 2016 Aug CHRS
6GM/VIAL A207366 001 Oct 06, 2016 Aug CTEC
VIRAZOLE
@ + BAUSCH 6GM/VIAL N018859 001 Dec 31, 1985 Aug DISC

RIFAMPIN
CAPSULE;ORAL
RIFADIN
@ + SANOFI AVENTIS US 150MG N050420 002 Apr CMS1

RILPIVIRINE HYDROCHLORIDE
TABLET, FOR SUSPENSION;ORAL
EDURANT PED
+! JANSSEN PRODS EQ 2.5MG BASE N219016 001 Mar 15, 2024 May CMFD

RILUZOLE
TABLET;ORAL
RILUZOLE
AB NORVIUM BIOSCIENCE 50MG A203042 001 Jul 01, 2013 Feb CAHN
@ PHARMOBEDIENT 50MG A203042 001 Jul 01, 2013 Aug DISC

RILZABRUTINIB
TABLET;ORAL
WAYRILZ
+! GENZYME CORP 400MG N219685 001 Aug 29, 2025 Aug NEWA

RISDIPLAM
TABLET;ORAL
EVRYSDI
+! GENENTECH INC 5MG N219285 001 Feb 11, 2025 Feb NEWA

RISEDRONATE SODIUM
TABLET, DELAYED RELEASE;ORAL
RISEDRONATE SODIUM
@ SUN PHARM 35MG A203925 001 Jul 09, 2019 Apr DISC

RISPERIDONE
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
RYKINDO
@ + SHANDONG LUYE 12.5MG N212849 001 Jan 13, 2023 Jul DISC
INJECTABLE;INTRAMUSCULAR
RISPERIDONE
AB AMNEAL 12.5MG/VIAL A218586 001 Sep 02, 2025 Aug NEWA
AB 25MG/VIAL A218586 002 Sep 02, 2025 Aug NEWA
AB 37.5MG/VIAL A218586 003 Sep 02, 2025 Aug NEWA
AB 50MG/VIAL A218586 004 Sep 02, 2025 Aug NEWA
AB NANOMI 25MG/VIAL A211220 001 Sep 02, 2025 Aug NEWA
AB 37.5MG/VIAL A211220 002 Sep 02, 2025 Aug NEWA
AB 50MG/VIAL A211220 003 Sep 02, 2025 Aug NEWA
SOLUTION;ORAL
RISPERIDONE
AA APOZEAL PHARMS 1MG/ML A078909 001 Jul 29, 2009 Jul CMFD
@ 1MG/ML A078909 001 Jul 29, 2009 Apr CAHN
@ LANNETT CO INC 1MG/ML A079158 001 Dec 03, 2010 Feb DISC
@ TARO 1MG/ML A090347 001 Feb 07, 2011 Jul DISC
TABLET;ORAL
RISPERIDONE
@ APOTEX INC 0.25MG A077953 001 Sep 15, 2008 Mar DISC
@ 0.5MG A077953 002 Sep 15, 2008 Mar DISC
@ 1MG A077953 003 Sep 15, 2008 Mar DISC
@ 2MG A077953 004 Sep 15, 2008 Mar DISC
@ 3MG A077953 005 Sep 15, 2008 Mar DISC
@ 4MG A077953 006 Sep 15, 2008 Mar DISC
AB RENATA 0.25MG A078707 001 Dec 29, 2008 Aug CAHN
AB 0.5MG A078707 002 Dec 29, 2008 Aug CAHN
AB 1MG A078707 003 Dec 29, 2008 Aug CAHN
AB 2MG A078707 004 Dec 29, 2008 Aug CAHN
AB 3MG A078707 005 Dec 29, 2008 Aug CAHN

TABLET;ORAL
RISPERIDONE

	AB			4MG	A078707	006	Dec 29, 2008	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

		@	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Jul DISC
		@		1MG	A078464	002	Apr 08, 2013	Jul DISC
		@		2MG	A078464	003	Apr 08, 2013	Jul DISC
		@		3MG	A078464	004	Apr 08, 2013	Jul DISC
		@		4MG	A078464	005	Apr 08, 2013	Jul DISC

RITONAVIR
CAPSULE;ORAL
RITONAVIR

>D>			NORVIUM BIOSCIENCE	100MG	A205024	001	Feb 16, 2024	Sep CAHN
>A>			QUAGEN	100MG	A205024	001	Feb 16, 2024	Sep CAHN

RIVAROXABAN
FOR SUSPENSION;ORAL
RIVAROXABAN

	AB		ALKEM LABS LTD	1MG/ML	A218502	001	Jun 26, 2025	Jun NFTG
>A>	AB		LUPIN LTD	1MG/ML	A218195	001	Sep 25, 2025	Sep NEWA

XARELTO

	AB	+!	JANSSEN PHARMS	1MG/ML	N215859	001	Dec 20, 2021	Jun CFTG

TABLET;ORAL
RIVAROXABAN

>A>	AB		AIPING PHARM INC	10MG	A216995	001	May 14, 2025	Sep CAHN
>A>	AB			15MG	A216995	002	May 14, 2025	Sep CAHN
>A>	AB			20MG	A216995	003	May 14, 2025	Sep CAHN
	AB		ALEMBIC	2.5MG	A210301	001	May 14, 2025	May NEWA
	AB			10MG	A210301	002	May 14, 2025	May NFTG
	AB			15MG	A210301	003	May 14, 2025	May NFTG
	AB			20MG	A210301	004	May 14, 2025	May NFTG
	AB		APOTEX	2.5MG	A217810	001	May 02, 2025	Apr NEWA
	AB		ASCENT PHARMS INC	2.5MG	A219332	001	May 14, 2025	May NEWA
	AB			10MG	A219332	002	May 14, 2025	May NFTG
	AB			15MG	A219332	003	May 14, 2025	May NFTG
	AB			20MG	A219332	004	May 14, 2025	May NFTG
	AB		AUROBINDO PHARMA LTD	2.5MG	A208544	001	Apr 10, 2025	Apr NEWA
	AB			10MG	A208544	002	May 15, 2025	May NEWA
	AB			15MG	A208544	003	May 15, 2025	May NEWA
	AB			20MG	A208544	004	May 15, 2025	May NEWA
	AB		BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	May NEWA
	AB			10MG	A218107	002	May 14, 2025	May NFTG
	AB			15MG	A218107	003	May 14, 2025	May NFTG
	AB			20MG	A218107	004	May 14, 2025	May NFTG
	AB		BRECKENRIDGE	10MG	A208220	001	May 15, 2025	May NEWA
	AB			15MG	A208220	002	May 15, 2025	May NEWA
	AB			20MG	A208220	003	May 15, 2025	May NEWA
>D>	AB		CHANGZHOU PHARM	10MG	A216995	001	May 14, 2025	Sep CAHN
	AB			10MG	A216995	001	May 14, 2025	May NFTG
>D>	AB			15MG	A216995	002	May 14, 2025	Sep CAHN
	AB			15MG	A216995	002	May 14, 2025	May NFTG
>D>	AB			20MG	A216995	003	May 14, 2025	Sep CAHN
	AB			20MG	A216995	003	May 14, 2025	May NFTG
	AB		DR REDDYS	2.5MG	A208534	001	May 14, 2025	May NEWA
	AB			10MG	A208534	002	May 14, 2025	May NFTG
	AB			15MG	A208534	003	May 14, 2025	May NFTG
	AB			20MG	A208534	004	May 14, 2025	May NFTG
	AB		INDOCO	2.5MG	A218445	001	Aug 11, 2025	Aug NEWA
	AB			10MG	A218445	002	Aug 11, 2025	Aug NEWA
	AB			15MG	A218445	003	Aug 11, 2025	Aug NEWA
	AB			20MG	A218445	004	Aug 11, 2025	Aug NEWA
		@	INVAGEN PHARMS	10MG	A208543	001	May 14, 2025	Aug DISC
	AB			10MG	A208543	001	May 14, 2025	May NFTG
		@		15MG	A208543	002	May 14, 2025	Aug DISC
	AB			15MG	A208543	002	May 14, 2025	May NFTG
		@		20MG	A208543	003	May 14, 2025	Aug DISC
	AB			20MG	A208543	003	May 14, 2025	May NFTG
	AB		LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb NFTG
	AB			10MG	A208555	002	May 14, 2025	May NFTG
	AB			15MG	A208555	003	May 14, 2025	May NFTG
	AB			20MG	A208555	004	May 14, 2025	May NFTG

TABLET;ORAL
RIVAROXABAN

	AB		MACLEODS PHARMS LTD	2.5MG	A213114	001	May 14, 2025	May NEWA
	AB			10MG	A213114	002	May 14, 2025	May NFTG
	AB			15MG	A213114	003	May 14, 2025	May NFTG
	AB			20MG	A213114	004	May 14, 2025	May NFTG
	AB		SCIEGEN PHARMS INC	2.5MG	A218117	001	Jul 31, 2025	Jul NEWA
	AB			10MG	A218117	002	Jul 31, 2025	Jul NEWA
	AB			15MG	A218117	003	Jul 31, 2025	Jul NEWA
	AB			20MG	A218117	004	Jul 31, 2025	Jul NEWA
	AB		SUNSHINE	10MG	A213348	001	May 14, 2025	May NFTG
	AB			15MG	A213348	002	May 14, 2025	May NFTG
	AB			20MG	A213348	003	May 14, 2025	May NFTG
	AB		TARO	2.5MG	A208557	001	Mar 03, 2025	Feb NFTG
>A>	AB			10MG	A208557	002	Oct 07, 2025	Sep NEWA
>A>	AB			15MG	A208557	003	Oct 07, 2025	Sep NEWA
>A>	AB			20MG	A208557	004	Oct 07, 2025	Sep NEWA

XARELTO

	AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb CFTG
	AB	+		10MG	N022406	001	Jul 01, 2011	May CFTG
	AB	+		15MG	N022406	002	Nov 04, 2011	May CFTG
	AB	+!		20MG	N022406	003	Nov 04, 2011	May CFTG

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

		@	ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar DISC
		@		9.5MG/24HR	A204403	002	Sep 03, 2015	Mar DISC
		@		13.3MG/24HR	A204403	003	Aug 31, 2015	Mar DISC
>A>	AB		YICHANG HUMANWELL	4.6MG/24HR	A215445	001	Sep 23, 2025	Sep NEWA
>A>	AB			9.5MG/24HR	A215445	002	Sep 23, 2025	Sep NEWA
>A>	AB			13.3MG/24HR	A215445	003	Sep 23, 2025	Sep NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL
RIZATRIPTAN BENZOATE

	AB		NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb CAHN
	AB			EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

		@	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun DISC
		@		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

	AP		MANKIND PHARMA	50MG/5ML (10MG/ML)	A219674	001	May 29, 2025	May NEWA
	AP			100MG/10ML (10MG/ML)	A219674	002	May 29, 2025	May NEWA
>D>		@	NORVIUM BIOSCIENCE	50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024	Sep CAHN
>D>		@		100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024	Sep CAHN
>A>		@	RISING	50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024	Sep CAHN
>A>		@		100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024	Sep CAHN

SOLUTION;INTRAVENOUS
ROCURONIUM BROMIDE

		+!	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	N217472	001	Jun 09, 2025	Jun NEWA
		+!		100MG/10ML (10MG/ML)	N217472	002	Jun 09, 2025	Jun NEWA

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

	AB		AUROBINDO PHARMA LTD	250MCG	A213298	002	Jan 31, 2025	Jan NEWA
		@	SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CAHN
		@		500MCG	A208236	001	Oct 03, 2018	Feb CAHN
>D>	AB		TORRENT	250MCG	A208272	002	Oct 18, 2024	Sep DISC
>A>		@		250MCG	A208272	002	Oct 18, 2024	Sep DISC

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

		@	AUROBINDO PHARMA USA	EQ 2MG BASE	A200462	001	Oct 15, 2012	Aug CAHN
		@		EQ 3MG BASE	A200462	002	Oct 15, 2012	Aug CAHN
		@		EQ 4MG BASE	A200462	003	Oct 15, 2012	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

		@	EQ 6MG BASE	A200462	004	Oct 15, 2012	Aug CAHN
		@	EQ 8MG BASE	A200462	005	Oct 15, 2012	Aug CAHN
		@	EQ 12MG BASE	A200462	006	Oct 15, 2012	Aug CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

>D>	AP	ANTHEA PHARMA	40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Sep CAHN
	AP		40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar NEWA
>D>	AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Sep CAHN
	AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar NEWA
>D>	AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Sep CAHN
	AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar NEWA
>A>	AP	NEOCUBES PHARMA	20MG/10ML (2MG/ML)	A219883	004	Oct 08, 2025	Sep NEWA
>A>	AP		40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Sep CAHN
>A>	AP		100MG/20ML (5MG/ML)	A219883	005	Oct 08, 2025	Sep NEWA
>A>	AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Sep CAHN
>A>	AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Sep CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL
CRESTOR

	AB	+ ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan CAHN
	AB	+	EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan CAHN
	AB	+	EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan CAHN
	AB	+!	EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan CAHN

ROSUVASTATIN CALCIUM

		@ MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Jun DISC
		@	EQ 10MG BASE	A207296	002	Nov 06, 2024	Jun DISC
		@	EQ 20MG BASE	A207296	003	Nov 06, 2024	Jun DISC
		@	EQ 40MG BASE	A207296	004	Nov 06, 2024	Jun DISC
>D>	AB	MANKIND PHARMA	EQ 5MG BASE	A206603	001	May 16, 2025	Sep DISC
>A>		@	EQ 5MG BASE	A206603	001	May 16, 2025	Sep DISC
	AB		EQ 5MG BASE	A206603	001	May 16, 2025	May NEWA
>D>	AB		EQ 10MG BASE	A206603	002	May 16, 2025	Sep DISC
>A>		@	EQ 10MG BASE	A206603	002	May 16, 2025	Sep DISC
	AB		EQ 10MG BASE	A206603	002	May 16, 2025	May NEWA
>D>	AB		EQ 20MG BASE	A206603	003	May 16, 2025	Sep DISC
>A>		@	EQ 20MG BASE	A206603	003	May 16, 2025	Sep DISC
	AB		EQ 20MG BASE	A206603	003	May 16, 2025	May NEWA
>D>	AB		EQ 40MG BASE	A206603	004	May 16, 2025	Sep DISC
>A>		@	EQ 40MG BASE	A206603	004	May 16, 2025	Sep DISC
	AB		EQ 40MG BASE	A206603	004	May 16, 2025	May NEWA
	AB	RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Aug CAHN
	AB		EQ 10MG BASE	A207062	002	Oct 31, 2016	Aug CAHN
	AB		EQ 20MG BASE	A207062	003	Oct 31, 2016	Aug CAHN
	AB		EQ 40MG BASE	A207062	004	Oct 31, 2016	Aug CAHN
	AB	ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	May CMFD
	AB		EQ 10MG BASE	A206513	002	Mar 01, 2019	May CMFD
	AB		EQ 20MG BASE	A206513	003	Mar 01, 2019	May CMFD
	AB		EQ 40MG BASE	A206513	004	Mar 01, 2019	May CMFD

RUFINAMIDE

SUSPENSION;ORAL
RUFINAMIDE

	AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Jun CAHN
	AB	MSN	40MG/ML	A214817	001	Apr 15, 2025	Apr NEWA

SACUBITRIL; VALSARTAN

TABLET;ORAL
SACUBITRIL AND VALSARTAN

	AB	DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan NEWA
	AB		49MG;51MG	A213627	002	Jan 13, 2025	Jan NEWA
	AB		97MG;103MG	A213627	003	Jan 13, 2025	Jan NEWA
	AB	HETERO LABS LTD III	24MG;26MG	A213668	001	Jul 17, 2025	Jul NEWA
	AB		49MG;51MG	A213668	002	Jul 17, 2025	Jul NEWA
	AB		97MG;103MG	A213668	003	Jul 17, 2025	Jul NEWA
	AB	LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan NEWA
	AB		49MG;51MG	A213808	002	Jan 08, 2025	Jan NEWA
	AB		97MG;103MG	A213808	003	Jan 08, 2025	Jan NEWA
	AB	MSN	24MG;26MG	A213748	001	Jul 16, 2025	Jul NEWA

TABLET;ORAL
SACUBITRIL AND VALSARTAN

AB			49MG;51MG	A213748	002	Jul 16, 2025	Jul NEWA
AB			97MG;103MG	A213748	003	Jul 16, 2025	Jul NEWA
AB		NOVUGEN PHARMA SDN	24MG;26MG	A213611	001	Jul 16, 2025	Jul NEWA
AB			49MG;51MG	A213611	002	Jul 16, 2025	Jul NEWA
AB			97MG;103MG	A213611	003	Jul 16, 2025	Jul NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL
SAFINAMIDE MESYLATE

AB		ZENARA	EQ 50MG BASE	A215913	001	Jun 13, 2025	Jun NEWA
AB			EQ 100MG BASE	A215913	002	Jun 13, 2025	Jun NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB		HOPEWELL PHARMA	100MG/PACKET	A216432	001	Sep 03, 2025	Aug NEWA
AB			500MG/PACKET	A216432	002	Sep 03, 2025	Aug NEWA

ZELVYSIA

AB		AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun CAHN
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Jun CAHN
AB		SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Apr NEWA
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Apr NEWA

TABLET;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB		AUROBINDO PHARMA	100MG	A216797	001	Jun 09, 2025	May NEWA
AB		ZENARA	100MG	A218797	001	Jun 11, 2025	May NEWA

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL
SAXAGLIPTIN

@		SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul DISC
@			EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul DISC

SCOPOLAMINE

SYSTEM;TRANSDERMAL
SCOPOLAMINE

AB		AMNEALS PHARMS	1MG/72HR	A218384	001	Jun 09, 2025	May NEWA
AB	!	RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr CHRS

TRANSDERM SCOP

AB	+	BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr CHRS

SEBETRALSTAT

TABLET;ORAL
EKTERLY

	+!	KALVISTA	300MG	N219301	001	Jul 03, 2025	Jul NEWA

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL
ELDEPRYL

>D>	@ +	NORVIUM BIOSCIENCE	5MG	N020647	001	May 15, 1996	Sep CAHN
>A>	@ +	QUAGEN	5MG	N020647	001	May 15, 1996	Sep CAHN

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

>D>	AB	I3 PHARMS	5MG	A074672	001	Apr 01, 1997	Sep CAHN
>A>	AB	MLV	5MG	A074672	001	Apr 01, 1997	Sep CAHN
>D>	@ +	NORVIUM BIOSCIENCE	5MG	N019334	001	Jun 05, 1989	Sep CAHN
>A>	@ +	QUAGEN	5MG	N019334	001	Jun 05, 1989	Sep CAHN

SELENIOUS ACID

SOLUTION;INTRAVENOUS
SELENIOUS ACID

AP	+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May CFTG
	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb CTEC
AP	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan CFTG
AP	+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb CFTG
AP		ASPIRO	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219633	001	Jun 11, 2025	May NFTG

		SOLUTION;INTRAVENOUS						
		SELENIOUS ACID						
	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219633	002	Jun 11, 2025	May	NEWA
	AP	CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jul	NEWA
	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jul	NEWA
	AP	FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan	NFTG
	@		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jul	DISC
	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb	CMS1
	AP	GLAND	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219629	001	Jul 08, 2025	Jun	NEWA
	AP	SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb	NEWA
		SELINEXOR						
		TABLET;ORAL						
		XPOVIO						
	+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar	NEWA
		SELPERCATINIB						
		CAPSULE;ORAL						
		RETEVMO						
	+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan	CAHN
	+!		80MG	N213246	002	May 08, 2020	Jan	CAHN
		TABLET;ORAL						
		RETEVMO						
	+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan	CAHN
	+		80MG	N218160	002	Apr 10, 2024	Jan	CAHN
	+		120MG	N218160	003	Apr 10, 2024	Jan	CAHN
	+!		160MG	N218160	004	Apr 10, 2024	Jan	CAHN
		SELUMETINIB SULFATE						
>A>		GRANULE;ORAL						
>A>		KOSELUGO						
>A>	+	ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	Sep	NEWA
>A>	+!		EQ 7.5MG BASE	N219943	002	Sep 10, 2025	Sep	NEWA
		SEMAGLUTIDE						
		SOLUTION;SUBCUTANEOUS						
		OZEMPIC						
>D>	+!	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017	Sep	DISC
>A>	@ +		2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017	Sep	DISC
		SEPIAPTERIN						
		POWDER;ORAL						
		SEPHIENCE						
	+	PTC THERAP	250MG/PACKET	N219666	001	Jul 28, 2025	Jul	NEWA
	+!		1GM/PACKET	N219666	002	Jul 28, 2025	Jul	NEWA
		SERTRALINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		SERTRALINE HYDROCHLORIDE						
AB	+!	ALMATICA	EQ 150MG BASE	N215133	001	Oct 04, 2021	Jul	CFTG
AB	+		EQ 200MG BASE	N215133	002	Oct 04, 2021	Jul	CFTG
AB		ZENARA	EQ 150MG BASE	A218853	001	Jul 16, 2025	Jul	NFTG
AB			EQ 200MG BASE	A218853	002	Jul 16, 2025	Jul	NFTG
		TABLET;ORAL						
		SERTRALINE HYDROCHLORIDE						
>D>	@	NORVIUM BIOSCIENCE	EQ 25MG BASE	A078626	001	Jan 31, 2008	Sep	CAHN
>D>	@		EQ 50MG BASE	A078626	002	Jan 31, 2008	Sep	CAHN
>D>	@		EQ 100MG BASE	A078626	003	Jan 31, 2008	Sep	CAHN
>A> AB		PHARMACO	EQ 25MG BASE	A076882	001	Feb 06, 2007	Sep	CAHN
>A> AB			EQ 50MG BASE	A076882	002	Feb 06, 2007	Sep	CAHN
>A> AB			EQ 100MG BASE	A076882	003	Feb 06, 2007	Sep	CAHN
>A>	@	QUAGEN	EQ 25MG BASE	A078626	001	Jan 31, 2008	Sep	CAHN
>A>	@		EQ 50MG BASE	A078626	002	Jan 31, 2008	Sep	CAHN
>A>	@		EQ 100MG BASE	A078626	003	Jan 31, 2008	Sep	CAHN
>D> AB		VIWIT PHARM	EQ 25MG BASE	A076882	001	Feb 06, 2007	Sep	CAHN
>D> AB			EQ 50MG BASE	A076882	002	Feb 06, 2007	Sep	CAHN

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

>D>	AB			EQ 100MG BASE	A076882	003	Feb 06, 2007	Sep CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
SEVELAMER CARBONATE

		@	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan DISC
		@		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan DISC
		@	TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Jun DISC
	AB			800MG/PACKET	A215909	001	Feb 27, 2025	Feb NEWA
		@		2.4GM/PACKET	A215909	002	Feb 27, 2025	Jun DISC
	AB			2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb NEWA

TABLET;ORAL
SEVELAMER CARBONATE

		@	EPIC PHARMA LLC	800MG	A212970	001	Apr 09, 2020	Jun CAHN

SEVELAMER HYDROCHLORIDE

TABLET;ORAL
SEVELAMER HYDROCHLORIDE

	BX		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar CTEC
	BX			800MG	A212599	002	Jul 11, 2023	Mar CTEC
	AB		NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL
SILDENAFIL CITRATE

	AB		APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
	AB		CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
		@	TARO	EQ 10MG BASE/ML	A215522	001	Nov 16, 2021	Aug DISC

TABLET;ORAL
SILDENAFIL CITRATE

	AB		JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb NEWA
		@	MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Aug DISC
>D>	AB			EQ 50MG BASE	A201171	002	Mar 25, 2019	Sep DISC
>A>		@		EQ 50MG BASE	A201171	002	Mar 25, 2019	Sep DISC
>D>	BX		UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Sep CTEC
>A>	AB			EQ 25MG BASE	A209302	003	Jun 15, 2021	Sep CTEC
>D>	BX			EQ 50MG BASE	A209302	001	Aug 25, 2020	Sep CTEC
>A>	AB			EQ 50MG BASE	A209302	001	Aug 25, 2020	Sep CTEC
>D>	BX			EQ 100MG BASE	A209302	002	Aug 25, 2020	Sep CTEC
>A>	AB			EQ 100MG BASE	A209302	002	Aug 25, 2020	Sep CTEC

SILODOSIN

CAPSULE;ORAL
RAPAFLO

		@ +	ABBVIE	4MG	N022206	001	Oct 08, 2008	Jul DISC
		@ +		8MG	N022206	002	Oct 08, 2008	Jul DISC

SILODOSIN

	AB	!	LUPIN LTD	4MG	A206541	001	Dec 03, 2018	Jul CHRS
		@	TORRENT	4MG	A210396	001	Feb 10, 2025	Jun DISC
	AB			4MG	A210396	001	Feb 10, 2025	Jan NEWA
		@		8MG	A210396	002	Feb 10, 2025	Jun DISC
	AB			8MG	A210396	002	Feb 10, 2025	Jan NEWA

SIMVASTATIN

TABLET;ORAL
SIMVASTATIN

	AB		GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb CAHN
	AB			10MG	A077752	001	Dec 20, 2006	Feb CAHN
	AB			20MG	A077752	002	Dec 20, 2006	Feb CAHN
	AB			40MG	A077752	003	Dec 20, 2006	Feb CAHN
	AB			80MG	A077752	004	Dec 20, 2006	Feb CAHN

SIPONIMOD

TABLET;ORAL
MAYZENT

		+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CTEC
	AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CTEC
	AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
		+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CTEC

		TABLET;ORAL						
		MAYZENT						
	AB	+!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr	CFTG
		SIPONIMOD						
		@ RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May	DISC
	AB		EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr	NFTG
		@	EQ 1MG BASE	A218444	002	Apr 22, 2025	May	DISC
	AB		EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr	NFTG
		@	EQ 2MG BASE	A218444	003	Apr 22, 2025	May	DISC
	AB		EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr	NFTG
		SIROLIMUS						
		POWDER;INTRAVENOUS						
		FYARRO						
		+! AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar	CAHN
		SOLUTION;ORAL						
		SIROLIMUS						
	AA	RISING	1MG/ML	A215116	001	Jul 15, 2025	Jul	NEWA
		SITAGLIPTIN HYDROCHLORIDE						
		SOLUTION;ORAL						
		BRYNOVIN						
		+! AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan	NEWA
		SODIUM ACETATE						
		SOLUTION;INTRAVENOUS						
		SODIUM ACETATE						
	AP	AMNEAL	100MEQ/50ML (2MEQ/ML)	A218469	001	Aug 08, 2025	Aug	NEWA
	AP		200MEQ/100ML (2MEQ/ML)	A218469	002	Aug 08, 2025	Aug	NEWA
>A>	AP	SOMERSET THERAPS LLC	100MEQ/50ML (2MEQ/ML)	A219826	001	Sep 18, 2025	Sep	NEWA
>A>	AP		200MEQ/100ML (2MEQ/ML)	A219826	002	Sep 18, 2025	Sep	NEWA
		SODIUM BICARBONATE						
		INJECTABLE;INJECTION						
		SODIUM BICARBONATE						
>D>	AP	ANTHEA PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Sep	CAHN
	AP		1MEQ/ML	A219701	001	Jun 26, 2025	Jun	NEWA
	AP	FRESENIUS KABI USA	0.5MEQ/ML	A206688	001	Aug 25, 2025	Aug	NEWA
	AP		1MEQ/ML	A206688	002	Aug 25, 2025	Aug	NEWA
>A>	AP	NEOCUBES PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Sep	CAHN
		SODIUM CHLORIDE						
		INJECTABLE;INJECTION						
		SODIUM CHLORIDE 0.9%						
		@ + MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Aug	DISC
		@ +	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Aug	DISC
		@ +	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Aug	DISC
		@ +	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Aug	DISC
		@ +	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Aug	DISC
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>	AP	GVS TM	900MG/100ML	A076316	001	Oct 27, 2004	Sep	CAHN
>D>	AP	HAEMONETICS	900MG/100ML	A076316	001	Oct 27, 2004	Sep	CAHN
	AP	+! OTSUKA ICU MEDCL	900MG/100ML	N016366	001		May	CAHN
		SOLUTION;INJECTION						
		SODIUM CHLORIDE 0.9%						
	AP	NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar	CAHN
	AP		180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar	CAHN
		SODIUM FERRIC GLUCONATE COMPLEX						
		INJECTABLE;INJECTION						
		FERRLECIT						
	AB	+! SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999	Aug	CAIN
		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE						
	AB	HIKMA	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	Aug	CAIN

SODIUM IODIDE I-131

SOLUTION;ORAL

SODIUM IODIDE I 131

AA		CARDINAL HLTH 414	250-1000mCi	A213615	001	Jun 12, 2025	Jun NEWA

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

	@	XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan DISC

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

AA		AMNEAL	0.5GM/ML	A203631	001	Sep 10, 2025	Aug NEWA

XYREM

AA	+!	JAZZ PHARMS	0.5GM/ML	N021196	001	Jul 17, 2002	Aug CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan CAHN

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		LYNE	15GM/60ML	A214912	001	Jun 10, 2025	May NEWA

SOLIFENACIN SUCCINATE

SUSPENSION;ORAL

VESICARE LS

	@ +	ASTELLAS	1MG/ML	N209529	001	May 26, 2020	Jul DISC

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB		BOSTAL	5MG	A210281	001	May 20, 2019	Aug CAHN
AB			10MG	A210281	002	May 20, 2019	Aug CAHN
	@	TORRENT	5MG	A209424	001	Mar 04, 2025	Jun DISC
AB			5MG	A209424	001	Mar 04, 2025	Feb NEWA
	@		10MG	A209424	002	Mar 04, 2025	Jun DISC
AB			10MG	A209424	002	Mar 04, 2025	Feb NEWA

SORAFENIB TOSYLATE

TABLET;ORAL

SORAFENIB TOSYLATE

	@	APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar DISC
AB			EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan NEWA

SPIRONOLACTONE

SUSPENSION;ORAL

SPIRONOLACTONE

AB		HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb NEWA

TABLET;ORAL

SPIRONOLACTONE

AB		ANNORA PHARMA	25MG	A217761	001	Jul 25, 2025	Jul NEWA
AB			50MG	A217761	002	Jul 25, 2025	Jul NEWA
AB			100MG	A217761	003	Jul 25, 2025	Jul NEWA
AB		GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan NEWA
AB			50MG	A219494	002	Jan 23, 2025	Jan NEWA
AB			100MG	A219494	003	Jan 23, 2025	Jan NEWA

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

>D>	@ +	HOSPIRA	100% (5.2ML)	N018801	006	May 02, 2023	Sep CMFD
>A>	+!		100% (5.2ML)	N018801	006	May 02, 2023	Sep CMFD

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

	@	TARO	100%	A077393	001	Aug 11, 2006	Aug DISC

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

	@ +	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Feb DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

>D>	AP		ADAPTIS	20MG/ML	A214308	001	May 22, 2020	Sep CAHN
	AP		FRESENIUS KABI USA	20MG/ML	A217885	001	Feb 21, 2025	Feb NEWA
>A>	AP		REGCON HOLDINGS	20MG/ML	A214308	001	May 22, 2020	Sep CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

	AP		FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Jan NEWA

SUCRALFATE

SUSPENSION;ORAL

SUCRALFATE

	AB		PADAGIS US	1GM/10ML	A211780	001	Apr 14, 2025	Apr NEWA

TABLET;ORAL

SUCRALFATE

	AB		CHARTWELL RX	1GM	A074415	001	Jun 08, 1998	Apr CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

SUGAMMADEX SODIUM

>A>	AP		B BRAUN MEDICAL	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214279	001	Aug 05, 2025	Sep CAHN
>D>	AP		FISIOPHARMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214279	001	Aug 05, 2025	Sep CAHN
	AP			EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214279	001	Aug 05, 2025	Jul NEWA

SULFACETAMIDE SODIUM

LOTION;TOPICAL

SULFACETAMIDE SODIUM

	@		TARO	10%	A078668	001	May 20, 2009	Jul DISC

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

>A>		@	PHARMOBEDIENT	10%	A040215	001	May 25, 1999	Sep CAHN
>D>		@	RENOVA PHARMS	10%	A040215	001	May 25, 1999	Sep CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@		AIPING PHARM INC	400MG;80MG	A070890	002	Nov 13, 1986	Aug CMS1

SULFANILAMIDE

CREAM;VAGINAL

AVC

>D>		@ +	NORVIUM BIOSCIENCE	15%	N006530	003	Jan 27, 1987	Sep CAHN
>A>		@ +	PHARMOBEDIENT	15%	N006530	003	Jan 27, 1987	Sep CAHN

SUPPOSITORY;VAGINAL

AVC

>D>		@	NORVIUM BIOSCIENCE	1.05GM	N006530	004	Jan 27, 1987	Sep CAHN
>A>		@	PHARMOBEDIENT	1.05GM	N006530	004	Jan 27, 1987	Sep CAHN

SULINDAC

TABLET;ORAL

SULINDAC

	AB		EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar CMS1

SUMATRIPTAN

SPRAY;NASAL

SUMATRIPTAN

>D>	AB		ADAPTIS	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep CAHN
>A>	AB		REGCON HOLDINGS	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

	AB		SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun CMFD

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>D>	AB		COREPHARMA	EQ 25MG BASE	A200263	001	Jun 19, 2012	Sep CAHN
>D>	AB			EQ 50MG BASE	A200263	002	Jun 19, 2012	Sep CAHN
>D>	AB			EQ 100MG BASE	A200263	003	Jun 19, 2012	Sep CAHN
	AB		IPCA LABS LTD	EQ 25MG BASE	A206019	001	Jul 15, 2025	Jul NEWA
	AB			EQ 50MG BASE	A206019	002	Jul 15, 2025	Jul NEWA
	AB			EQ 100MG BASE	A206019	003	Jul 15, 2025	Jul NEWA
		@	SUN PHARM INDS	EQ 25MG BASE	A078295	001	Aug 10, 2009	Jul DISC
		@		EQ 50MG BASE	A078295	002	Aug 10, 2009	Jul DISC
		@		EQ 100MG BASE	A078295	003	Aug 10, 2009	Jul DISC
>A>	AB		ZHEJIANG	EQ 25MG BASE	A200263	001	Jun 19, 2012	Sep CAHN
>A>	AB			EQ 50MG BASE	A200263	002	Jun 19, 2012	Sep CAHN
>A>	AB			EQ 100MG BASE	A200263	003	Jun 19, 2012	Sep CAHN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

	AB		FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan CAHN
	AB			EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan CAHN
	AB			EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan CAHN
	AB			EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan CAHN
	AB		MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb NEWA
	AB			EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb NEWA
	AB			EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb NEWA
	AB			EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb NEWA

SUNVOZERTINIB

TABLET;ORAL

ZEGFROVY

		+	DIZAL JIANGSU	150MG	N219839	001	Jul 02, 2025	Jul NEWA
		+!		200MG	N219839	002	Jul 02, 2025	Jul NEWA

SUZETRIGINE

TABLET;ORAL

JOURNAVX

		+!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan NEWA

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

	AB		AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan CAHN
	AB			EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan CAHN
	AB			EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan CAHN
		@	HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Jul DISC
		@		EQ 1MG BASE	A210929	002	Apr 17, 2023	Jul DISC
		@		EQ 5MG BASE	A210929	003	Apr 17, 2023	Jul DISC

INJECTABLE;INJECTION

PROGRAF

	AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC

TACROLIMUS

	AP		NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA

OINTMENT;TOPICAL

TACROLIMUS

	BX		ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC

TADALAFIL

TABLET;ORAL

TADALAFIL

>D>	AB1		FOURRTS LABS	2.5MG	A217606	001	Aug 13, 2024	Sep CAHN
>D>	AB1			5MG	A217606	002	Aug 13, 2024	Sep CAHN
>D>	AB1			10MG	A217606	003	Aug 13, 2024	Sep CAHN
>D>	AB1			20MG	A217606	004	Aug 13, 2024	Sep CAHN
>A>	AB1		HIBROW HLTHCARE	2.5MG	A217606	001	Aug 13, 2024	Sep CAHN
>A>	AB1			5MG	A217606	002	Aug 13, 2024	Sep CAHN
>A>	AB1			10MG	A217606	003	Aug 13, 2024	Sep CAHN

TABLET;ORAL
TADALAFIL

>A>	AB1			20MG	A217606	004	Aug 13, 2024	Sep CAHN
>D>	BX		UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Sep CTEC
>A>	AB1			2.5MG	A211298	001	Oct 23, 2020	Sep CTEC
>D>	BX			5MG	A211298	002	Oct 23, 2020	Sep CTEC
>A>	AB1			5MG	A211298	002	Oct 23, 2020	Sep CTEC
>D>	BX			10MG	A211298	003	Oct 23, 2020	Sep CTEC
>A>	AB1			10MG	A211298	003	Oct 23, 2020	Sep CTEC
>D>	BX			20MG	A211298	004	Oct 23, 2020	Sep CTEC
>A>	AB1			20MG	A211298	004	Oct 23, 2020	Sep CTEC

TALAZOPARIB TOSYLATE
CAPSULE;ORAL
TALZENNA

		@ +	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
		@ +		EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
		@ +		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
		@ +		EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
		@ +		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
		@ +		EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TALETRECTINIB ADIPATE
CAPSULE;ORAL
IBTROZI

		+!	NUVATION	EQ 200MG BASE	N219713	001	Jun 11, 2025	Jun NEWA

TAMOXIFEN CITRATE
TABLET;ORAL
TAMOXIFEN CITRATE

		@	APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
		@		EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC

TAMSULOSIN HYDROCHLORIDE
CAPSULE;ORAL
FLOMAX

		@ +	SANOFI	0.4MG	N020579	001	Apr 15, 1997	Feb DISC

TAMSULOSIN HYDROCHLORIDE

	AB		ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Feb CMFD
	AB		GRAVITI PHARMS	0.4MG	A219767	001	May 01, 2025	Apr NEWA
	AB	!	ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Feb CHRS

TAPINAROF
CREAM;TOPICAL
VTAMA

		+!	ORGANON LLC	1%	N215272	001	May 23, 2022	May CAHN

TAVABOROLE
SOLUTION;TOPICAL
TAVABOROLE

		@	AMNEAL	5%	A212256	001	Nov 25, 2020	Jul DISC
		@	TARO	5%	A212215	001	May 07, 2021	Jul DISC

TAZAROTENE
CREAM;TOPICAL
TAZAROTENE

	AB		COSETTE	0.05%	A208662	002	Mar 10, 2025	Feb NEWA
>A>	AB		SUN PHARMA CANADA	0.1%	A208258	001	Apr 03, 2017	Sep CAHN
>D>	AB		TARO	0.1%	A208258	001	Apr 03, 2017	Sep CAHN

GEL;TOPICAL
TAZORAC

	AB	+!	ABBVIE	0.05%	N020600	001	Jun 13, 1997	Aug CAHN
	AB	+!		0.1%	N020600	002	Jun 13, 1997	Aug CAHN

LOTION;TOPICAL
ARAZLO

		+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019	Aug CTEC
	AB	+!		0.045%	N211882	001	Dec 18, 2019	Jul CFTG

TAZAROTENE

		@	PADAGIS ISRAEL	0.045%	A215393	001	Jul 29, 2025	Aug DISC
	AB			0.045%	A215393	001	Jul 29, 2025	Jul NFTG

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

OSTEOLITE

	@		SUN PHARM INDS INC	N/A	N017972	001		Feb CAHN

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

DRAXIMAGE DTPA

AP		+!	JUBILANT	N/A	N018511	001	Dec 29, 1989	Mar CFTG

TECHNETIUM TC-99M PENTETATE KIT

AP			CURIUM	N/A	A215146	001	Mar 26, 2025	Mar NFTG

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

	@		SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	May DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION;INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

	@		SUN PHARM INDS INC	12mCi/ML	N017321	001		May CAHN
	@			24mCi/ML	N017321	002		May CAHN
	@			48mCi/ML	N017321	003		May CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW V4

		+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jun CTNA
	@			0.25-3 CI/GENERATOR	N017243	002		Jun CTNA

SOLUTION;INTRAVENOUS, ORAL

DRYTEC

	@	+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Jun CTNA
	@			830-16600mCi/GENERATOR	N017693	001		Jun CTNA

TELMISARTAN

TABLET;ORAL

MICARDIS

	@	+	BOEHRINGER INGELHEIM	80MG	N020850	002	Nov 10, 1998	Jul DISC
AB		+		80MG	N020850	002	Nov 10, 1998	Feb CHRS

TELMISARTAN

AB		!	INVENTIA	80MG	A205150	003	Oct 30, 2015	Feb CHRS
AB			MACLEODS PHARMS LTD	20MG	A203986	001	Jan 15, 2025	Jan NEWA
AB				40MG	A203986	002	Jan 15, 2025	Jan NEWA
AB				80MG	A203986	003	Jan 15, 2025	Jan NEWA
>D>		@	TORRENT	20MG	A203171	001	Jul 07, 2014	Sep CMFD
>A>	AB			20MG	A203171	001	Jul 07, 2014	Sep CMFD
>D>		@		40MG	A203171	002	Jul 07, 2014	Sep CMFD
>A>	AB			40MG	A203171	002	Jul 07, 2014	Sep CMFD
>D>		@		80MG	A203171	003	Jul 07, 2014	Sep CMFD
>A>	AB			80MG	A203171	003	Jul 07, 2014	Sep CMFD

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

	@		SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009	Mar DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

	@		EIRGEN	5MG	A203898	001	Feb 10, 2016	Aug CAHN
	@			20MG	A203898	002	Feb 10, 2016	Aug CAHN
AB				100MG	A203898	003	Feb 10, 2016	Aug CAHN
AB				140MG	A203898	004	Feb 10, 2016	Aug CAHN
AB				180MG	A203898	005	Feb 10, 2016	Aug CAHN
AB				250MG	A203898	006	Feb 10, 2016	Aug CAHN
	@		NEXTSOURCE	5MG	A203898	001	Feb 10, 2016	Mar CAHN
	@			20MG	A203898	002	Feb 10, 2016	Mar CAHN
	@			100MG	A203898	003	Feb 10, 2016	Mar CAHN
AB				100MG	A203898	003	Feb 10, 2016	Mar CMFD
	@			140MG	A203898	004	Feb 10, 2016	Mar CAHN
AB				140MG	A203898	004	Feb 10, 2016	Mar CMFD

		CAPSULE;ORAL						
		TEMOZOLOMIDE						
	@		180MG	A203898	005	Feb 10, 2016	Mar	CAHN
AB			180MG	A203898	005	Feb 10, 2016	Mar	CMFD
	@		250MG	A203898	006	Feb 10, 2016	Mar	CAHN
AB			250MG	A203898	006	Feb 10, 2016	Mar	CMFD
	@	TRI-SOURCE PHARMA	5MG	A203898	001	Feb 10, 2016	Apr	CAHN
	@		20MG	A203898	002	Feb 10, 2016	Apr	CAHN
AB			100MG	A203898	003	Feb 10, 2016	Apr	CAHN
AB			140MG	A203898	004	Feb 10, 2016	Apr	CAHN
AB			180MG	A203898	005	Feb 10, 2016	Apr	CAHN
AB			250MG	A203898	006	Feb 10, 2016	Apr	CAHN
	TERAZOSIN HYDROCHLORIDE							
		CAPSULE;ORAL						
		TERAZOSIN HYDROCHLORIDE						
AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219482	001	May 12, 2025	May	NEWA
AB			EQ 2MG BASE	A219482	002	May 12, 2025	May	NEWA
AB			EQ 5MG BASE	A219482	003	May 12, 2025	May	NEWA
AB			EQ 10MG BASE	A219482	004	May 12, 2025	May	NEWA
	@	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
	@		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
	@		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
	@		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN
	TERBINAFINE HYDROCHLORIDE							
		TABLET;ORAL						
		TERBINAFINE HYDROCHLORIDE						
	@	BRECKENRIDGE PHARM	EQ 250MG BASE	A077714	001	Jun 04, 2010	Mar	DISC
	TERIFLUNOMIDE							
		TABLET;ORAL						
		TERIFLUNOMIDE						
	@	APOTEX	7MG	A209601	001	Nov 02, 2018	Feb	DISC
	@		14MG	A209601	002	Nov 02, 2018	Feb	DISC
AB		CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Mar	NEWA
AB			14MG	A218663	002	Apr 07, 2025	Mar	NEWA
>A>	@	SOMERSET THERAPS LLC	7MG	A209702	001	Feb 28, 2020	Sep	CAHN
>A>	@		14MG	A209702	002	Feb 28, 2020	Sep	CAHN
>D>	@	WELDING	7MG	A209702	001	Feb 28, 2020	Sep	CAHN
	@		7MG	A209702	001	Feb 28, 2020	Jun	CAHN
>D>	@		14MG	A209702	002	Feb 28, 2020	Sep	CAHN
	@		14MG	A209702	002	Feb 28, 2020	Jun	CAHN
	TERIPARATIDE							
		SOLUTION;SUBCUTANEOUS						
		BONSITY						
		ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Feb	CPOT
		FORTEO						
AP	+!	LILLY	0.56MG/2.24ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Feb	CPOT
		TERIPARATIDE						
AP	+!	ALMAJECT	0.56MG/2.24ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb	CPOT
AP	+!		0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb	CTEC
AP		APOTEX	0.56MG/2.24ML (0.25MG/ML)	A211097	001	Nov 16, 2023	Feb	CPOT
AP		TEVA PHARMS USA	0.56MG/2.24ML (0.25MG/ML)	A208569	001	Nov 16, 2023	Feb	CPOT
	TESTOSTERONE							
		GEL, METERED;TRANSDERMAL						
		TESTOSTERONE						
	@	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019	Aug	DISC
		SOLUTION, METERED;TRANSDERMAL						
		TESTOSTERONE						
	@	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan	DISC
	@	TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Jun	DISC
	TESTOSTERONE UNDECANOATE							
		CAPSULE;ORAL						
		KYZATREX						
>D>	+	MARIUS	100MG	N213953	001	Jul 27, 2022	Sep	DISC
>A>	@ +		100MG	N213953	001	Jul 27, 2022	Sep	DISC
	+		100MG	N213953	001	Jul 27, 2022	Aug	CAHN

CAPSULE;ORAL
KYZATREX

	+		150MG		N213953	002	Jul 27, 2022	Aug CAHN
	+!		200MG		N213953	003	Jul 27, 2022	Aug CAHN

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

AA	+!	SOLIS PHARMS	80MG/15ML		A085186	001		Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

	@	AJANTA PHARMA LTD	300MG		A218401	002	Mar 26, 2025	Jul DISC
AB			300MG		A218401	002	Mar 26, 2025	Mar NEWA
	@		450MG		A218401	001	Jan 13, 2025	Jul DISC
AB			450MG		A218401	001	Jan 13, 2025	Jan NEWA
AB		MPP PHARMA	400MG		A040560	003	Apr 21, 2006	Jun CAHN
AB	!		600MG		A040560	002	Apr 21, 2006	Jun CAHN
	@	RHODES PHARMS	300MG		A214113	001	May 11, 2023	Jan DISC

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
THIAMINE HYDROCHLORIDE

AP		GLAND	100MG/ML		A217800	001	Feb 24, 2025	Feb NEWA

THIOTEPA

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL
THIOTEPA

>D> AP		BELOTECA	15MG/VIAL		A217559	001	Aug 20, 2024	Sep CAHN
>A> AP		REGCON HOLDINGS	15MG/VIAL		A217559	001	Aug 20, 2024	Sep CAHN

POWDER;INTRAVENOUS
TEPADINA AND SODIUM CHLORIDE

	+!	ADIENNE SA	200MG		N208264	003	Apr 10, 2025	May NEWA

SOLUTION;INTRAVENOUS
TEPYLUTE

	+!	SHORLA	100MG/10ML (10MG/ML)		N216984	002	Feb 26, 2025	Mar NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL
TIAGABINE HYDROCHLORIDE

	@	SUN PHARM INDS	2MG		A077555	001	Nov 04, 2011	Jun DISC
	@		4MG		A077555	002	Nov 04, 2011	Jun DISC

TICAGRELOR

TABLET;ORAL
BRILINTA

AB	+	ASTRAZENECA	60MG		N022433	002	Sep 03, 2015	Mar CTEC

TICAGRELOR

AB		ALEMBIC	90MG		A208576	001	May 01, 2025	Apr NEWA
AB		APOTEX	90MG		A208584	001	May 01, 2025	Apr NEWA
AB		INVAGEN PHARMS	90MG		A208537	001	May 05, 2025	Apr NEWA
AB		MSN	90MG		A208596	001	Apr 07, 2020	Mar CMFD
	@		90MG		A208596	001	Apr 07, 2020	Feb CAHN
AB		MYLAN	60MG		A208597	001	Jul 09, 2021	Jul CMFD
AB			90MG		A208597	002	Jul 09, 2021	Jul CMFD
AB		SUNSHINE	90MG		A208508	001	Apr 06, 2020	Mar CMFD
AB		WATSON LABS INC	60MG		A208390	001	Sep 04, 2018	Mar CMFD
AB			90MG		A208390	002	Sep 04, 2018	Mar CMFD

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

	@	APOTEX	250MG		A075089	001	Jul 01, 1999	Mar DISC

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC
BETIMOL

	@ +	THEA PHARMA	0.25%		N020439	001	Mar 31, 1995	Jun DISC

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

		@	APOTEX	EQ 0.5% BASE	A204936	001	Apr 17, 2015	May DISC
>A>		@	PHARMOBEDIENT	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Sep CAHN
>D>		@	RENOVA PHARMS	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Sep CAHN

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL

TIOPRONIN

	AB		AMNEAL	100MG	A216278	002	Aug 29, 2025	Aug NEWA

VENXXIVA

	AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Aug CTNA
	AB			300MG	A216990	002	Jan 30, 2024	Aug CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB		ANDA REPOSITORY	EQ 4MG BASE	A213365	001	May 13, 2024	Sep CAHN
>A>	AB			EQ 6MG BASE	A213365	002	May 13, 2024	Sep CAHN
	AB		RUBICON RESEARCH	EQ 2MG BASE	A213798	001	May 27, 2020	Aug CAHN
	AB			EQ 4MG BASE	A213798	002	May 27, 2020	Aug CAHN
	AB			EQ 6MG BASE	A213798	003	May 27, 2020	Aug CAHN
		!		EQ 8MG BASE	A213798	004	Aug 28, 2025	Aug NFTG
>D>	AB		SOMERSET THERAPS LLC	EQ 4MG BASE	A213365	001	May 13, 2024	Sep CAHN
>D>	AB			EQ 6MG BASE	A213365	002	May 13, 2024	Sep CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

	AB		RISING	EQ 2MG BASE	A076354	001	Mar 28, 2003	Aug CMFD
	AB			EQ 4MG BASE	A076354	002	Mar 28, 2003	Aug CMFD

TOBRAMYCIN

POWDER;INHALATION

TOBI PODHALER

		+!	VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb CAHN

SOLUTION;INHALATION

TOBI

	AN	+!	VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

		@	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Aug DISC

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

	AB		AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Aug NEWA
		@	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Aug CTNA
		@	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr DISC
>A>	AB		SINOTHERAPEUTICS INC	EQ 11MG BASE	A216001	001	Sep 30, 2025	Sep NEWA
		@	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Aug CTNA
		@		EQ 22MG BASE	A214264	002	Aug 19, 2021	Aug CTNA

XELJANZ XR

	AB	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Aug CTEC
		+		EQ 11MG BASE	N208246	001	Feb 23, 2016	Apr CTEC

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

>A>		@	ANDA REPOSITORY	EQ 400MG BASE	A073290	001	Nov 27, 1991	Sep CAHN
>D>		@	TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991	Sep CAHN

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

	AB		PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar CAHN
	AB			2MG	A204721	002	Jan 24, 2020	Mar CAHN
	AB		RISING	1MG	A210775	001	Dec 30, 2019	Jul CAHN
	AB			2MG	A210775	002	Dec 30, 2019	Jul CAHN

TOLVAPTAN

TABLET;ORAL

JYNARQUE

AB2		+	OTSUKA	15MG	N204441	001	Apr 23, 2018	Apr CFTG
AB2		+		30MG	N204441	002	Apr 23, 2018	Apr CFTG
AB		+!		45MG	N204441	003	Apr 23, 2018	Apr CFTG
AB2		+		60MG	N204441	004	Apr 23, 2018	Apr CFTG
AB		+		90MG	N204441	005	Apr 23, 2018	Apr CFTG

SAMSCA

AB1		+	OTSUKA	15MG	N022275	001	May 19, 2009	Apr CTEC
AB1		+!		30MG	N022275	002	May 19, 2009	Apr CTEC

TOLVAPTAN

AB1			ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr CTEC
AB1				30MG	A211891	001	May 19, 2020	Apr CTEC
AB1			APOTEX	15MG	A207605	002	Sep 06, 2022	Apr CTEC
AB1				30MG	A207605	001	May 19, 2020	Apr CTEC
AB1			ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr CTEC
AB1				30MG	A206119	002	Feb 15, 2022	Apr CTEC
AB1			HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr CTEC
AB1				30MG	A205646	001	Jul 16, 2021	Apr CTEC
AB2			LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr NFTG
AB2				30MG	A216063	002	Apr 23, 2025	Apr NFTG
AB				45MG	A216063	003	Apr 23, 2025	Apr NFTG
AB2				60MG	A216063	004	Apr 23, 2025	Apr NFTG
AB				90MG	A216063	005	Apr 23, 2025	Apr NFTG
AB1			MSN	15MG	A216949	001	Jun 21, 2023	Apr CTEC
AB1				30MG	A216949	002	Jun 21, 2023	Apr CTEC

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB			RUBICON	15MG	A216683	001	May 27, 2025	May NEWA
AB				25MG	A216683	002	May 27, 2025	May NEWA
AB				50MG	A216683	003	May 27, 2025	May NEWA
AB			ZYDUS PHARMS USA INC	50MG	A078877	003	Oct 23, 2024	May CTEC

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

AB2			AJANTA PHARMA LTD	25MG	A219564	001	Sep 02, 2025	Aug NEWA
AB2				50MG	A219564	002	Sep 02, 2025	Aug NEWA
AB2				100MG	A219564	003	Sep 02, 2025	Aug NEWA
AB2				150MG	A219564	004	Sep 02, 2025	Aug NEWA
AB2				200MG	A219564	005	Sep 02, 2025	Aug NEWA

TABLET;ORAL

TOPIRAMATE

>A> AB			PHARMACO	25MG	A077733	001	Mar 27, 2009	Sep CAHN
>A> AB				50MG	A077733	002	Mar 27, 2009	Sep CAHN
>A> AB				100MG	A077733	003	Mar 27, 2009	Sep CAHN
>A> AB				200MG	A077733	004	Mar 27, 2009	Sep CAHN
	@		SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	May CAHN
	@			50MG	A090353	002	Sep 01, 2010	May CAHN
	@			100MG	A090353	003	Sep 01, 2010	May CAHN
	@			200MG	A090353	004	Sep 01, 2010	May CAHN
	@		SUN PHARM	200MG	A090278	004	Mar 27, 2009	May DISC
>D> AB			VIWIT PHARM	25MG	A077733	001	Mar 27, 2009	Sep CAHN
>D> AB				50MG	A077733	002	Mar 27, 2009	Sep CAHN
>D> AB				100MG	A077733	003	Mar 27, 2009	Sep CAHN
>D> AB				200MG	A077733	004	Mar 27, 2009	Sep CAHN

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB			COREPHARMA	5MG	A076894	001	May 31, 2005	Apr CAHN
AB				10MG	A076894	002	May 31, 2005	Apr CAHN
AB				20MG	A076894	003	May 31, 2005	Apr CAHN
AB				100MG	A076894	004	May 31, 2005	Apr CAHN
>D> AB			HIKMA	5MG	A076943	001	Mar 01, 2005	Sep DISC
>A>	@			5MG	A076943	001	Mar 01, 2005	Sep DISC
>D> AB				10MG	A076943	002	Mar 01, 2005	Sep DISC
>A>	@			10MG	A076943	002	Mar 01, 2005	Sep DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

	AB		APDM PHARMS	50MG	A090404	001	Jan 31, 2011	Feb CAHN
		@	APOTEX	50MG	A075981	001	Jul 10, 2002	Mar DISC
>D>		@	GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Sep CMFD
>A>	AB			50MG	A075968	001	Jun 25, 2002	Sep CMFD
		@	MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Feb DISC
	AB		SENORES PHARMS	50MG	A090404	001	Jan 31, 2011	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

	AB1	!	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Jan CTEC
	AB1			200MG	A200503	002	Aug 29, 2011	Jan CTEC
	AB1			300MG	A200503	003	Aug 29, 2011	Jan CTEC
	AB1		MACLEODS PHARMS LTD	100MG	A209404	001	Jan 31, 2025	Jan NEWA
	AB1			200MG	A209404	002	Jan 31, 2025	Jan NEWA
	AB1			300MG	A209404	003	Jan 31, 2025	Jan NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

TRAMETINIB DIMETHYL SULFOXIDE

		@	HIKMA	EQ 0.5MG	A219002	001	Aug 06, 2024	Feb CAHN
		@		EQ 2MG	A219002	002	Aug 06, 2024	Feb CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

		@	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Jan DISC
>A>	AP		MILLA PHARMS	100MG/ML	A212676	001	Jul 17, 2019	Sep CAHN
>D>	AP		PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Sep CAHN

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

	AP		HERITAGE	1GM/100ML (10MG/ML)	A218896	001	Jun 02, 2025	Aug CAHN
	AP		RTU PHARMA SA	1GM/100ML (10MG/ML)	A218896	001	Jun 02, 2025	May NEWA

TABLET;ORAL

TRANEXAMIC ACID

	AB		APPCO	650MG	A218729	001	Jun 11, 2025	May NEWA
	AB		BIONPHARMA	650MG	A219123	001	Aug 19, 2025	Aug NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

	AT2	+!	SANDOZ	0.004%	N021994	001	Sep 21, 2006	Feb CTEC

TRAVOPROST

		@	ALEMBIC	0.004%	A210458	001	Dec 20, 2019	Feb DISC
	AT2		APOTEX	0.004%	A203431	001	Jul 10, 2015	Feb CTEC
		!	CHARTWELL RX	0.004%	A091340	001	Mar 01, 2013	Feb CTEC
	AT2		GLAND	0.004%	A218159	001	Jul 12, 2024	Feb CTEC
	AT2		MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Feb CTEC
	AT2		MYLAN	0.004%	A205050	001	Jul 07, 2017	Feb CTEC
	AT2		SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Feb CTEC

TREOSULFAN

POWDER;INTRAVENOUS

GRAFAPEX

		+!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan CAHN
		+!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan CAHN
		+!	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan NEWA
		+!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan NEWA

TREPROSTINIL

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

		@ +	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Jun DISC
		@ +		0.2MG/ML	N021272	007	Sep 28, 2023	Jun DISC
		@ +		20MG/ML	N021272	005	Jul 30, 2021	Jun DISC

POWDER;INHALATION

TYVASO DPI

		+!	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan CHRS
		+!		0.048MG/INH	N214324	003	May 23, 2022	Jan CHRS
		+!		0.08MG/INH	N214324	005	Oct 24, 2024	Jan CHRS

TREPROSTINIL SODIUM

POWDER;INHALATION

YUTREPIA

	+!	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025	May	NEWA
	+!		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025	May	NEWA
	+!		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025	May	NEWA
	+!		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025	May	NEWA

TRETINOIN

CAPSULE;ORAL

TRETINOIN

	@	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb	DISC
AB	!	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb	CHRS

CREAM;TOPICAL

TRETINOIN

AB		ALEMBIC	0.025%	A218399	001	Aug 14, 2025	Aug	NEWA
AB		ENCUBE	0.025%	A217831	001	Jul 10, 2025	Jul	NEWA

GEL;TOPICAL

AVITA

	@	RISING	0.025%	N020400	001	Jan 29, 1998	Aug	CAHN

RETIN-A

AB	+!	BAUSCH	0.01%	N017955	001		Jan	CAHN

TRETINOIN

AB		AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan	NEWA
AB			0.025%	A218245	001	Feb 27, 2025	Feb	NEWA
AB		ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb	NEWA
AB			0.025%	A217587	001	Mar 03, 2025	Feb	NEWA
	@	RISING	0.04%	A202567	001	Jul 17, 2013	Aug	CAHN
	@		0.1%	A202026	001	Jul 17, 2013	Aug	CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

	@	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul	DISC

GEL;TOPICAL

ARISTOGEL

	@ +	ASTELLAS	0.1%	A083380	001		Feb	CRLD

INJECTABLE;INJECTION

KENALOG-10

AB	+	APOTHECON	10MG/ML	N012041	001		Feb	CTEC

TRIAMCINOLONE ACETONIDE

AB		DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb	NEWA
AB			40MG/ML	A218421	001	Apr 11, 2025	Apr	NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

	@	BEACH PRODS	0.025%	A204608	001	Jul 07, 2016	May	CAHN
AT	!	XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb	CAHN
AT	!		0.1%	A088451	001	Apr 03, 1985	Feb	CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

>D> AT		CINTEX SVCS	0.05%	A213619	001	Nov 10, 2020	Sep	CAHN
	@	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul	DISC
	@	GLENMARK SPECLT	0.1%	A208320	001	Aug 22, 2017	Jul	DISC
>A> AT		SENORES PHARMS	0.05%	A213619	001	Nov 10, 2020	Sep	CAHN
AT		SUN PHARMA CANADA	0.1%	A040037	001	Sep 30, 1994	Aug	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE;INJECTION

ARISTOSPAN

	@ +	ETHYPHARM INC	5MG/ML	N016466	001		May	CAHN
	@ +		20MG/ML	N016466	002		May	CAHN

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		CHARTWELL RX	2MG/5ML	A040251	001	Sep 27, 1999	Aug	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

TIGAN

		+!	PH HEALTH	100MG/ML	N017530	001		Aug CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

SURMONTIL

		@ +	TEVA WOMENS	EQ 25MG BASE	N016792	001		Jun CAHN
		@ +		EQ 50MG BASE	N016792	002		Jun CAHN
		@ +		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun CAHN

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

>A>	AB		CHARTWELL RX	20MG	A215781	001	Feb 16, 2022	Sep CAHN
>D>	AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Sep CAHN
	AB			20MG	A215781	001	Feb 16, 2022	Feb CAHN

URSODIOL

CAPSULE;ORAL

URSODIOL

>D>		@	NORVIUM BIOSCIENCE	300MG	A090530	001	Feb 17, 2010	Sep CAHN
>A>		@	QUAGEN	300MG	A090530	001	Feb 17, 2010	Sep CAHN

TABLET;ORAL

URSO 250

		@ +	ABBVIE	250MG	N020675	001	Dec 10, 1997	Jun DISC
	AB	+		250MG	N020675	001	Dec 10, 1997	Jun CAHN

URSO FORTE

		@ +	ABBVIE	500MG	N020675	002	Jul 21, 2004	Jun DISC
	AB	+!		500MG	N020675	002	Jul 21, 2004	Jun CAHN

URSODIOL

	AB	!	ZYDUS LIFESCIENCES	500MG	A211145	002	Oct 30, 2018	Jun CHRS

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

		@	APOTEX	EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar DISC

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

		+	NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	Feb CTEC

VALBENAZINE TOSYLATE

		@	ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024	Feb DISC
		@		EQ 60MG BASE	A216137	002	Aug 07, 2024	Feb DISC
		@		EQ 80MG BASE	A216137	003	Aug 07, 2024	Feb DISC

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

	AB		SPH ZHONGXI PHARM	EQ 450MG BASE	A218027	001	Apr 16, 2025	Apr NEWA

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

		@	PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005	Apr CAHN

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

		@ +	CARMEL BIOSCIENCES	4MG/ML	N209139	001	Dec 19, 2017	May CPOT

VALSARTAN

	AB	!	NOVITIUM PHARMA	4MG/ML	A214102	001	Nov 02, 2021	May CTEC
		!		4MG/ML	A214102	001	Nov 02, 2021	May CPOT
	AB		RUBICON	4MG/ML	A216460	001	Jun 05, 2025	May NEWA

TABLET;ORAL

VALSARTAN

>A>	AB		ACME LABS	40MG	A205347	001	Apr 09, 2018	Sep CAHN
>A>	AB			80MG	A205347	002	Apr 09, 2018	Sep CAHN

TABLET;ORAL
VALSARTAN

>A>	AB			160MG	A205347	003	Apr 09, 2018	Sep CAHN
>A>	AB			320MG	A205347	004	Apr 09, 2018	Sep CAHN
>D>		@	RENATA	40MG	A218169	001	Aug 05, 2024	Sep CAHN
		@		40MG	A218169	001	Aug 05, 2024	Aug CAHN
		@		40MG	A218169	001	Aug 05, 2024	Feb DISC
	AB			40MG	A218169	001	Aug 05, 2024	Jan CAHN
>D>		@		80MG	A218169	002	Aug 05, 2024	Sep CAHN
		@		80MG	A218169	002	Aug 05, 2024	Aug CAHN
		@		80MG	A218169	002	Aug 05, 2024	Feb DISC
	AB			80MG	A218169	002	Aug 05, 2024	Jan CAHN
>D>		@		160MG	A218169	003	Aug 05, 2024	Sep CAHN
		@		160MG	A218169	003	Aug 05, 2024	Aug CAHN
		@		160MG	A218169	003	Aug 05, 2024	Feb DISC
	AB			160MG	A218169	003	Aug 05, 2024	Jan CAHN
>D>		@		320MG	A218169	004	Aug 05, 2024	Sep CAHN
		@		320MG	A218169	004	Aug 05, 2024	Aug CAHN
		@		320MG	A218169	004	Aug 05, 2024	Feb DISC
	AB			320MG	A218169	004	Aug 05, 2024	Jan CAHN
>A>		@	SOMERSET THERAPS LLC	40MG	A218169	001	Aug 05, 2024	Sep CAHN
>A>		@		80MG	A218169	002	Aug 05, 2024	Sep CAHN
>A>		@		160MG	A218169	003	Aug 05, 2024	Sep CAHN
>A>		@		320MG	A218169	004	Aug 05, 2024	Sep CAHN
>D>	AB		SQUARE PHARMS	40MG	A205347	001	Apr 09, 2018	Sep CAHN
>D>	AB			80MG	A205347	002	Apr 09, 2018	Sep CAHN
>D>	AB			160MG	A205347	003	Apr 09, 2018	Sep CAHN
>D>	AB			320MG	A205347	004	Apr 09, 2018	Sep CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL
VANCOMYCIN HYDROCHLORIDE

		@	ABON PHARMS LLC	EQ 125MG BASE	A065478	001	Apr 09, 2012	Jul CAHN
		@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Jul CAHN

INJECTABLE;INJECTION
VANCOCIN HYDROCHLORIDE

		@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr CAHN
		@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr CAHN
		@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr CAHN
		@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr CAHN
		@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr CAHN
		@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr CAHN
		@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr CAHN
		@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr CAHN
		@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr CAHN

VANCOMYCIN HYDROCHLORIDE

		@	HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009	Jul DISC
	AP		MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan CMFD
	AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan CMFD
		@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar CAHN
		@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar CAHN
		@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar CAHN
		@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar CAHN

POWDER;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

	AP		GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar NEWA
	AP			EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar NEWA
	AP			EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar NEWA
	AP	+!	MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Mar CFTG
>A>	AP		STERISCIENCE	EQ 750MG BASE/VIAL	A215324	001	Oct 02, 2025	Sep NEWA
>A>	AP			EQ 1.25GM BASE/VIAL	A215324	002	Oct 02, 2025	Sep NEWA
>A>	AP			EQ 1.5GM BASE/VIAL	A215324	003	Oct 02, 2025	Sep NEWA

POWDER;INTRAVENOUS, ORAL
VANCOMYCIN HYDROCHLORIDE

		+!	ZHEJIANG NOVUS PHARM	EQ 1.5MG BASE/VIAL	N210274	007	Aug 01, 2025	Aug NEWA
		+!		EQ 750MG BASE/VIAL	N210274	005	Aug 01, 2025	Aug NEWA
		+!		EQ 1.25GM BASE/VIAL	N210274	006	Aug 01, 2025	Aug NEWA

SOLUTION;INTRAVENOUS
TYZAVAN

		+!	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Jul CTNA
		+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Jul CTNA

		SOLUTION;INTRAVENOUS						
		TYZAVAN						
		+!	EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Jul	CTNA
		+!	EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Jul	CTNA
		+!	EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Jul	CTNA
		+!	EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Jul	CTNA
		+!	EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Jul	CTNA
	VARENICLINE TARTRATE							
		TABLET;ORAL						
		CHANTIX						
>D>		@ + PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Sep	CMFD
>A>	AB	+	EQ 0.5MG BASE	N021928	001	May 10, 2006	Sep	CMFD
>D>		@ +	EQ 1MG BASE	N021928	002	May 10, 2006	Sep	CMFD
>A>	AB	+	EQ 1MG BASE	N021928	002	May 10, 2006	Sep	CMFD
		VARENICLINE TARTRATE						
	AB	AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr	NEWA
	AB		EQ 1MG BASE	A214595	002	May 02, 2025	Apr	NEWA
	AB	HANDA PHARMS LLC	EQ 0.5MG BASE	A213268	001	May 21, 2025	May	NEWA
	AB		EQ 1MG BASE	A213268	002	May 21, 2025	May	NEWA
>A>	AB	KANCHAN HLTHCARE	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Sep	CAHN
>A>	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Sep	CAHN
>D>	AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Sep	CAHN
>D>	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Sep	CAHN
	AB	NORVIUM BIOSCIENCE	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	CAHN
	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	May	CAHN
	AB	PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Jul	CAHN
	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Jul	CAHN
		@ PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb	DISC
		@	EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb	DISC
	AB	RHODES PHARMS	EQ 0.5MG BASE	A213268	001	May 21, 2025	Jul	CAHN
	AB		EQ 1MG BASE	A213268	002	May 21, 2025	Jul	CAHN
	AB	SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar	NEWA
	AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar	NEWA
	AB	VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr	NEWA
	AB		EQ 1MG BASE	A212879	002	May 06, 2025	Apr	NEWA
	VASOPRESSIN							
		SOLUTION;INTRAVENOUS						
		VASOPRESSIN IN DEXTROSE 5%						
	AP	GLAND	40UNITS/100ML (0.4UNITS/ML)	A216963	002	Aug 22, 2025	Aug	NFTG
		VASOPRESSIN IN SODIUM CHLORIDE 0.9%						
		@ + LONG GROVE PHARMS	50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	May	DISC
		VASOSTRICT						
	AP	+! PH HEALTH	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Aug	CFTG
	VENLAFAXINE HYDROCHLORIDE							
		CAPSULE, EXTENDED RELEASE;ORAL						
		VENLAFAXINE HYDROCHLORIDE						
	AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
	AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
	AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN
	AB	SCIEGEN PHARMS INC	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Jul	CAHN
	AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Jul	CAHN
	AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Jul	CAHN
		TABLET;ORAL						
		VENLAFAXINE HYDROCHLORIDE						
>D>		@ NORVIUM BIOSCIENCE	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
>D>		@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
>D>		@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
>D>		@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
>D>		@	EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN
>A>		@ PHARMOBEDIENT	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
>A>		@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
>A>		@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
>A>		@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
>A>		@	EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN

		TABLET, EXTENDED RELEASE;ORAL						
		VENLAFAXINE HYDROCHLORIDE						
	AB	ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
	AB		EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
>A>	AB	ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Sep	CAHN
>D>	AB	DEXCEL	EQ 75MG BASE	A213927	001	Jan 21, 2021	Sep	CAHN
	AB	MPP PHARMA	EQ 150MG BASE	A205468	002	Mar 24, 2017	May	CAHN
	AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	May	CAHN
	@	TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jun	DISC
	AB		EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
	@		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jun	DISC
	AB		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
	@		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jun	DISC
	AB		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
	@		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jun	DISC
	AB		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA
		VIBEGRON						
		TABLET;ORAL						
		GEMTESA						
		+! SUMITOMO PHARMA AM	75MG	N213006	001	Dec 23, 2020	Aug	CAHN
		VIGABATRIN						
		FOR SOLUTION;ORAL						
		VIGABATRIN						
>D>	AA	DEXCEL	500MG/PACKET	A214992	001	May 13, 2021	Sep	DISC
>A>		@	500MG/PACKET	A214992	001	May 13, 2021	Sep	DISC
		TABLET;ORAL						
		VIGABATRIN						
		@ AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb	DISC
		@ CARNEGIE	500MG	A215519	001	Apr 28, 2023	May	CAHN
		@ RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan	DISC
		VIMSELTINIB						
		CAPSULE;ORAL						
		ROMVIMZA						
		+ DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb	NEWA
		+	20MG	N219304	002	Feb 14, 2025	Feb	NEWA
		+!	30MG	N219304	003	Feb 14, 2025	Feb	NEWA
		VORICONAZOLE						
		FOR SUSPENSION;ORAL						
		VORICONAZOLE						
	AB	HETERO LABS LTD V	200MG/5ML	A211598	001	Aug 08, 2025	Aug	NEWA
	AB	ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar	CAHN
>D>		INJECTABLE;INTRAVENOUS						
>D>		VFEND						
>D>	AP	+! PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	Sep	CDFR
>D>		VORICONAZOLE						
>D>	AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Sep	CDFR
>D>	AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Sep	CDFR
>D>		@ EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Sep	CDFR
>D>	AP	GLAND	200MG/VIAL	A211099	001	Mar 31, 2020	Sep	CDFR
>D>	AP	HIKMA	200MG/VIAL	N208562	001	Mar 09, 2017	Sep	CDFR
>D>	AP	MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Sep	CDFR
>D>		@ PHARMOBEDIENT	200MG/VIAL	A210849	001	Oct 11, 2022	Sep	CDFR
>D>	AP	SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	Sep	CDFR
>D>	AP	SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Sep	CDFR
>D>	AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Sep	CDFR
>D>	AP	ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	Sep	CDFR
>A>		POWDER;INTRAVENOUS						
>A>		VFEND						
>A>	AP	+! PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	Sep	CDFR
>A>		VORICONAZOLE						
>A>	AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Sep	CDFR
>A>	AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Sep	CDFR
>A>		@ EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Sep	CDFR
>A>	AP	GLAND	200MG/VIAL	A211099	001	Mar 31, 2020	Sep	CDFR
>A>	AP	HIKMA	200MG/VIAL	N208562	001	Mar 09, 2017	Sep	CDFR
>A>	AP	MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Sep	CDFR
>A>		@ PHARMOBEDIENT	200MG/VIAL	A210849	001	Oct 11, 2022	Sep	CDFR
>A>	AP	SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	Sep	CDFR

>A>		POWDER;INTRAVENOUS						
>A>		VORICONAZOLE						
>A>	AP	SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Sep CDFR	
>A>	AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Sep CDFR	
>A>	AP	ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	Sep CDFR	
		WARFARIN SODIUM						
		TABLET;ORAL						
		WARFARIN SODIUM						
	@	AIPING PHARM INC	1MG	A200104	001	Jun 27, 2013	Jul CAHN	
	@		2MG	A200104	002	Jun 27, 2013	Jul CAHN	
	@		2.5MG	A200104	003	Jun 27, 2013	Jul CAHN	
	@		3MG	A200104	004	Jun 27, 2013	Jul CAHN	
	@		4MG	A200104	005	Jun 27, 2013	Jul CAHN	
	@		5MG	A200104	006	Jun 27, 2013	Jul CAHN	
	@		6MG	A200104	007	Jun 27, 2013	Jul CAHN	
	@		7.5MG	A200104	008	Jun 27, 2013	Jul CAHN	
	@		10MG	A200104	009	Jun 27, 2013	Jul CAHN	
		ZALEPLON						
		CAPSULE;ORAL						
		SONATA						
	@ +	PFIZER	5MG	N020859	001	Aug 13, 1999	Aug DISC	
	@ +		10MG	N020859	002	Aug 13, 1999	Aug DISC	
		ZALEPLON						
AB	!	UNICHEM	10MG	A078989	002	Jun 06, 2008	Aug CHRS	
		ZANUBRUTINIB						
		CAPSULE;ORAL						
		BRUKINSA						
	@ +	BEONE MEDICINES USA	80MG	N213217	001	Nov 14, 2019	Aug DISC	
	+!		80MG	N213217	001	Nov 14, 2019	Apr CAHN	
		TABLET;ORAL						
		BRUKINSA						
	+!	BEONE MEDICINES USA	160MG	N218785	001	Jun 10, 2025	Jun NEWA	
		ZINC ACETATE						
		CAPSULE;ORAL						
		GALZIN						
	+	ETON	EQ 25MG ZINC	N020458	001	Jan 28, 1997	Jan CAHN	
	+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997	Jan CAHN	
		ZINC CHLORIDE						
		INJECTABLE;INJECTION						
		ZINC CHLORIDE						
AP		RK PHARMA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	May CAHN	
AP		STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr NEWA	
		ZINC SULFATE						
		SOLUTION;INTRAVENOUS						
		ZINC SULFATE						
AP		ASPIRO	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A219585	001	May 01, 2025	Apr NEWA	
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A219585	002	May 01, 2025	Apr NEWA	
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A219585	003	May 01, 2025	Apr NEWA	
>A> AP		RK PHARMA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Sep CAHN	
>A> AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Sep CAHN	
>A> AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	Sep CAHN	
>D> AP		STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Sep CAHN	
AP			EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	May NEWA	
>D> AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Sep CAHN	
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	May NEWA	
>D> AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	Sep CAHN	
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	May NEWA	

ZIPRASIDONE MESYLATE

POWDER;INTRAMUSCULAR

ZIPRASIDONE MESYLATE

AP			STERISCIENCE	EQ 20MG BASE/VIAL	A217595	001	Sep 03, 2025	Aug NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

	@		APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar DISC
>D>	@		NOVAST LABS	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Sep CAHN
>A>	@			EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Sep CAHN

SOLUTION;INTRAVENOUS

ZOLEDRONIC ACID

	@		HOSPIRA	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Aug DISC

ZOLMITRIPTAN

SPRAY;NASAL

ZOLMITRIPTAN

AB			PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Apr CHRS

ZOMIG

AB		+!	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr CHRS

ZOLPIDEM TARTRATE

TABLET;ORAL

AMBIEN

AB		+	COSETTE	5MG	N019908	001	Dec 16, 1992	Jan CAHN
AB		+!		10MG	N019908	002	Dec 16, 1992	Jan CAHN

ZOLPIDEM TARTRATE

	@		APOTEX INC	5MG	A077884	001	Apr 23, 2007	Mar DISC
	@			10MG	A077884	002	Apr 23, 2007	Mar DISC

TABLET;SUBLINGUAL

EDLUAR

AB		+	VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb CAHN
AB		+!		10MG	N021997	002	Mar 13, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB		+	COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan CAHN
AB		+!		12.5MG	N021774	001	Sep 02, 2005	Jan CAHN

ZOLPIDEM TARTRATE

	@		APOTEX	6.25MG	A200266	001	Sep 10, 2013	Mar DISC
	@			12.5MG	A200266	002	Sep 10, 2013	Mar DISC

ZONGERTINIB

TABLET;ORAL

HERNEXEOS

		+!	BOEHRINGER INGELHEIM	60MG	N219042	001	Aug 08, 2025	Aug NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

	@		APOTEX	25MG	A077642	001	Dec 22, 2005	Mar DISC
	@			50MG	A077642	002	Dec 22, 2005	Mar DISC
	@			100MG	A077642	003	Dec 22, 2005	Mar DISC
	@		CHARTWELL RX	25MG	A077650	001	Apr 20, 2006	Aug CAHN
	@			50MG	A077650	002	Apr 20, 2006	Aug CAHN
	@			100MG	A077650	003	Apr 20, 2006	Aug CAHN
	@		MACLEODS PHARMS LTD	25MG	A219507	001	May 12, 2025	Jul DISC
AB				25MG	A219507	001	May 12, 2025	May NEWA
	@			50MG	A219507	002	May 12, 2025	Jul DISC
AB				50MG	A219507	002	May 12, 2025	May NEWA
	@			100MG	A219507	003	May 12, 2025	Jul DISC
AB				100MG	A219507	003	May 12, 2025	May NEWA
	@		SUN PHARM INDS (IN)	25MG	A077634	001	Mar 17, 2006	Jul DISC
	@			50MG	A077634	002	Mar 17, 2006	Jul DISC
	@			100MG	A077634	003	Mar 17, 2006	Jul DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

@	STRIDES PHARMA	250MG;125MG	A217241	001	Jan 17, 2025	Jul DISC
		250MG;125MG	A217241	001	Jan 17, 2025	Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA	0.2055MG/SPRAY	A216561	001	Jan 27, 2025	Jan NEWA

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@	AIPING PHARM INC	5MG	A202277	002	Mar 11, 2014	Jul CAHN
@		10MG	A202277	004	Mar 11, 2014	Jul CAHN
@	TARO	5MG	A078072	001	Jul 22, 2009	Aug DISC
@		5MG	A078072	003	Jul 22, 2009	Aug DISC

CETIRIZINE HYDROCHLORIDE HIVES

@	AIPING PHARM INC	5MG	A202277	001	Mar 11, 2014	Jul CAHN
@		10MG	A202277	003	Mar 11, 2014	Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	TARO	10MG	A078072	002	Jul 22, 2009	Aug DISC
@		10MG	A078072	004	Jul 22, 2009	Aug DISC

ZYRTEC ALLERGY

+	KENVUE BRANDS	5MG	N019835	003	Nov 16, 2007	Apr CMFD

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Jun DISC

CHLORHEXIDINE GLUCONATE

CLOTH;TOPICAL

READYPREP CHG

+!	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018	Aug CHRS
+		2%	N207964	001	Nov 20, 2018	Aug CRLD

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@	APOTEX	100MG	A074948	001	Jun 19, 1998	Mar DISC
@		200MG	A074948	002	Jul 26, 2002	Mar DISC

CLOTRIMAZOLE

CREAM;VAGINAL

TRIVAGIZOLE 3

	SUN PHARMA CANADA	2%	N021143	001	Apr 12, 2000	Aug CAHN

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

>A>	DR REDDYS	10%	A214613	001	Oct 03, 2025	Sep NEWA
>A>	SUN PHARMA CANADA	10%	A214454	001	Oct 26, 2023	Sep CAHN
>D>	TARO	10%	A214454	001	Oct 26, 2023	Sep CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

@	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019	Aug DISC
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	May CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

	CONTRACT PHARMACAL	60MG	A219032	001	Feb 28, 2025	Feb NEWA
		180MG	A219032	002	Feb 28, 2025	Feb NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

		AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Apr NEWA
>A>		L PERRIGO CO	60MG;120MG	A216792	001	Oct 07, 2025	Sep NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

		RUBICON	0.05MG/SPRAY	A219060	001	Aug 15, 2025	Aug NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

		STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021	Aug CMFD

SUSPENSION/DROPS;ORAL

IBUPROFEN

		AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	May CMFD

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	@	AUROBINDO PHARMA LTD	200MG;30MG	A213565	001	Mar 10, 2023	Sep CMFD
>A>			200MG;30MG	A213565	001	Mar 10, 2023	Sep CMFD
		STRIDES PHARMA	200MG;30MG	A077628	001	Aug 14, 2006	Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	@	APOTEX	5MG	A211443	001	Apr 21, 2021	Jan DISC
		SANKALP LIFECARE	5MG	A211551	001	Nov 20, 2018	Jul CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>A>		ANNORA PHARMA	1.5MG	A219102	001	Sep 30, 2025	Sep NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

IMODIUM A-D

	@ +	KENVUE BRANDS	1MG/5ML	N019487	001	Mar 01, 1988	Apr DISC
>A>	+!		1MG/7.5ML	N019487	002	Jul 08, 2004	Sep CDFR

LOPERAMIDE HYDROCHLORIDE

>A>		BIONPHARMA	1MG/7.5ML	A220100	001	Sep 19, 2025	Sep NEWA
	@	PAI HOLDINGS	1MG/5ML	A074352	001	Nov 17, 1995	Feb CAHN
>A>		PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	Sep CDFR
	@	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997	Apr DISC

>D>	SUSPENSION;ORAL						
>D>	IMODIUM A-D						
>D>	+!	KENVUE BRANDS	1MG/7.5ML	N019487	002	Jul 08, 2004	Sep CDFR
>D>	LOPERAMIDE HYDROCHLORIDE						
>D>		PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	Sep CDFR

LORATADINE

CAPSULE;ORAL

LORATADINE

		AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023	Jun CMFD
	@	CATALENT PHARMA	10MG	A215127	001	Feb 28, 2025	Jun DISC
			10MG	A215127	001	Feb 28, 2025	Feb NEWA

SUSPENSION;ORAL

LORATADINE

	@ +	SUN PHARMA CANADA	1MG/ML	N021734	001	Oct 04, 2005	Aug CAHN
	@ +	TARO	1MG/ML	N021734	001	Oct 04, 2005	Aug DISC

TABLET;ORAL

LORATADINE

>A>		ADAPTIS	10MG	A219223	001	Nov 21, 2024	Sep CAHN
>D>		MARKSANS PHARMA	10MG	A219223	001	Nov 21, 2024	Sep CAHN

TABLET, CHEWABLE;ORAL

LORATADINE

		SUN PHARM	10MG	A210088	002	Apr 25, 2025	Apr NEWA

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

		TARO	5%	A217998	001	Jun 30, 2025	Jun NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

	@	AUROBINDO PHARMA	0.05MG/SPRAY	A217498	001	Nov 22, 2024	May DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

>A>		ADAPTIS	220MG	A074635	001	Jan 13, 1997	Sep CAHN
>D>		CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997	Sep CAHN
	@	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018	Apr DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

		DR REDDYS LABS SA	EQ 2MG BASE	A215276	001	Jul 17, 2025	Jul NEWA
			EQ 4MG BASE	A215276	002	Jul 17, 2025	Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

		BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017	May CMFD
			EQ 0.2% BASE	A206087	001	Dec 05, 2017	Feb CMFD
		FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Jul NEWA
		GLENMARK PHARMS INC	EQ 0.2% BASE	A219557	001	Feb 28, 2025	Feb NEWA
		RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CMFD
			EQ 0.2% BASE	A204620	001	Jun 16, 2020	Apr CMFD

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

	@	APOTEX	20MG	A210070	001	Feb 11, 2019	Jan DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

		MARKSANS PHARMA	EQ 20MG BASE	A218829	001	Aug 07, 2025	Aug NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

	+!	BAYER HEALTHCARE LLC	17GM/PACKET	N022015	002	Oct 06, 2006	Aug NEWA

POLYETHYLENE GLYCOL 3350

		ANI PHARMS	17GM/PACKET	A202850	002	Nov 30, 2021	Aug NEWA
		ANNORA PHARMA	17GM/PACKET	A214990	002	Apr 14, 2021	Aug NEWA
		AUROBINDO PHARMA LTD	17GM/PACKET	A209017	002	Apr 23, 2024	Aug NEWA
		NOVEL LABS INC	17GM/PACKET	A091077	002	Jun 27, 2011	Aug NEWA
		SHREE HARI INTL	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Aug CAHN

POTASSIUM IODIDE

TABLET;ORAL

THYROSAFE

		BTG INTL	130MG	A076350	002	Apr 02, 2025	Mar NFTG

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2025

NO SEPTEMBER 2025 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA							
N 216793 001	>A>	11673877	Mar 27, 2038	DS DP U-2830			
	>A>	12383543	Jul 28, 2037	U-2830			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA							
N 216793 002	>A>	11673877	Mar 27, 2038	DS DP U-2830			
	>A>	12383543	Jul 28, 2037	U-2830			
ACALABRUTINIB - CALQUENCE							
N 210259 001		10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
		10167291	Jul 01, 2036	DP U-2519			
		10167291	Jul 01, 2036	DP U-2666			
		10167291	Jul 01, 2036	DP U-2667			
		10167291	Jul 01, 2036	DP U-2668			
		10167291	Jul 01, 2036	DP U-2669			
		10167291	Jul 01, 2036	DP U-2670			
		10167291	Jul 01, 2036	DP U-2671			
		10167291	Jul 01, 2036	DP U-2682			
		10167291	Jul 01, 2036	DP U-2683			
		10167291	Jul 01, 2036	DP U-2684			
		10167291	Jul 01, 2036	DP U-2685			
		10167291	Jul 01, 2036	DP U-2686			
		10167291	Jul 01, 2036	DP U-2687			
		10167291	Jul 01, 2036	DP U-4109			
		10272083	Jan 21, 2035	U-2519			
		10272083	Jan 21, 2035	U-2682			
		10272083	Jan 21, 2035	U-2683			
		10272083	Jan 21, 2035	U-2684			
		10272083	Jan 21, 2035	U-2685			
		10272083	Jan 21, 2035	U-2686			
		10272083	Jan 21, 2035	U-2687			
		10272083	Jan 21, 2035	U-4109			
		9758524	Jul 11, 2032	U-2145			
		9758524	Jul 11, 2032	U-4108			
		9796721	Jul 01, 2036	DS DP U-2145			
		9796721	Jul 01, 2036	DS DP U-2666			
		9796721	Jul 01, 2036	DS DP U-2667			
		9796721	Jul 01, 2036	DS DP U-2668			
		9796721	Jul 01, 2036	DS DP U-2669			
		9796721	Jul 01, 2036	DS DP U-2670			
		9796721	Jul 01, 2036	DS DP U-2671			
		9796721	Jul 01, 2036	DS DP U-4108			
ACALABRUTINIB MALEATE - CALQUENCE							
N 216387 001		10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
		10272083	Jan 21, 2035	U-2682			
		10272083	Jan 21, 2035	U-2683			
		10272083	Jan 21, 2035	U-2684			
		10272083	Jan 21, 2035	U-2685			
		10272083	Jan 21, 2035	U-2686			
		10272083	Jan 21, 2035	U-2687			
		10272083	Jan 21, 2035	U-4109			
		11059829	Jul 01, 2036	DS DP U-2145			
		11059829	Jul 01, 2036	DS DP U-2666			
		11059829	Jul 01, 2036	DS DP U-2667			
		11059829	Jul 01, 2036	DS DP U-2668			
		11059829	Jul 01, 2036	DS DP U-2669			
		11059829	Jul 01, 2036	DS DP U-2670			
		11059829	Jul 01, 2036	DS DP U-2671			
		11059829	Jul 01, 2036	DS DP U-4108			
		9758524	Jul 11, 2032	U-2145			
		9758524	Jul 11, 2032	U-4108			
ACECLIDINE HYDROCHLORIDE - VIZZ							
N 218585 001		10052313	Mar 24, 2034	DP U-3741		NCE	Jul 31, 2030
		11179328	Mar 24, 2034	U-3741			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACECLIDINE HYDROCHLORIDE - VIZZ							
N 218585 001		12128036	Oct 08, 2039	U-3741			
	>A>	12414942	Mar 15, 2044	U-3741			
		9844537	Mar 24, 2034	DP U-3741			
ACETAMINOPHEN - ACETAMINOPHEN							
A 214331 002						PC	Jan 07, 2026
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ							
N 208653 002		8748413	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ							
N 208653 003		8748413	Jul 01, 2030	DS DP			
ACETYLCYSTEINE - ACETADOTE							
N 021539 001						>A> D-196	Nov 26, 2027
ACOLTREMON - TRYPTYR							
N 217370 001		10028920	Sep 08, 2031	U-1900		NCE	May 28, 2030
		11850221	Dec 16, 2042	DP U-1900			
		12336971	Dec 16, 2042	U-1900			
		9095609	Sep 08, 2031	DP U-1900			
		9433679	Sep 08, 2031	U-1900			
ACORAMIDIS HYDROCHLORIDE - ATTRUBY							
N 216540 001		9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031
ADAGRASIB - KRAZATI							
N 216340 001		12281113	Sep 10, 2041	DS DP			
		12336995	Feb 05, 2041	U-3953			
		12383503	Aug 21, 2043	DP			
AFAMELANOTIDE - SCENESSE							
N 210797 001		8334265	Jan 20, 2033	U-2638			
ALBUMIN HUMAN - OPTISON							
N 020899 001						NPP	May 09, 2028
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT							
N 021747 001		7396341	Oct 10, 2026	DP	Y		
		7837235	Mar 13, 2028	DP	Y		
		8733341	Oct 16, 2030	DP	Y		
		9027967	Mar 31, 2027	DP	Y		
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944 001		12233033	Aug 23, 2038	U-2106			
		12233033	Aug 23, 2038	U-2224			
		12233033	Aug 23, 2038	U-3180			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944 002		12233033	Aug 23, 2038	U-2106			
		12233033	Aug 23, 2038	U-2224			
		12233033	Aug 23, 2038	U-3180			
AMIKACIN SULFATE - ARIKAYCE KIT							
N 207356 001		12168021	May 15, 2035	U-2414			
		12168022	May 15, 2035	U-2414			
		12377114	May 15, 2035	U-2414			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER							
N 200656 001	>A>	12390398	May 03, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER							
N 200656	002	>A> 12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER							
N 200656	003	>A> 12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	004	>A> 12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	005	>A> 12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	006	>A> 12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	007	>A> 12390398	May 03, 2036	DP			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN							
N 020965	001	11179574	Oct 13, 2036			U-804	
		11446512	Jan 17, 2037			U-804	
		11697028	Oct 13, 2036			U-804	
		12290700	Oct 13, 2036			U-804	
		12296011	Jan 12, 2038			U-3163	
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ							
N 208081	001	12280146	Dec 08, 2043	DP			
AMISULPRIDE - BARHEMSYS							
N 209510	001	12005042	Feb 09, 2038			U-1744	
		12005042	Feb 09, 2038			U-2754	
		12005042	Feb 09, 2038			U-3467	
		12194022	Mar 10, 2031			U-1744	
		12194022	Mar 10, 2031			U-3467	
		12329740	Feb 09, 2038			U-2754	
		12329740	Feb 09, 2038			U-3467	
AMISULPRIDE - BARHEMSYS							
N 209510	002	12005042	Feb 09, 2038			U-1744	
		12005042	Feb 09, 2038			U-2754	
		12005042	Feb 09, 2038			U-3467	
		12194022	Mar 10, 2031			U-1744	
		12194022	Mar 10, 2031			U-3467	
		12329740	Feb 09, 2038			U-2754	
		12329740	Feb 09, 2038			U-3467	
AMLODIPINE BENZOATE - KATERZIA							
N 211340	001	12336984	Oct 06, 2037			U-3447	
		12336984	Oct 06, 2037			U-3448	
AMLODIPINE BESYLATE - NORLIQVA							
N 214439	001	12005141	Feb 24, 2041	DP		U-3309	
		12005141	Feb 24, 2041	DP		U-3310	
		12005141	Feb 24, 2041	DP		U-3311	
		12226528	Feb 24, 2041	DP		U-3309	
		12226528	Feb 24, 2041	DP		U-3310	
		12226528	Feb 24, 2041	DP		U-3311	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	001		10322117	Jan 23, 2038	DP		NP	Jun 05, 2028
			10799487	Jan 23, 2038	DP U-3448			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	002		10322117	Jan 23, 2038	DP		NP	Jun 05, 2028
			10799487	Jan 23, 2038	DP U-3448			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	003		10322117	Jan 23, 2038	DP		NP	Jun 05, 2028
			10799487	Jan 23, 2038	DP U-3448			
APALUTAMIDE - ERLEADA								
N 210951	001		12303493	Dec 03, 2035	DP			
			12303497	Jan 30, 2040	U-4201			
			12303497	Jan 30, 2040	U-4202			
APALUTAMIDE - ERLEADA								
N 210951	002		12303493	Dec 03, 2035	DP			
			12303497	Jan 30, 2040	U-4201			
			12303497	Jan 30, 2040	U-4202			
APIXABAN - ELIQUIS								
N 202155	001		6967208	Nov 21, 2026	DS DP U-1167		NPP	Apr 17, 2028
			6967208	Nov 21, 2026	DS DP U-1200		PED	Oct 17, 2028
			6967208	Nov 21, 2026	DS DP U-1301			
			6967208	Nov 21, 2026	DS DP U-1302			
			6967208	Nov 21, 2026	DS DP U-1323			
			6967208	Nov 21, 2026	DS DP U-1501			
			6967208	Nov 21, 2026	DS DP U-1502			
			6967208	Nov 21, 2026	DS DP U-1729			
			6967208	Nov 21, 2026	DS DP U-1730			
			6967208	Nov 21, 2026	DS DP U-4178			
			6967208*PED	May 21, 2027				
			9326945	Feb 24, 2031	DP			
			9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS								
N 202155	002		6967208	Nov 21, 2026	DS DP U-1200		NPP	Apr 17, 2028
			6967208	Nov 21, 2026	DS DP U-1301		PED	Oct 17, 2028
			6967208	Nov 21, 2026	DS DP U-1302			
			6967208	Nov 21, 2026	DS DP U-1323			
			6967208	Nov 21, 2026	DS DP U-4178			
			6967208*PED	May 21, 2027				
			9326945	Feb 24, 2031	DP			
			9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS								
N 202155	003		6967208	Nov 21, 2026	DS DP U-4179		NS	Apr 17, 2028
			6967208*PED	May 21, 2027			PED	Oct 17, 2028
			9326945	Feb 24, 2031	DP			
			9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS SPRINKLE								
N 220073	001		11896586	Nov 22, 2040	DP U-4180		NP	Apr 17, 2028
			11896586*PED	May 22, 2041			PED	Oct 17, 2028
			6967208	Nov 21, 2026	DS DP U-4180			
			6967208*PED	May 21, 2027				
APOMORPHINE HYDROCHLORIDE - ONAPGO								
N 214056	001						NP	Feb 03, 2028
APREMILAST - OTEZLA XR								
N 210745	001	>A>	10092541	May 29, 2034	U-2659			
		>A>	11752129	May 27, 2042	DP U-4264			
		>A>	11752129	May 27, 2042	DP U-4265			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT DELIST REQUESTED	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA XR							
N 210745 001	>A>	11752129	May 27, 2042		DP U-4266		
	>A>	11969409	May 27, 2042		DP		
	>A>	7427638	Feb 16, 2028	DS	DP		
APREPITANT - CINVANTI							
N 209296 001		12290520	Sep 18, 2035		DP		
APREPITANT - APONVIE							
N 216457 001		12290520	Sep 18, 2035		DP		
APROCITENTAN - TRYVIO							
N 217686 001		12297189	Feb 26, 2038		DP		
ARIPIPRAZOLE - MEZOFY							
N 211448 001		9694008	Aug 07, 2033		DP		
ARIPIPRAZOLE - MEZOFY							
N 211448 002		9694008	Aug 07, 2033		DP		
ARIPIPRAZOLE - MEZOFY							
N 211448 003		9694008	Aug 07, 2033		DP		
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533 001		11969469	Oct 24, 2033		DP		
		12251381	Apr 06, 2039		U-543		
		12311027	Sep 19, 2033		DP U-543		
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533 002		11969469	Oct 24, 2033		DP		
		12251381	Apr 06, 2039		U-543		
		12311027	Sep 19, 2033		DP U-543		
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533 003		11969469	Oct 24, 2033		DP		
		12251381	Apr 06, 2039		U-543		
		12311027	Sep 19, 2033		DP U-543		
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533 004		11969469	Oct 24, 2033		DP		
		12251381	Apr 06, 2039		U-543		
		12311027	Sep 19, 2033		DP U-543		
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT							
N 209830 001		12251381	Apr 06, 2039		U-543		
ARTICAINE HYDROCHLORIDE - CYKLX							
N 218643 001						>A> NP	Aug 15, 2028
ASCIMINIB HYDROCHLORIDE - SCEMBLIX							
N 215358 001		12252478	May 14, 2040		DP		
		12252479	May 17, 2040		U-1374		
ASCIMINIB HYDROCHLORIDE - SCEMBLIX							
N 215358 002		12252478	May 14, 2040		DP		
		12252479	May 17, 2040		U-1374		
ASCIMINIB HYDROCHLORIDE - SCEMBLIX							
N 215358 003		12252478	May 14, 2040		DP		
		12252479	May 17, 2040		U-1374		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATOGEPANT - QULIPTA						
N 215206 001	12090148	Jul 29, 2041	U-3534			
	12350259	Feb 27, 2043	U-4234			
	12383545	Jun 06, 2039	U-3534			
ATOGEPANT - QULIPTA						
N 215206 002	12090148	Jul 29, 2041	U-3534			
	12383545	Jun 06, 2039	U-3534			
ATOGEPANT - QULIPTA						
N 215206 003	12383545	Jun 06, 2039	U-3534			
ATORVASTATIN CALCIUM - ATORVALIQ						
N 213260 001	12370136	Jun 07, 2037	DP			
ATRASENTAN HYDROCHLORIDE - VANRAFIA						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	12370174	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			
AVACINCAPTAD PEGOL SODIUM - IZERVAY						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS U-3673			
AVAPRITINIB - AYVAKIT						
N 212608 004	12252494	Apr 10, 2040	U-3506			
AVATROMBOPAG MALEATE - DOPTELET SPRINKLE						
N 219696 001	7638536	Jul 28, 2027	DS DP			
AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO						
N 217906 001	7112592	Jan 07, 2026	DS DP U-4147		NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)						
N 219616 001	11400090	Oct 29, 2038	U-4196		NCE	May 08, 2030
	11517573	Sep 11, 2040	U-4196			
	11517573	Sep 11, 2040	U-4205			
	11873296	Dec 29, 2042	DP U-4196			
	7897792	Feb 09, 2027	DS DP			
	7928109	Aug 21, 2029	DS DP			
	8247411	Apr 17, 2028	DS DP			
BACLOFEN - BACLOFEN						
A 214445 001					PC	Jul 14, 2025
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 001					M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 002					M-187	Dec 19, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	003					M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410	001					M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410	002	10392406	Apr 27, 2036	DS			
		10633397	Apr 27, 2036	U-2816			
		10633397	Apr 27, 2036	U-3000			
		10759814	Aug 09, 2037	DS DP			
		11261198	Sep 25, 2038	DP			
		11306106	Aug 09, 2037	U-2816			
		11306106	Aug 09, 2037	U-3000			
		11925648	Apr 21, 2041	DP			
		8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410	003	10392406	Apr 27, 2036	DS			
		10633397	Apr 27, 2036	U-2816			
		10633397	Apr 27, 2036	U-3000			
		10759814	Aug 09, 2037	DS DP			
		11261198	Sep 25, 2038	DP			
		11306106	Aug 09, 2037	U-2816			
		11306106	Aug 09, 2037	U-3000			
		11925648	Apr 21, 2041	DP			
		8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 80							
N 020911	001	9463289	May 18, 2031	DP	Y		
		9808587	May 18, 2031	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR 40							
N 020911	002	9463289	May 18, 2031	DP	Y		
		9808587	May 18, 2031	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	001	10561808	Jan 01, 2032	DP	Y		
		11395889	May 18, 2031	DP	Y		
		12296089	Jan 26, 2038	DP			
		8132712	Sep 07, 2028	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	002	10561808	Jan 01, 2032	DP	Y		
		11395889	May 18, 2031	DP	Y		
		12296089	Jan 26, 2038	DP			
		8132712	Sep 07, 2028	DP	Y		
BEDAQUILINE FUMARATE - SIRTURO							
N 204384	002					ODE*	Aug 09, 2026
BELUMOSUDIL MESYLATE - REZUROCK							
N 214783	001	>A> 10183931	Oct 07, 2033	U-3246			
		>A> 10183931	Oct 07, 2033	U-4260			
		>A> 10696660	Oct 07, 2033	U-3246			
		>A> 10696660	Oct 07, 2033	U-4260			
		>A> 8357693	Oct 30, 2029	DS DP U-4259			
BELZUTIFAN - WELIREG							
N 215383	001	12358870	Jun 30, 2042	DP		I-968	May 14, 2028
		9908845	Sep 05, 2034	DS DP U-3201			
		9908845	Sep 05, 2034	DS DP U-4176			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BELZUTIFAN - WELIREG							
N 215383	001	9908845	Sep 05, 2034	DS DP U-4195			
		RE49948	Sep 05, 2034	DS DP U-3201			
		RE49948	Sep 05, 2034	DS DP U-4176			
		RE49948	Sep 05, 2034	DS DP U-4195			
BEMPEDOIC ACID - NEXLETOL							
N 211616	001	12398087	Jun 19, 2040	DS DP			
		12404227	Jun 19, 2040	DS U-4258			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET							
N 211617	001	12398087	Jun 19, 2040	DS DP			
		12404227	Jun 19, 2040	DS U-4258			
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO							
N 205580	001	12138248	Jan 28, 2031	DP			
		12350257	Jan 28, 2031	DP U-1542			
		12350257	Jan 28, 2031	DP U-1971			
		12350257	Jan 28, 2031	DP U-1972			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA							
N 208194	001	12138248	Jan 28, 2031	DP			
		12350257	Jan 28, 2031	DP U-1542			
		12350257	Jan 28, 2031	DP U-1971			
		12350257	Jan 28, 2031	DP U-1972			
BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA							
N 212209	001	12208086	Jul 29, 2042	DP			
BENZGALANTAMINE GLUCONATE - ZUNVEYL							
N 218549	001	12208167	Feb 26, 2044	DP U-713			
BENZGALANTAMINE GLUCONATE - ZUNVEYL							
N 218549	002	12208167	Feb 26, 2044	DP U-713			
BENZGALANTAMINE GLUCONATE - ZUNVEYL							
N 218549	003	12208167	Feb 26, 2044	DP U-713			
BENZOYL PEROXIDE - EPSOLAY							
N 214510	001	12257348	May 23, 2041	DP U-3947			
		12295935	Dec 27, 2040	U-3356			
		12350382	Feb 03, 2028	DP			
BENZOYL PEROXIDE; TRETINOIN - TWYNEO							
N 214902	001	12257348	May 23, 2041	DP U-3987			
		12295935	Dec 27, 2040	U-3987			
		12357602	Jul 12, 2038	DP U-3987			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO							
N 214094	001	>A> 10125102	Apr 07, 2035	DS U-3010		>A> ODE-333	Dec 03, 2027
		>A> 10125102*PED	Oct 07, 2035			>A> PED	Jun 03, 2028
		>A> 10329260	Mar 09, 2035	DS			
		>A> 10329260*PED	Sep 09, 2035				
		>A> 10662160	Nov 01, 2039	DS U-3010			
		>A> 10662160*PED	May 01, 2040				
		>A> 10689346	Mar 09, 2035	U-3010			
		>A> 10689346*PED	Sep 09, 2035				
		>A> 11117867	Nov 01, 2039	DP U-3010			
		>A> 11117867*PED	May 01, 2040				
		>A> 11230530	Mar 09, 2035	U-3300			
		>A> 11230530*PED	Sep 09, 2035				
		>A> 11618733	Nov 01, 2039	U-3300			
		>A> 11618733*PED	May 01, 2040				
		>A> 11708333	Mar 09, 2035	U-3300			
		>A> 11708333*PED	Sep 09, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO									
N 214094	001	>A>	12116346	Mar 09, 2035	DS				
		>A>	12116346*PED	Sep 09, 2035					
		>A>	12344585	Nov 01, 2039		U-3010			
		>A>	12344585*PED	May 01, 2040					
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO									
N 214094	002	>A>	10125102	Apr 07, 2035	DS	U-3010		>A> ODE-333	Dec 03, 2027
		>A>	10125102*PED	Oct 07, 2035				>A> PED	Jun 03, 2028
		>A>	10329260	Mar 09, 2035	DS				
		>A>	10329260*PED	Sep 09, 2035					
		>A>	10662160	Nov 01, 2039	DS	U-3010			
		>A>	10662160*PED	May 01, 2040					
		>A>	10689346	Mar 09, 2035		U-3010			
		>A>	10689346*PED	Sep 09, 2035					
		>A>	11117867	Nov 01, 2039	DP	U-3010			
		>A>	11117867*PED	May 01, 2040					
		>A>	11230530	Mar 09, 2035		U-3300			
		>A>	11230530*PED	Sep 09, 2035					
		>A>	11618733	Nov 01, 2039		U-3300			
		>A>	11618733*PED	May 01, 2040					
		>A>	11708333	Mar 09, 2035		U-3300			
		>A>	11708333*PED	Sep 09, 2035					
		>A>	12116346	Mar 09, 2035	DS				
		>A>	12116346*PED	Sep 09, 2035					
		>A>	12344585	Nov 01, 2039		U-3010			
		>A>	12344585*PED	May 01, 2040					
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY									
N 210251	001		7390791	Jan 07, 2025	DS DP				
			7390791*PED	Jul 07, 2025					
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY									
N 210251	002		7390791	Jan 07, 2025	DS DP				
			7390791*PED	Jul 07, 2025					
BINIMETINIB - MEKTOVI									
N 210498	001		7777050	Mar 13, 2026	DS DP				
BIRCH TRITERPENES - FILSUVEZ									
N 215064	001		12268695	Jan 04, 2039		U-3811			
			8828444	Jun 21, 2026	DP				
BOSENTAN - BOSENTAN									
A 213154	001							PC	Feb 14, 2026
BRENSOCATIB - BRINSUPRI									
N 217673	001		10287258	Jan 21, 2035	DS	U-4257		NCE	Aug 12, 2030
			10669245	Jan 21, 2035	DS	U-4257			
			11655221	Jan 21, 2035	DP	U-4257			
			11655222	Jan 21, 2035	DS	U-4257			
			11655223	Jan 21, 2035	DS	U-4257			
			11655224	Jan 21, 2035	DP	U-4257			
			11673871	Jan 21, 2035	DP	U-4257			
			11773069	Jan 21, 2035	DP	U-4257			
			11814359	Jan 21, 2035	DS	U-4257			
			12054465	Jan 21, 2035	DS	U-4257			
			12059424	Feb 21, 2040	DP				
			12201638	Mar 01, 2039	DP				
			9522894	Mar 12, 2035	DS				
			9815805	Jan 21, 2035		U-4257			
BRENSOCATIB - BRINSUPRI									
N 217673	002		10287258	Jan 21, 2035	DS	U-4257		NCE	Aug 12, 2030
			10669245	Jan 21, 2035	DS	U-4257			
			11655221	Jan 21, 2035	DP	U-4257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRENSOCATIB - BRINSUPRI							
N 217673 002		11655222	Jan 21, 2035	DS U-4257			
		11655223	Jan 21, 2035	DS U-4257			
		11655224	Jan 21, 2035	DP U-4257			
		11673871	Jan 21, 2035	DP U-4257			
		11773069	Jan 21, 2035	DP U-4257			
		11814359	Jan 21, 2035	DS U-4257			
		12054465	Jan 21, 2035	DS U-4257			
		12059424	Feb 21, 2040	DP			
		12201638	Mar 01, 2039	DP			
		9522894	Mar 12, 2035	DS			
		9815805	Jan 21, 2035	U-4257			
BREXPIPRAZOLE - REXULTI							
N 205422 001						M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI							
N 205422 002						M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI							
N 205422 003						M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI							
N 205422 004						M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI							
N 205422 005						M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI							
N 205422 006						M-315	May 09, 2028
BUDESONIDE - TARPEYO							
N 215935 001		12171882	Jan 23, 2043	U-4085			
		12171882	Jan 23, 2043	U-4086			
		12171883	Jan 23, 2043	DP			
		12311057	Jan 23, 2043	DP U-4085			
		12311057	Jan 23, 2043	DP U-4086			
		12311057	Jan 23, 2043	DP U-4204			
BUMETANIDE - ENBUMYST							
N 219500 001	>A>	11123319	Dec 04, 2040	DP			
BUPIVACAINE - EXPAREL							
N 022496 001		12226610	Feb 02, 2043	U-4148			
		12226610	Feb 02, 2043	U-4149			
		12226610	Feb 02, 2043	U-4150			
		12251468	Jul 02, 2044	DP U-4152			
		12296047	Jan 22, 2041	DP U-4184			
		12318483	Jul 02, 2044	U-4152			
		12370142	Jul 02, 2044	DP U-4152			
BUPIVACAINE - EXPAREL							
N 022496 002		12226610	Feb 02, 2043	U-4148			
		12226610	Feb 02, 2043	U-4149			
		12226610	Feb 02, 2043	U-4150			
		12251468	Jul 02, 2044	DP U-4152			
		12296047	Jan 22, 2041	DP U-4184			
		12318483	Jul 02, 2044	U-4152			
		12370142	Jul 02, 2044	DP U-4152			
BUPRENORPHINE - SUBLOCADE							
N 209819 001						M-314	Feb 21, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - SUBLOCADE							
N 209819	002					M-314	Feb 21, 2028
BUPRENORPHINE - BRIXADI							
N 210136	001	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI							
N 210136	002	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI							
N 210136	003	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI							
N 210136	004	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI							
N 210136	005	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI							
N 210136	006	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI							
N 210136	007	12161640	Jul 26, 2032	DP		U-4100	
		12318379	Jul 26, 2032	DP		U-4100	
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY							
N 215430	001	12310961	Jan 20, 2043			U-3419	
		12357697	Jan 20, 2043			U-3419	
		12390428	Dec 01, 2041			U-3419	
CABOTEGRAVIR - APRETUDE							
N 215499	001	8410103	Feb 04, 2031	DS	DP		
CABOTEGRAVIR SODIUM - VOCABRIA							
N 212887	001 >A>	8410103	Feb 04, 2031	DS	DP	U-3348	
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT							
N 212888	001	11389448	Apr 13, 2032		DP		
		12178815	Jul 18, 2038			U-3348	
		8410103	Feb 04, 2031	DS	DP	U-3348	
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT							
N 212888	002	11389448	Apr 13, 2032		DP		
		12178815	Jul 18, 2038			U-3348	
		8410103	Feb 04, 2031	DS	DP	U-3348	
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	001	11098015	Jan 15, 2030			U-1220	
		11098015	Jan 15, 2030			U-1480	
		11098015	Jan 15, 2030			U-2488	
		11098015	Jan 15, 2030			U-3225	
		11098015	Jan 15, 2030			U-4131	
		11098015	Jan 15, 2030			U-4156	
		12128039	Feb 10, 2032		DP	U-1220	
		12128039	Feb 10, 2032		DP	U-1480	
		12128039	Feb 10, 2032		DP	U-2488	
		12128039	Feb 10, 2032		DP	U-3225	
		12128039	Feb 10, 2032		DP	U-4131	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	12128039	Feb 10, 2032	DP U-4156			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 208418 004	10130646	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 208418 005	10130646	Jul 25, 2037	DP			
CANAGLIFLOZIN - INVOKANA						
N 204042 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN - INVOKANA						
N 204042 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	002					NPP	Dec 18, 2027
						PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	003					NPP	Dec 18, 2027
						PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	004					NPP	Dec 18, 2027
						PED	Jun 18, 2028
CANTHARIDIN - YCANTH							
N 212905	001	12233042	Aug 22, 2038	DP U-3663			
		12290651	Feb 19, 2041	DP			
CAPIVASERTIB - TRUQAP							
N 218197	001	12252495	Oct 10, 2028	U-3762			
CAPIVASERTIB - TRUQAP							
N 218197	002	12252495	Oct 10, 2028	U-3762			
CAPMATINIB HYDROCHLORIDE - TABRECTA							
N 213591	001	10596178	Jul 22, 2035	DP			
		12208101	Jul 22, 2035	DP			
CAPMATINIB HYDROCHLORIDE - TABRECTA							
N 213591	002	10596178	Jul 22, 2035	DP			
		12208101	Jul 22, 2035	DP			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	001	12194150	Dec 21, 2041	U-219			
		12201596	Dec 21, 2041	U-1649			
		12201596	Dec 21, 2041	U-4004			
		12201596	Dec 21, 2041	U-4005			
		12263148	Dec 21, 2041	U-1649			
		12263148	Dec 21, 2041	U-219			
		12263148	Dec 21, 2041	U-4004			
		12263148	Dec 21, 2041	U-4005			
		12263149	Dec 21, 2041	U-1649			
		12263149	Dec 21, 2041	U-219			
		12263149	Dec 21, 2041	U-4004			
		12263149	Dec 21, 2041	U-4005			
		12274793	Oct 07, 2034	DP			
		12295931	Dec 21, 2041	U-1649			
		12295931	Dec 21, 2041	U-219			
		12295931	Dec 21, 2041	U-4004			
		12295931	Dec 21, 2041	U-4005			
		12303481	Dec 21, 2041	U-1649			
		12303481	Dec 21, 2041	U-219			
		12303481	Dec 21, 2041	U-4004			
		12303481	Dec 21, 2041	U-4005			
		12303482	Dec 21, 2041	U-1649			
		12303482	Dec 21, 2041	U-219			
		12303482	Dec 21, 2041	U-4004			
		12303482	Dec 21, 2041	U-4005			
		12303605	Oct 07, 2034	DP			
		12370163	Dec 21, 2041	U-1649			
		12370163	Dec 21, 2041	U-219			
		12370163	Dec 21, 2041	U-4004			
		12370163	Dec 21, 2041	U-4005			
	>A>	12403099	Oct 07, 2034	DP			

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 002	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	>A> 12403099	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	>A> 12403099	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT								
N 217186 004		12194150	Dec 21, 2041		U-219			
		12201596	Dec 21, 2041		U-1649			
		12201596	Dec 21, 2041		U-4004			
		12201596	Dec 21, 2041		U-4005			
		12263148	Dec 21, 2041		U-1649			
		12263148	Dec 21, 2041		U-219			
		12263148	Dec 21, 2041		U-4004			
		12263148	Dec 21, 2041		U-4005			
		12263149	Dec 21, 2041		U-1649			
		12263149	Dec 21, 2041		U-219			
		12263149	Dec 21, 2041		U-4004			
		12263149	Dec 21, 2041		U-4005			
		12274793	Oct 07, 2034		DP			
		12295931	Dec 21, 2041		U-1649			
		12295931	Dec 21, 2041		U-219			
		12295931	Dec 21, 2041		U-4004			
		12295931	Dec 21, 2041		U-4005			
		12303481	Dec 21, 2041		U-1649			
		12303481	Dec 21, 2041		U-219			
		12303481	Dec 21, 2041		U-4004			
		12303481	Dec 21, 2041		U-4005			
		12303482	Dec 21, 2041		U-1649			
		12303482	Dec 21, 2041		U-219			
		12303482	Dec 21, 2041		U-4004			
		12303482	Dec 21, 2041		U-4005			
		12303605	Oct 07, 2034		DP			
		12370163	Dec 21, 2041		U-1649			
		12370163	Dec 21, 2041		U-219			
		12370163	Dec 21, 2041		U-4004			
		12370163	Dec 21, 2041		U-4005			
	>A>	12403099	Oct 07, 2034		DP			
CARBOPLATIN - KYXATA								
N 219921 001	>A>	12427104	Apr 01, 2045		DP			
CARBOPLATIN - KYXATA								
N 219921 002	>A>	12427104	Apr 01, 2045		DP			
CARBOPLATIN - KYXATA								
N 219921 003	>A>	12427104	Apr 01, 2045		DP			
CARFILZOMIB - KYPROLIS								
N 202714 001		7417042	Jul 20, 2026	DS	DP		M-14	May 22, 2028
		7417042*PED	Jan 20, 2027				PED	Nov 22, 2028
		7737112	Dec 07, 2027		DP			
		7737112*PED	Jun 07, 2028					
		9493582	Feb 27, 2033		DP			
		9493582*PED	Aug 27, 2033					
		RE47954	Oct 21, 2029		U-3449			
		RE47954*PED	Apr 21, 2030					
CARFILZOMIB - KYPROLIS								
N 202714 002		7417042	Jul 20, 2026	DS	DP		M-14	May 22, 2028
		7417042*PED	Jan 20, 2027				PED	Nov 22, 2028
		7737112	Dec 07, 2027		DP			
		7737112*PED	Jun 07, 2028					
		9493582	Feb 27, 2033		DP			
		9493582*PED	Aug 27, 2033					
		RE47954	Oct 21, 2029		U-3449			
		RE47954*PED	Apr 21, 2030					
CARFILZOMIB - KYPROLIS								
N 202714 003		7417042	Jul 20, 2026	DS	DP		M-14	May 22, 2028
		7417042*PED	Jan 20, 2027				PED	Nov 22, 2028
		7737112	Dec 07, 2027		DP			
		7737112*PED	Jun 07, 2028					

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARFILZOMIB - KYPROLIS						
N 202714 003	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CASIMERSEN - AMONDYS 45						
N 213026 001	RE48960	Feb 16, 2029	DS DP U-3087			
	RE48960	Feb 16, 2029	DS DP U-3088			
CEDAZURIDINE; DECITABINE - INQOVI						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041	U-2865			
	12239653	Feb 24, 2041	U-2866			
CERITINIB - ZYKADIA						
N 211225 001	12357630	Dec 13, 2037	U-3096			
CHENODIOL - CTEXLI						
N 219488 001					NP	Feb 21, 2028
CHLOROPROCAINE HYDROCHLORIDE - IHEEZO						
N 216227 001	11969403	May 14, 2039	DP			
CLASCOTERONE - WINLEVI						
N 213433 001	12337002	Jul 24, 2028	DP U-3280			
	8865690	Dec 27, 2025	U-2942			
CLINDAMYCIN PHOSPHATE - XACIATO						
N 215650 001	12303563	Sep 22, 2036	DP			
COBICISTAT - TYBOST						
N 203094 002	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8148374	Sep 03, 2029	DS DP U-4162			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-4162			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
COLCHICINE - GLOPERBA						
N 210942 001	12274751	Nov 22, 2036	U-2814			
COLCHICINE - LODOCO						
N 215727 001	12233035	Nov 01, 2033	U-4132			
	12280025	Nov 01, 2033	U-4168			
	12364675	Nov 01, 2033	U-3639			
COPPER - MIUDELLA						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COPPER - MIUDELLA						
N 218201 001	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
COPPER CU-64 DOTATATE - DETECTNET						
N 213227 001	10383961	Jul 02, 2033	U-2951			
CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
CORTICOTROPIN - ACTHAR GEL						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
CORTICOTROPIN - PURIFIED CORTROPHIN GEL						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
	12324787	Oct 27, 2043	DP			
CRINECERFONT - CRENESSITY						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
CRINECERFONT - CRENESSITY						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRINECERFONT - CRENESSITY									
N 218808 002		10905690	Jan 21, 2035		U-4049			NCE	Dec 13, 2029
		11311544	Jan 21, 2035		U-4049				
		11730739	Jan 21, 2035		U-4049				
		12128033	Jun 09, 2041	DS	U-4049				
CRINECERFONT - CRENESSITY									
N 218808 003		10905690	Jan 21, 2035		U-4049			NCE	Dec 13, 2029
		11311544	Jan 21, 2035		U-4049				
		11730739	Jan 21, 2035		U-4049				
		12128033	Jun 09, 2041	DS	U-4049				
CRINECERFONT - CRENESSITY									
N 218820 001		10905690	Jan 21, 2035		U-4049			NCE	Dec 13, 2029
		11311544	Jan 21, 2035		U-4049				
		11730739	Jan 21, 2035		U-4049				
		12128033	Jun 09, 2041	DS	U-4049				
CYCLOBENZAPRINE HYDROCHLORIDE - TONMYA									
N 219428 001	>A>	10117936	Mar 14, 2034		DP		>A>	NP	Aug 15, 2028
	>A>	10864175	Mar 14, 2034		DP				
	>A>	9636408	Mar 14, 2034		DP				
	>A>	9956188	Mar 14, 2034		DP				
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE									
N 212501 001		12329767	Feb 15, 2036		DP				
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE									
N 212501 002		12329767	Feb 15, 2036		DP				
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE									
N 212501 003		12329767	Feb 15, 2036		DP				
CYCLOSPORINE - RESTASIS MULTIDOSE									
N 050790 002		8292129	Feb 25, 2031		DP	Y			
		8561859	Apr 16, 2032		DP	Y			
		9669974	May 11, 2034		DP	Y			
		9676525	Feb 07, 2034		DP	Y			
DACOMITINIB - VIZIMPRO									
N 211288 001		7772243	May 05, 2028	DS	DP				
DACOMITINIB - VIZIMPRO									
N 211288 002		7772243	May 05, 2028	DS	DP				
DACOMITINIB - VIZIMPRO									
N 211288 003		7772243	May 05, 2028	DS	DP				
DAPAGLIFLOZIN - FARXIGA									
N 202293 002		12213988	Apr 01, 2041		U-4140				
	>A>	12409186	Apr 01, 2041		U-4140				
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ									
N 214985 001								M-200	Sep 30, 2027
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ									
N 214985 002								M-200	Sep 30, 2027
DAROLUTAMIDE - NUBEQA									
N 212099 001		10835515	Jan 28, 2036		DP U-2605			I-971	Jun 03, 2028
		10835515	Jan 28, 2036		DP U-4208				
		10835515	Jan 28, 2036		DP U-4209				
		10835515	Jan 28, 2036		DP U-4210				
		12329742	May 14, 2042		DP				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAROLUTAMIDE - NUBEQA						
N 212099 001	8975254	Mar 25, 2033	DS DP U-4208			
	8975254	Mar 25, 2033	DS DP U-4209			
	8975254	Mar 25, 2033	DS DP U-4210			
	9657003	Oct 27, 2030	DS DP U-4208			
	9657003	Oct 27, 2030	DS DP U-4209			
	9657003	Oct 27, 2030	DS DP U-4210			
DELGOCITINIB - ANZUPGO						
N 219155 001	8609647	Sep 19, 2031	DS DP U-4237		NCE	Jul 23, 2030
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	12161653	Feb 17, 2032	U-1940			
DEURUXOLITINIB PHOSPHATE - LEQSELVI						
N 217900 001	12247034	May 10, 2044	DS DP			
	12285432	Aug 11, 2042	U-3976			
	12364699	Oct 10, 2044	U-3976			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
	RE50453	May 01, 2027	DS DP			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4218			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK							
N 218730	002	7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-4090			
		8354427	Jul 06, 2026	U-4091			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-4082			
		8598181	May 01, 2027	U-4090			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-4084			
		8754224	Dec 28, 2026	DS DP			
		8865902	May 17, 2032	DS DP			
		9012496	Jul 15, 2033	U-4097			
		9181192	May 17, 2032	DS DP U-4094			
		9512079	May 17, 2032	DS DP U-4098			
		9670163	Dec 28, 2026	DP U-4080			
		9931334	Dec 28, 2026	DP U-4080			
		9974781	Apr 09, 2027	DP U-4082			
		RE50453	May 01, 2027	DS DP			
DEXAMETHASONE - DEXTENZA							
N 208742	001					NPP	Apr 07, 2028
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI							
N 215390	001	12364683	Jan 12, 2043	U-4029			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI							
N 215390	002	12364683	Jan 12, 2043	U-4029			
DIAZEPAM - VALTOCO							
N 211635	001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
		12324852	Oct 16, 2032	U-4173			
		12337061	Jun 13, 2032	U-4173			
		8927497	Jul 21, 2025	DP U-4173			
DIAZEPAM - VALTOCO							
N 211635	002	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
		12324852	Oct 16, 2032	U-4173			
		12337061	Jun 13, 2032	U-4173			
		8927497	Jul 21, 2025	DP U-4173			
DIAZEPAM - VALTOCO							
N 211635	003	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
		12324852	Oct 16, 2032	U-4173			
		12337061	Jun 13, 2032	U-4173			
		8927497	Jul 21, 2025	DP U-4173			
DIAZOXIDE CHOLINE - VYKAT XR							
N 216665	001	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
		12343348	Nov 12, 2035	U-4211			
	>A>	12419895	Nov 12, 2035	U-4275			
		7572789	Dec 20, 2026	DS DP			
		7799777	Mar 05, 2029	DS			
		9757384	Nov 12, 2035	U-4167			
DIAZOXIDE CHOLINE - VYKAT XR							
N 216665	002	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
		12343348	Nov 12, 2035	U-4211			
	>A>	12419895	Nov 12, 2035	U-4275			
		7572789	Dec 20, 2026	DS DP			
		7799777	Mar 05, 2029	DS			
		9757384	Nov 12, 2035	U-4167			
DIAZOXIDE CHOLINE - VYKAT XR							
N 216665	003	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
		12343348	Nov 12, 2035	U-4211			
	>A>	12419895	Nov 12, 2035	U-4275			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIAZOXIDE CHOLINE - VYKAT XR									
N 216665	003		7572789	Dec 20, 2026	DS	DP			
			7799777	Mar 05, 2029	DS				
			9757384	Nov 12, 2035		U-4167			
DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)									
N 215400	001		10532049	Feb 26, 2039		DP			
			11304942	Feb 26, 2039		DP			
			11819501	Feb 26, 2039		U-4188			
			11819501	Feb 26, 2039		U-848			
DIHYDROERGOTAMINE MESYLATE - ATZUMI									
N 217901	001		10758532	Dec 11, 2039		DP		NP	Apr 30, 2028
			10792253	Aug 04, 2037		DP			
			11744967	Oct 12, 2041		DP			
			11872314	Aug 04, 2037		DP			
			12102754	Oct 12, 2041		DP			
			12263162	Dec 11, 2039		DP			
DIROXIMEL FUMARATE - VUMERITY									
N 211855	001		8669281	Oct 29, 2033	DS	DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY									
N 212304	001		12161767	Dec 30, 2036	DS	DP	U-3334		
			12168075	Dec 30, 2036			U-3334		
DONEPEZIL HYDROCHLORIDE - ADLARITY									
N 212304	002		12161767	Dec 30, 2036	DS	DP	U-3334		
			12168075	Dec 30, 2036			U-3334		
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE									
A 208328	001							PC	Jul 15, 2025
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE									
A 208328	002							PC	Jul 15, 2025
DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)									
N 219407	001	>A>	10294477	May 01, 2035	DS	DP	U-3010		
		>A>	9127276	May 01, 2034	DS				
		>A>	9181549	May 01, 2034	DS				
		>A>	9315811	Oct 21, 2032		U-3010			
		>A>	9670492	Aug 28, 2034	DS				
DORDAVIPRONE HYDROCHLORIDE - MODEYSO									
N 219876	001		10172862	Jan 30, 2037		U-4254	>A>	NCE	Aug 06, 2030
			10369154	Jan 30, 2037		U-4254			
			11976068	Mar 01, 2036		DP			
			12102639	Jan 30, 2037		U-4254			
			9265765	Jul 26, 2034		DP			
			9629842	Apr 30, 2032		U-4254			
			RE46290	Apr 30, 2032		U-4254			
DOXERCALCIFEROL - HECTOROL									
N 020862	001							M-14	Jun 11, 2028
DOXERCALCIFEROL - HECTOROL									
N 020862	002							M-14	Jun 11, 2028
DOXERCALCIFEROL - HECTOROL									
N 020862	003							M-14	Jun 11, 2028
DROSPIRENONE - SLYND									
N 211367	001		12280151	Jun 28, 2031		DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ESTETROL - NEXTSTELLIS						
N 214154 001	12233074	Feb 09, 2043	DP U-3152			
	7732430	Jan 15, 2028	DP U-3152			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 001	12171742	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 002	12171742	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 003	12171742	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 004	12171742	Apr 13, 2037	DP			
DUVELISIB - COPIKTRA						
N 211155 001	12213983	Apr 26, 2035	U-2412			
DUVELISIB - COPIKTRA						
N 211155 002	12213983	Apr 26, 2035	U-2412			
EDARAVONE - RADICAVA ORS						
N 215446 001	12194025	Nov 12, 2041	U-4111			
	12285409	Nov 01, 2039	DP			
	12310946	Nov 12, 2041	U-4111			
ELACESTRANT HYDROCHLORIDE - ORSERDU						
N 217639 001	11819480	Feb 28, 2037	U-3523			
ELACESTRANT HYDROCHLORIDE - ORSERDU						
N 217639 002	11819480	Feb 28, 2037	U-3523			
ELAFIBRANOR - IQIRVO						
N 218860 001	12233038	Mar 30, 2037	U-1854			
	12295927	Mar 30, 2037	U-1854			
	12295928	Mar 30, 2037	U-1854			
	12310935	Mar 30, 2037	U-1854			
ELAMIPRETIDE HYDROCHLORIDE - FORZINITY						
N 215244 001					>A> NCE	Sep 19, 2030
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4221			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	RE50453	May 01, 2027	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4222			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	RE50453	May 01, 2027	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	RE50453	May 01, 2027	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	12350262	Jul 17, 2038	U-4220			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	RE50453	May 01, 2027	DS DP			
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 001					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 002					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 003					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 004					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 216620 001					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 216620 002					PC	Nov 09, 2025
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	11813275	Apr 03, 2034	U-3759			
	11813275	Apr 03, 2034	U-3760			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4171			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4171			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 001	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 002	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 003	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 004	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 001	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	004	12263153	Apr 03, 2034	U-4154			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY							
N 208351	001	7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE							
A 208452	001					PC	Nov 23, 2025
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	001	7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	002	7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
ENCORAFENIB - BRAFTOVI							
N 210496	001					I-957	Dec 20, 2027
ENCORAFENIB - BRAFTOVI							
N 210496	002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
		10005761	Aug 27, 2030	U-2802			
		10005761	Aug 27, 2030	U-2803			
		10005761	Aug 27, 2030	U-3738			
		10005761	Aug 27, 2030	U-4051			
		10258622	Nov 21, 2032	U-2802			
		10258622	Nov 21, 2032	U-4051			
		8541575	Feb 26, 2030	DS DP U-2335			
		8541575	Feb 26, 2030	DS DP U-2802			
		8541575	Feb 26, 2030	DS DP U-2803			
		8541575	Feb 26, 2030	DS DP U-3738			
		8541575	Feb 26, 2030	DS DP U-4051			
		9314464	Jul 04, 2031	U-2336			
		9314464	Jul 04, 2031	U-2802			
		9314464	Jul 04, 2031	U-2803			
		9314464	Jul 04, 2031	U-3738			
		9314464	Jul 04, 2031	U-4051			
		9474754	Aug 05, 2033	U-2802			
		9474754	Aug 05, 2033	U-4051			
		9850230	Aug 27, 2030	U-2334			
		9850230	Aug 27, 2030	U-2802			
		9850230	Aug 27, 2030	U-2803			
		9850230	Aug 27, 2030	U-3738			
		9850230	Aug 27, 2030	U-4051			
ENSARTINIB HYDROCHLORIDE - ENSACOVE							
N 218171	001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
		8551995	Feb 09, 2029	DS			
		9126947	Nov 29, 2031	DS			
		9296724	Jun 18, 2029	DS U-4099			
ENSARTINIB HYDROCHLORIDE - ENSACOVE							
N 218171	002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
		8551995	Feb 09, 2029	DS			
		9126947	Nov 29, 2031	DS			
		9296724	Jun 18, 2029	DS U-4099			
ENSIFENTRINE - OHTUVAYRE							
N 217389	001	12251384	Jun 25, 2044	DP			
	>A>	12409180	Feb 20, 2043	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENTRECTINIB - ROZLYTREK						
N 212725 001	8299057	Mar 10, 2032	DS DP			
ENTRECTINIB - ROZLYTREK						
N 212725 002	8299057	Mar 10, 2032	DS DP			
ENTRECTINIB - ROZLYTREK						
N 218550 001					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
ENZALUTAMIDE - XTANDI						
N 203415 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
ENZALUTAMIDE - XTANDI						
N 213674 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
ENZALUTAMIDE - XTANDI						
N 213674 002	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
A 218271 001					PC	Feb 21, 2026
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
A 218271 002					PC	Feb 21, 2026
EPINEPHRINE - EPINEPHRINE						
A 213708 001					PC	Jun 03, 2025
EPINEPHRINE - EPINEPHRINE						
A 219239 001					CGT	Sep 03, 2025
EPINEPHRINE - ADRENALIN						
N 204200 001	12280024	Mar 13, 2035	DP			
EPINEPHRINE - ADRENALIN						
N 204640 001	12280024	Mar 13, 2035	DP			
EPINEPHRINE - NEFFY						
N 214697 001	12324838	Feb 06, 2039	DP			
EPINEPHRINE - NEFFY						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039	U-3979			
	11173209	Feb 06, 2038	U-3979			
	11191838	Feb 06, 2039	DP U-3979			
	11717571	Feb 06, 2039	U-3979			
	11744895	Feb 06, 2039	U-3979			
	11918655	Feb 06, 2039	U-3979			
	12324838	Feb 06, 2039	DP			
EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)						
N 217388 001	8101743	Apr 01, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 001					PC	Nov 02, 2025
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 002					PC	Nov 02, 2025
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 003					PC	Nov 02, 2025
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 004					PC	Nov 02, 2025
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	12325714	Sep 27, 2033	DS DP			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV						
N 218718 001	12178824	Jun 24, 2041	DP			
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA						
N 209627 001	12303518	Jun 21, 2039	DP			
ETRASIMOD ARGININE - VELSIPITY						
N 216956 001	12377071	Jan 06, 2036	U-4255			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	7612109	Feb 05, 2026	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	7612109	Feb 05, 2026	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	7612109	Feb 05, 2026	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	7612109	Feb 05, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FINERENONE - KERENDIA							
N 215341	001					I-970	Jul 11, 2028
FINERENONE - KERENDIA							
N 215341	002					I-970	Jul 11, 2028
FINERENONE - KERENDIA							
N 215341	003	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
		RE49826	Jul 29, 2035	DS		NS	Jul 11, 2028
FISH OIL TRIGLYCERIDES - OMEGAVEN							
N 210589	001	9566260	Jul 30, 2026	DP U-2366			
FISH OIL TRIGLYCERIDES - OMEGAVEN							
N 210589	002	9566260	Jul 30, 2026	DP U-2366			
FITUSIRAN SODIUM - QFITLIA							
N 219019	001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
		9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
		9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
FITUSIRAN SODIUM - QFITLIA							
N 219019	002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
		9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
		9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
FLORBETABEN F-18 - NEURACEQ							
N 204677	001	9308284	Jul 14, 2032	DP			
FLORBETAPIR F-18 - AMYVID							
N 202008	001	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID							
N 202008	002	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID							
N 202008	003	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID							
N 202008	004	7687052	Apr 30, 2027	DS DP U-4217			
		8506929	Apr 30, 2027	DS DP U-4217			
FLOTUFOLASTAT F-18 GALLIUM - POSLUMA							
N 216023	001	12357711	Nov 22, 2038	DS			
		12377176	Nov 22, 2038	DS			
		12390540	Aug 23, 2038	DS			
FLUOCINOLONE ACETONIDE - ILUVIEN							
N 201923	001	9849027	Nov 07, 2028	DP U-4157			
		9849027	Nov 07, 2028	DP U-708			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	001 >A>	12396986	Nov 29, 2030	DP			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	002 >A>	12396986	Nov 29, 2030	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER							
N 208798	008	8714149	Feb 25, 2032	DP			
		8714149*PED	Aug 25, 2032				

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE			PATENT CODES	PATENT DELIST REQUESTED		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSCARBIDOPA; FOSLEVODOPA - VYALEV											
N 216962	001		12251365	Jun 10, 2040			U-4030			NP	Oct 16, 2027
FOSDENOPTERIN HYDROBROMIDE - NULIBRY											
N 214018	001	>A>	7504095	Apr 09, 2029		DP	U-3092				
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO											
N 210493	001		12208109	Jun 02, 2037		DP					
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO											
N 210493	002		12208109	Jun 02, 2037		DP					
FUROSEMIDE - FUROSCIX											
N 209988	001		12370168	Apr 03, 2034		DP	U-3462				
FUTIBATINIB - LYTGOBI											
N 214801	001		9108973	Feb 13, 2033	DS	DP	U-3456				
FUTIBATINIB - LYTGOBI											
N 214801	002	>A>	10434103	Mar 31, 2036	DS	DP				NCE	Sep 30, 2027
		>A>	11833151	Nov 05, 2039		DP				ODE*	Sep 30, 2029
		>A>	9108973	Feb 13, 2033	DS	DP	U-3456				
GALLIUM GA-68 GOZETOTIDE - GOZELLIX											
N 219592	001		11027031	Jul 28, 2035			U-3317				
GEMCITABINE HYDROCHLORIDE - INLEXZO											
N 219683	001	>A>	10729823	Aug 19, 2034		DP			>A>	NP	Sep 09, 2028
		>A>	12403086	Jun 28, 2030		DP					
		>A>	8679094	Apr 15, 2032		DP					
GEPIRONE HYDROCHLORIDE - EXXUA											
N 021164	001		7538116	Sep 02, 2026			U-3699				
GEPIRONE HYDROCHLORIDE - EXXUA											
N 021164	002		7538116	Sep 02, 2026			U-3699				
GEPIRONE HYDROCHLORIDE - EXXUA											
N 021164	003		7538116	Sep 02, 2026			U-3699				
GEPIRONE HYDROCHLORIDE - EXXUA											
N 021164	004		7538116	Sep 02, 2026			U-3699				
GEPOTIDACIN MESYLATE - BLUJEPA											
N 218230	001		8389524	Feb 12, 2029	DS	DP	U-4166			NCE	Mar 25, 2030
										GAIN	Mar 25, 2035
GLECAPREVIR; PIBRENTASVIR - MAVYRET											
N 209394	001		10028937	Jun 10, 2030			U-2141			I-967	Jun 10, 2028
			10028937	Jun 10, 2030			U-3237				
			10028937	Jun 10, 2030			U-4206				
			10028937*PED	Dec 10, 2030							
			10039754	Jun 10, 2030			U-2141				
			10039754	Jun 10, 2030			U-3237				
			10039754	Jun 10, 2030			U-4206				
			10039754*PED	Dec 10, 2030							
			10286029	Mar 14, 2034			U-3237				
			10286029	Mar 14, 2034			U-4206				
			10286029*PED	Sep 14, 2034							
			11484534	Mar 14, 2034			U-3237				
			11484534	Mar 14, 2034			U-4206				
			11484534*PED	Sep 14, 2034							
			8648037	Jan 19, 2032	DS	DP	U-2141				
			8648037	Jan 19, 2032	DS	DP	U-3237				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 209394	001		8648037	Jan 19, 2032	DS DP U-4206			
			8648037*PED	Jul 19, 2032				
			9586978	Nov 06, 2030	U-2141			
			9586978	Nov 06, 2030	U-3237			
			9586978	Nov 06, 2030	U-4206			
			9586978*PED	May 06, 2031				
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 215110	001		10028937	Jun 10, 2030	U-3238		I-967	Jun 10, 2028
			10028937	Jun 10, 2030	U-4206			
			10028937*PED	Dec 10, 2030				
			10039754	Jun 10, 2030	U-3238			
			10039754	Jun 10, 2030	U-4206			
			10039754*PED	Dec 10, 2030				
			10286029	Mar 14, 2034	U-3238			
			10286029	Mar 14, 2034	U-4206			
			10286029*PED	Sep 14, 2034				
			8648037	Jan 19, 2032	DS DP U-3238			
			8648037	Jan 19, 2032	DS DP U-4206			
			8648037*PED	Jul 19, 2032				
			9586978	Nov 06, 2030	U-3238			
			9586978	Nov 06, 2030	U-4206			
			9586978*PED	May 06, 2031				
GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO								
N 216903	001		12383491	Oct 25, 2038	DP			
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH								
N 214520	001		7696182	May 16, 2026	DS DP U-3774			
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH								
N 214520	002		7696182	May 16, 2026	DS DP U-3774			
HYDROCHLOROTHIAZIDE - INZIRQO								
N 219141	001		11878022	Jan 23, 2044	DP U-4138			
			11878022	Jan 23, 2044	DP U-4139			
HYDROCORTISONE - KHINDIVI								
N 218980	001		11904046	Feb 23, 2043	DP U-4216			
			12133914	Feb 23, 2043	U-4215			
HYDROXYUREA - XROMI								
N 216593	001	>A>	12409156	Dec 23, 2041	DP			
IBRUTINIB - IMBRUVICA								
N 205552	001		8476284	Dec 28, 2026	U-1650			
			8476284	Dec 28, 2026	U-1946			
			8476284*PED	Jun 28, 2027				
			8497277	Dec 28, 2026	U-1491			
			8497277	Dec 28, 2026	U-1650			
			8497277	Dec 28, 2026	U-1946			
			8497277	Dec 28, 2026	U-2241			
			8497277	Dec 28, 2026	U-2242			
			8497277	Dec 28, 2026	U-3422			
			8497277*PED	Jun 28, 2027				
			9540382	Aug 18, 2033	U-1650			
			9540382	Aug 18, 2033	U-1684			
			9540382	Aug 18, 2033	U-1946			
			9540382*PED	Feb 18, 2034				
IBRUTINIB - IMBRUVICA								
N 205552	002		8476284	Dec 28, 2026	U-1650			
			8476284	Dec 28, 2026	U-1946			
			8476284*PED	Jun 28, 2027				
			8497277	Dec 28, 2026	U-1491			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 205552	002	8497277	Dec 28, 2026	U-1650			
		8497277	Dec 28, 2026	U-1946			
		8497277	Dec 28, 2026	U-2241			
		8497277	Dec 28, 2026	U-2242			
		8497277	Dec 28, 2026	U-3422			
		8497277*PED	Jun 28, 2027				
		9540382	Aug 18, 2033	U-1491			
		9540382	Aug 18, 2033	U-1650			
		9540382	Aug 18, 2033	U-1946			
		9540382*PED	Feb 18, 2034				
IBRUTINIB - IMBRUVICA							
N 217003	001	12201690	Jun 14, 2039	DP			
		12364698	Apr 06, 2036	DP			
ICOSAPENT ETHYL - VASCEPA							
N 202057	001	12171738	Feb 09, 2030	U-4105			
ICOSAPENT ETHYL - VASCEPA							
N 202057	002	12171738	Feb 09, 2030	U-4105			
ILOPROST - AURLUMYN							
N 217933	001	>A> 12409183	Jul 18, 2044	U-4263			
		>A> 12409184	Aug 06, 2041	DP			
IMETELSTAT SODIUM - RYTELO							
N 217779	001	12171778	Jun 16, 2039	U-3956			
		>A> 9388415	Sep 09, 2026	U-3956			
		>A> 9388416	Sep 09, 2026	U-3956			
IMETELSTAT SODIUM - RYTELO							
N 217779	002	12171778	Jun 16, 2039	U-3956			
		>A> 9388415	Sep 09, 2026	U-3956			
		>A> 9388416	Sep 09, 2026	U-3956			
INCLISIRAN SODIUM - LEQVIO							
N 214012	001	10125369	Aug 18, 2034	DS DP U-4249			
		10131907	Aug 24, 2028	DS DP U-4249			
		10851377	Aug 25, 2036	U-4249			
		8106022	Dec 12, 2029	DS DP U-4249			
		8222222	Dec 29, 2027	U-4249			
		8809292	May 10, 2027	DS DP U-4249			
		8828956	Dec 04, 2028	DS DP U-4249			
		9370582	Dec 04, 2028	DS DP U-4249			
IOMEPROL - IOMERVU							
N 216016	001					NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016	002					NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016	003					NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016	004					NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016	005					NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016	006					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IOMEPROL - IOMERVU						
N 216016 007					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 008					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 009					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 010					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 011					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 012					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 013					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 001					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 002					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 003					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 004					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 005					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 006					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 007					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 008					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 009					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 010					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 011					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 012					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 013					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	8474447	Jan 17, 2030	DP	Y		
IPTACOPAN HYDROCHLORIDE - FABHALTA						
N 218276 001	10093663	Jul 14, 2034	U-3980		I-963	Mar 20, 2028
	10093663	Jul 14, 2034	U-4161			
	12285422	Aug 30, 2038	U-4181			
	12384758	May 17, 2041	U-3980			
	12384758	May 17, 2041	U-4161			
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	12364691	Jun 12, 2033	U-1848			
IRON SUCROSE - IRON SUCROSE						
A 208977 001					CGT	Feb 08, 2026
IRON SUCROSE - IRON SUCROSE						
A 212559 002					CGT	Feb 07, 2026
IRON SUCROSE - IRON SUCROSE						
A 212559 003					CGT	Feb 07, 2026
IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE						
A 214051 001					PC	Jan 11, 2025
IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE						
A 214051 002					PC	Jan 11, 2025
IVACAFTOR - KALYDECO						
N 203188 001	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Jun 21, 2028
	11564916	Aug 13, 2029	U-3530			
	11564916*PED	Feb 13, 2030				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4126			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8354427*PED	Jan 06, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 001	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4126			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4128			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2963			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2964			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 003	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)						
N 210491 001	RE50453	May 01, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	RE50453	May 01, 2027	DS DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	10076513	Dec 04, 2028	DP		U-2411	
		10076513*PED	Jun 04, 2029				
		10597384	Dec 04, 2028	DS DP		U-2777	
		10597384*PED	Jun 04, 2029				
		10646481	Aug 13, 2029	DP			
		10646481*PED	Feb 13, 2030				
		11052075	Dec 04, 2028	DP		U-3181	
		11052075*PED	Jun 04, 2029				
		11564916	Aug 13, 2029			U-3529	
		11564916*PED	Feb 13, 2030				
		12065432	Dec 04, 2028			U-3984	
		12065432*PED	Jun 04, 2029				
		7495103	May 20, 2027	DS DP			
		7495103*PED	Nov 20, 2027				
		7973038	Nov 08, 2026			U-1973	
		7973038*PED	May 08, 2027				
		8324242	Aug 05, 2027			U-1311	
		8324242	Aug 05, 2027			U-1911	
		8324242*PED	Feb 05, 2028				
		8410274	Dec 28, 2026	DP			
		8410274*PED	Jun 28, 2027				
		8507534	Sep 20, 2030	DS DP			
		8507534*PED	Mar 20, 2031				
		8653103	Dec 04, 2028	DP			
		8653103*PED	Jun 04, 2029				
		8716338	Sep 20, 2030	DP		U-1718	
		8716338	Sep 20, 2030	DP		U-1910	
		8716338*PED	Mar 20, 2031				
		8741933	Nov 08, 2026			U-1717	
		8741933	Nov 08, 2026			U-1909	
		8741933*PED	May 08, 2027				
		8754224	Dec 28, 2026	DS DP			
		8754224*PED	Jun 28, 2027				
		8846718	Jul 02, 2029			U-1717	
		8846718	Jul 02, 2029			U-1908	
		8846718*PED	Jan 02, 2030				
		8993600	Dec 11, 2030	DP			
		8993600*PED	Jun 11, 2031				
		9150552	Dec 04, 2028			U-1908	
		9150552*PED	Jun 04, 2029				
		9192606	Sep 29, 2029	DP		U-1912	
		9192606*PED	Mar 29, 2030				
		9216969	Nov 08, 2026	DS DP			
		9216969*PED	May 08, 2027				
		9670163	Dec 28, 2026	DP		U-1911	
		9670163*PED	Jun 28, 2027				
		9931334	Dec 28, 2026	DP		U-2276	
		9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	10597384	Dec 04, 2028	DS DP		U-2777	
		10597384*PED	Jun 04, 2029				
		10646481	Aug 13, 2029	DP			
		10646481*PED	Feb 13, 2030				
		11052075	Dec 04, 2028	DP		U-3181	
		11052075*PED	Jun 04, 2029				
		11564916	Aug 13, 2029			U-3529	
		11564916*PED	Feb 13, 2030				
		12065432	Dec 04, 2028			U-3984	
		12065432*PED	Jun 04, 2029				
		7495103	May 20, 2027	DS DP			
		7495103*PED	Nov 20, 2027				
		7973038	Nov 08, 2026			U-1973	
		7973038*PED	May 08, 2027				
		8324242	Aug 05, 2027			U-1911	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	003	8741933*PED	May 08, 2027				
		8754224	Dec 28, 2026	DS DP			
		8754224*PED	Jun 28, 2027				
		8846718	Jul 02, 2029	U-3427			
		8846718*PED	Jan 02, 2030				
		8993600	Dec 11, 2030	DP			
		8993600*PED	Jun 11, 2031				
		9150552	Dec 04, 2028	U-3427			
		9150552*PED	Jun 04, 2029				
		9192606	Sep 29, 2029	DP U-3428			
		9192606*PED	Mar 29, 2030				
		9216969	Nov 08, 2026	DP			
		9216969*PED	May 08, 2027				
		9670163	Dec 28, 2026	DP U-3429			
		9670163*PED	Jun 28, 2027				
		9931334	Dec 28, 2026	DP U-3429			
		9931334*PED	Jun 28, 2027				
IVERMECTIN - IVERMECTIN							
A 215922	002					CGT	Oct 01, 2025
LACTULOSE - LACTULOSE							
A 217914	001					CGT	Sep 13, 2025
LACTULOSE - LACTULOSE							
A 217914	002					CGT	Sep 13, 2025
LAMOTRIGINE - LAMICTAL XR							
N 022115	001	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	002	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	003	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	004	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	005	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115	006	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - SUBVENITE							
N 218879	001	>A> 11596634	May 29, 2040	U-4271			
		>A> 11596634	May 29, 2040	U-4272			
		>A> 11596634	May 29, 2040	U-4273			
		>A> 11612566	May 29, 2040	U-4271			
		>A> 11612566	May 29, 2040	U-4272			
		>A> 11612566	May 29, 2040	U-4273			
LANDIOLOL HYDROCHLORIDE - RAPIBLYK							
N 217202	001	10722516	Apr 25, 2034	U-4235			
LAROTRECTINIB SULFATE - VITRAKVI							
N 210861	001	11337967	May 16, 2037	U-4123			
		11974998	May 16, 2037	U-4124			
LAROTRECTINIB SULFATE - VITRAKVI							
N 210861	002	11337967	May 16, 2037	U-4123			
		11974998	May 16, 2037	U-4124			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI								
N 210861	002		11337967	May 16, 2037	U-4123			
			11974998	May 16, 2037	U-4124			
LAROTRECTINIB SULFATE - VITRAKVI								
N 211710	001		11337967	May 16, 2037	U-4123			
			11974998	May 16, 2037	U-4124			
LASMIDITAN SUCCINATE - REYVOW								
N 211280	001		12257246	Jul 07, 2030	U-2718			
LASMIDITAN SUCCINATE - REYVOW								
N 211280	002		12257246	Jul 07, 2030	U-2718			
LASMIDITAN SUCCINATE - REYVOW								
N 211280	003		12257246	Jul 07, 2030	U-2718			
LAZERTINIB MESYLATE - LAZCLUZE								
N 219008	001		12138351	Apr 13, 2041	DP			
LAZERTINIB MESYLATE - LAZCLUZE								
N 219008	002		12138351	Apr 13, 2041	DP			
LEFAMULIN ACETATE - XENLETA								
N 211672	001		8071643	Mar 25, 2033	DS DP			
LEFAMULIN ACETATE - XENLETA								
N 211673	001		12121582	Jun 14, 2036	DP			
			8071643	Mar 25, 2033	DS DP			
LENACAPAVIR SODIUM - YEZTUGO								
N 220018	001		10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
			11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
			11807625	Nov 25, 2040	U-4190			
			9951043	Feb 28, 2034	DS DP U-4190			
LENACAPAVIR SODIUM - YEZTUGO								
N 220020	001		10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
			11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
			9951043	Feb 28, 2034	DS DP U-4190			
LENVATINIB MESYLATE - LENVIMA								
N 206947	001		12083112	Mar 03, 2036	U-3996			
			12083112	Mar 03, 2036	U-3997			
			12083112*PED	Sep 03, 2036				
			12226409	May 15, 2038	U-4146			
			12226409*PED	Nov 15, 2038				
LENVATINIB MESYLATE - LENVIMA								
N 206947	002		12083112	Mar 03, 2036	U-3996			
			12083112	Mar 03, 2036	U-3997			
			12083112*PED	Sep 03, 2036				
			12226409	May 15, 2038	U-4146			
			12226409*PED	Nov 15, 2038				
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)								
N 209935	001	>A>	12419894	Apr 14, 2036	DP			
LEUPROLIDE ACETATE - ELIGARD KIT								
N 021343	001	>A>	12397120	Dec 22, 2041	U-4001			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021379 001	>A>	12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021488 001	>A>	12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021731 001	>A>	12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - FENSOLVI KIT							
N 213150 001	>A>	12397120	Dec 22, 2041	U-3611			
LEUPROLIDE MESYLATE - CAMCEVI ETM							
N 219745 001						>A> NS	Aug 25, 2028
LEVACETYLLEUCINE - AQNEURSA							
N 219132 001	>A>	11400067	Apr 19, 2037	U-4170			
LEVOKETOCONAZOLE - RECORLEV							
N 214133 001		12377096	Mar 02, 2040	U-4236		NCE*	Dec 30, 2026
		9918984	May 03, 2028	U-3283			
LINAGLIPTIN - TRADJENTA							
N 201280 001		12178819	May 04, 2027	DP			
		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 001		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 002		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 003		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026 001		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR							
N 208026 002		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
LIRAGLUTIDE - LIRAGLUTIDE							
A 214568 001						>A> PC	Feb 24, 2026
LISDEXAMFETAMINE DIMESYLATE - ARYNTA							
N 219847 001		11576878	Aug 30, 2040	DP			
	>A>	12433859	Apr 16, 2040	DP U-842			
LISINOPRIL - QBRELIS							
N 208401 001		12186360	Nov 06, 2035	DP			
	>A>	12433931	Nov 06, 2035	U-1723			
	>A>	12433931	Nov 06, 2035	U-1864			
	>A>	12433931	Nov 06, 2035	U-3			
LONAFARNIB - ZOKINVY							
N 213969 001		7838531	Jul 26, 2029	U-3070			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LONAFARNIB - ZOKINVY							
N 213969 002		7838531	Jul 26, 2029	U-3070			
LOSARTAN POTASSIUM - ARBLI							
N 218772 001		11890273	Oct 07, 2041	DP			
		12156869	Oct 07, 2041	DP U-4158			
		12156869	Oct 07, 2041	DP U-4159			
		12156869	Oct 07, 2041	DP U-4160			
LOTILANER - XDEMVY							
N 217603 001		12171750	Dec 14, 2038	U-3674			
		12213964	Dec 14, 2038	DP			
		12364685	Dec 14, 2038	DP			
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500 001		11753419	Dec 10, 2040	DP	Y		
	>A>	12409176	Mar 15, 2039	U-4261			
	>A>	12410195	Dec 10, 2040	DP			
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500 002		11753419	Dec 10, 2040	DP	Y		
	>A>	12409176	Mar 15, 2039	U-4261			
	>A>	12410195	Dec 10, 2040	DP			
		RE48825	Mar 12, 2029	DS			
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500 003		11753419	Dec 10, 2040	DP	Y		
	>A>	12409176	Mar 15, 2039	U-4261			
	>A>	12410195	Dec 10, 2040	DP			
		RE48825	Mar 12, 2029	DS			
LURBINECTEDIN - ZEPZELCA							
N 213702 001		12324806	May 29, 2040	U-4212			
LUTETIUM LU 177 DOTATATE - LUTATHERA							
N 208700 001	>A>	12415003	Jul 25, 2038	U-4036			
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO							
N 215833 001		10406240	Aug 15, 2028	DS DP U-4169		I-965	Mar 28, 2028
		11318121	Aug 15, 2028	DS DP U-4169			
		11951190	Nov 12, 2035	U-4169			
		12208102	Sep 18, 2041	U-4169			
MACITENTAN - OPSUMIT							
N 204410 001		10946015	Sep 11, 2026	DP U-1445		M-187	Feb 28, 2028
		10946015*PED	Mar 11, 2027			PED	Aug 28, 2028
		7094781	Dec 05, 2025	DS DP			
		7094781*PED	Jun 05, 2026				
		8268847	Apr 18, 2029	U-1446			
		8268847*PED	Oct 18, 2029				
		8367685	Oct 04, 2028	DP U-1445			
		8367685*PED	Apr 04, 2029				
		9265762	May 29, 2027	DP U-1820			
		9265762*PED	Nov 29, 2027				
MACITENTAN; TADALAFIL - OPSYNVI							
N 218490 001		10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
		10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
		7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
		7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
		8268847	Apr 18, 2029	DP U-3882			
		8268847*PED	Oct 18, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MACITENTAN; TADALAFIL - OPSYNVI								
N 218490	002	10946015	Sep 11, 2026		DP U-3881		NP	Mar 22, 2027
		10946015*PED	Mar 11, 2027				ODE-475	Mar 22, 2031
		7094781	Dec 05, 2025	DS	DP		PED	Sep 22, 2027
		7094781*PED	Jun 05, 2026				PED	Sep 22, 2031
		8268847	Apr 18, 2029		DP U-3882			
		8268847*PED	Oct 18, 2029					
MAGNESIUM SULFATE - MAGNESIUM SULFATE								
A 219777	001						CGT	Feb 01, 2026
MAGNESIUM SULFATE - MAGNESIUM SULFATE								
A 219777	004						CGT	Feb 01, 2026
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE								
N 215344	001	12239659	Jun 14, 2044		U-4143			
		12290529	Aug 02, 2044		DP			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 214662	002	12350267	Oct 26, 2032		U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 219485	001	10512657	Oct 26, 2032		U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040		U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032		U-4186			
		11260053	May 26, 2031		U-4187			
		11376251	Oct 26, 2032		U-4187			
		11497745	Feb 12, 2040		U-4187			
		12296050	Oct 05, 2043		DP U-4186			
		12296050	Oct 05, 2043		DP U-4187			
		12350267	Oct 26, 2032		U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 219485	002	10512657	Oct 26, 2032		U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040		U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032		U-4186			
		11260053	May 26, 2031		U-4187			
		11376251	Oct 26, 2032		U-4187			
		11497745	Feb 12, 2040		U-4187			
		12296050	Oct 05, 2043		DP U-4186			
		12296050	Oct 05, 2043		DP U-4187			
		12350267	Oct 26, 2032		U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 219485	003	10512657	Oct 26, 2032		U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040		U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032		U-4186			
		11260053	May 26, 2031		U-4187			
		11376251	Oct 26, 2032		U-4187			
		11497745	Feb 12, 2040		U-4187			
		12296050	Oct 05, 2043		DP U-4186			
		12296050	Oct 05, 2043		DP U-4187			
		12350267	Oct 26, 2032		U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 219485	004	10512657	Oct 26, 2032		U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040		U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032		U-4186			
		11260053	May 26, 2031		U-4187			
		11376251	Oct 26, 2032		U-4187			
		11497745	Feb 12, 2040		U-4187			
		12296050	Oct 05, 2043		DP U-4186			
		12296050	Oct 05, 2043		DP U-4187			
		12350267	Oct 26, 2032		U-3973			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MARIBAVIR - LIVTENCITY						
N 215596 001	12213989	Nov 18, 2042	U-4137			
	12295940	Oct 11, 2043	DS DP			
MELOXICAM - QAMZOVA						
N 217593 001	12059423	Jul 19, 2040	DS DP			
MELOXICAM - XIFYRM						
N 218395 001	12263176	Jul 31, 2041	DP			
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			
	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			
	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			
	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			
	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO						
N 215431 001	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	12370196	Dec 29, 2041	U-1719			
	9821075	Apr 11, 2036	DP U-1719			
MERCAPTOPURINE - MERCAPTOPURINE						
A 216418 001					CGT	Aug 25, 2025
MESNA - MESNA						
A 218871 001					CGT	Jul 13, 2025
METHOCARBAMOL - ATMEKSI						
N 219843 001	12390439	Oct 09, 2044	DP U-4253			
METHOTREXATE - OTREXUP						
N 204824 001	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 002	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 003	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 004	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 005	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 006	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 007	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 008	12357642	Mar 19, 2030	DP			
METHOTREXATE SODIUM - XATMEP						
N 208400 001 >A>	12396947	Jan 02, 2033	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 001	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 002	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLNALTREXONE BROMIDE - RELISTOR									
N 021964	003		12303592	Aug 03, 2027		DP U-4197			
			12303592	Aug 03, 2027		DP U-4198			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI									
N 209388	001		12194008	Dec 22, 2029		U-2843			
			12194009	Dec 22, 2029		U-2843			
			12377064	Nov 17, 2038		U-2843			
METRONIDAZOLE - LIKMEZ									
N 216755	001		12257236	Jan 16, 2039		DP U-3169			
			12257236	Jan 16, 2039		DP U-4163			
			12257236	Jan 16, 2039		DP U-4164			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%									
N 216142	001	>A>	12403173	Dec 15, 2037		DP			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%									
N 216142	002	>A>	12403173	Dec 15, 2037		DP			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%									
N 216142	003	>A>	12403173	Dec 15, 2037		DP			
MIGALASTAT HYDROCHLORIDE - GALAFOLD									
N 208623	001		12280042	May 30, 2038	DS	U-2371			
MIGLUSTAT - OPFOLDA									
N 215211	001		12246062	Sep 16, 2038		U-3726			
MIRABEGRON - MYRBETRIQ									
N 202611	001		12059409	Sep 28, 2029		DP			
			12059409*PED	Mar 28, 2030					
			12097189	Sep 28, 2029		U-2996			
			12097189	Sep 28, 2029		U-3670			
			12097189*PED	Mar 28, 2030					
MIRABEGRON - MYRBETRIQ									
N 202611	002		12059409	Sep 28, 2029		DP			
			12059409*PED	Mar 28, 2030					
			12097189	Sep 28, 2029		U-2996			
			12097189	Sep 28, 2029		U-3670			
			12097189*PED	Mar 28, 2030					
MIRDAMETINIB - GOMEKLI									
N 219379	001		11066358	Feb 17, 2041	DS			NCE	Feb 11, 2030
			11084780	Feb 17, 2041	DS			ODE-488	Feb 11, 2032
			11453641	Feb 17, 2041		U-4130			
			11571402	Feb 17, 2041		DP			
			11806321	Feb 17, 2041		U-4130			
			11806322	Apr 09, 2043		U-4130			
			11819487	Feb 17, 2041		U-4130			
			11839595	Mar 16, 2043		U-4130			
			11883375	Mar 16, 2043		U-4130			
			12011424	Feb 17, 2041		U-4130			
			12029711	Mar 15, 2044		DP U-4130			
			12037306	Feb 17, 2041		U-4130			
			12090128	Feb 17, 2041		DP U-4130			
			12220390	Mar 16, 2043		U-4130			
			12257215	Mar 16, 2043		U-4130			
			12263146	Feb 17, 2041		U-4130			
			12295925	Feb 17, 2041		U-4130			
			12324791	Mar 16, 2043		U-4130			
			12357597	Feb 17, 2041		U-4130			
			12390430	Oct 10, 2044		U-4130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIRDAMETINIB - GOMEKLI						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12383517	Mar 15, 2044	DP U-4130			
	12390430	Oct 10, 2044	U-4130			
MIRDAMETINIB - GOMEKLI						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12383517	Mar 15, 2044	DP U-4130			
	12390430	Oct 10, 2044	U-4130			
MITOMYCIN - JELMYTO						
N 211728 001	12268745	Jan 20, 2031	U-4172			
MITOMYCIN - ZUSDURI						
N 215793 001	10039832	Jan 20, 2031	U-4256		NP	Jun 12, 2028
	9040074	Jan 20, 2031	DP U-4256			
	9950069	Jan 20, 2031	DP U-4256			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	12303635	Apr 08, 2039	DS DP			
MONOMETHYL FUMARATE - BAFIERTAM						
N 210296 001	10918615	Feb 27, 2035	DP U-1384			
	10918616	Feb 27, 2035	U-1384			
	10918617	Feb 27, 2035	DP			
	10945985	Feb 27, 2035	DP			
	11590095	Feb 27, 2035	U-1384			
MOTIXAFORTIDE ACETATE - APHEXDA						
N 217159 001	12257285	Dec 29, 2041	DP			
	12268725	Dec 29, 2041	DP			
MOXIDECTIN - MOXIDECTIN						
N 210867 001					NPP	Feb 07, 2028

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MYCOPHENOLATE MOFETIL - MYHIBBIN							
N 216482 001		12194143	Aug 16, 2039	DP U-1752			
		12226526	Aug 16, 2039	DP U-1752			
NALDEMEDINE TOSYLATE - SYMPROIC							
N 208854 001		12350377	May 13, 2033	DP			
		RE46365	Feb 24, 2031	DS DP			
NALMEFENE HYDROCHLORIDE - OPVEE							
N 217470 001		12290596	Aug 04, 2042	U-4182			
NALOXONE HYDROCHLORIDE - KLOXXADO							
N 212045 001	>A>	12414915	Aug 26, 2034	DP			
NEDOSIRAN SODIUM - RIVFLOZA							
N 215842 001						NPP	Mar 27, 2028
NEDOSIRAN SODIUM - RIVFLOZA							
N 215842 002						NPP	Mar 27, 2028
NEDOSIRAN SODIUM - RIVFLOZA							
N 215842 003						NPP	Mar 27, 2028
NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE							
A 203640 001						PC	Nov 19, 2025
NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE							
A 203640 002						PC	Nov 19, 2025
NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE							
A 203640 003						PC	Nov 19, 2025
NILOTINIB TARTRATE - DANZITEN							
N 219293 001	>A>	12403140	Feb 18, 2040	DP			
NILOTINIB TARTRATE - DANZITEN							
N 219293 002	>A>	12403140	Feb 18, 2040	DP			
NIMODIPINE - NYMALIZE							
N 203340 002		12186308	Apr 16, 2038	DP U-2804			
NIRAPARIB TOSYLATE - ZEJULA							
N 214876 001		11730725	Jan 25, 2039	DP			
NIRAPARIB TOSYLATE - ZEJULA							
N 214876 002		11730725	Jan 25, 2039	DP			
NIRAPARIB TOSYLATE - ZEJULA							
N 214876 003		11730725	Jan 25, 2039	DP			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)							
N 217188 001						D-195	Jan 31, 2028
NIROGACESTAT HYDROBROMIDE - OGSIVEO							
N 217677 001		12234210	Jul 08, 2042	DP			
		12247012	Jul 08, 2042	DP			
		12297177	Aug 09, 2039	DP			
		7795447	Aug 18, 2030	DS			
		7951958	Mar 11, 2025	DS			

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIROGACESTAT HYDROBROMIDE - OGSIVEO								
N 217677	002		12234210	Jul 08, 2042	DP			
			12247012	Jul 08, 2042	DP			
			12297177	Aug 09, 2039	DP			
			7795447	Aug 18, 2030	DS			
			7951958	Mar 11, 2025	DS			
NIROGACESTAT HYDROBROMIDE - OGSIVEO								
N 217677	003		12234210	Jul 08, 2042	DP			
			12247012	Jul 08, 2042	DP			
			12297177	Aug 09, 2039	DP			
			7795447	Aug 18, 2030	DS			
			7951958	Mar 11, 2025	DS			
NITRIC OXIDE - INOMAX								
N 020845	003	>A>	11931377	Jun 30, 2029	DS DP		U-3903	
		>A>	11931377*PED	Dec 30, 2029				
			9279794	Feb 19, 2035	DP		U-1823	
			9279794*PED	Aug 19, 2035				
NITRIC OXIDE - INOMAX								
N 020845	004	>A>	11931377	Jun 30, 2029	DS DP		U-3903	
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE								
N 214313	001		12290494	Mar 08, 2041	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE								
N 214313	002		12290494	Mar 08, 2041	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 214628	001		12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 214628	002		12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 214628	003		12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 215700	001		RE49422	Feb 26, 2035	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 215700	002		RE49422	Feb 26, 2035	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N 215700	003		10251848	Feb 26, 2035	DP			
			RE49422	Feb 26, 2035	DP			
			RE49443	Feb 26, 2035	DP			
OCTREOTIDE ACETATE - MYCAPSSA								
N 208232	001		12246054	Feb 03, 2036			U-2857	
			12251418	Feb 03, 2036			U-2857	
OCTREOTIDE ACETATE - BYNFEZIA PEN								
N 213224	001		12350475	Dec 29, 2041			U-4007	
			12350475	Dec 29, 2041			U-4008	
			12350475	Dec 29, 2041			U-4009	
ODEVIXIBAT - BYLVAY								
N 215498	001		10011633	Nov 08, 2031			U-3186	
			10011633	Nov 08, 2031			U-3648	
			10093697	Nov 08, 2031			U-3186	
			10093697	Nov 08, 2031			U-3648	
			10487111	Nov 08, 2031			U-3186	

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 001	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
ODEVIXIBAT - BYLVAY						
N 215498 002	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
ODEVIXIBAT - BYLVAY						
N 215498 004	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI								
N 213378	003	12194035	Aug 23, 2031		U-3141			
		12390474	Nov 12, 2041	DP				
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI								
N 213378	004	12194035	Aug 23, 2031		U-3141			
		12390474	Nov 12, 2041	DP				
OLAPARIB - LYNPARZA								
N 208558	001	12178816	Oct 07, 2029	DP				
OLAPARIB - LYNPARZA								
N 208558	002	12178816	Oct 07, 2029	DP				
OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)								
N 218614	001	9127276	May 01, 2034	DS			ODE-515	Dec 19, 2031
		9157082	Apr 27, 2032		U-4050			
		9163239	May 01, 2034	DS				
		9181549	May 01, 2034	DS				
		9593333	Feb 14, 2034		U-4050			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT								
N 206756	001	7396341	Oct 10, 2026	DP		Y		
		7396341*PED	Apr 10, 2027					
		7837235	Mar 13, 2028	DP		Y		
		7837235*PED	Sep 13, 2028					
		8733341	Oct 16, 2030	DP		Y		
		9027967	Mar 31, 2027	DP		Y		
OLUTASIDENIB - REZLIDHIA								
N 215814	001	12275715	Sep 18, 2035	DS	DP U-3684			
OMADACYCLINE TOSYLATE - NUZYRA								
N 209816	001	9265740	Oct 24, 2030	DP	U-1569			
OMADACYCLINE TOSYLATE - NUZYRA								
N 209817	001	9265740	Mar 05, 2029	DP				
OMAVELOXOLONE - SKYCLARYS								
N 216718	001						M-270	Dec 20, 2027
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP								
N 213593	001	12329752	Jul 16, 2039	DP				
OMIDENEPAG ISOPROPYL - OMLONTI								
N 215092	001	12290511	Dec 27, 2038		U-3454			
		12295946	Jan 08, 2035	DP	U-3454			
OSILODROSTAT PHOSPHATE - ISTURISA								
N 212801	001	10709691	Oct 12, 2035		U-2770			
		10709691	Oct 12, 2035		U-4177			
		8609862	Jan 13, 2031		U-2770			
		8609862	Jan 13, 2031		U-4177			
OSILODROSTAT PHOSPHATE - ISTURISA								
N 212801	002	10709691	Oct 12, 2035		U-2770			
		10709691	Oct 12, 2035		U-4177			
		8609862	Jan 13, 2031		U-2770			
		8609862	Jan 13, 2031		U-4177			
OXYCODONE HYDROCHLORIDE - OXYCONTIN								
N 022272	001	12246094	Aug 24, 2027	DP				
		12280152	Aug 24, 2027	DP				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE						
N 208552 001	12350255	Jun 11, 2035	U-3494			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 001	8481573	Mar 24, 2033	DS DP U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 002	8481573	Mar 24, 2033	DS DP U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 003	8481573	Mar 24, 2033	DS DP U-2774			
PALBOCICLIB - IBRANCE						
N 207103 001	>A> 10723730	Feb 08, 2034	DS DP		>A> M-14	Sep 16, 2028
	>A> 10723730*PED	Aug 08, 2034			>A> PED	Mar 16, 2029
	>A> RE47739	Mar 05, 2027	DS DP			
	>A> RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 207103 002	>A> 10723730	Feb 08, 2034	DS DP		>A> M-14	Sep 16, 2028
	>A> 10723730*PED	Aug 08, 2034			>A> PED	Mar 16, 2029
	>A> RE47739	Mar 05, 2027	DS DP			
	>A> RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 207103 003	>A> 10723730	Feb 08, 2034	DS DP		>A> M-14	Sep 16, 2028
	>A> 10723730*PED	Aug 08, 2034			>A> PED	Mar 16, 2029
	>A> RE47739	Mar 05, 2027	DS DP			
	>A> RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 212436 001	>A> 10723730	Feb 08, 2034	DS DP		>A> M-14	Sep 16, 2028
	>A> 10723730*PED	Aug 08, 2034			>A> PED	Mar 16, 2029
	>A> 11065250	Aug 19, 2036	DP			
	>A> 11065250*PED	Feb 19, 2037				
	>A> RE47739	Mar 05, 2027	DS DP			
	>A> RE47739*PED	Sep 05, 2027				

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE							
N 212436 002	>A>	10723730	Feb 08, 2034	DS DP		>A> M-14	Sep 16, 2028
	>A>	10723730*PED	Aug 08, 2034			>A> PED	Mar 16, 2029
	>A>	11065250	Aug 19, 2036	DP			
	>A>	11065250*PED	Feb 19, 2037				
	>A>	RE47739	Mar 05, 2027	DS DP			
	>A>	RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE							
N 212436 003	>A>	10723730	Feb 08, 2034	DS DP		>A> M-14	Sep 16, 2028
	>A>	10723730*PED	Aug 08, 2034			>A> PED	Mar 16, 2029
	>A>	11065250	Aug 19, 2036	DP			
	>A>	11065250*PED	Feb 19, 2037				
	>A>	RE47739	Mar 05, 2027	DS DP			
	>A>	RE47739*PED	Sep 05, 2027				
PALIPERIDONE PALMITATE - INVEGA HAFYERA							
N 207946 005		12208100	May 07, 2041	U-3359			
		12208100	May 07, 2041	U-4110			
PALIPERIDONE PALMITATE - INVEGA HAFYERA							
N 207946 006		12208100	May 07, 2041	U-3359			
		12208100	May 07, 2041	U-4110			
PALOPEGTERIPARATIDE - YORVIPATH							
N 216490 001		12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
		12403182	Nov 12, 2042	DP U-3982			
PALOPEGTERIPARATIDE - YORVIPATH							
N 216490 002		12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
		12403182	Nov 12, 2042	DP U-3982			
PALOPEGTERIPARATIDE - YORVIPATH							
N 216490 003		12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
		12403182	Nov 12, 2042	DP U-3982			
PALOVAROTENE - SOHONOS							
N 215559 001		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 002		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 003		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 004		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 005		12201614	Jun 08, 2037	U-4031			
PATISIRAN SODIUM - ONPATTRO							
N 210922 001		8168775	Aug 10, 2032	DS DP U-2378			
PEGCETACOPLAN - EMPAVELI							
N 215014 001		10875893	Nov 15, 2033	DS U-3124		I-972	Jul 28, 2028
		10875893	Nov 15, 2033	DS U-4242			
		11040107	Apr 09, 2038	DP U-3172			
		11040107	Apr 09, 2038	DP U-3173			
		11040107	Apr 09, 2038	DP U-3174			
		11040107	Apr 09, 2038	DP U-4241			
		11292815	Nov 15, 2033	DS DP U-3124			
		11292815	Nov 15, 2033	DS DP U-3354			
		11292815	Nov 15, 2033	DS DP U-4242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - EMPAVELI						
N 215014 001	11292815	Nov 15, 2033	DS DP U-4243			
	11661441	Jan 13, 2033	DS U-3124			
	11661441	Jan 13, 2033	DS U-4242			
	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
	11844841	Dec 09, 2038	DP U-4241			
	12290566	Dec 14, 2038	DP U-4174			
	12290566	Dec 14, 2038	DP U-4175			
	12290566	Dec 14, 2038	DP U-4238			
	12290566	Dec 14, 2038	DP U-4239			
	12290566	Dec 14, 2038	DP U-4240			
	9169307	Nov 18, 2027	DS U-3123			
	9169307	Nov 18, 2027	DS U-4244			
PEGULICIANINE ACETATE - LUMISIGHT						
N 214511 001	11592396	Sep 01, 2030	DS			
PEMETREXED - PEMFEXY						
N 209472 001	12115164	Feb 19, 2036	U-4246			
	12115164	Feb 19, 2036	U-4247			
	12115164	Feb 19, 2036	U-4248			
PERAMPANEL - PERAMPANEL						
A 209801 001					PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL						
A 209801 002					PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL						
A 209801 003					PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL						
A 209801 004					PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL						
A 209801 005					PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL						
A 209801 006					PC	Nov 25, 2025
PHENTOLAMINE MESYLATE - RYZUMVI						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			
	12350366	Jan 31, 2034	DP			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV						
N 203826 004	12257342	Sep 26, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV						
N 203826 005	12257342	Sep 26, 2036	DP			
PHYTONADIONE - PHYTONADIONE						
A 214966 001					CGT	Sep 06, 2025
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
PONESIMOD - PONVORY						
N 213498 001	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 002	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 003	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 004	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 005	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 006	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 007	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 008	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 009	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 010	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
N 212832 004	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
N 212832 005	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
PROGESTERONE - PROGESTERONE						
A 218391 001					>A> CGT	Mar 22, 2026
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 001					>A> M-14	Jul 10, 2028
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 002					>A> M-14	Jul 10, 2028

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE							
N 217604 001		12233166	Jun 18, 2038	DP			
RAMIPRIL - VOSTALLY							
N 219757 001		12343338	Aug 16, 2039	DP U-4233			
RELUGOLIX - ORGOVYX							
N 214621 001		12325714	Sep 27, 2033	DS DP			
		12336990	Sep 29, 2037	U-3020			
REPOTRECTINIB - AUGTYRO							
N 218213 001		12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
		12310968	Jul 20, 2036	U-3755			
REPOTRECTINIB - AUGTYRO							
N 218213 002		12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
		12310968	Jul 20, 2036	U-3755			
RESMETIROM - REZDIFFRA							
N 217785 001		12377104	Feb 04, 2045	U-3861			
RESMETIROM - REZDIFFRA							
N 217785 002		12377104	Feb 04, 2045	U-3861			
RESMETIROM - REZDIFFRA							
N 217785 003		12377104	Feb 04, 2045	U-3861			
REVEFENACIN - YUPELRI							
N 210598 001		12285417	Aug 29, 2039	U-2440			
REVUMENIB CITRATE - REVUFORJ							
N 218944 001						ODE-504	Nov 15, 2031
						ODE-505	Nov 15, 2031
REVUMENIB CITRATE - REVUFORJ							
N 218944 002						ODE-504	Nov 15, 2031
						ODE-505	Nov 15, 2031
REVUMENIB CITRATE - REVUFORJ							
N 218944 003						ODE-504	Nov 15, 2031
						ODE-505	Nov 15, 2031
RIBOCICLIB SUCCINATE - KISQALI							
N 209092 001	>A>	12419894	Apr 14, 2036	DP			
RIFAXIMIN - XIFAXAN							
N 021361 002		8309569	Jul 18, 2029	U-1707	Y		
		8309569	Jul 18, 2029	U-1708	Y		
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022 001						>A> NPP	Mar 15, 2027
						>A> PED	Sep 15, 2027
RILPIVIRINE HYDROCHLORIDE - EDURANT PED							
N 219016 001						>A> NP	Mar 15, 2027
						>A> PED	Sep 15, 2027
RILZABRUTINIB - WAYRILZ							
N 219685 001	>A>	11708370	Feb 20, 2041	DS		>A> NCE	Aug 29, 2030
	>A>	12178818	Oct 13, 2040	U-4267			
	>A>	8940744	Sep 06, 2033	DS DP U-4270			
	>A>	9266895	Sep 06, 2033	DS DP U-4268			
	>A>	9580427	Mar 01, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RILZABRUTINIB - WAYRILZ							
N 219685 001	>A>	9994576	Sep 06, 2033	DS DP U-4268			
	>A>	9994576	Sep 06, 2033	DS DP U-4269			
RIPRETINIB - QINLOCK							
N 213973 001		12213967	Dec 30, 2040	DP			
		12213968	Dec 30, 2040	DP			
		12226406	Dec 30, 2040	DP			
		12295944	Aug 12, 2040	U-4183			
		12318373	Aug 12, 2040	U-4191			
		12318374	Dec 30, 2040	DP			
RISDIPLAM - EVRYSDI							
N 213535 001		12350273	Oct 01, 2038	U-1943			
RISDIPLAM - EVRYSDI							
N 219285 001		11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
		11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
		12122789	Apr 15, 2041	DS DP			
		12350273	Oct 01, 2038	U-1943			
		9586955	Feb 08, 2033	DS DP			
		9969754	May 11, 2035	DS DP U-1943			
RISPERIDONE - UZEDY							
N 213586 001		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 002		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 003		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 004		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 005		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 006		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 007		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
ROFLUMILAST - ZORYVE							
N 215985 001		12220409	Jun 07, 2037	DP			
		12257242	Jun 07, 2037	DP			
		12310956	Jun 07, 2037	U-3748			
		12336983	Jun 07, 2037	DP			
ROFLUMILAST - ZORYVE							
N 215985 002		12220409	Jun 07, 2037	DP			
		12257242	Jun 07, 2037	DP			
		12310956	Jun 07, 2037	U-3970			
		12336983	Jun 07, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - ZORYVE						
N 217242 001	11129818	Aug 25, 2037	U-3773		I-969	May 22, 2028
	11129818	Aug 25, 2037	U-4203			
	11819496	Jun 07, 2037	U-3773			
	11819496	Jun 07, 2037	U-4203			
	11992480	Jun 07, 2037	U-3773			
	11992480	Jun 07, 2037	U-4203			
	12005051	Jun 07, 2037	U-3773			
	12005051	Jun 07, 2037	U-4203			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3773			
	12310956	Jun 07, 2037	U-4203			
	12329751	Dec 03, 2041	U-3773			
	12336983	Jun 07, 2037	DP			
	>A> 12390453	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3773			
	9907788	Jun 07, 2037	U-4203			
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	12226419	May 20, 2031	DP			
	12233067	Jul 28, 2040	U-4151			
SEBETRALSTAT - EKTERLY						
N 219301 001	10364238	Nov 26, 2035	DS DP		NCE	Jul 03, 2030
	10611758	Nov 26, 2035	U-4223			
	11001578	Nov 26, 2035	DS DP			
	11084809	Nov 26, 2035	DS DP U-4223			
	11198691	Nov 26, 2035	U-4223			
	11230537	Dec 25, 2037	DS DP			
	11234939	Jan 26, 2039	DP U-4223			
	11739068	Jun 23, 2037	U-4223			
SECNIDAZOLE - SOLOSEC						
N 209363 001	12280037	Dec 11, 2041	U-3302			
SELADELPAR LYSINE - LIVDELZI						
N 217899 001	7301050	Aug 02, 2026	DS DP			
SELINEXOR - XPOVIO						
N 212306 001	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 002	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 003	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 004	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 005	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELPERCATINIB - RETEVMO						
N 213246 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
SELPERCATINIB - RETEVMO						
N 213246 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
SELPERCATINIB - RETEVMO						
N 218160 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 003					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO							
N 218160	004					M-311	Sep 27, 2027
						M-312	Sep 27, 2027
						ODE*	May 08, 2027
						ODE*	May 08, 2027
						ODE*	May 08, 2027
						ODE*	Sep 21, 2029
						ODE*	Sep 21, 2029
						ODE*	May 29, 2031
						ODE*	May 29, 2031
						ODE*	May 29, 2031
SELUMETINIB SULFATE - KOSELUGO							
N 213756	001	12220403	Mar 26, 2029	DP			
		12318367	Mar 26, 2029	DP			
	>A>	12364684	Mar 26, 2029	U-4274			
		7425637	Mar 13, 2026	DS			
		8178693	Mar 13, 2026	DS DP			
	>A>	9562017	Dec 12, 2026	DS U-4274			
SELUMETINIB SULFATE - KOSELUGO							
N 213756	002	12220403	Mar 26, 2029	DP			
		12318367	Mar 26, 2029	DP			
	>A>	12364684	Mar 26, 2029	U-4274			
		7425637	Mar 13, 2026	DS			
		8178693	Mar 13, 2026	DS DP			
	>A>	9562017	Dec 12, 2026	DS U-4274			
SELUMETINIB SULFATE - KOSELUGO							
N 219943	001	>A> 7425637	Mar 13, 2026	DS			
		>A> 8178693	Mar 13, 2026	DS DP			
		>A> 9156795	Dec 12, 2026	DS DP			
		>A> 9562017	Dec 12, 2026	DS U-4274			
SELUMETINIB SULFATE - KOSELUGO							
N 219943	002	>A> 7425637	Mar 13, 2026	DS			
		>A> 8178693	Mar 13, 2026	DS DP			
		>A> 9156795	Dec 12, 2026	DS DP			
		>A> 9562017	Dec 12, 2026	DS U-4274			
SEMAGLUTIDE - OZEMPIC							
N 209637	001	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
		10357616	Jan 20, 2026	DP	Y		
		10376652	Jan 20, 2026	DP	Y		
		11097063	Jul 17, 2026	DP	Y		
		8684969	Oct 20, 2025	DP	Y		
		8920383	Jul 17, 2026	DP	Y		
		9108002	Jan 20, 2026	DP	Y		
		9132239	Feb 01, 2032	DP	Y		
		9457154	Sep 27, 2027	DP	Y		
		9616180	Jan 20, 2026	DP	Y		
		9687611	Feb 27, 2027	DP	Y		
		9775953	Jul 17, 2026	DP	Y		
		9861757	Jan 20, 2026	DP	Y		
		RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC							
N 209637	002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
		10357616	Jan 20, 2026	DP	Y		
		10376652	Jan 20, 2026	DP	Y		
		11097063	Jul 17, 2026	DP	Y		
		8684969	Oct 20, 2025	DP	Y		
		8920383	Jul 17, 2026	DP	Y		
		9108002	Jan 20, 2026	DP	Y		
		9132239	Feb 01, 2032	DP	Y		
		9457154	Sep 29, 2027	DP	Y		
		9616180	Jan 20, 2026	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 002	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 003	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	12295988	Oct 10, 2038	U-2628			
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - RYBELSUS						
N 213051 001	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 002	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 004	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - RYBELSUS						
N 213051 005	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 006	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
SEMAGLUTIDE - WEGOVY						
N 215256 001	11478533	May 13, 2040	U-3861		>A> I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 002	11478533	May 13, 2040	U-3861		>A> I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 003	11478533	May 13, 2040	U-3861		>A> I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 004	11478533	May 13, 2040	U-3861		>A> I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 005	11478533	May 13, 2040	U-3861		>A> I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEPIAPTERIN - SEPHIENCE						
N 219666 001	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			
SEPIAPTERIN - SEPHIENCE						
N 219666 002	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			
SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE						
A 218853 001					CGT	Jan 18, 2026
SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE						
A 218853 002					CGT	Jan 18, 2026
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001	8039435	Aug 21, 2032	DS DP		NPP	Dec 20, 2027
					ODE-508	Dec 20, 2031
					ODE-509	Dec 20, 2031
SILDENAFIL CITRATE - LIQREV						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIPONIMOD - MAYZENT							
N 209884 001		11944602	Apr 23, 2036	U-3889			
SIPONIMOD - MAYZENT							
N 209884 002		11944602	Apr 23, 2036	U-3889			
SIPONIMOD - MAYZENT							
N 209884 003		11944602	Apr 23, 2036	U-3889			
SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN							
N 219122 001		11944621	Oct 23, 2040	DP			
		12295953	Oct 23, 2040	DP			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE							
N 201444 001		12304813	Feb 10, 2030	DP			
SODIUM OXYBATE - LUMRYZ							
N 214755 001		12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ							
N 214755 002		12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ							
N 214755 003		12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ							
N 214755 004		12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM THIOSULFATE - SODIUM THIOSULFATE							
N 203923 001		12304813	Feb 10, 2030	DP			
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 214187 002						ODE*	Mar 19, 2027
SOFPIRONIUM BROMIDE - SOFDRA							
N 217347 001		12156865	May 22, 2034	DP U-2398			
		12357609	May 22, 2034	DP U-2398			
	>A>	12398102	May 22, 2034	DP U-2398			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI							
N 211230 001		12194016	Mar 19, 2040	U-4106			
		12209059	Jun 07, 2026	U-2548			
		12263145	Dec 30, 2042	U-3693			
		12318362	Mar 19, 2040	U-3765			
		12384743	Nov 01, 2038	DS DP U-2548			
		12390419	Sep 05, 2037	DP U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI							
N 211230 002		12194016	Mar 19, 2040	U-4106			
		12209059	Jun 07, 2026	U-2548			
		12384743	Nov 01, 2038	DS DP U-2548			
		12390419	Sep 05, 2037	DP U-2548			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE							
N 022306 001	>A>	12390431	Aug 14, 2038	U-2769			
	>A>	12403109	Aug 14, 2028	U-2769			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOTALOL HYDROCHLORIDE - SOTYLIZE						
N 205108 001	12290495	Apr 01, 2034	U-2096			
	12290495	Apr 01, 2034	U-2494			
SOTORASIB - LUMAKRAS						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SOTORASIB - LUMAKRAS						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SOTORASIB - LUMAKRAS						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE						
N 215143 001	12295932	Nov 02, 2041	DP			
SUGAMMADEX SODIUM - BRIDION						
N 022225 001					NPP	Dec 12, 2027
					PED	Jun 12, 2028
SUGAMMADEX SODIUM - BRIDION						
N 022225 002					NPP	Dec 12, 2027
					PED	Jun 12, 2028
SUNVOZERTINIB - ZEGFROVY						
N 219839 001	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
SUNVOZERTINIB - ZEGFROVY						
N 219839 002	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
SUZETRIGINE - JOURNAVX						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
TACROLIMUS - ENVARSUS XR						
N 206406 001	12403095	May 30, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR							
N 206406 002		12403095	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR							
N 206406 003		12403095	May 30, 2028	DP			
TADALAFIL - TADLIQ							
N 214522 001		12186322	Dec 24, 2038	DP U-3397			
TAFAMIDIS - VYNDAMAX							
N 212161 001	>A>	7214695	Dec 19, 2026	DS DP			
	>A>	7214696	Dec 19, 2026	U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL							
N 211996 001	>A>	7214695	Dec 19, 2026	DS DP			
	>A>	7214696	Dec 19, 2026	U-2524			
TALETRECTINIB ADIPATE - IBTROZI							
N 219713 001		9187489	Jun 03, 2033	DS DP U-4207		NCE	Jun 11, 2030
		9751887	Jun 03, 2033	DS DP U-4207			
TAPINAROF - VTAMA							
N 215272 001		10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
		10426743	May 19, 2036	U-4048			
		11497718	Nov 13, 2039	U-4048			
		11612573	May 19, 2036	U-2625			
		11612573	May 19, 2036	U-4048			
		11938099	Nov 13, 2039	U-4048			
TASIMELTEON - HETLIOZ							
N 205677 001		12201604	Jan 25, 2033	U-3003			
		12201604	Jan 25, 2033	U-3865			
TASIMELTEON - HETLIOZ LQ							
N 214517 001		12201604	Jan 25, 2033	U-3003			
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK							
N 211723 001		12161645	Sep 12, 2031	U-2853			
		12162865	May 21, 2034	U-2736			
		12168014	May 03, 2038	U-2736			
		12168014	May 03, 2038	U-2852			
		12168014	May 03, 2038	U-2853			
		12168015	Sep 12, 2031	DS DP			
		12168016	Sep 12, 2031	U-2736			
		12168016	Sep 12, 2031	U-2853			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205435 001						NPP	Apr 04, 2028
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205436 001						NPP	Apr 04, 2028
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY							
N 208464 001		7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
TERAZOSIN HYDROCHLORIDE - TEZRULY							
N 218139 001	>A>	11224572	Feb 01, 2041	DP U-3990			
	>A>	11224572	Feb 01, 2041	DP U-3991			
	>A>	12427108	Feb 01, 2041	DP U-3990			
	>A>	12427108	Feb 01, 2041	DP U-3991			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - TLANDO							
N 208088 001		12310978	Feb 21, 2039	U-4194			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 001		12357643	Mar 15, 2033	DP U-2506			
	>A>	12403146	Mar 29, 2041	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 002		12357643	Mar 15, 2033	DP U-2506			
	>A>	12403146	Mar 29, 2041	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 003		12357643	Mar 15, 2033	DP U-2506			
	>A>	12403146	Mar 29, 2041	DP U-2506			
TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE							
A 217227 001						CGT	Jun 25, 2025
THIOTEPA - TEPADINA AND SODIUM CHLORIDE							
N 208264 003		9931458	May 31, 2037	DP			
THIOTEPA - TEPYLUTE							
N 216984 002		11975013	Aug 16, 2041	DP			
TICAGRELOR - TICAGRELOR							
A 208390 001						PC	Oct 28, 2025
TICAGRELOR - TICAGRELOR							
A 208531 001						PC	Oct 28, 2025
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 001		7396341	Oct 10, 2026	DP	Y		
		7396341*PED	Apr 10, 2027				
		7837235	Mar 13, 2028	DP	Y		
		7837235*PED	Sep 13, 2028				
		8733341	Oct 16, 2030	DP	Y		
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP	Y		
		9027967*PED	Sep 30, 2027				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 002		7396341	Oct 10, 2026	DP	Y		
		7396341*PED	Apr 10, 2027				
		7837235	Mar 13, 2028	DP	Y		
		7837235*PED	Sep 13, 2028				
		8733341	Oct 16, 2030	DP	Y		
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP	Y		
		9027967*PED	Sep 30, 2027				
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)							
N 215866 001		12295987	Dec 30, 2041	U-4192			
		12295987	Dec 30, 2041	U-4193			
		12343382	Jul 22, 2039	U-4229			
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)							
N 215866 002		12295987	Dec 30, 2041	U-4192			
		12295987	Dec 30, 2041	U-4193			
		12343382	Jul 22, 2039	U-4229			
		12343382	Jul 22, 2039	U-4230			
		12343382	Jul 22, 2039	U-4231			
		12343382	Jul 22, 2039	U-4232			

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 002	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 003	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 004	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 006	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 007	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 008	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 009	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 010	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 011	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 012	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 001	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 002	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 003	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 004	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 005	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 006	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 007	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 008	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 009	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 010	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 011	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 012	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001	7166722	Nov 16, 2028	DS DP			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002	7166722	Nov 16, 2028	DS DP			
TIZANIDINE HYDROCHLORIDE - ONTRALFY						
N 216190 001	12263158	May 07, 2042	DP U-2779			
TOFACITINIB CITRATE - XELJANZ						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
TOFACITINIB CITRATE - XELJANZ						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
TOLVAPTAN - TOLVAPTAN						
A 216063 001					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 002					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 003					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 004					PC	Nov 08, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOLVAPTAN - TOLVAPTAN						
A 216063 005					PC	Nov 08, 2025
TOPIRAMATE - TOPIRAMATE						
A 216683 003					CGT	Feb 01, 2026
TOPIRAMATE - TOPIRAMATE						
A 217795 001					PC	Jan 05, 2026
TOPIRAMATE - EPRONTIA						
N 214679 001	12290503	Aug 21, 2040	DP U-3413			
	12290503	Aug 21, 2040	DP U-3414			
	12290503	Aug 21, 2040	DP U-3415			
TRAVOPROST - IDOSE TR						
N 218010 001	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
TREOSULFAN - GRAFAPEX						
N 214759 001	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					ODE-513	Jan 21, 2032
					ODE-514	Jan 21, 2032
TREOSULFAN - GRAFAPEX						
N 214759 002	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					ODE-513	Jan 21, 2032
					ODE-514	Jan 21, 2032
TREPROSTINIL - TYVASO DPI						
N 214324 001	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 002	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 003	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 004	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 005	11357782	May 14, 2027	U-1849			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 001	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 002	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 003	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL SODIUM - YUTREPIA							
N 213005	003	11744836	May 05, 2037	DP			
		12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA							
N 213005	004	10898494	May 05, 2037	U-4200		NP	May 23, 2028
		11660304	May 05, 2037	U-4200			
		11712442	May 05, 2037	U-4200			
		11744835	May 05, 2037	DP			
		11744836	May 05, 2037	DP			
		12390475	May 05, 2037	DP			
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR							
N 215760	001	>A> 12358861	May 03, 2039	DS DP U-4262			
		>A> 12358862	May 03, 2039	DS DP U-4262			
TRILACICLIB DIHYDROCHLORIDE - COSELA							
N 214200	001	12168666	Nov 13, 2040	DS DP			
TUCATINIB - TUKYSA							
N 213411	001	7452895	Nov 16, 2025	DS DP U-2788			
		7452895	Nov 16, 2025	DS DP U-4153			
TUCATINIB - TUKYSA							
N 213411	002	7452895	Nov 16, 2025	DS DP U-2788			
		7452895	Nov 16, 2025	DS DP U-4153			
UBROGEPANT - UBRELVY							
N 211765	001	12168004	Jan 30, 2035	DP			
		12194030	Dec 22, 2041	U-4121			
		12194030	Dec 22, 2041	U-4122			
		12220408	Jan 30, 2035	DP			
		12310953	Jan 30, 2035	DP			
		12329750	Dec 22, 2041	U-4213			
UBROGEPANT - UBRELVY							
N 211765	002	12168004	Jan 30, 2035	DP			
		12220408	Jan 30, 2035	DP			
		12310953	Jan 30, 2035	DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA							
N 203975	001	>A> 12396986	Nov 29, 2030	DP			
UPADACITINIB - RINVOQ							
N 211675	001	>A> 12365689	Oct 17, 2036	U-3945		I-966	Apr 28, 2028
UPADACITINIB - RINVOQ LQ							
N 218347	001	12365689	Oct 17, 2036	U-3945			
VAMOROLONE - AGAMREE							
N 215239	001	12201639	Mar 17, 2040	DS DP U-3747			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962	001	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962	002	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962	003	12161690	Nov 06, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 004	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 005	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 006	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 007	12161690	Nov 06, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 003	12186362	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 004	12186362	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 005	12186362	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 006	12186362	Jan 30, 2035	DP			
VIBEGRON - GEMTESA						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
	12357636	May 04, 2042	U-4219			
VIGABATRIN - VIGAFYDE						
N 217684 001	12290499	Oct 17, 2042	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 001	9662338	Apr 02, 2035	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 002	9662338	Apr 02, 2035	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 003	9662338	Apr 02, 2035	DP			
VIMSELTINIB - ROMVIMZA						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
VIMSELTINIB - ROMVIMZA						
N 219304 002	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
VIMSELTINIB - ROMVIMZA						
N 219304 003	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
VONOPRAZAN FUMARATE - VOQUEZNA						
N 215151 001					NCE	May 03, 2027
					GAIN	May 03, 2032

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VONOPRAZAN FUMARATE - VOQUEZNA						
N 215151 002					NCE	May 03, 2027
					GAIN	May 03, 2032
VOSORITIDE - VOXZOGO						
N 214938 001	12233106	Jul 11, 2042	U-3927			
VOSORITIDE - VOXZOGO						
N 214938 002	12233106	Jul 11, 2042	U-3927			
VOSORITIDE - VOXZOGO						
N 214938 003	12233106	Jul 11, 2042	U-3927			
VUTRISIRAN SODIUM - AMVUTTRA						
N 215515 001					I-964	Mar 20, 2028
ZANUBRUTINIB - BRUKINSA						
N 218785 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2537		ODE*	Nov 14, 2026
	10570139	Apr 22, 2034	U-2666		ODE*	Aug 31, 2028
	10570139	Apr 22, 2034	U-3063		ODE*	Sep 14, 2028
	10570139	Apr 22, 2034	U-3486		ODE*	Jan 19, 2030
	10570139	Apr 22, 2034	U-3860		ODE*	Mar 07, 2031
	10927117	Aug 15, 2037	DS DP			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11591340	Aug 15, 2037	U-3727			
	11591340	Aug 15, 2037	U-3728			
	11591340	Aug 15, 2037	U-3729			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 218785 001	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	12233069	Jun 10, 2040	DP			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
ZONGERTINIB - HERNEXEOS						
N 219042 001	11608343	Jul 21, 2041	DS DP U-4245		NCE	Aug 08, 2030
	12171739	Nov 15, 2026	DS DP			
ZURANOLONE - ZURZUVAE						
N 217369 001	11884696	Aug 23, 2037	U-2552			
ZURANOLONE - ZURZUVAE						
N 217369 002	11884696	Aug 23, 2037	U-2552			
ZURANOLONE - ZURZUVAE						
N 217369 003	11884696	Aug 23, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm